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Asthma effects 5.4 million people in the United Kingdom. It is a chronic respiratory 
condition defined as frequent episodes of breathlessness, chest tightness and wheezing. 
An asthma attack is the progressive worsening of these symptoms, and can lead to 
increased healthcare resource use and reduced quality of life. It can be a costly disease, 
with over £1 billion of direct costs in England and Wales and over £130 million spent in 
Scotland.  
 
Patient reported outcome measures (PROMs) can be used to measure quality of life, but 
it is currently not clear which preference-based measures are more appropriate for asthma. 
In most studies, quality of life is measured by PROMs at particular time points, such as 
baseline and 12 months, however an asthmatic episode may occur in between these time 
points due to the unpredictable nature of these events. Therefore, the loss in quality of life 
associated with an episode may not be fully captured. Alternatively, an event could occur 
at 12 months. This may result in an underestimation of quality of life, measured by the 
area under the curve technique.  
 
Consequently, this thesis explored quality of life in acute asthmatics. Firstly, a systematic 
review explored the cost effectiveness of non-pharmacological asthma management 
interventions and the methodologies used to estimate costs and outcomes in the included 
studies. Secondly, a prospective cohort study estimated the loss in quality of life 
associated with an asthma-related crisis event (A&E attendance or hospital admission) 
using PROMs. Thirdly, the preference-based measures from the cohort study data set 
were compared using psychometric techniques. 
 
This thesis has indicated that largest decreases in quality of life occurred during the first 
four weeks from the crisis event for all PROMs considered. The EQ-5D-5L and the AQL-
5D had better psychometric performance compared to the other preference-based 
measures. 
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ASTHMA, A COMMON LUNG CONDITION: 
BACKGROUND TO THE DISEASE AND ECONOMICS 
 
“What people need to know is that asthma isn’t a minor ‘wheeze-disease’. 
It kills over five thousand people in America every year, and I could’ve 
been one of them.” 
(Jackie Joyner-Kersee, retired American athlete) 
 
Preface 
Asthma is more serious than people tend to think. Some people may not fully understand 
the condition, and how it can impact someone’s life. It can be unpleasant to live with this 
condition day in and day out, especially if the sufferer has a severe case that is not well 
controlled. A wheeze is just one of the symptoms that may be experienced with asthma; 
three more common symptoms frequently associated with this disease are shortness of 
breath, coughing and chest tightness. These symptoms often appear sporadically and can 
be time varying.  
 
Economics in health care is crucial for society. We are dependent on our health care 
services and with an increasing population; the demand for health care services will 
inevitably increase. However, the budget for such services can only stretch so far, and 
efficiency, efficacy, and effectiveness are often the terms health care policy makers take 
into consideration. They make frequent decisions about the health care services and 
resources to see if they should be increased, reduced or even cut completely from the 
sector. These decisions are important because resources are scarce, and so policy makers 
have to decide and prioritise services, where if they seek to maximise the benefits from a 
given budget then they provide those services that have the greatest benefit for a given 
cost. To guide them into making these tough decisions, health economists use a process 
of economic evaluation in order to evaluate and analyse costs and benefits in health care.  
 




This chapter provides an opening introduction into asthma. It will highlight how this lung 
condition has affected different socio-economic groups across the world, and explore the 
prevalence of this condition in different countries. Definitions and diagrams will aid the 
explanation of the lung condition further. Following this, I will provide information about 
what triggers contribute to asthma flare-ups and severe asthma attacks. Each individual 
will have different severities of asthma, but all individuals have the chance of suffering 
from an asthma attack. The chapter will also discuss what happens during an asthma 
attack and how to manage and treat asthma. To round off this chapter, I will discuss, the 
core economic concepts involved in economic evaluation and consider how these can be 
used to explore asthma further. The chapter will conclude with the aims and structure of 
this thesis. 
 
1.1 The Prevalence and Cost of Asthma  
Statistics show that asthma is a common condition with increasing global prevalence 
(Braman, 2006), with 5.4 million people suffering from asthma in the United Kingdom 
(UK) (Royal College of Physicians, 2014). For the UK, this equates to 1 person in every 
12 adults suffering with this condition, with deaths of 3 times a day (Asthma UK, 2014). 
The true global prevalence of asthma can be difficult to obtain due to gaps in asthma 
statistics. From the latest Global Burden of Disease Study, it has been reported that as 
many as 334 million people in the world suffer from asthma (Global asthma network, 
2014), however since the analysis took place between 2008 and 2010, the global asthma 
prevalence could have changed since then.  
 
An earlier analysis conducted between 2000 and 2002 stated that there were 235 million 
people who suffered from asthma (WHO, 2015a). The difference between these different 
year periods (2008 to 2010, and 2000 to 2002) in the number of asthma sufferers is just 
short of 100 million people. This difference cannot fully confirm that the burden of 
asthma has increased by this amount because of the shortfalls in the literature (Global 
asthma network, 2014). Despite this, asthma continues to grow across all demographic 
groups, affecting people of different ages, ethnic groups and races, across developing and 
developed countries and within urban and rural areas (Ferkol and Schraufnagel, 2014).  
 
A previous study helped to identify the prevalence of asthma in different countries by 
asking individuals asthma related questions using a World Health Survey (WHS) (To et 




al., 2012). These individuals were based across 70 different countries where the sample 
was stratified by age, gender, and urban or rural living environments. Figure 1 shows the 
worldwide prevalence of clinical asthma with five countries showing areas of the highest 
prevalence. The term clinical asthma, means doctor diagnosed asthma and/or been 
previously treated for asthma or having recently taken asthma medications over the last 2 
weeks (To et al., 2012). Brazil, the Netherlands, UK, Sweden, and Australia are the 
countries showing the highest prevalence of clinical asthma. They had prevalence’s of 
13.0%, 15.3%, 18.2%, 20.2% and 21.5% respectively, with a range of asthma prevalence 




The range of prevalence for doctor diagnosed asthma - which simply means being 
diagnosed with asthma – was very similar to the prevalence of clinical asthma being 
between 0.2% (China) and 21.0% (Australia) of the included countries (To et al., 2012). 
A further question asked in the WHS referred to experience of wheezing in the last year. 
This was termed symptoms of asthma, meaning, whistling or wheezing attacks occurred 
Figure 1: Worldwide prevalence of clinical asthma 
        Figure taken from: (To et al., 2012) 
Reproduced with permission of the © BMC Public Health Journal 2018.  




over the last year (To et al., 2012).  The highest prevalent countries for the symptoms of 
asthma (Figure 2) were the same as the highest prevalent countries for clinical asthma 
but with the increasing rates observed in order of Sweden (21.6%), Brazil (22.6%), the 
UK (22.6%), the Netherlands (22.7%) and Australia (27.4%). 
 
 
There were very minimal differences in clinical asthma between urban (4.91%) and rural 
(4.86%) locations, in most regions, except the Western Pacific (To et al., 2012). 
Interestingly, another study highlighted that people from Latino and African-American 
backgrounds showed higher rates of asthma diagnoses and severity, particularly in inner-
city urban areas (Gold et al., 2013) and most asthma deaths occur in low and lower middle 
income countries (WHO, 2015a). However, despite this global representation of asthma 
prevalence in Figure 1 and Figure 2, only ages between 18 and 45 years were captured 
through the WHS, which omits populations outside of this range. Asthma sufferers older 
than 45 years were excluded, perhaps due to the overlap between asthma and Chronic 
Obstructive Pulmonary Disease (COPD), where the latter has higher prevalence in those 
over 40 years. (WHO., 2016). Nevertheless, it has been reported that 10-14 year olds and 
75-79 year olds bear the greatest asthma burden categorised as a disability and early death 
(Global asthma network, 2014).  
          Figure taken from: (To et al., 2012) 
Reproduced with permission of the © BMC Public Health Journal 2018.  
 
Figure 2: Worldwide prevalence of wheezing asthma 





There are a number of other conditions that are associated with asthma (Boulet and 
Boulay, 2011). The more commonly reported ones known to have this association are 
chronic rhinitis, chronic sinusitis, gastroesophageal reflux disease (GERD), obstructive 
sleep apnoea, physiological disturbances, (such as; depression and anxiety), chronic 
respiratory infections, COPD, hyperventilation syndrome, vocal cord dysfunction, 
hormonal disturbances, obesity and smoking (Boulet and Boulay, 2011). Asthma can 
contribute to the development or worsening of these comorbidities through various 
factors such as reduced activities, poor quality of sleep and taking oral corticosteroids as 
part of medication (Boulet and Boulay, 2011). It is presently unclear which age groups 
present with higher prevalence of comorbidities associated with asthma. Further research 
is needed to ascertain this, particularly in children (de Groot et al., 2010).  
 
The economic costs associated with asthma are high, because of the morbidity and 
mortality from asthma and other associated comorbidities (Mukherjee et al., 2014). Costs 
are further attributed to poor asthma management, smoking, asthma severity, age, gender 
and disability status (Bahadori et al., 2009). Poor asthma management – often associated 
with low socioeconomic status - or sub-optimal use of asthma medications and services, 
results in significantly larger expenses on healthcare and society compared to those 
patients who have relatively well-controlled asthma (Gold et al., 2013).  
 
Both direct and indirect costs are considered in the costing of asthma care. Direct costs 
are associated with inpatient care, physician and nursing care, bloods, drugs, diagnostic 
tests and devices, accident and emergency (A&E) care, ambulances, research and 
education (Bahadori et al., 2009). Indirect costs are associated with lost days at work or 
school, caring time for children, travel and waiting time (Bahadori et al., 2009). It is 
known for direct costs to be much higher than indirect costs (Bahadori et al., 2009). There 
are discrepancies amongst studies on the definitions of direct and indirect costs, and so 
these terms should be used with caution.(Drummond et al., 2015) 
 
The direct health care costs for patient care and management of asthma in England & 
Wales, and Scotland, are estimated at over £1 billion and over £130 million per year. 
(Mukherjee et al., 2014). For England and Wales, 20% of this cost is spent on asthma 
patients who are hospitalised, where around 1400 patients are admitted to hospital each 




week (Asthma UK, 2015). It has also been reported that indirect costs (time off work and 
productivity losses) amount to £6 billion in the UK (Scott, 2015). With such increasing 
prevalence, the burden of asthma will continue to cause a major cost impact on healthcare 
services and on society, unless costs can be reduced and asthma management improved. 
The National Health Service (NHS) cannot withstand this level of high cost, as resources 
are scarce and funds are limited. Therefore, it is important to continually find ways that 
can improve the health care system and society. In order to relate to the extent of this 
burden, it is important to understand how asthma is defined and how debilitating it can 
be. To help identify with this, the next section will define asthma and highlight the typical 
symptoms associated with this condition.  
 
1.2 Definition and Symptoms of Asthma  
Asthma is a common, chronic respiratory condition that affects the lung function (Cartier, 
1994). It is defined as frequent episodes of breathlessness and wheezing (whistling 
sounds), which varies amongst individuals (WHO, 2015a). Symptoms can include 
tightness of the chest, shortness of breath, wheezing or coughing (Royal College of 
Physicians, 2014). The coughing is usually presented in the form of a dry, hoarse cough 
that often makes the throat sore and irritated. These symptoms can be worse at night or 
in the morning, and can even disrupt sleep, hence affecting sleeping patterns (National 
Heart Lung and Blood Institute, 2007).  
 
A person with asthma presents with irreversible inflamed and narrower airways compared 
to an individual who does not have asthma or a respiratory condition (WHO, 2015a). The 
airways transport oxygen to the lungs, and so those who have asthma have reduced 
airflow. Various triggers, which exacerbate the condition and lead to an asthma attack, 
can expedite the decrease of airflow to the lungs. Examples of such triggers will be 
explained in more detail, later on in this chapter.  
 
Asthma severity can range from mild to severe. This is often identified from the frequency 
of symptoms, which can occur as often as several times a day or multiple times a week. 
Individuals who do physical activity can also experience worsening of their symptoms 
(WHO, 2015a). More severe asthmatics have difficulties most of the time and this can 
hinder their usual activities and performances in the workplace or school environment 
(Cartier, 1994).  





Providing a comprehensive definition for asthma, and its severity or frequency of 
symptoms has proven challenging (Stirling and Chung, 2001, Royal College of 
Physicians, 2014). It is recognised that the frequency of asthma symptoms, the lung 
function impairment and the control of asthma symptoms through treatment management 
all have a factor in determining the definition (Stirling and Chung, 2001). Severe asthma 
indicates more frequent occurrences of asthma attacks, stronger medications, and possible 
admissions to hospital or A&E attendances (Royal College of Physicians, 2014).  
 
Asthma symptoms can occur at any age (National Heart Lung and Blood Institute, 2007). 
They can appear dormant and resurface some years later. It is not truly known what causes 
the onset of these asthma symptoms, but we are aware of who is more likely to get asthma 
and the certain triggers which activate this condition (WHO, 2015a). The next section 
will discuss these typical triggers 
 
1.3 What Causes Asthma and how is it diagnosed?  
A person with asthma usually has this condition because of genetic factors combined with 
an allergic reaction to environmental stimuli (WHO, 2015a). In the absence of a gold 
standard definition, it is difficult to diagnose newly presenting cases, although it is 
clinically appropriate to identify any presence of more than one of the typical symptoms, 
(shortness of breath, tight chest, wheezing and coughing), as a starting point for a 
diagnosis (British Thoracic Society. Scottish Intercollegiate Guidelines Network, 2014). 
Asthma can develop early in life as a child, or later in life as an adult (late-onset asthma), 
whilst at work (occupational asthma) or even seasonal (Royal College of Physicians, 
2014). People with asthma can have allergic or non-allergic asthma.  
 
The National Institute for Health and Care Excellence (NICE) recommend that lung 
function tests are performed to help confirm the diagnosis of asthma in individuals 
(National Institue for Health and Care Excellence, 2015). In particular, NICE prefers the 
use of spirometry compared to the peak expiratory flow (PEF) to examine the breathing 
capacity of an individual. However, once diagnosed, the PEF is a good indicator that is 
used for asthma monitoring (British Thoracic Society. Scottish Intercollegiate Guidelines 
Network, 2016). It is an instrument that measures airflow in the airways. This enables 




clinicians and people with asthma to see what their best/normal PEF reading is, and if the 
readings fall, then both parties know that the person with asthma requires further medical 
assistance. Furthermore, trials of different treatment strategies are being undertaken to 
identify which medications work best for the patient (British Thoracic Society. Scottish 
Intercollegiate Guidelines Network, 2014).    
 
Factors such as age, sex, and atopic (hyper allergic) history in both patient and family, 
and abnormal lung function also play a role in the diagnosis (British Thoracic Society. 
Scottish Intercollegiate Guidelines Network, 2014). For children, it is likely that males 
grow out of their asthma during puberty, whereas females are more likely to remain with 
their asthma during adolescence. For those who have coexisting atopy, such as eczema or 
allergic rhinitis (hay fever), or have a family history of atopy, in particular maternal atopy, 
then they have an increased risk of being diagnosed with asthma. However, this risk is 
not only limited to these individuals. Smokers or exposure to smoke, being premature at 
birth, or having bronchiolitis when a young child, also increases the risk of asthma 
diagnosis further.  
 
Environmental factors also cause asthma symptoms to be noticeable – the range is 
extensive (Royal College of Physicians, 2014, British Thoracic Society. Scottish 
Intercollegiate Guidelines Network, 2014). Exposure to irritants; such as pollen, dust 
mites, animal fur, cigarette smoke, pollution and chemical fumes, are some of the 
common allergens and airborne irritants that might stimulate symptoms in people who 
have asthma. Other triggers include, a sudden change in temperature or weather 
conditions, whether that be rain, extreme heat, sudden icy conditions, or thunderstorms 
can be further triggers, which worsen asthma symptoms. Food allergies and particular 
medicines, (e.g. aspirin, ibuprofen, beta-blockers), might play a role too, and it may be 
surprising to some, but emotional changes can also cause an effect, including laughter 
and stress. Exposure to these triggers can result in a person suffering from an asthma 
attack. The onset of an asthma attack can happen very quickly without any noticeable 
developments and can get progressively worse over time, which could be fatal and cause 
death. To understand what happens to an asthma sufferer during an asthma attack, the 
next section will detail the scientific process.  
 




1.4 What does an Asthma Attack mean?  
An asthma attack is an acute response to triggers, which causes a person’s asthma 
symptoms to worsen. The chest tightness, wheezing, breathlessness and/or coughing can 
suddenly escalate and lead to increased difficulties in speaking, walking, eating, sleeping 
and undertaking usual activities (Asthma UK, 2015). When asthma attacks occur, 
structural changes in the airways take place, (in both cases of mild or severe asthma), and 
the airways narrow causing airway obstruction. The structural changes in the airways are 
called airway remodelling, and the smooth muscle usually becomes scarred and enlarged 
due to hypertrophy (increase in cell size) and hyperplasia (increase in the number of 
muscle cells) spreading through the airways (Jarjour and Kelly, 2002, Holgate, 2008).  
 
Asthma attacks can vary in terms of severity, and physicians often categorize them as 
mild, moderate, severe and life threatening (British Thoracic Society. Scottish 
Intercollegiate Guidelines Network, 2016).  Sometimes asthma symptoms can be eased 
by taking the prescribed medications, usually a Ventolin inhaler (Asthma UK, 2015). 
However, if the patient does not get any relief from the Ventolin inhaler, then depending 
on the severity of their symptoms, a GP visit or A&E attendance usually follows. Patients 
may call the ambulance service immediately, or at the GP visit, the GP may refer the 
patients to hospital. Upon attendance to hospital, initial assessment of clinical features 
(e.g. ability to talk in sentences), PEF, oxygen levels and blood gases are taken routinely, 
in order to categorize the acute asthma into mild, moderate, severe or life threatening 
asthma (British Thoracic Society. Scottish Intercollegiate Guidelines Network, 2016). 
Once the test results categorize the asthma, decisions are made to admit patients and 
decide on their treatment pathway. The median length of stay is reported as 7 days 
(Gibbison et al., 2013), where physicians and nurses aim to get the patient’s PEF to 
between 70% and 75% of their normal PEF before discharge (British Thoracic Society. 
Scottish Intercollegiate Guidelines Network, 2016, Camargo et al., 2009). In addition, 
patients are likely to have been experiencing their asthma symptoms for a few days prior 
to admission, with symptoms rapidly increasing two or three days before an asthma attack 
(Asthma UK, 2016). 
 
 
Having an asthma attack is unpleasant and can leave someone distressed and out of 
control. To prevent regular occurrences of these asthma attacks, it remains important to 




have a good asthma management plan and strategy that allows the person with asthma to 
be able to control their symptoms and minimize the likelihood of a severe asthma attack. 
People who don’t have well-controlled asthma  often have low asthma control test scores, 
concurrent with low health-related quality of life (HRQL) scores (Guilbert et al., 2011). 
These individuals are at higher risk of having extra GP visits, A&E attendances and 
hospital admissions (Guilbert et al., 2011). Controlling the occurrence of asthmatic events 
and managing symptoms properly has benefits for both asthma sufferers and the 
healthcare services in general. Therefore, the next section will discuss what common steps 
are taken to manage asthma. 
 
1.5 Asthma management and Treatment  
Monitoring treatment, after diagnosis has been made, usually occurs in an asthma review 
which takes place once every year (British Thoracic Society. Scottish Intercollegiate 
Guidelines Network, 2014). This is subject to the individual being “well” in between each 
period of review, as otherwise additional appointments may have to be made to extend 
the asthma management further. Additional appointments occur because of unscheduled 
GP appointments, A&E attendances or hospital admissions due to asthma during the year.  
 
The management of asthma can be categorised into self-management, pharmacological 
and non-pharmacological management (British Thoracic Society. Scottish Intercollegiate 
Guidelines Network, 2014). Self-management is defined as individual tasks to manage 
the condition (medically and emotionally), with support on how to recognise and act on 
deterioration (Pinnock, 2015). Potential methods for effective self-management are 
education based management with information technology (IT), and personalised asthma 
action plans (PAAPs) (British Thoracic Society. Scottish Intercollegiate Guidelines 
Network, 2014). The PAAPs enable the recording of loss of asthma control and include 
specific advice about how to recognise this. They also cover action points that should be 
taken when asthma deteriorates. However, this style of PAAP will not suit all patients, as 
some patients will be illiterate, or blind. To cater for the illiterate population, a study 
conducted in Turkey designed a pictorial asthma action plan and tested its effectiveness 
combined with a standardised educational program (Pur Ozyigit et al., 2014). They 
discovered that for their female population aged between 18 and 55 years old, their asthma 
control and HRQL improved over a 6 month period. It was also shown that the pictorial 
asthma action plan and the education program worked effectively together as there were 




no hospital admissions over this 6 month period and fewer A&E attendances were seen. 
Even though, this study showed comprehensive findings, the male population were 
excluded from this study design, and therefore not generalizable to the male population.  
 
During the approach of an asthma plan, it is important to have a good relationship with 
the clinician or healthcare professional that is involved. This professional partnership will 
gain patient confidence, knowledge and skills, and hopefully the patient will become 
more willing to discuss their treatment and come to a joint decision on how to move 
forward to better improve health (Bateman et al., 2008). Some studies which include trials 
in self-management of asthma have used both primary care and secondary care population 
groups (British Thoracic Society. Scottish Intercollegiate Guidelines Network, 2014). 
Even though this can be a difficult task to get the patients involved and compliant to the 
trial investigation, it has been shown to reduce A&E attendances, hospital admissions and 
use of health care resources.  
 
Pharmacological management follows a cycle in a step-wise motion, which is seen in 
Figure 3 (Bateman et al., 2008). Firstly, there is assessment of the asthma control, if the 
asthma is not controlled then increasing the treatment is considered, otherwise if 
controlled for ≥ 3 months then reducing the treatment is considered, and then finally 
control is to be maintained (van Weel et al., 2008). A preventer medication (helps to 
prevent an asthma attack) and reliever medication (helps to improve symptoms when 


















For the non-pharmacological asthma management, it is important to minimise risk to the 
patients by reducing exposure to their known triggers, which cause their asthma to flare- 
up (Funston and Higgins, 2014). This will play a huge part in keeping their asthma 
controlled, and reduce any sudden asthma attacks, which may require a hospital 
admission and more intensive forms of treatment. Further education programmes are 
encouraged, through health professionals and also school staff (Lawlor, 2015). For 
Figure 3: The step-wise process displayed as part of asthma pharmacological 
management with different treatment options available. 
Figure taken from: (Bateman et al., 2008) 
Reproduced with permission of the © ERS 2018. European Respiratory Journal Jan 
2008, 31(1)143-178; DOI: 10.1183/09031936.00138707 




children, it is vital that school staff members are aware of asthma and its difficulties so 
that they are fully equipped if a child’s asthma condition deteriorates whilst on their 
school premises (Lawlor, 2015).  
 
It is also important to realise that it is not just down to the healthcare practitioners and the 
educational programs to help manage asthma, but it also lies in the hands of the person 
who has asthma. People with asthma have to want to improve their asthma control and 
management. An effective way of doing this, in addition to what has already been outlined 
above, is by doing physical activity. A group of mild to moderate asthma patients have 
been shown to improve their asthma control and quality of life over a four month period 
after starting a physical activity program (Mancuso et al., 2013). After being monitored 
for a further six months, their asthma control and quality of life had resided to a steady 
controlled state. However, the HRQL questionnaire (Asthma Quality of Life 
Questionnaire) that was used to capture this data was only asked at baseline, 4, 8, and 12 
months, and so we are unaware of any potential drops in asthma control and quality of 
life in between these time points. This study also leaves a thought, as to whether the same 
results would occur for those with more severe asthma. The importance of quality of life, 
what it is, and how it relates to asthma sufferers will be discussed in the next section.  
 
1.6 Quality of life in asthmatics 
The term ‘quality of life’, can be used in different contexts such as housing, relationships, 
work and social life. HRQL specifically relates to an individual’s health and any clinical 
interventions associated with this. Quality of life in asthma patients can deteriorate 
differently from person to person, depending on the severity of their condition (Royal 
College of Physicians, 2014), with some factors being more detrimental than others. It is 
important to be able to maintain or improve someone’s quality of life especially if they 
are bearing the burden of distress from it on a daily basis.  
 
Typically, the areas of concern for measuring HRQL are the individual’s physical, mental 
and social attributes (Andresen and Meyers, 2000). Other areas may also be assessed, but 
this is often related to whether a generic or disease-specific approach is taken (Guyatt et 
al., 1999). The term generic means how the particular HRQL aspects relate to people in 
general, (i.e. it can be used across a range of different conditions), and the disease-specific 
term means how particular HRQL aspects relate to people with a specific disease or 




condition.  HRQL can be measured on a utility scale (a scale for valuing health), with 0 
representing the dead state and 1 representing the perfect health state (Kopec and 
Willison, 2003).  
 
To determine what factors really reduced HRQL in asthmatics, a study was conducted 
where they interviewed 150 patients who were 18-70 years old and presented them with 
a list of 152 items (Juniper et al., 1992). This list of 152 items was generated in the item 
selection phase where people with asthma were interviewed and it included what was 
important to patients with asthma. The 150 patients included in this phase of the study 
then identified the most important items from this list, and amongst the obvious physical 
and environmental items, tiredness, irritability and mood changes also seemed to reduce 
HRQL. The aim from this study was to create a questionnaire that can be used to assess 
HRQL in asthmatics; the Asthma Quality of Life Questionnaire (AQLQ). The AQLQ is 
a disease-specific questionnaire and is composed of 32 questions with 4 domains, which 
are symptoms, activity limitation, emotional function and environmental stimuli. Each 
question can be responded to on a 7 point scale ranging from severely impaired (score 0) 
to not impaired at all (score 7) (Young et al., 2011).  
 
A study assessing the quality of life in bronchial asthma patients showed that out of the 4 
domains, the symptom domain showed the maximum number of limitations of this 
questionnaire (Nalina et al., 2015).  In addition, females had more of a limitation in their 
quality of life compared to males, accompanied with patients being obese. Age and BMI 
were also associated with lower HRQL according to Nalina et al. (2015). Another study 
used a generic quality of life questionnaire, the 15D, to assess what factors influenced 
quality of life with asthma patients (Al-kalemji et al., 2013). The 15D is composed of 15 
different dimensions with 5 different levels for each dimension. The levels range from no 
problems for level 1 to severe problems for level 5, and it is a self-completed 
questionnaire with utility values ranging between 0 and 1. The results of this study 
showed that anxiety, depression, smoking, female gender and obesity were all associated 
with lower levels of quality of life in asthmatics. However, there was a significant number 
of participants who were obese and had psychiatric comorbidities, and so these 
individuals may have had an effect on the outcome of the results. It is interesting to see 
here that a generic quality of life questionnaire was used for this study (Al-kalemji et al., 
2013), but for the earlier study a disease-specific quality of life questionnaire was used 




(Nalina et al., 2015). Despite this difference, the results show correlations between both 
studies for gender and BMI as being factors that have an effect on the quality of life of 
asthmatics.  
 
HRQL are useful measures in studies. Types of economic evaluations, e.g. a cost-utility 
analysis (CUA), are often undertaken (see section 1.8.1 for the outline of different types 
of economic evaluations) with the value of different interventions compared, Quality 
Adjusted Life Years (QALYs), (which incorporates quality of life and life expectancy) 
(Whitehead and Ali, 2010).  QALYs are important for the patients and healthcare system 
to ensure effective decisions are made by policy and decision makers to maximise the 
value that can be obtained from the budget for health care interventions (Kind et al., 
2009). NICE recommends the use of QALYs when conducting health technology 
assessments, to enable comparability between different interventions for different 
diseases, for fair judgement and to measure their clinical effectiveness (Ara and Wailoo, 
2011, NICE, 2013). There are several ways in which we can obtain a QALY for health 
economic analysis, and in the next section, I will explain how we can obtain QALYs for 
asthma by using different quality of life measures.   
 
1.7  Measuring & valuing quality of life  
There are different ways in which quality of life can be measured, and as mentioned 
above, there are several ways in which we can obtain QALYs for our analyses. Generic 
and disease-specific questionnaires can be used to capture HRQL, and other methods 
involving groups of people can be used to gather information by way of direct elicitation 
techniques (Drummond et al., 2015).  
 
In the previous section, I gave examples of two different questionnaires that have been 
used in other studies to capture the HRQL in asthmatics; the AQLQ (disease-specific 
questionnaire) and the 15D (generic questionnaire). There are many other questionnaires, 
which can be used to capture quality of life in general, and this will form part of the 
discussion in the section below. Converting the scores from completed questionnaires 
into values, which can be used for QALYs, enables a CUA to be undertaken. However, 
the conversion may not be that simple, and other options may need to be considered, such 
as mapping.  





This section will discuss the different direct elicitation methods that can be used as an 
alternative or in conjunction with questionnaires. There will also be discussions on the 
use of generic and disease-specific questionnaires, and how they can assist in the process 
of valuation.  
 
1.7.1 Direct Elicitation methods  
There are three widely used direct elicitation methods. They are the time trade-off, the 
standard gamble and the visual analogue scale. Both the time trade-off (TTO) and the 
standard gamble have been used in the development of well-known questionnaires, (the 
EQ-5D, the SF-6D and the HUI).  
 
The idea behind the TTO is to consider two different health states (Figure 4 and Figure 
5). Typically, one of the states will match a particular health description (e.g. Stage III 
breast cancer, or severe cystic fibrosis), and the other state will often represent full health 
(e.g. Healthy individual with no health impediments). The respondent will be faced with 
a question about these two health states and asked whether they would be willing to give 
up any life years from the diseased health state, in order to live for a shorter number of 
years in full health, followed by death (Attema et al., 2013). The typical approach is to 
ask this question over and over again at different intervals in order to reach the point of 
indifference. For example, one will start at the half-way point in healthy life years 
remaining and move up or down in intervals depending on a yes or no response to living 
in the diseased health state. If the respondent responds with yes (in that they would prefer 
half the stated period in full health, compared to a specific period in current health), then 
the question would be asked again decreasing the years of full health in intervals, 
otherwise the years would increase in intervals. When the point of indifference has been 
reached, dividing this by the total number of life years questioned, will be the utility score 







































40 remaining life years; followed by death 
A: Diseased health state (e.g. Stage III breast cancer or cystic fibrosis) 
B: Full Health (e.g. healthy individual with no health impediments) 
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Diseased Health state 
Figure 5: Graphical representation of time trade-off 




On the other hand, the standard gamble takes more of a direct approach and also considers 
the respondents risk attitude (Gafni, 1994). The standard gamble tends to start with a 
50:50 choice between two alternatives (Figure 6). On one alternative, the gamble lies 
with a certain probability of being in ‘full health’ or 1 − 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 being ‘dead’. The 
other alternative is remaining in the diseased health state. In this case, the probability (p) 
is varied until a point of indifference is met, where the point of indifference (p) becomes 




























Diseased health state 
Full health 
Dead 
1 - p 
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Figure 6: Standard gamble example 




The third most widely used direct elicitation method is the EQ visual analogue scale 
(VAS), and this can be thought of as a thermometer scale that has fixed, equal intervals 
(Drummond et al., 2015). It is one of the simplest methods of measuring quality of life. 
As long as the EQ VAS has fixed, equal intervals, it can be scaled differently (e.g. from 
0 to 1, or 0 to 10 or 0 to 100).  
 
The respondents who answer these questions can differ from study to study depending on 
whose preferences the study wishes to take. Some studies believe that the preferences of 
the public should be the preference chosen in direct elicitation techniques and others 
believe the patients should be chosen instead. It is thought that the public are more 
representable of the population. The public are also the taxpayers in the UK, and because 
the NHS has a public funded system where the population’s tax contributes to this, it is 
also considered that the general population should have a right in valuing health states 
(Drummond et al., 2015). Despite this argument, the general population may not fully 
understand the constraints of living in a particular chronic health state if they have not 
experienced it before. Even though there are health state descriptions to support and 
consolidate the general population’s thought process, areas of certain conditions can still 
be misinterpreted (Stamuli, 2011). Therefore, it is argued that the individuals who 
actually suffer from chronic health conditions should be the ones to value them, because 
they are the most knowledgeable about their condition and know the true merits of it. 
However, when comparing these two perspectives from the general population and the 
patients themselves, it can be noticed that the utility values concluded from participating 
in the direct elicitation methods can be lower or higher by the general population or 
patients respectively (Suarez-Almazor et al., 2001, Suarez-Almazor and Conner-Spady, 
2001).  
 
Research has shown that patients adapt to their health state as they get used to their 
condition over time, which may lead to higher valuations (Whitehead and Ali, 2010). This 
could be a disadvantage to patients because using their ‘higher’ preferences could lead to 
a lower QALY gain estimate when comparing interventions and deciding on which 
treatments should be implemented (Drummond et al., 2015). Some studies highlight this 
difference found between public and patient preferences (Ubel et al., 2003), and 
particularly noticed this when valuing severe health states (De Wit et al., 2000). However 




other studies do not acknowledge a strong difference between patient and public valuation 
(Stamuli, 2011).  
 
Measuring utilities using the direct elicitation techniques mentioned above can be a time-
consuming process and there are other methods, which can be used to estimate utilities. 
A simpler approach is to use questionnaires that are multi-attribute and have scores; often 
termed generic questionnaires. The most commonly used generic questionnaires will be 
highlighted in the next section. 
 
1.7.2 Preference-based measure: Questionnaires  
Generic questionnaires are regularly used in studies and aim to cover a broad range of 
health dimensions that could be applicable to a variety of diseases. Examples of 
commonly used generic questionnaires are the EuroQol 5 Dimensions (EQ-5D), the Short 
Form 6 Dimensions (SF-6D) and the Health Utilities Index (HUI) (Conner-Spady and 
Suarez-Almazor, 2003, Whitehead and Ali, 2010). Examples of other less commonly 
used questionnaires, at least in the UK/Europe, are the 15 Dimensions (15D), developed 
in Finland, and the Assessment of Quality of Life (AQoL), developed in Australia.  
 
Amongst the three aforementioned most commonly used generic questionnaires, there 
have been many comparison studies which have found that each questionnaire produces 
different estimations of utility values for the same health-related condition. For example, 
it has been shown that the mean utility values have been estimated to be 0.79 (95% CI 
0.78 – 0.81) for the EQ-5D, 0.77 (95% CI 0.76 – 0.77) for the SF-6D and 0.56 (95% CI 
0.55 – 0.57) for the HUI3 for people with hearing impairments (Barton et al., 2005). The 
differences in utility values are related to how each preference-based measure has been 
measured (e.g. the description of health states; the elicitation techniques and the 
population group involved) and valued (e.g. algorithms). Therefore, it is important to be 
aware of these differences in generic questionnaires, especially when comparing 
preference-based outcome results with other studies.  
 
There are now two versions of the EQ-5D, the original renamed to be the EQ-5D-3L and 
the newest formed version called the EQ-5D-5L (Devlin and Krabbe, 2013). The EQ-5D-
3L was originally created by using the TTO technique on approximately 3000 members 




of the UK adult general population (Rabin and de Charro, 2001). The adult members had 
to give preferences for the scoring function of six previously developed attributes by the 
EuroQol Group (members are from multiple countries), and econometric modelling was 
used to develop the scoring function. The six attributes that were initially created by the 
EuroQol Group were mobility, self-care, main activity, social relationships, pain and 
mood.  However, these six attributes were soon revisited and reduced to five attributes; 
mobility, self-care, usual activity, pain/discomfort and anxiety/depression. From these 
attributes, each one was subjected to 3 levels (no problems, some problems, and severe 
problems), and this meant that there could be a combination of 243 different health states. 
When the questionnaire is completed, each attribute and its associated level is recorded 
as a 5 digit number, where no problems, some problems and severe problems are noted 
as 1, 2, and 3 respectively. The 5 digit number (e.g. 12321 for no problems in mobility, 
some problems in self-care, severe problems doing usual activities, some problems with 
pain/discomfort and no problems with anxiety/depression), is then converted into a utility 
value using an algorithm, where the range of utility values could be from -0.594 (33333) 
to 1.000 (11111) (Kind et al., 1999). The EQ-5D-3L was based on preferences from the 
UK population, however, other countries also wanted to translate this questionnaire and 
re-estimate utility scores based on valuations for their own population. Therefore 
developments of this translation took place, where over 170 are available for self-
completion in different languages. 
 
The EQ-5D-5L is based on the same five attributes that were created by the EuroQol 
Group for the EQ-5D-3L, but with 5 levels attached to each attribute instead (Herdman 
et al., 2011). The 5 levels are no problems, slight problems, moderate problems, severe 
problems, and extreme problems. The idea behind the creation of the new 5 level version, 
was to help detect the smaller health changes that are sometimes seen in patients who 
have milder conditions, with the hope that this would reduce ceiling effects. The creation 
of the 5 levels involved face-to-face interviews with members of the general public. There 
were two occurrences of this, with the first interview pooling potential names for the 
levels, and the second interview choosing two alternative 5 level options testing out its 
face validity and content validity amongst a mixed group of healthy and chronically ill 
individuals. With the 5 level option and the same five attributes, this allows 3125 different 
possible combination of health states. For the new EQ-5D-5L questionnaire, there have 
been developments of a mapping process from the EQ-5D-3L to the EQ-5D-5L to enable 




values to be used (van Hout et al., 2012, NICE, 2017) (Section 1.7.3 will discuss the 
process of mapping).  
 
One of the other most commonly used preference-based measures  is the SF-6D. This was 
developed from another questionnaire, called the Short Form 36 (SF-36) a generic 
questionnaire that is widely used in health studies. A disadvantage that the SF-36 has, is 
that although it is detailed and is well used to judge the effectiveness of interventions, it 
doesn’t have the ability to estimate QALYs for cost utility analyses in economic 
evaluations. Therefore, Brazier et al. (2002) created an instrument from the SF-36 that 
would enable analysts to calculate QALYs (SF-6D), by providing an estimation of 
preference-based values from the general population. The SF-6D was formed by taking 
the 11 items from the SF-36 and reducing them to form 8 dimensions, where 2 of the 
dimensions were later combined. The 6 dimensions were named as physical functioning, 
role limitations, social functioning, pain, mental health and vitality. The six dimensions 
each had a level (ranging from 1 to 4 or 1 to 6) with decreasing limitation in activities, 
with 4 or 6 being the most limited. There are 18,000 unique combinations of health states 
that can be derived from this multi-attribute system.  
 
Unlike the EQ-5D, the SF-6D used a different elicitation technique which was the 
standard gamble. This approach was done using 836 members of the UK general 
population, where each individual provided a valuation for 6 health states. The population 
was varied by age group, education and social class. It wasn’t possible to provide 
estimations for all the 18,000 health states, and so 249 estimations were valued instead, 
which was enough to generate a model.  
 
The third most commonly used preference-based measure is the Health Utilities Index 
(HUI) (Horsman et al., 2003).  There are two types (HUI2 and HUI3) which are known 
to be used more often because of their multi-attributes which are considered to be of 
higher importance compared to HUI1 (Feeny et al., 2002). It is recommended that HUI3 
should be used in primary analysis as it is the more descriptive measure (this was 
developed after HUI2 to adapt the measure to be more applicable to clinical studies). The 
HUI2 has some dimensions in the questionnaire that the HUI3 doesn’t have, and so it is 
still seen as a secondary option and may be more suited to particular studies. The general 
public were also involved in developing this questionnaire, and both the standard gamble 




and the EQ VAS techniques were used. However, this time, the population were from 
Canada and were the schoolchildren’s parents. There are slight variations in the different 
dimensions, with HUI2 having sensation, mobility, emotion, cognition, self-care, pain 
and fertility as dimensions, and HUI3 having vision, hearing, speech, ambulation, 
dexterity, emotion, cognition and pain as dimensions. The levels within the dimensions 
varied as well with HUI2 ranging from 1 to 5, and HUI3 ranging from 1 to 6 with the 
higher numbers representing the most limitations.  
 
Aside from these generic preference-based questionnaires, there are also other condition 
specific measures (preference-based and non-preference-based measures) which can be 
used to do the former. It has been argued that they are more suited for specific conditions, 
because the condition-specific questionnaires, ask questions which are more sensitive to 
the condition of interest (Chen et al., 2005). However, it is also recognised that 
preference-based condition specific measures might lead to exaggerated health problems, 
leading the utility values to be incomparable (Brazier and Tsuchiya, 2010). Nevertheless, 
there is limited evidence for this, and so preference-based condition-specific measures 
continue to be developed and compared. Examples of such preference-based condition-
specific measures include three which were derived from the Health Assessment 
Questionnaire for arthritis, Quality of life Questionnaire for Cancer 30 for cancer, and the 
Multiple Sclerosis Impact Scale 29 for multiple sclerosis (Versteegh et al., 2012b). Other 
examples include a preference-based condition specific measure for asthma using the 
AQLQ (Yang et al., 2011), and for urinary incontinence using the King’s Health 
Questionnaire (Brazier et al., 2008). Further examples of non-preference-based condition-
specific questionnaires are the Chronic Respiratory Questionnaire (Guyatt et al., 1999) 
and the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) 
(Bellamy et al., 1988).   
 
From the above two techniques, (direct elicitation methods and preference-based 
measures), the HRQL can be estimated to derive a QALY. As the QALY quantifies 
quality of life and quantity, the approach used to estimate the QALY is the area under the 
curve method (Manca et al., 2005). Data can be collected at particular time points, in 
order to capture any change, and the HRQL can be multiplied by the time point (see 
Figure 7 for an example). In a trial, the QALYs gained are often summarised across 
participants to form, for example, mean estimates (Smith et al., 2009).  









The approach of capturing quality of life at set time points, such as the above at baseline, 
six months and nine months (Figure 7),  is often undertaken in many studies (perhaps at 
different time points). With quality of life measured at set time points over a period of 
time, it is common to use the assumption of linear interpolation in between the time 
points, as illustrated above for the total area under the curve approach.  However, quality 
of life could be different in different people, (i.e. lower or higher in between these points), 
and if this is the case, then this would not be captured at these measurement points. 
Situations when this might occur, are when estimating the quality of life in someone who 
has a chronic condition, such as asthma, as asthma attacks can be sporadic and cause 
immediate and reduced quality of life when they occur (Figure 8). 
Figure 7: Estimating QALYs using the area under the curve method 
Figure taken from Manca et al. (2005) 
Reproduced with permission of the © Health Economics Journal 2018.  
 







For example, using the graph above, (Figure 8), if only two quality of life time points 





 × 0.7 = 0.35 𝑄𝐴𝐿𝑌𝑠 
 
However, if including the time point captured at 3 months in the estimation in addition to 
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=  0.117 + 0.0375 + 0.0292 + 0.005 + 0.0583 = 0.247 𝑄𝐴𝐿𝑌𝑠 
 
From the two examples above, it is evident, that by just having 2 time points at 0 and 6 
months, the first QALY estimation (0.35), is higher than the second QALY estimation 























Figure 8: An example of estimated utility values at different time points for 
someone who has an asthma attack at 3 months 




first QALY estimation is an overestimation compared to the second. This example shows 
that it takes 2 months to recover from the crisis event, and revert back to a utility value of 
0.7. This indicates that the decision to choose when to collect utility data and how often 
utility is measured is important. If the time between one time point and another is too 
wide apart, then the QALY loss may be underestimated, and if the time points are too 
close together then this may cause a participant burden to arise and be impracticable for 
the participant to complete. A judgement on what is necessary to capture such information 
should be made, with careful consideration of the participant population.  
 
In some cases, studies may wish to use the condition-specific measures in economic 
evaluations (see section 1.8), but in order to estimate QALYs they will need to convert 
the values from the condition-specific measure into utility data, so that they can be used 
in analyses such as CUA. This allows the prediction of  preference-based values 
(Drummond et al., 2015). This process is called mapping or cross-walking and is 
recognised by NICE in populating economic models (NICE, 2013).   
 
1.7.3 Mapping 
The process of mapping involves three important stages, and involves two datasets, with 
one of them termed the ‘estimation’ data set and the other one termed the ‘study’ data set 
(Chuang and Whitehead, 2012). The estimation data set will hold information from the 
same population group regarding a preference-based measure and a non-preference-based 
measure that was used. The study data set will only hold one of these measures; the non-
preference-based measure. It is important that the characteristics of the population from 
the two data sets are alike to enhance the generalizability of the estimation, and it is also 
important to ensure that there is overlapping content of the two measures used to capture 
the relationship for estimation on the HRQL (Longworth and Rowen, 2013). Once these 
data sets have been identified, the first step is to establish the statistical relationship 
between the two measures (preference-based and non-preference-based) in the estimation 
data set by typically using regression method techniques (Brazier et al., 2010) as this will 
help to inform which model type should be used (Longworth and Rowen, 2013). The next 
step will be to use the result from the regression to enable a prediction of the preference-
based measure in the study data set, (i.e. the condition specific score and other scores used 
in the mapping function). Lastly, the predicted results can then be used in economic 
evaluations such as the cost utility analysis (NICE, 2013).  





If using mapping methods to predict EQ-5D values, condition-specific measures are not 
the only measures that can be used. Other options are generic-based measures, clinical 
indicators of disease therapy and sociodemographic variables (Longworth and Rowen, 
2013). Nevertheless, it should be acknowledged that different model types have been used 
amongst mapping studies. The tobit regression model has been used in a mapping study 
from an oral health related quality of life measure (Oral Health Impact Profile) to a 
generic measure (Euroqol) (Brennan and Spencer, 2006). This is different to the ordinary 
least squares regression model which has been used in several studies. The latter has 
mapped from a cancer specific questionnaire (EORTC QLQ-C30), a health assessment 
questionnaire (HAQ), a multiple sclerosis specific questionnaire (MSIS-29), and oxford 
hip score questionnaire (OHS) to the EQ-5D or other preference-based measures 
(Versteegh et al., 2012a, Kontodimopoulos et al., 2009, Pinedo-Villanueva et al., 2013). 
An alternative method to mapping is the Rasch analysis which has been recently used in 
the development of a preference-based asthma measure, the AQL-5D (Young et al., 
2011).  
 
Quality of life can be used in analyses to complement healthcare decisions. There is a 
particular technique called the CUA that uses QALYs to aid decisions, and other 
techniques are used to address other health outcomes. These techniques will be discussed 
in more detail in the next section and they all come under one umbrella term; economic 
evaluation.  
 
1.8 Economic evaluation 
Economic evaluation is an important method, which is used to help make informed 
decisions about the healthcare system. Often policy makers question whether a particular 
service or treatment option is running efficiently and consider how to improve it. 
Alternatively, they may wish to decide which treatment to provide. When considering 
these decisions, then forgoing the benefit of a particular service or treatment option might 
be necessary, if such services or treatment options were to change. This is known as the 
‘opportunity cost’, and how large or small this cost is, can depend on how the health care 
system is run (Palmer and Raftery, 1999). Taking the example of the UK’s publicly 
funded health care system, the allocation of funding for different services is dependent 
on a fixed budget that is set each year by the government. With resources (such as; 




facilities, equipment, staff and time) being scarce, choices have to be made which leaves 
the opportunity costs to fall against the health outcomes. The reason for this is because 
the increase in costs for one service means that the health benefits gained in patients from 
another service cannot be continued due to the resources being unavailable. In order to 
make these informed decisions, health economists analyse and compare the costs and 
consequences of alternative courses of action (Drummond et al., 2015).  The costs and 
the consequences can be considered in different ways (Byford and Raftery, 1998). These 
perspectives are typically divided into the health provider, the patient, the third party 
payer or a broader societal perspective. The focus could be only on health care resources 
used (e.g. costs associated with the time allocated for GP visit or the length of stay in 
hospital), or it could be inclusive of patient costs too (e.g. transportation costs to and from 
hospital, medication costs, loss of productivity). How broad or narrow a perspective 
taken, is the decision of the researcher before a study commences and this should be stated 
explicitly (Byford and Raftery, 1998). There are different techniques that can be used in 
the approach of economic evaluation and some are considered full or partial economic 
evaluations. The different types of economic evaluations will be discussed below in the 
next section. 
 
1.8.1 Analysis techniques  
A full economic evaluation is ‘the comparative analysis of alternative courses of action 
in terms of both their costs and consequences’ (Drummond et al., 2015). There are three 
techniques which are considered to take the defined approach. These are cost benefit 
analysis (CBA), cost effectiveness analysis (CEA), and CUA. There are other approaches 
which are partial economic evaluations, and examples of these are cost consequences 
analysis (CCA) and cost minimization analysis (CMA) (Drummond et al., 2015). A CCA 
provides a list of disaggregated costs and outcomes with no analytical decision made by 
the author, but instead allows the reader or decision-maker to decide on which treatment 
option is worth being carried out. On the other hand, a CMA, is an analysis where both 
treatment options are assumed to be providing the same therapeutic effect, leaving just 
the costs of both treatments left to be compared against each other to identify the cheaper 
treatment.  
 
CBA was the first type of a full economic evaluation technique to be recognised, and is 
an analysis of costs and benefits measured in monetary units. The costs are thought of as 




the value of the resources used, and the benefits are thought of as the value placed upon 
the outcome. However, there have been difficulties in converting the health benefits into 
a monetary value, for example in increased survival, so it is not commonly used in health 
technology assessments, (Pinto-Prades et al., 2009).   
 
CEA is another type of a full economic evaluation which looks at costs in monetary terms 
but compares this to a non-monetary objective, such as the number of life years saved or 
alternative intervention programmes. Once the alternatives have been compared, then 
decisions can start to be made about whether the alternatives are cost effective or not. 
This is typically done by calculating the incremental cost effectiveness ratio (ICER) 
which is calculated by the incremental change in costs divided by the incremental change 
in effectiveness.  
 
𝐼𝐶𝐸𝑅 =  
(𝐶2 −  𝐶1)
(𝐸2 −  𝐸1)
 
C are the costs of the interventions; E are the effects of the interventions 
 
The idea behind the ICER is to choose interventions which have the lowest ICER in order 
to get value for money. However, there is often uncertainty around the value of the ICER 
on a patient or parameter level and so statistical analysis surrounding the ICER is often 
performed (O'Brien and Briggs, 2002). The ICER can be graphically represented on a 




































In addition to calculating the ICER, some studies also calculate the Net Monetary Benefit 
(NMB), which is a re-arrangement of the ICER formula providing a simplified ranking 
process from most cost effective to least cost effective at a given threshold.  
 
𝑁𝑀𝐵 = (𝜆 × ∆𝐸) −  ∆𝐶  
λ is the WTP threshold; ∆𝐸 is the incremental effectiveness; ∆𝐶 is the incremental costs 
 
The NMB has an advantage over the ICER, as it is able to quantify the sampling 
uncertainty that arises from the ICER and bootstrapping, and display this as a function of 
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Figure 9: The Cost-Effectiveness Plane showing four quadrants where an ICER 
could be located. 




Finally, CUA is a type of CEA that takes into account the health benefits of the patients 
by analysing their utility, which can be understood as a person’s preference in relation to 
their health outcomes. The utilities are scored between 0 (death state) and 1 (full health 
state) and can be obtained in various ways as discussed earlier in section 1.7. For this 
analysis the costs are often compared with QALYs, although other comparisons could be 
the disability adjusted life year (DALY) or the healthy years equivalents (HYEs). The 
willingness to pay (WTP) threshold of acceptability of an intervention ranges between 
£20,000 and £30,000 per QALY in the UK according to NICE (McCabe et al., 2008). If 
the ICER falls between this range, then the intervention is deemed to be cost-effective, 
however sensitivity analyses are also usually taken into account to address the uncertainty 
issues before a decision is made.   
 
1.9  The importance of my study  
The extensive review of the literature shows how significant the condition of asthma is, 
and indicates that this is a condition that requires addressing in research for both medical 
and economic reasons. Having an asthma attack can be triggered by many factors, and 
even with knowledge of these triggers, individuals can become subject to asthma attacks 
beyond their control causing A&E attendance or hospital admission. With asthma being 
costly to society, it is important to focus on ways by which this can be reduced, as 
healthcare resources are scarce and consideration needs to be given to the efficiency, 
effectiveness and efficacy of interventions (e.g. new treatments and therapies). 
  
One of the main drivers of this PhD research, stemmed from an earlier study called 
ARRISA (Smith et al., 2012). The current literature lacks high quality primary care 
research in non-pharmacological asthma interventions, and shows that people with severe 
and poorly controlled asthma were often omitted from studies due to their complexity in 
other clinical and psychosocial characteristics (Yoon et al., 1991, Smith et al., 2007). This 
lead to the development of the ARRISA study, which involved the design of an asthma 
risk register intervention, which was used on computer systems in primary care practices, 
to flag up patients who were categorised as at-risk (Smith et al., 2012). This cluster trial, 
only collected routine data, (e.g. primary care based clinical data, medications, and 
secondary care), and so permission was not granted from the patients to ask them to 
complete quality of life questionnaires, such as the EQ-5D. They also defined moderate 
to severe exacerbations as those resulting in out of hours contact, a course of oral 




prednisolone, accident and emergency (A& E) attendance, hospitalization and death. A 
later study, which is currently in process of recruitment, is an expansion of the ARRISA 
study using more study sites in the UK, (ARRISA-UK) (NETSCC, 2015). The latter study 
uses a term ‘crisis events’, which is defined as people who have A&E attendances, 
hospitalizations and deaths. Therefore, due to the emphasis on poor non-pharmacological 
research and the focus on at-risk asthma patients from these studies above, it was clear 
that further work was required to strengthen these areas.  
 
As discussed earlier in the previous sections, CUA is a type of economic evaluation that 
analyses costs and health benefits measured in QALYs. From the incorporation of 
QALYs in their analysis, this gives the advantage of being able to compare interventions 
with others in unrelated disease areas. That said, the difficulty lies within the methods 
used previously, as they may not capture the true quality of life associated with asthma.  
 
For example, quality of life are captured at specific time points (e.g. baseline, 3 months, 
6 months), and when estimating the QALYs, linear interpolation is assumed (see Figure 
7). Howbeit, with an asthma attack being such a critical event, the recovery process can 
be quite erratic over the course of the event. Therefore, the assumption of a steady 
improvement from baseline to 3 months for example, would be suggesting inaccuracy in 
the estimation, such that an asthma attack could be missed, and the recovery of the attack 
in between. Getting the timing right when estimating quality of life in people with asthma 
is imperative (Schilling et al., 2016, Luyten et al., 2011), and it is important to measure 
this at the earliest opportunity, so as to minimize bias in the estimation (Dritsaki et al., 
2017). Consequently, within this study an alternative approach was taken to provide an 
estimation in capturing the loss in quality of life associated with an asthma-related crisis 
event (A&E attendance or hospital admission). Participants were monitored over an 8 
week period.   
 
By estimating this loss in quality of life more accurately over 8 weeks, this will enable 
future studies to count the number of A&E attendances and hospital admissions, and in 
turn estimate the total loss in quality of life. For example, the ARRISA study (Smith et 
al., 2012) only used routine data, and so this will be useful to capture the loss in quality 
of life associated with a crisis event. Outside of this study, it will then be possible to 
estimate the benefits of interventions that seek to reduce asthma-related A&E attendances 




or hospital admissions, and compare them to the benefits of other health care 
interventions. Thereby, this will enable interventions that are able to achieve the greatest 
benefit for a given cost (i.e. constitute best value for money) to be identified.    
 
 
1.10 Conclusion  
It is clear that asthma is a concerning lung condition that needs to be clinically and 
economically improved across the world. The prevalence of asthma appears to be 
continually increasing, with parts of Europe, Australia and Brazil having the highest 
impacts of the asthma burden.  Having frequent asthma symptoms that can progressively 
worsen, when exposed to a certain trigger can cause constriction of the airways, a build-
up of sticky mucus and reduced air flow leading to an asthma attack which could be a 
life-threatening emergency. Different treatments, time and patience is required to attempt 
to control and even eradicate these symptoms completely in order to prevent the 
occurrence of asthma attacks.  
 
Finding a way to control and manage these asthma symptoms in patients is important. If 
management of asthma is improved, this will hopefully lead to fewer asthma symptoms 
being presented, fewer or no asthma attacks, and increased quality of life. However, 
resources are scarce and there are different ways to measure and value quality of life, with 
consideration of whose preferences to take into account and which perspective to address 
in economic evaluations. To date, there is not a definite direction of which approach to 
take, but there are valid reasons for both preferences and perspectives. 
 
Economic evaluations, in particular CUA, are a useful method when comparing 
interventions against the same or different disease populations, by taking into account the 
costs and quality of life. These analyses help to infer how resources should be distributed 
in the healthcare service and help policy makers decide what the best value is for money.   
 
In line with this, the next chapter will systematically and critically review economic 
evaluation studies, which are investigating non-pharmacological asthma interventions. 
Systematic reviews are fundamental in understanding information across a large number 
of studies, where they help to build research questions and provide evidence for 




rationales. Currently, a lot of work has been done on pharmacological interventions, 
however, less work has explored non-pharmacological interventions, as the ARRISA 
study stated (Smith et al., 2012). Therefore, the next chapter (Chapter 2) will explore 
non-pharmacological intervention studies in more detail, and also discuss the 
methodologies used to estimate costs and benefits in their studies.  
 
In Chapter 3, the methodology of a cohort study design will be detailed which 
investigates estimating the loss in quality of life associated with an asthma-related crisis 
event (A&E attendance and hospital admission). The two chapters that follow this, 
(Chapter 4 and Chapter 5), will provide the results of this cohort study using various 
statistical analyses, of which include descriptive statistics, multi-level modelling and 
psychometric techniques. The final chapter, (Chapter 6), will bring the whole thesis 
together in a discussion, which will provide a summary of findings and reflection of the 
works by highlighting the contribution to the literature, strengths and limitations and 
suggestions for future research.     





ECONOMIC EVALUATION EVIDENCE FOR NON-
PHARMACOLOGICAL ASTHMA MANAGEMENT 
INTERVENTIONS: SYSTEMATIC REVIEW 
 
“Since the effects of choosing one course of action over another will not 
only have effects on health, but also on health care resources as well as 
other effects outside of health care, informing health care decisions 
requires consideration of costs and benefits.” (Drummond et al., 2015) 
 
Preface 
As highlighted in the previous chapter, the prevalence of asthma is continuingly 
increasing. Everyday activities can be challenging for some people who have asthma, and 
in extreme circumstances, their asthma symptoms can worsen and lead to an attack, 
potentially leading to either an A&E attendance or hospital admission. Managing asthma 
is important to help reduce these adverse events and improve quality of life. A method of 
analysing asthma and investigating ways to improve outcomes is through economic 
evaluation, particularly the CUA for incorporation of QALYs in the analysis. Different 
interventions and conditions can be compared by analysing the costs and health outcomes. 
This can help to identify which service constitutes the best value for money. Indicating 
what is best value for money, is important given our scarce resources in healthcare. One 
of the ways to inform this comparison is through systematic reviews, as they provide an 
in depth, structured review which systematically addresses a research question by 
reviewing current evidence. This chapter will review non-pharmacological asthma studies 
systematically, (as these have been less explored compared to pharmacological 
interventions, and are also more relevant in the context of the ARRISA studies (Smith et 
al., 2012, NETSCC, 2015)), and will provide: 
1. An update of an earlier systematic review by exploring which additional studies 
are cost effective. 
2. An extension by critically exploring in detail the methodologies used to estimate 
the costs and benefits in all studies.   







Initially, before the systematic review was conducted, a targeted scoping search of 
reviews was done to gather evidence of what was previously found in this area of asthma 
and economics. The rationale for doing this search was to use the conclusions found from 
reviewing the reviews, to help develop the aims and objectives of the more structured 
systematic literature review which will be discussed further in this chapter. 
 
To highlight some of the evidence found in the literature, an initial search was conducted 
using Medline (Ovid), Embase (Ovid), and National Health Services Economic 
Evaluation Database (NHS EED). These databases are recommended by NICE, and 
previous studies have also highlighted that these databases will identify the majority of 
economic evaluation published literature (Sassi et al., 2002, Alton et al., 2006, Royle and 
Waugh, 2003). The key search terms were informed by Yong and Shafie (2014) and 
WHO (2015b), with restrictions of these appearing only in the titles and abstracts. The 
terms were (Asthma OR “Asthma-related” OR Exacerbation OR wheezing OR “shortness 
of breath”) AND (Pharmacoeconomics OR Econ* OR “Economic evaluation” OR Cost* 
OR “Cost benefit” OR “Cost utility” OR “Cost effectiveness”). There were no restrictions 
placed on the period of years for inclusion, therefore all articles were searched from 1946 
to Present for Medline, and from 1974 to 15 January 2015 for Embase. After conducting 
this search and screening the articles, 8 were identified as reviews and categorized into 
four different sub-groups; analytical standard and guideline advice reviews, all 
intervention reviews, pharmacological reviews and management reviews. These are now 
discussed below. 
 
2.1.1 Analytical standard & Guideline Advice Reviews 
Two studies were identified within this group (Persson and Ghatnekar, 2003, Feenstra et 
al., 2002). Many cost effectiveness studies have been carried out within the area of 
asthma, and guidelines are already in place for cost effectiveness studies (Drummond and 
Jefferson, 1996). However, Persson and Ghatnekar (2003) noticed that limited studies 
have focused on analysing and evaluating the analytical standards and adherence to such 
standards in cost effectiveness asthma treatment studies.  





Therefore, their aim was to focus on evaluating the analytical standards, (as referred to in 
guidelines and textbooks) in cost effectiveness asthma studies, which focused on inhaled 
corticosteroids (ICS) up until the year 2000. They conducted a search using Medline and 
Embase databases and assessed their included studies for adherence to standards based 
on study design, perspective and costs, outcome measures, marginal cost analysis 
(additional cost for one extra unit gained) and sensitivity analysis coupled with validity 
and discussion. From their included 18 studies, they found analytical standards had 
continued to improve over time. However, Persson and Ghatnekar (2003) noted room for 
improvement in the studies in relation to the costs and perspectives in individual studies, 
and also the study design and methodologies. They concluded that further research needs 
to comply with these principles in order to improve the generalizability of health 
economic studies.  
 
On the other hand, Feenstra et al. (2002) conducted a systematic search for economic 
literature that was compared against four guidelines (The Netherlands: Guidelines for 
general practitioners & Paediatric pulmonologists, the American guidelines: from the 
National Institutes of Health, and the British Thoracic Society) used to analyse long-term 
care. Long-term care was considered to be one of the three important aspects of 
interventions for asthma patients, and the comparison was done to possibly add additional 
advice in the guidelines and enhance cost effectiveness research. The cost effectiveness 
evidence provided well matched advice for the inhaled steroids, despite no mention of 
this in the guidelines. However, there was limited evidence for comparing inhaled steroids 
to cromolyn, and also comparing different short-acting bronchodilators. Nevertheless, 
self-management programs and inpatient rehabilitation was seen to be cost effective in 
severe asthmatic children, but the result for mild to moderate asthmatics remained 
inconclusive.  
 
Even though Feenstra et al. (2002) provided more of a broader search compared to 
Persson and Ghatnekar (2003) in terms of the number of databases used, Feenstra et al. 
(2002) still limited the studies to those mostly from high income countries, (including 
studies from the USA, UK, and the Netherlands). This may have limited the demographic 
and socioeconomic generalizability of the study.  
 




2.1.2 All Interventions 
The quality of health economic asthma intervention studies (of all types) were explored 
between the years 2002 and 2007 (Campbell et al., 2008). From inputting search terms 
into Medline and NHSEED, there were 40 papers that were included in this analysis. The 
Quality of Health Economic Studies (QHES) tool was used to quality assess the studies 
with the majority of the studies (65%) scoring between 50 and 74 out of 100, where a 
score of 100 would be the best quality score. It was concluded that the studies provided 
strong economic evaluation evidence but some lacked an appropriate time horizon that 
was deemed long enough for the chronic state of the condition. In comparison, another 
study addressing the clinical, economic and humanistic characteristics of asthma reported 
that clinical studies showed high quality scores for study design, setting, participants, and 
statistical methods (Ismaila et al., 2013). However, there was insufficient evidence 
documented for any sources of bias, handling of missing data, loss to follow up and the 
way sensitivity analyses were performed.  
 
The issue of time horizon was also considered by Feenstra et al. (2002), who believed 
that a follow up time of less than 3 months was unacceptable, and studies were excluded 
if they fell into this category. Persson and Ghatnekar (2003), Campbell et al. (2008) and 
Yong and Shafie (2014) also noted the importance of the follow up time and mentioned 
that this should be long enough to assess effectiveness, but no numerical length was 
provided. Additionally, three studies (Persson and Ghatnekar, 2003, Feenstra et al., 2002, 
Ismaila et al., 2013) discussed  the reporting of costs in their reviewed studies. Indeed it 
was highlighted that the costs estimated in the studies and their perspectives chosen, were 
not completely related to each other (Ismaila et al., 2013). This lead to inconclusive 
findings amongst the rates of resource utilization, asthma-related costs and the difference 
in quality of life for asthma individuals (Ismaila et al., 2013). In order for cost 
effectiveness to be addressed, it is essential for direct costs to be estimated (Feenstra et 
al., 2002). More importantly, Persson and Ghatnekar (2003) and Willems et al. (2006), 
state that a societal perspective is more comprehensive as all costs and health effects are 
taken into account regardless of who is the payer of costs or receiver of effects.  
 




2.1.3 Pharmacological Review 
There was only one review study identified which had a pharmacological focus only 
(Norman et al., 2013). The focus was on Omalizumab and its clinical and cost 
effectiveness in asthma patients aged between 6 and 11 years old. From comparison of 
papers within this area, it was concluded that the drug did improve patients’ health 
outcomes, however it caused a significant implication on cost and was above the threshold 
deemed acceptable by NICE.  
 
2.1.4 Non-Pharmacological Reviews 
In the last category, the three studies related to management, with Willems et al. (2006) 
addressing the issue of self-management interventions in asthma individuals. The second, 
investigating the different inhaler devices in children aged between 5 and 15 year olds 
(Peters et al., 2002), and the third aiming to investigate enhanced management in 
asthmatics (Yong and Shafie, 2014).  
 
From the 21 included studies in the review of Willems et al. (2006), the self-management 
intervention was a peak flow monitoring intervention which seemed to be cost effective. 
However, this conclusion was taken with caution due to the low methodological quality 
of the papers, and the included studies being limiting in their perspectives chosen. This 
therefore, didn’t provide a comprehensive cost analysis. In conjunction, Yong and Shafie 
(2014) also concluded that enhanced asthma management interventions were overall cost-
reducing, but there were some reservations about this due to studies not providing a total 
cost of the interventions. Like Campbell et al. (2008) the QHES checklist was used to 
quality assess the included studies, but Yong and Shafie (2014) used a modified version 
of the QHES checklist to account for the double barrelled questions within the checklist. 
It was reported that the QHES scores of the same studies included in the reviews of 
Campbell et al. (2008) and Yong and Shafie (2014) were mostly lower for Yong and 
Shafie (2014). Moreover, in line with Campbell et al. (2008), it was noticed that longer 
time horizons were required from the studies to capture the chronic condition of asthma 
more effectively.   
 




2.1.5 Importance of this systematic review 
The above reviews have provided an overview in relation to different asthma 
interventions. Much work has focused on pharmacological interventions on asthma, and 
fewer works have considered non-pharmacological interventions, as  highlighted in an 
earlier review (Yong and Shafie, 2014). It has been recognised that there needs to be 
clearer reporting of methods, outcome measures and all appropriate costs to improve 
generalizability and validity (Yong and Shafie, 2014, Feenstra et al., 2002). In recognition 
of these weaknesses, it seems appropriate to expand knowledge further in non-
pharmacological asthma studies and draw upon more of the methodologies used in such 
studies, as the above reviews discussed have been heavily focussed on clinical 
interventions and their level of cost effectiveness. Even though the areas covered are 
relevant aspects that are important when making healthcare decisions, the methodologies 
of the papers have been poorly discussed. In order to ensure healthcare decisions are made 
appropriately, it is essential to critically appraise the evidence upon which they are based.  
 
Due to the paucity of non-pharmacological research in asthma patients, an earlier ongoing 
cluster randomised control trial, the ARISSA-UK study (NETSCC, 2015), is exploring a 
non-pharmacological intervention in primary care (at-risk registers to stop asthma crisis). 
However, this study only plans to use routine data, and patient data reporting their quality 
of life is not planned. Therefore, there is an inability to conduct a CUA using QALYs 
from this study, (which is a method favoured by NICE to compare the costs and benefits 
of health interventions and enhance comparability amongst other studies). In light of this 
study and others, it is important to know what methods are used to estimate costs and 
benefits, in order to provide replicability in reporting and comparability across studies. 
Therefore, there is reason to explore these objectives further in a systematic review 
focused on non-pharmacological interventions, as it will further inform the methods used 
in the ARISSA-UK study (NETSCC, 2015), and provide knowledge on what PROMs 
have been used to measure quality of life in people with asthma. Gaining knowledge from 
this systematic review about the different PROMs used to measure quality of life in 
asthma, will also assist in the development of a prospective cohort study which will aim 
to estimate the utility loss associated with an asthma-related crisis event. The results from 
this prospective cohort study, will inform the ARISSA-UK study (NETSCC, 2015) by 
enabling the assignment of a QALY loss to each asthma-related A&E attendance or 
hospital admission (crisis event).   






Due to an earlier comprehensive review discussing enhanced asthma management 
interventions (Yong and Shafie, 2014), it seemed appropriate to update and extend this 
work to include a more critical review about the methodologies used to estimate costs and 
outcomes. The update will involve a continuation of their outcome measure of comparing 
the cost effectiveness of interventions from post 2012 until January 2016, and the 
extension will cover all relevant papers that meet the inclusion criteria from 1990 to 
January 2016 to explore the methods used. The protocol for this review was registered 
with PROSPERO International Prospective Register of Systematic Reviews with 
registration number: CRD42016032963. This study will also help to address the methods 




The objectives for this study involved an update and expansion of a previous review by 
Yong and Shafie (2014). 
 
The update investigated the cost effectiveness of enhanced asthma management 
interventions from 2012 to January 2016, to investigate which interventions were deemed 
to be cost effective.  
 
The expansion sought to detect the array of methods used in estimating and evaluating 
both costs and outcomes for economic analyses. This study is particularly interested in 
identifying the methods used in costing all of the NHS costs, including the study 
intervention costs. This is because the cost of developing and executing an intervention 
is part of the total costs of the intervention, and so the methods behind this are just as 
important.   
 
2.3 Methods 
2.3.1 Search strategy  
As the secondary objective for this review, was to update Yong and Shafie (2014), and 
the fact that this paper was comprehensive with good reasoning, it seemed appropriate to 




use the search terms presented. The databases that Yong and Shafie (2014) used were 
ScienceDirect, Wiley Online Library, EbscoHost, Embase (via OvidSP), Medline (via 
OvidSP) and Scopus. Even though there were a number of databases used here, there 
were still some relevant databases which appeared worthy of being searched. Therefore, 
to add to this list of databases, CINAHL (via EbscoHost), Cochrane (CENTRAL), NHS 
Economic Evaluation Database (NHS EED), ClinicalTrials.gov, ProQuest and Open Grey 
were also included in the search strategy. The latter three databases were included to 
identify any unpublished material. The search terms for the additional databases were 
adapted slightly from Yong and Shafie (2014).  
 
All of the search terms consisted of short words used to capture studies, which focused 
on asthma, non-pharmacological interventions, and economic evaluations.  
 
Table 1 shows the combinations of words used to identify relevant papers for this review. 
Asterisks and quotations were used for an inclusive search and to retrieve papers, which 
included the specific quoted phrases.  The databases were searched from 1990 until 
January 2016 to ensure the papers found were replicable and also widen the search using 
the additional databases. The start date of this search was the same start date used in the 
Yong and Shafie 2012 study, to ensure that any relevant papers meeting the research 
question were detected for this review.  
 
Table 1: List of databases searched systematically with their corresponding search 
terms. 
Databases Search terms 
Sciencedirect 
(asthma* OR (inflammatory OR airway) 
disease) AND ((asthma W/5 (pharmacy 
OR pharmacist)) AND (intervention OR 
manage*)) AND (“economic evaluation” 
OR “pharmacoeconomic” OR “cost 
effectiveness” OR “cost benefit” OR “cost 
utility” OR cost analysis OR (asthma W/5 
cost)) 




Databases Search terms 
Wiley Online Library 
(asthma* OR “asthma* manage”) AND 
(intervene* OR manage) AND 
(“economic evaluation” OR cost analysis 
OR “cost effectiveness” OR “cost benefit” 
OR “cost utility” OR asthma cost) 
EbscoHost (includes CINAHL) 
asthma* AND (asthma* N15 ((pharmacy 
OR pharmacist) OR (intervent* OR 
manage*))) AND (econom* OR cost 
analysis OR “cost effectiveness” OR “cost 
benefit” OR “cost utility” OR 
pharmacoeconom* OR “healthcare cost” 
OR asthma N10 cost) 
Embase & Medline (via Ovid SP) 
asthma*.ti OR “asthma* manage”.ti) 
AND (intervene* OR manage)) AND 
(“economic evaluation” OR cost analysis 
OR “cost effectiveness” OR “cost benefit” 
OR “cost utility” OR asthma cost) 
Scopus 
TITLE-ABS-KEY (asthma* OR 
respiratory) AND TITLE-ABS-KEY 
(asthma* pharmacy* manage* OR 
“pharmac* intervention” OR “asthma* 
manage*”) AND TITLE-ABS-KEY 
((asthma OR pharmac*) W/15 economics 
OR pharmacoeconomics OR “cost 
effectiveness” OR “cost benefit” OR “cost 
utility” OR cost analysis OR (economic 
evaluation) OR healthcare cost) 
Cochrane (CENTRAL) 
asthma* AND (interven* OR manage*) AND 
(pharmacoeconom* OR "economic 
evaluation" OR "cost effectiveness" OR "cost 
benefit" OR "cost utility") 
NHS EED 
asthma* AND (interven* OR manage*) AND 
(pharmacoeconom* OR "economic 




Databases Search terms 
evaluation" OR "cost effectiveness" OR "cost 
benefit" OR "cost utility") 
ClinicalTrials.gov 
(asthma* OR “asthma* manage”) AND 
(intervene* OR manage) AND (“economic 
evaluation” OR cost analysis OR “cost 
effectiveness” OR “cost benefit” OR “cost 
utility” OR asthma cost) 
ProQuest 
asthma* AND (asthma* N/15 ((pharmacy OR 
pharmacist) OR (interven* OR manage*))) 
AND ("economic evaluation" OR "cost 
effectiveness" OR "cost utility" OR "cost 
benefit" OR pharmacoeconom*) 
Open Grey 
asthma* AND (interven* OR manage*) AND 
(pharmacoeconom* OR "cost effectiveness" 
OR "cost benefit" OR "cost utility" OR 
"economic evaluation") 
 
2.3.2 Eligibility criteria 
The articles that were considered for inclusion in this review were those defined as an 
economic evaluation. For the purpose of this review, this could be a CEA, CUA, CBA or 
a cost consequences analysis (CCA). These types of economic evaluations were chosen, 
because the primary objective of this study was to identify the methods used to estimate 
both the costs and outcomes analysed. Therefore, the types of economic evaluations 
didn’t have to satisfy the definition of a full economic evaluation defined by Drummond 
et al. (2015) as ‘the comparative analysis of alternative courses of actions in terms of both 
their costs and consequences’. Other types of economic studies were excluded, as well as 
letters, editorials, magazines, conference abstracts and reviews.  
 
The population criteria for this review were people who had asthma of all severity types 
and all ages. There were no other restrictions on the population group; both genders, 
different socio-economic environments and different countries were included in the 
criteria. The intervention of focus for the papers reviewed were non-pharmacological 
asthma interventions. This included interventions which didn’t have a medication 




intervention; such as an asthma educational intervention, an environmental intervention 
or a self-management intervention. However, comparators could be pharmacological, 
non-pharmacological or usual care alternatives. Only studies written in English of full 
original research papers were included in this review. Table 2 shows the inclusion criteria 
for this systematic review. 
 
Table 2: Inclusion criteria for the included studies in the systematic review 
Category Inclusion Exclusion 
Study design 
Economic Evaluation:  
Cost-effectiveness analysis 















abstracts, and reviews. 
Language English only studies Non-English studies 
Population 
Asthma of all severity types 
Male and Female 
Any age 











Comparator Non-pharmacological N/A 








Usual care alternative 
 
2.3.3 Data extraction process 
Once the said databases were searched, all of the studies which appeared were transferred 
into EndNote Software manager to store as one collective. Any duplicates found within 
the EndNote programme were removed electronically. After this stage was completed, 
the titles and abstracts were ready to screen for inclusion. The title and abstract screening 
process was done independently by two reviewers (CJCB & AP or CJCB & RFSK). If 
from reading the title, it wasn’t obvious to include the study, then the abstract was read 
for further consideration. At this stage, three decisions were made; definitely include, 
definitely don’t include, or read the full text. One reviewer, (CJCB), then compared the 
two screening outcomes from each reviewer and discussed with the other reviewer if there 
were any discrepancies. Once discrepancies were discussed, a final decision was made on 
whether the article should be considered for inclusion at this stage. After this stage had 
been completed, the full texts were read and a final decision was made on the included 
studies.  
 
The included studies were then organised in the data extraction table ready for the data to 
be extracted under the headings of first author, year, country of population, study design, 
patient population, intervention and control characteristics, study perspective, time 
horizon, discount rate, price year, resource use, methods of estimating & valuing 
resources and intervention cost component, cost results, outcome measures, method of 
estimating outcomes, outcome results, response rates, ICER, statistical analysis, 
sensitivity analysis (see Table 3). The data was extracted by two independent reviewers, 
and then compared against each other to see if there were any areas of discrepancies. The 








Table 3: Pre-designed data extraction table 
Study details First author; Publication year; Country of 
population 
Study design  
Patient population 
Study perspective; time horizon; discount 
rate 
Currency & price year 
Intervention & Comparator details Description of Intervention & Comparator 
 
Resources & outcomes Range of resource use measured 
Types of outcomes measured 
Methods Method of estimating & valuing resource 
use 
Method of estimating intervention cost 
component 
Methods of estimating & valuing 
outcomes  
Results No.; mean age; gender (%); ethnicity (%) 




ICER or Net benefit/Net present value  
Statistical analysis; sensitivity analysis 
 
2.3.4 Quality assessment process 
The quality assessment process was the same as the data extraction process i.e. each paper 
was individually quality assessed by two independent reviewers and checked by one 
reviewer for any discrepancies. Again, discrepancies were resolved through discussion to 
arrive at a final decision. There were two quality of life checklists that were used in this 
review. The main one was the QHES checklist that was adapted by Yong and Shafie 
(2014), but originally designed by Chiou et al. (2003). Due to part of this review featuring 
as an update, it seemed reasonable to include the adapted QHES checklist for consistency. 
This adapted version was easy to use and assign quality values to the individual papers 
due to Yong and Shafie (2014) including separate weighted values to multiple criteria 
(see Appendix 1). By assigning scores to individual components of the QHES checklist, 
an overall score ranging from 0 to 100 was estimated for each study, with less than 25 




indicating extremely poor quality, 25-49 indicating poor quality, 50-74 indicating fair 
quality and greater than 74 indicating high quality.  
 
In addition to this tool, and for model based studies that were included in this review, the 
Philips et al. (2004) criteria was also used to provide a more in-depth quality assessment 
for this category of study designs.  
 
2.4 Results 
From the extensive search strategy, 2118 studies were found from the databases used. 
After electronically and manually removing 287 duplicates from this total, we were left 
with 1831 studies, of which the titles and abstracts were screened. At this stage, the 
excluded records from this figure were due to the wrong population (12.5%), other types 
of economic studies (65.0%), not being original research (2.0%), pharmacological 
interventions (10.8%), reviews, guidelines or workshops (6.6%), animal research (0.06%) 
and other (3.0%). Exclusion of these studies, allowed 116 studies to be assessed by full 
text which lead to a further 52 studies being excluded. These were excluded due to other 
types of economic studies (65.4%), not the intervention (21.2%), review (1.9%), and other 
(11.5%). This left 64 studies included in the analysis (Figure 10). 
 
The 64 included studies, included all of the 49 papers that Yong and Shafie (2014) 
identified between the years 1990 and 2012, and 15 additional papers. However, out of 
the 15 additional papers that were identified from searching the database from 1990 until 
January 2016, 5 papers (Castro et al., 2003, Flores et al., 2009, Higgins et al., 1998, 
Karnick et al., 2007, Atherly et al., 2009) were found that could have been identified from 
the period of 1990 to 2012 that Yong and Shafie (2014) screened. These papers could 
have been additionally found due to using a wider search strategy.   
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2.4.1 Characteristics of the 15 additional papers 
Table 4 describes the characteristics of the included studies found in addition to Yong 
and Shafie (2014).  
 
Overall, from the fifteen additional papers found, there were five CEA studies (Atherly 
et al., 2009, Flores et al., 2009, Lara et al., 2013, Mogasale and Vos, 2013, Ryan et al., 
2012), one CUA (Willems et al., 2007), four CBA studies (Bhaumik et al., 2013, Fabian 
et al., 2014, Karnick et al., 2007, Tai and Bame, 2011) and five CCA studies (Higgins et 
al., 1998, Castro et al., 2003, McCowan et al., 1997, Turcotte et al., 2014, Smith et al., 
2012). Of these studies, there were seven randomised control trials (Castro et al., 2003, 
Flores et al., 2009, Karnick et al., 2007, McCowan et al., 1997, Ryan et al., 2012, Smith 
et al., 2012, Willems et al., 2007), three before and after studies (Higgins et al., 1998, 
Lara et al., 2013, Turcotte et al., 2014), two model-based studies (Fabian et al., 2014, 
Mogasale and Vos, 2013), two cohort studies (Bhaumik et al., 2013, Tai and Bame, 2011) 
and one quasi experimental study (Atherly et al., 2009).  
 
The majority of these studies were based in the United States (Atherly et al., 2009, 
Bhaumik et al., 2013, Castro et al., 2003, Fabian et al., 2014, Flores et al., 2009, Higgins 
et al., 1998, Karnick et al., 2007, Tai and Bame, 2011, Turcotte et al., 2014), second to 
that European (McCowan et al., 1997, Ryan et al., 2012, Smith et al., 2012, Willems et 
al., 2007), one Caribbean (Lara et al., 2013) and one Australian (Mogasale and Vos, 
2013).  
 
The population groups chosen were mostly children focused (Atherly et al., 2009, 
Bhaumik et al., 2013, Fabian et al., 2014, Flores et al., 2009, Higgins et al., 1998, Karnick 
et al., 2007, Lara et al., 2013, McCowan et al., 1997, Tai and Bame, 2011, Turcotte et al., 
2014) with one adult only study (Castro et al., 2003), and combination of the two 
(Mogasale and Vos, 2013, Ryan et al., 2012, Smith et al., 2012, Willems et al., 2007). 
Only seven studies (Bhaumik et al., 2013, Castro et al., 2003, Higgins et al., 1998, 
Karnick et al., 2007, Lara et al., 2013, Ryan et al., 2012, Turcotte et al., 2014) stated the 
ethnic background of the populations chosen, with five of those representing a mixed 
ethnic population (Bhaumik et al., 2013, Castro et al., 2003, Higgins et al., 1998, Karnick 
et al., 2007, Turcotte et al., 2014).  




The interventions compared in these papers were mainly educational based provided by 
school, health professionals, or environmental assessors (Atherly et al., 2009, Bhaumik 
et al., 2013, Castro et al., 2003, Flores et al., 2009, Higgins et al., 1998, Karnick et al., 
2007, Lara et al., 2013, Turcotte et al., 2014, Willems et al., 2007); asthma management 
based using applications and/ or at-risk registers (McCowan et al., 1997, Mogasale and 
Vos, 2013, Ryan et al., 2012, Smith et al., 2012, Tai and Bame, 2011) and appliances 
based (Fabian et al., 2014).  
 
The study perspectives chosen were varied, including societal (Atherly et al., 2009, 
Bhaumik et al., 2013, Tai and Bame, 2011, Willems et al., 2007), governmental (Fabian 
et al., 2014), payer (Karnick et al., 2007), and healthcare (Mogasale and Vos, 2013, Ryan 
et al., 2012, Smith et al., 2012, Willems et al., 2007), though almost half did not state 
which perspective was taken (Castro et al., 2003, Flores et al., 2009, Higgins et al., 1998, 
Lara et al., 2013, McCowan et al., 1997, Turcotte et al., 2014). The time horizon of these 
studies ranged from 3 months (Atherly et al., 2009) to 10 years, with the longer horizon 
being a model-based study (Fabian et al., 2014). Two studies had a time horizon of 6 
months (Castro et al., 2003, Ryan et al., 2012), about half of the studies had a time horizon 
of 1 year (Flores et al., 2009, Higgins et al., 1998, Lara et al., 2013, Mogasale and Vos, 
2013, Smith et al., 2012, Turcotte et al., 2014, Willems et al., 2007), and the other few 
ranged between just under 2 years to 4 years (Karnick et al., 2007, Bhaumik et al., 2013, 
McCowan et al., 1997).  
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Abbreviations: ANCOVA = Analysis of Covariance; ANOVA = Analysis of Variance; AQLQ = Asthma Quality of Life Questionnaire; AUS = Australian; CBA = Cost Benefit Analysis; 
CCA = Cost Consequences Analysis; CEA = Cost Effectiveness Analysis; Com. = Comparator; CUA = Cost Utility Analysis; ED = Emergency Department; GBP = Great British 
Pound; GINA = Global Initiative for Asthma; GP = General Practitioner; HEPA = High-Efficiency Particulate Air; ICCs = Intra-cluster correlation coefficient; ICER = Incremental 
Cost Effectiveness Ratio; Int. = Intervention; No. = Number; QALY = Quality Adjusted Life Year; RCT = Randomised Control Trial; US = United States.  
 
 




2.4.2 Cost effectiveness of 15 additional papers 
Two thirds of the studies (10 studies) were a mixture of CEA, CUA or CBA studies, with 
the remaining third (5 studies) being CCA studies. Out of the five CEA studies, two 
studies found the intervention evaluated to be dominant (the intervention was less costly 
and more effective) compared to the comparator (Flores et al., 2009, Lara et al., 2013), 
two studies found the intervention to be cost-effective (the Incremental Cost 
Effectiveness Ratio (ICER) was lower than the stated willingness to pay threshold) 
(Atherly et al., 2009, Mogasale and Vos, 2013) and one didn’t report their ICER (Ryan 
et al., 2012).  
 
The two dominant studies had the same time horizons of 1 year, but differed in their 
country of population with one based in the United States (Flores et al., 2009) and the 
other based in the Caribbean (Lara et al., 2013). The two studies which stated that the 
interventions were cost effective (Atherly et al., 2009, Mogasale and Vos, 2013), both 
had varied time horizons (3 months and 1 year respectively), perspectives (societal and 
healthcare respectively), and thresholds. The stated threshold for Atherly et al. (2009) was 
AUS $50,000/DALY, whereas Mogasale and Vos (2013) didn’t state the willingness to 
pay threshold. The final CEA study that didn’t report an ICER stated that the intervention 
of a mobile phone self-monitoring system was not cost-effective (Ryan et al., 2012).  This 
was due to there being no significant differences between the intervention (mobile phone 
technology) and the control group (paper based monitoring) in the clinical outcomes and 
self-efficacy, and the healthcare costs being the same with an additional increase in the 
cost of the intervention components. 
 
The only CUA study (Willems et al., 2007) presented with a cost effective ICER had a 
time horizon of 1 year based on a societal and healthcare perspective separately. Only one 
CBA study (Bhaumik et al., 2013) out of three CBA studies produced positive net present 
values for the adjusted cost savings for year 1, 2, and 3, meaning that the benefits 
outweighed the costs and the intervention should be implemented. The five CCA studies 
did not present an ICER value, and so therefore were not compared for cost effectiveness. 
However, where available their cost and outcome results are displayed in Table 4.  




2.4.3 Quality assessment for the 15 additional papers 
The QHES checklist score (Yong and Shafie, 2014) varied across the 15 additional studies 
found, although the variation was only seen in the moderate and high quality categories.  
None of the studies scored within the poor quality range (25% to 49%) or the extremely 
poor quality range (< 25%). Eight studies scored within the range of fair quality (50% to 
74%) (McCowan et al., 1997, Fabian et al., 2014, Castro et al., 2003, Atherly et al., 2009, 
Turcotte et al., 2014, Lara et al., 2013, Higgins et al., 1998, Tai and Bame, 2011), with 
three being borderline for either poor quality; 50.5% and 51% respectively (McCowan et 
al., 1997, Tai and Bame, 2011) or high quality; 74% (Higgins et al., 1998). The remaining 
seven studies (Flores et al., 2009, Ryan et al., 2012, Mogasale and Vos, 2013, Karnick et 
al., 2007, Smith et al., 2012, Willems et al., 2007, Bhaumik et al., 2013) scored within 
the range of high quality (>74%). Figure 11 below shows the quality scores for the 15 
additional studies and Appendix IV shows the table of scores. 
 
*Full table of the QHES criteria and scoring system can be found in Appendix I 
 
Out of the included studies, there were two model based studies, where one was a discrete 
event simulation model simulating 1 million children and different health outcomes over 
Figure 11: Quality assessment for the 15 additional studies found post-2012 and in 
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a range of interventions (Fabian et al., 2014), and the other was a simple decision tree 
model with an intervention and comparator arm developed from trial data (Mogasale and 
Vos, 2013). As two studies were model-based, the Phillips checklist (Philips et al., 2004) 
was also used to provide a further in-depth review of the quality. Fabian et al. (2014) 
provided a sound quality for the majority of the assessment categories, however reference 
to cycle length, internal consistency or methodological, structural and heterogeneity 
uncertainty was not mentioned. Mogasale and Vos (2013) also provided a good quality 
assessment overall, but was lacking in areas considering cycle length and uncertainties. 
There were also some areas of the quality assessment where clarity could have been 
improved, usually around justifications.  
 
2.4.4 Methods used to estimate and value costs for all 64 papers 
Most of the papers were transparent about the range of resources that were estimated, 
however amongst these papers, not all reported the associated unit cost, and so the finer 
details of how these resources were estimated were missed (see Appendix II). Most 
papers included asthma-related hospitalizations (72%) and emergency department visits 
(70%) as resources that were measured, with physician visits (58%), other healthcare 
professional visits (28%), lost productivity (38%) and medication use (44%) being other 
resources most commonly identified. All resources, were appropriately chosen in line 
with the studies perspectives.  
 
The resource use data was often gathered using multiple methods, meaning that amongst 
the included papers, about two-thirds would estimate the resources by using more than 
one method. This often depended on what type of resource use was being estimated, 
where quite commonly those papers who wanted to capture hospital-related costs, 
patients’ quality of life and patients’ loss of productivity costs were obtained from 
different sources.  
 
With awareness of additional methods that was often used to estimate resources in each 
individual paper, data was mostly gathered from medical or computerised records (19%) 
for hospital related costs (Bratton et al., 2001, Bunting and Cranor, 2006, Castro et al., 
2003, Doan et al., 1996, Levenson et al., 1997, van der Meer et al., 2011, Runge et al., 
2006, Ryan et al., 2012, Shelledy et al., 2009, Shelledy et al., 2005, Smith et al., 2012, 
Steuten et al., 2007, Tschopp et al., 2005, Wood and Bolyard, 2011), wage rates by 




employers or case managers for loss in productivity (22%) (Bhaumik et al., 2013, Bolton 
et al., 1991, Bunting and Cranor, 2006, Flores et al., 2009, Gallefoss and Bakke, 2001, 
Ghosh et al., 1998, van der Meer et al., 2011, Mogasale and Vos, 2013, Polisena et al., 
2007, Runge et al., 2006, Steuten et al., 2007, Sullivan et al., 2005, Tai and Bame, 2011, 
Willems et al., 2007) and by patient or parent self-reported data (80%) for also gathering 
information about loss in productivity and quality of life (Bunting and Cranor, 2006, 
Castro et al., 2003, Drummond et al., 1994, Flores et al., 2009, Lindberg et al., 2002, van 
der Meer et al., 2011, Runge et al., 2006, Schermer et al., 2002, Shelledy et al., 2005, 
Steuten et al., 2007, Sullivan et al., 2002, Tschopp et al., 2002, Willems et al., 2007). 
Claims, billing or reimbursement data (25%) was often used for those countries who 
operate on healthcare insurance systems to also capture hospital-related costs (D'Souza et 
al., 2010, Greineder et al., 1999, Johnson et al., 2003, Rossiter et al., 2000, Suh et al., 
2000, Sullivan et al., 2005, Tinkelman and Wilson, 2004, Bolton et al., 1991, Willems et 
al., 2007, Wood and Bolyard, 2011, Chan and Wang, 2004, Fabian et al., 2014, Gallefoss 
and Bakke, 2001, Gordois et al., 2007, Kattan et al., 2005, Sullivan et al., 2002). Costing 
manuals for healthcare were mostly used to gather the unit costs of resources amongst the 
papers; such as the Dutch Drug Compendium, 2000 and the Dutch Manual for Costing in 
Economic Evaluations (Kamps et al., 2004) and the Pharmacy price listing (Higgins et 
al., 1998). 
 
For the papers who reported the methods used to estimate the resource use in more detail, 
(the extra detail including the unit costs and more information about what sources were 
used and calculations performed to estimate the resource use), the bottom-up approach 
(78%) was generally a more popular method used to estimate and value the resource-use 
costs including most of the intervention component costs, as opposed to the top-down 
approach (Anderson et al., 2004, Bolton et al., 1991, Bratton et al., 2001, Drummond et 
al., 1994, Franco et al., 2007, Higgins et al., 1998, Johnson et al., 2003, Karnick et al., 
2007, Lucas et al., 2001, Rossiter et al., 2000, Shelledy et al., 2009, Shelledy et al., 2005, 
Tai and Bame, 2011). The bottom-up approach is defined as the individual’s healthcare 
service use aggregated and the top-down approach is where the total healthcare service 
costs are divided by activity days (Chapko et al., 2009).  
 
The methods used to estimate the lost productivity also varied with the variations 
including the human capital approach; each hour lost at work per patient (Runge et al., 




2006, Sullivan et al., 2005, Schermer et al., 2002), the friction cost method; each hour 
lost at work until the employer replaces the patient who is unable to work (Steuten et al., 
2007, Willems et al., 2007), or using the caregivers income multiplied by the midpoint of 
the family’s income (Flores et al., 2009). Other studies, (Bunting and Cranor, 2006, 
Kamps et al., 2004) stated lost productivity as an outcome measure, but the approach 
taken to calculate this was not specified. On occasions, reference to where the values were 
taken from to conduct the calculation was also mentioned, e.g. Federal Statistics Office 
(Tschopp et al., 2002, Tschopp et al., 2005).  
 
The methods used to estimate the intervention components’ resource use was not always 
clearly stated, with all of the necessary individual components needed to form the 
successful running of the intervention and the costing behind this, not often reported. Staff 
costs, program materials and training were the most commonly reported intervention 
component costs, however, only some studies stated the unit costs of the components (see 
Appendix II). Only a select few papers took into account any associated travel costs 
involved with the intervention (Gallefoss and Bakke, 2001, Ghosh et al., 1998, Kattan et 
al., 2005, van der Meer et al., 2011, Rhee et al., 2012, Runge et al., 2006), and some 
studies reimbursed participants for taking part in their research (Atherly et al., 2009, 
Flores et al., 2009, Rhee et al., 2012, Turcotte et al., 2014, Wood and Bolyard, 2011). 
Likewise, with estimating the wider resource use, some papers were more detailed with 
the micro-costing of the intervention components (which were then summed) than others 
(see Appendix V for breakdown of micro-costing).  
 
2.4.5 Methods used to estimate and value outcomes (1990 to January 
2012) 
The outcomes measured across the 64 papers varied widely, and this is depicted in 
Appendix III, with multiple data collection methods sometimes used within each study. 
The hospital visits and emergency department visits were the most frequently stated 
resource use, and they were also the most common type of outcomes measured. Over two-
thirds (46 papers or 45 papers respectively) identified the emergency department visits or 
hospitalizations, followed by approximately one-third (26 papers and 29 papers 
respectively) investigating quality of life and physician (GP) visits. Other papers focused 
on reporting a wide range of other outcomes, of which some included intensive care 
admissions (Franco et al., 2007, Levenson et al., 1997, Shelledy et al., 2005, Turcotte et 




al., 2014), frequency of exacerbations and symptoms (Flores et al., 2009, McCowan et 
al., 1997, Ng et al., 2006, Ryan et al., 2012, Tagaya et al., 2005), asthma knowledge 
(Atherly et al., 2009, Chan and Wang, 2004, Lucas et al., 2001, Polisena et al., 2007), 
peak expiratory flow (Chan and Wang, 2004, Franco et al., 2007, Ghosh et al., 1998, 
Kauppinen et al., 1998, Kauppinen et al., 1999, Kauppinen et al., 2001, Lindberg et al., 
2002, McLean et al., 2003, Neri et al., 1996, Runge et al., 2006, Tagaya et al., 2005), 
forced expiratory volume (Bunting and Cranor, 2006, Franco et al., 2007, Gallefoss and 
Bakke, 2001, Kauppinen et al., 1998, Kauppinen et al., 1999, Kauppinen et al., 2001, 
Lindberg et al., 2002, Neri et al., 1996, Runge et al., 2006, Schermer et al., 2002, Shelledy 
et al., 2009, Willems et al., 2007), force vital capacity (Franco et al., 2007, Gallefoss and 
Bakke, 2001, Kauppinen et al., 1998, Kauppinen et al., 1999, Kauppinen et al., 2001, 
Lindberg et al., 2002, Neri et al., 1996, Runge et al., 2006, Shelledy et al., 2009, Willems 
et al., 2007) and medications (Franco et al., 2007, Karnick et al., 2007, Kattan et al., 2005, 
Polisena et al., 2007, Runge et al., 2006, Taitel et al., 1995, Tinkelman and Wilson, 2004, 
Watanabe et al., 1998).  
 
There was a wide selection of health questionnaires used to collect data in the studies, 
and this is shown in Figure 12. Most of the questionnaires used to capture quality of life 
and other outcome measures were patient self-report, where this data was often collected 
at face to face visits (Franco et al., 2007, Gallefoss and Bakke, 2001, Kamps et al., 2004, 
Kauppinen et al., 1998, Kauppinen et al., 1999, Kauppinen et al., 2001, Lara et al., 2013, 
Polisena et al., 2007, Ryan et al., 2012, Sullivan et al., 2005, Woods et al., 2012) or 
telephone interview sessions (Anderson et al., 2004, Bolton et al., 1991, Bratton et al., 
2001, Donald et al., 2008, Flores et al., 2009, Greineder et al., 1999, Karnick et al., 2007, 
Kattan et al., 2005, Lucas et al., 2001, Mogasale and Vos, 2013, Ng et al., 2006, Sullivan 
et al., 2002, Watanabe et al., 1998, Woods et al., 2012). Other options of completing 
questionnaire data was by parent-reported questionnaires (Lara et al., 2013, Lindberg et 
al., 2002, Rhee et al., 2012, Woods et al., 2012), caregivers’ questionnaires (Sullivan et 
al., 2005) or case managers self-reported questionnaires (Bhaumik et al., 2013, Xu et al., 
2010). In addition, some of the questionnaires were posted to the participant (Bratton et 
al., 2001, Ryan et al., 2012). Within the different types of health questionnaires, some 
included generic questionnaires (such as; the EuroQol-5 Dimensions 3L (EQ-5D 3L) 
(Lindberg et al., 2002, van der Meer et al., 2011, Steuten et al., 2007, Willems et al., 
2007), Short Form 36 Questionnaire (SF-36) (Lucas et al., 2001, Shelledy et al., 2009), 




Short Form 6 Dimensions (SF-6D) (Willems et al., 2007) and 15 Dimensions (15D) 
(Kauppinen et al., 1998, Kauppinen et al., 1999, Kauppinen et al., 2001, McLean et al., 
2003)), and more disease- specific questionnaires (such as; the Asthma Quality of Life 
Questionnaire (AQLQ) (Castro et al., 2003, Chan and Wang, 2004, Franco et al., 2007, 
Schermer et al., 2002, Tschopp et al., 2005, Willems et al., 2007) and St. Georges 
Respiratory Questionnaire (SGRQ) (Gallefoss and Bakke, 2001, Kauppinen et al., 1998, 
Kauppinen et al., 1999, Kauppinen et al., 2001, Shelledy et al., 2009)), with the most 
common being the AQLQ, followed by the SGRQ and in joint third the EQ-5D and 15D. 
The studies which used the EQ-5D and SF-6D converted the scores into utility values and 
used these to estimate QALYs. Other studies which didn’t estimate QALYs used total 
and/or overall mean scores from the health questionnaires in their analysis.  
 
Patient diaries were also used in several of the studies to collect data (Chan and Wang, 
2004, Ghosh et al., 1998, Kamps et al., 2004, Lindberg et al., 2002, McLean et al., 2003, 
Schermer et al., 2002, Tagaya et al., 2005), as well as medical records (Anderson et al., 
2004, Doan et al., 1996, Drummond et al., 1994, Higgins et al., 1998, McCowan et al., 
1997, Neri et al., 1996, Runge et al., 2006, Ryan et al., 2012, Shelledy et al., 2005, Smith 
et al., 2012, Willems et al., 2007) and claims data (Bunting and Cranor, 2006, D'Souza et 
al., 2010, Greineder et al., 1999, Johnson et al., 2003, Rossiter et al., 2000, Suh et al., 
2000, Sullivan et al., 2002, Taitel et al., 1995) to gather information. A small number of 
studies additionally addressed airway responsiveness (Kauppinen et al., 1998, Kauppinen 
et al., 1999, Kauppinen et al., 2001) and the peak expiratory flow (Chan and Wang, 2004, 
Franco et al., 2007, Ghosh et al., 1998, Kauppinen et al., 1998, Kauppinen et al., 1999, 
Kauppinen et al., 2001, Lindberg et al., 2002, McLean et al., 2003, Neri et al., 1996) of 
patients. Therefore, histamine was used to estimate the former (airway responsiveness) 
and a peak expiratory flow meter was used to address the latter (peak expiratory flow) in 
these studies. There were other lung function tests that were used to estimate the forced 
expiratory volume and forced vital capacity and this was measured by spirometry. 
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Figure 12: Different health questionnaires used in the studies 





This systematic review updated and extended previous work that evaluated the cost 
effectiveness of non-pharmacological asthma interventions with databases searched from 
1990 until 2012 (Yong and Shafie, 2014). Due to Yong and Shafie (2014) having an 
applied focus on cost effectiveness, the methodologies used  in the estimation of costs 
and outcomes in the studies found was not described or critiqued in their systematic 
review. Therefore, this systematic review explored both cost effectiveness and methods 
used to estimate costs and outcomes from 1990 until January 2016.  
 
2.5.1 Main findings  
In general, the additional studies found were mostly educational and self-management 
based interventions with almost half having interventions that were deemed cost effective 
or dominant. These findings were in line with Yong and Shafie (2014). On the other hand, 
the quality of studies have since improved with the additional studies presenting with fair 
(50%-74%) to high (>74%) quality. Multiple methods were often used to gather resource 
use data with self-report being the most common, the bottom-up approach being the most 
common estimation method of resource use gathered, and health related questionnaires 
being a common outcome measure with AQLQ and EQ-5D being the most common 
HRQL questionnaires. 
 
2.5.2 Comparison with other studies  
Earlier systematic reviews of asthma interventions also highlighted the importance of the 
quality assessment in studies (Willems et al., 2006, Campbell et al., 2008, Ismaila et al., 
2013, Persson and Ghatnekar, 2003). One study in particular believed their peak flow 
monitoring intervention was cost effective, however, this could not be confirmed due to 
the low quality of the study (Willems et al., 2006). This review shows that the quality of 
studies has much improved since then, with nearly 50% of the studies found post 2012 
presenting with high quality. The improvement in the quality of studies observed, stems 
from an earlier systematic review, which explored the quality of health economic asthma 
intervention studies (Campbell et al., 2008). For a like for like comparison, the mean 
QHES score for policy interventions from Campbell et al. (2008), (equivalent to non-
pharmacological interventions in this present systematic review) was 61.4 for the 14 
studies that this applied to. In comparison, the mean QHES score for the studies in Yong 




and Shafie (2014) post-2008, was 75.6 (for the 8 studies that this applied to), and the 
mean QHES score for the additional studies identified in this review post-2012 was 75.1 
(for the 7 studies that this applied to). Therefore, it is evident that there is an improvement 
in quality scores from the studies identified in Campbell et al. (2008) (mean QHES score 
= 61.4 for studies before 2008) through to Yong and Shafie (2014) (mean QHES score = 
75.6 for studies 2008-2012) and this present review study (mean QHES score = 75.1 for 
studies 2012-2014). 
 
Although improvement has been noticed in the quality of the studies, some still have 
inadequate follow up which can reduce validity and generalizability (Woolard et al., 
2004). It was previously acknowledged that a short time horizon was inadequate for 
chronic conditions (Campbell et al., 2008), with a time horizon of 3 months or less 
considered to be unacceptable (Feenstra et al., 2002). The additional studies found in this 
review presented with one study having a time horizon of 3 months (Atherly et al., 2009), 
and others longer at between 6 months and 10 years.   
 
As different cost perspectives are used amongst the included studies in this review, it 
becomes difficult to compare the total costs associated with each intervention. An earlier 
review noted that the author’s definitions of direct medical costs, direct non-medical costs 
and indirect costs sometimes varied, where costs assigned to direct non-medical costs 
should have been assigned to indirect costs (Willems et al., 2006). Previous literature 
discusses that a societal perspective is important to synthesize the evidence and gain a 
proper understanding on peak flow monitoring interventions (Willems et al., 2006, 
Drummond et al., 2015, Jonsson, 2009). However, perspectives chosen can differ from 
country to country and the definitions of societal perspective can also vary.   
 
It was surprising that only about a quarter of papers included lost productivity as an 
outcome measure. Due to asthma being a chronic condition, it is thought that more papers 
would have discussed lost productivity, and the possible implications that this may have 
on presenteeism and/or absenteeism. However, if such items, such as lost productivity 
have not been collected, then routinely available data, (e.g. from medical notes) can be 
used as an alternative as a way of applying the findings (Smith et al., 2012). With patients 
who have asthma attacks where they are often not well enough to continue at work or 




with their usual activities, it is important to include nonmedical resource use and 
productivity costs in studies (Ramsey et al., 2015).  
 
In all of the included studies in this review, the intervention details were often reported, 
but the detail surrounding the costs of conducting the interventions with the associated 
unit costs were limited. Three studies provided comprehensive details about how they 
estimated the intervention costs, including the breakdown of the intervention components, 
their associated unit costs and the methods chosen to estimate such costs (Willems et al., 
2007, van der Meer et al., 2011, Rhee et al., 2012). The common approach between all 
three was a microcosting approach. Difficulties can sometimes occur with this approach 
when prices for certain resources are not always available from various data sources, 
leaving room for customization (Raftery, 2000).  
 
From the 26 studies which also incorporated quality of life as an outcome measure, there 
were over 20 different questionnaires that were used to measure this. Many of the 
questionnaires used to analyse quality of life were more specific to asthma, but there did 
not appear to be a preferred measure that was used across the studies. The EQ-5D-3L 
questionnaire (five dimensions with 3 levels: no problems, moderate problems, extreme 
problems) was used across a number of studies, but often used alone and not in 
conjunction with another quality of life questionnaire. As discussed by Yong and Shafie 
(2014), EQ-5D-3L might not be the best tool to use for quality of life in asthma, as it is 
not seen as sensitive enough to detect differences in HRQOL particularly in people with 
mild asthma. However, there have been recent developments of a new EQ-5D-5L 
questionnaire which includes the same five dimensions but with 5 levels: no problems, 
slight problems, moderate problems, severe problems or extreme problems (Herdman et 
al., 2011). The newly developed EQ-5D-5L tool may be more suitable as it was designed 
to be more sensitive and reduce ceiling effects. This has been confirmed in several studies 
which have shown increased reliability, sensitivity and validity (Janssen et al., 2013, 
Herdman et al., 2011). 
 
2.5.3 Strengths and limitations 
A comprehensive search was conducted using a variety of different databases in order to 
capture a breadth of studies for this review. Bias was reduced by including two reviewers 
in the screening, data extraction and quality assessment processes. The methods used to 




estimate both costs and outcomes of all studies found between 1990 and 2016 were 
critically assessed for non-pharmacological intervention studies. This time period shows 
that a vast array of studies have been encompassed, stretching back to when the earliest 
asthma guideline was introduced (Bousquet et al., 2007). The included studies help to 
understand how asthma interventions and methodologies chosen have evolved over the 
years, with discussions leading to recommendations for future practice. A limitation of 
this review is that only English language studies were included in this review with 
restrictions placed during the database search, and therefore it is not possible to 
acknowledge how many non-English studies have been excluded from this review. It is 
therefore apparent that due to this selection bias, additional studies may have been 
relevant for inclusion in this review.  
 
2.5.4 Directions for future research 
In light of the above, there are many areas for which focus is required when conducting 
an asthma study. The main recommendations are to use time horizons greater than 3 
months to ensure adequate follow up, to include all relevant costs and benefits that have 
been accounted for as asthma is a chronic condition, (particularly the high cost drivers 
(Ramsey et al., 2015)) and to conduct a micro-costing approach where possible. For 
economic evaluations where QALYs are estimated, the EQ-5D-5L can be used as a 
generic measure. However, even though this has been proven in earlier studies to show 
positive results in terms of increased sensitivity and validity compared to the EQ-5D-3L, 
due to it being a relatively new questionnaire, it may be advisable to use this in 
conjunction with a more established disease specific questionnaire. Due to the difficulties 
that arise in economic evaluations and to ensure the comparability across different 
countries and decision makers (Wilkinson et al., 2016), it may be useful to adhere to an 
international reference case (Bill and Melinda Gates Foundation, 2014, Wilkinson et al., 
2016), which is a useful guide from the planning stages of research through to reporting 
findings and completion. Future research should also ensure that the appropriate 
guidelines and checklists are adhered to, such as the TiDieR checklist (Hoffmann et al., 
2014), the CHEERS statement (Husereau et al., 2013), CONSORT statement (Schulz et 
al., 2010) and the COMET initiative (COMET initiative, 2011-2017) for ease of 
replicability of both the intervention and control groups by clinicians or researchers 
looking to implement or expand research ideas respectively. The TiDieR checklist 
provides a minimum number of items, which are recommended to use when describing 




an intervention. The CHEERS checklist (Husereau et al., 2013) provides detailed 
recommendations for reporting of health economic evaluations from what should be 
included in the title and abstract through to describing any conflicts of interest. The 
CONSORT statement, is similar to the CHEERS statement, except the reporting guideline 
recommendations are for reporting randomized trials. Finally, the COMET initiative 
allows people to identify the ‘core outcome sets’, which are an agreed set of standardized 
outcomes that represent the recommended minimum outcomes that should be measured 
and reported for a specific condition in clinical trials. For asthma studies, core outcomes 
for measuring quality of life have not yet been identified, but there are some existing 
instruments which are used as supplemental (standardized and used in relation to the aim 
of the study) (Wilson et al., 2012). All of the above checklists and statements, will in turn 
aid the comparability of studies.  
 
This systematic review also highlights that less than half of the papers focused on quality 
of life as an outcome measure, measured it prospectively at set time points over the time 
horizon period. Though the most common time horizon being 12 months, the follow ups 
varied from 2-4 times during the year. As asthma attacks can occur at sporadic intervals, 
quality of life could be measured more frequently in future research to capture the true 




In summary, the additional 15 studies included were of fair to high quality. In alliance 
with the previous review, most of the additional studies found had dominant or cost 
effective interventions which were educational or management based. The methods used 
to estimate costs and outcomes were varied, with the bottom-up approach being the most 
common approach. However, the reporting of unit cost values were lacking amongst some 
studies, with only a few studies providing detailed micro-costing methodologies for the 
intervention components. The most common method of collecting outcome results was 
through patient self-reported data, coupled with medical or claims records and telephone 
or face to face visits. For future studies, a thorough description of methods used in all 
components of the study is needed, including reporting of unit costs and a common quality 
of life measure to provide more comparability.  
 




As noted in this review, there were many quality of life tools identified in the included 
papers, with very few papers using the same quality of life tools. This shows that a general 
consensus of quality of life tools used across asthma studies is yet to be reached. It was 
also noted that the follow up time points to assess quality of life in these studies were 
quite varied occurring at fixed time points during the year. Due to these fixed time points, 
it is possible that the changes in quality of life associated with potential hospital 
admissions or A&E attendances due to an asthma attack could have been missed. 
Therefore, an attempt to address this issue was conducted in the following chapter where 
different quality of life instruments were used to estimate quality of life in patients with 
more acute asthma. Chapter 3 provides a thorough overview of a cohort observational 
study design developed to investigate the quality of life of acute asthmatics when 
presenting in hospital. Patients were followed up for a period of 8 weeks. Full details of 
the study design will be provided, including inclusion criteria, outcome measures and 
statistical analysis. The study was registered on ClinicalTrials.gov with the identification 
number as NCT02771678.   





ESTIMATING THE LOSS IN QUALITY OF LIFE 
ASSOCIATED WITH AN ASTHMA-RELATED CRISIS 
EVENT (ESQUARE): METHODOLOGY 
 
“What we observe is not nature itself, but nature exposed to our method of 
questioning.” 
(Werner Karl Heisenberg, German physicist) 
 
Preface 
The studies included in the synthesis of the systematic review, included a variety of 
different study designs. Some were randomised controlled trials, 
prospective/retrospective cohort studies, or model based studies. Part of the conclusions 
from the previous systematic review (CHAPTER 2) related to different quality of life 
measures and showed that it was necessary to agree on a single quality of life tool to 
enable comparability between studies. The importance of this is that when conducting 
economic evaluations and deciding on which health product is more cost effective, a 
common quality of life tool enables decisions to be made on a level playing field. It was 
also recommended that future research should adhere to guidelines and checklists that are 
appropriate for the study design, as this will also improve the comparability of studies 
and provide a good base for other clinicians and researchers to implement and expand on 
in the future. 
 
In light of the conclusions from the previous chapter, this chapter (CHAPTER 3) will 
investigate the quality of life in acute asthmatics by using different quality of life 
measures. The particular focus will be on acute asthmatics who present to A&E or are 
admitted to hospital following an asthma attack (referred to as an asthma-related crisis 
event). As previously discussed, asthma is a chronic condition, and occurrence of an 
attack can be sporadic. With previous literature measuring quality of life at set time points 
(e.g. baseline, 6 months and 12 months), and the assumption of linear interpolation, the 
probability of capturing the full changes in quality of life associated with an asthma attack 




is small. Therefore, investigating quality of life at a point where a chronic episode is 
occurring (Mason et al., 2014), may allow us to better understand the condition and 
provide an extended way of measuring quality of life in asthmatics. Better understanding 
of a chronic episode, will in turn lead to better estimations when conducting economic 
evaluations.  
 
The research study detailed in this chapter has an observational study design. There are 
three main types of observational studies, (cohort, cross-sectional and case-control), and 
a brief description of these are detailed below.  
 
Cohort study 
A prospective cohort study follows a patient population group over a period of time to 
establish whether an outcome has been reached (Euser et al., 2009, Song and Chung, 
2010). In this type of study, patients are recruited before the outcomes have been 
expressed in any one of the patients. The researchers then assess the variables that might 
have an influence on the outcome of interest.  
 
On the other hand, a retrospective cohort study already has a set of data that has been 
collected over a period of time (Euser et al., 2009, Song and Chung, 2010). Therefore the 
outcomes of interest are already identified from the dataset, but the data is examined 
historically to investigate how the patients developed the outcomes, as the initial baseline 
would still remain free from the outcome of interest.  
 
Cross-sectional study 




This type of study is usually less costly than a cohort study and quick to conduct due to a 
smaller sample size (Song and Chung, 2010). Cases are identified by having the outcome 
of interest (e.g. particular condition) and are matched with controls who are from the same 
population group but are free from the outcome of interest with a risk to exposure (bmj, 




2017). It is always conducted retrospectively as the outcome of interest is investigated 
historically (Song and Chung, 2010).  
 
In light of the main observational studies described above, a prospective cohort study 
approach was taken for this research study in order to compare participants’ quality of 
life over a fixed time period. This approach allows the outcome measures to be closely 
monitored making it easier to estimate the occurrence of an asthma-related crisis event 
and examine how quality of life corresponds with these outcome measures chosen. The 
downfall is that a large sample size is required in order to allow for the inevitable loss to 
follow up and to ensure enough participants are recruited into the study to provide valid 
conclusions. However, large sample sizes has cost implications.  
 
This chapter will highlight the aims and objectives of this prospective cohort study, the 
recruitment approach, the study methods, data management and analysis. The three main 
research questions that this study aims to address are: 
 
What is the loss in quality of life associated with an asthma-related crisis event?  
 
To what extent does this loss vary depending upon which patient reported outcome 
measures is used? 
 
What is the comparative performance of different generic and/or disease-specific 
questionnaire(s) when they are used to assess quality of life in acute asthmatics?  
 
The findings in relation to these questions are addressed in chapters 4 and 5 respectively, 
and the methods for both are outlined below. 
 
3.1  Aims and Objectives of study 
Some of the studies which were included in the systematic review (Chapter 2) measured 
quality of life using either generic or disease-specific questionnaires. The most commonly 
used generic questionnaires were the EQ-5D and the 15 Dimensions (15D) (Willems et 
al., 2007, van der Meer et al., 2011, Kauppinen et al., 1999, Kauppinen et al., 2001, 
Kauppinen et al., 1998, Steuten et al., 2007, Lindberg et al., 2002, Tagaya et al., 2005, 




McLean et al., 2003). Several studies found their mean changes in utility values held 
statistical significant difference (Lindberg et al., 2002, van der Meer et al., 2011, Willems 
et al., 2007). One study stated that their QALY estimates might have been more accurate 
if they had included more follow up time points (van der Meer et al., 2011).   
 
Often studies estimated quality of life at specific time points, such as baseline, 4 months, 
8 months and 12 months (Willems et al., 2007). Figure 13 shows an example of four 
utility values estimated from measuring quality of life at four different time points during 
one year, with the assumption of linear interpolation. However assuming linear 
interpolation in between these time points may not be adequate for estimating episodic 
quality of life as indicated in other studies (Mason et al., 2014, Franklin et al., 2017, 
Jakovljević et al., 2015, Fowler et al., 2014, Insinga et al., 2007, Barton et al., 2011). It is 
known that asthma attacks are unpredictable, and if quality of life is assessed between 
specific time points (e.g. baseline and 4 months), then the total QALY score could 
potentially be underestimated if the individual has had an attack in between these points, 
but has somewhat or wholly recovered by the point of the 4 month measurement, (see 
Figure 14 as an example). Equally, if the asthma attack occurs at the 4 month time point, 
but is short-lived, then the use of linear interpolation may mean that the total QALY score 
is underestimated. Either way there is a potential for the utility estimation, QALY and 
cost-effectiveness to be incorrect. Thus, it is possible that treatments could be 
recommended for provision when they are not in fact cost effective, or even maybe not 
recommended when they are in fact cost effective.  
 
Figure 13: Assumption of linear interpolation amongst four utility values at 4 time 

































A recent study addressed the importance of this when exploring the utility decrement 
associated with an asthma attack requiring hospitalization in children (Franklin et al., 
2017). However, the literature did not provide a suitable utility decrement for children, 
and so an alternative adult utility decrement was used instead (Lloyd et al., 2007, Luskin 
et al., 2014) . This study used three health related quality of life questionnaires to collect 
data at two time points (baseline and week 4), to estimate the mean change in quality of 
life (Lloyd et al., 2007). However the patients were recruited from outpatient clinics or 
primary care offices and not at time of the asthma attack, and so the asthma attack period 
was not closely monitored (Lloyd et al., 2007).  
 
Therefore, due to the gap in the evidence highlighted above, the aim of this study was to 
estimate the loss associated with an asthma-related crisis event more regularly over a 
shorter time period, and to compare the performance of several instruments in order to 
see if one would be preferred over another. For this study, the definition of an asthma-
related crisis event was patients who attended the A&E department or were admitted to 
hospital due to an asthma attack that they were unable to control themselves, and therefore 



























Figure 14: An asthma-related crisis event (utility value of 0.2) that could be missed 
at the two month time point 




 The idea was to estimate the loss in quality of life more accurately by using different 
quality of life methods through patient reported outcome measures (PROMs) and to 
assess the mean changes between more regular time points over a period of 8 weeks.  
 
Several research questions are pertinent in this prospective cohort study, which this thesis 
aims to address in chapters 4 and 5. The questions detailed below help to better understand 
the quality of life surrounding the asthma-related crisis event and possible implications 
of this on the patients’ productivity.  
 
The research questions of interest for this study are as follows: 
 
1) When did the asthma-related crisis event peak (e.g. on route to hospital, after 2 
hours in hospital)?  
2) What are the mean quality of life scores, utility values, and peak flow and 
symptom scores for patients reporting these at weekly, monthly and daily time points 
during the 8-week study?  
3) What is the loss in quality of life associated with an asthma-related crisis event?  
4) What is the relationship, (if any), between the demographic variables (e.g. age, 
gender, smoking status etc.) and utility estimates (EQ-5D-5L, AQL-5D and TTO)?   
5) What is the productivity loss & out of pocket cost associated with an asthma-
related crisis event?  
6) What is the comparative performance of different generic and/or disease-specific 
questionnaire(s) when they are used to assess quality of life in acute asthmatics?  
a. With respect to convergent validity:  
i. What is the correlation between the utility values for EQ-5D-5L, 
AQL-5D and TTO?  
b. With respect to discriminative validity:  
i. Are there any differences between the three PEF groups (<50% 
best / predicted PEF, 50-75% best / predicted PEF and >75% best / predicted PEF) 
and utility values?  
ii. Are there any differences between patients’ reporting asthma 
improvement (if any) at week 4 compared to baseline and the utility values?  
c. With respect to responsiveness:  




i. What is the sensitivity to change between patients’ reporting 
asthma improvement (if any) at week 4 compared to baseline and the utility 
values? 
 
Chapter 4 will discuss research questions one to five, and chapter 5 will discuss research 
question 6.  
 
3.2  Study participants & sample size 
Acute asthma participants were recruited from three hospital sites; Norfolk and Norwich 
University Hospital (NNUH) (primary site), Queen Elizabeth Hospital Birmingham 
(secondary site), and Aberdeen Royal Infirmary (tertiary site) from 11th May 2016 until 
the 31st May 2017. All three hospital sites had staggered commencement for screening 
and recruitment in 2016 due to different times of the approval process, where Norwich, 
Aberdeen and Birmingham commenced recruitment in May, August and November 
respectively. Participants were screened for eligibility and considered for inclusion into 
the study if they met the inclusion criteria displayed in Table 5. 
 
One of the quality of life questions that I asked participants to complete was called the 
time trade off (TTO). The sample size was chosen to reflect the same size as that used in 
previous literature when using the TTO valuation approach and other similar quality of 
life measures (Perez et al., 1997, Hamilton et al., 2015, Stiggelbout et al., 1995). 
Originally, the aim was to recruit 100 participants informed from the literature above. 
However, due to the large unforeseen number of participants who did not complete the 
study due to withdrawals or loss to follow up, the sample size was increased to recruit 
more than 100 participants, with 200 being the limit of participants recruited. The age 
range of the included sample (18 years and older) was chosen based on the knowledge 
that children might have difficulties with the TTO task. The TTO can be challenging for 
children to understand and provide realistic answers because they may lack the cognitive 
skills needed to evaluate the state of their health (Thorrington and Eames, 2015).   
 
A post-hoc power calculation was conducted to determine the power required to compare 
the mean difference between two different time points which is large enough to detect a 
difference. The effect size, sample size, and standard deviation difference were all taken 




into account to estimate the power for a one-sample t-test to account for the paired nature 
of the data.  The standard deviation difference and sample (N) used in Table 22 to test 
for significance between AQLQ baseline and AQLQ week 8, was also used to estimate 
the post-hoc power calculation. The minimal important difference (MID) for the AQLQ 
was reported as 0.5 (Juniper et al., 1993). Therefore, based on a MID of 0.5, N of 65 and 
the standard deviation of the difference between the two time points of 1.5, the estimated 
power was 75%. This indicates that the total sample size for this study based on a power 
calculation of 75%, would be 65. To take into account the potential loss to follow up, with 
a 50% drop out rate, the estimated total sample size required based on the AQLQ overall 
data from Table 22, would be (65 / 0.5)= 130 participants.  This would give confidence 
in determining whether a MID exists in the mean difference. 
 
Table 5: Eligibility criteria 
Inclusion Exclusion 
18 years old and older; male or female Younger than 18 years old 
Attended A&E or admission to hospital 
following an asthma attack 
Did not attend A&E or get admitted to 
hospital following an asthma attack 
Has asthma alone, or asthma with Chronic 
Obstructive Pulmonary Disease (COPD) 
or asthma with a respiratory infection; 
main diagnosis is asthma. 
Main diagnosis is not asthma 
Speaks English Does not speak English 
Not in need of help from carer/guardian to 
complete questionnaires 
In need of help from carer/guardian to 
complete questionnaires 
Not hypoxaemic 
Remains hypoxaemic despite oxygen 
therapy 
Not participated in the study before Has participated in the study before 
Able to give informed consent Impaired capacity to consent 
 




3.3  Participant recruitment approach 
Recruitment from the NNUH was done primarily by myself (chief investigator) and 
another researcher when cover was required. For the other two hospital sites in 
Birmingham and Aberdeen, research nurses and the principal investigator conducted 
recruitment. As patient’s were attending hospital in an acute state, initial treatment was 
provided to the patient first, before study recruitment was allowed. The researchers would 
then give the patient’s a participant information sheet (PIS) (Appendix VIa) if they met 
the inclusion criteria. 
 
Participants were recruited as early as possible into the study from when they presented 
at hospital with their acute asthma attack (either A&E, short stay units or the respiratory 
wards). This was to ensure that the baseline data capturing the participant’s quality of life 
was recorded as close as possible to their acute event to enable accurate estimation in loss 
in quality of life. Failure to do this, would risk underestimating the loss in quality of life 
if the patient was nearer recovery (Dritsaki et al., 2017). An earlier acute asthma study 
also recruited participants from A&E departments who were able to verbally consent 
(Goodacre et al., 2014).  
 
Once participants were consented into the study, the original consent form (Appendix 
VIb) was filed in the medical notes, a copy was given to the patient and a copy was kept 
for the researcher’s file. A patient and General Practitioner (GP) details form was also 
completed for contact details for the duration of the study. A written letter notified the 
participants’ GP (Appendix VIc) of their inclusion in the study, and this was 
accompanied with a copy of the PIS.  
 
3.4  Follow up 
Participants were consented into the study and followed up for a period of 8 weeks. 
During this time period, the participants were asked to complete questionnaires at 
different time points; some daily, some weekly and some monthly. Upon consent, 
participants were asked to complete baseline questionnaires and received a pack of 
questionnaires in hospital for the first 4 weeks (week 1 to week 4) of the study (see section 
3.5 for further information on outcomes). Face to face or telephone follow ups were 
also conducted at 4 weeks and 8 weeks. These were chosen in order to correspond with 




the routine follow up times of 4 and / or 8 weeks at the primary site. Accordingly, the 
plan was to hold face to face appointments at this site at these times. If the participants 
were recruited from the primary site, then follow ups at 4 weeks or 8 weeks, may have 
been delivered in conjunction with their routine follow-up appointment at approximately 
4 weeks after they were discharged from hospital following their acute event. However, 
in some circumstances, this was not always possible due to the participants not attending 
their appointments or the appointments not being scheduled to align with the 4 and 8 week 
follow up points. Therefore, in these circumstances, the follow-ups were conducted over 
the telephone. Similarly, in the secondary and tertiary hospital sites, the follow-ups were 
conducted over the telephone at 4 weeks and 8 weeks by the chief investigator.  
 
In addition to these follow-ups, the participants also received telephone calls at 3 weeks 
and 6 weeks to see how they were progressing with the study and to remind them about 
the upcoming follow-up appointments or telephone calls in the coming weeks. During the 
week 3 call, participants were asked if they were happy to continue with the study, and if 
so, the chief investigator (I) posted out the second pack of questionnaires to the 
participants for the last 4 weeks (week 5 to week 8) of the study. Freepost envelopes were 
provided in both packs of questionnaires – the first received in hospital, and the second 
posted out at 3 weeks – to allow the participant to post back all of the questionnaires from 
the study. Participants also received ‘love2shop’ vouchers to thank them for their time in 
contributing to the research study. A total of £30 was given to the participants if they 
completed the study; £15 was posted to them with the 2nd study pack of questionnaires 
and a further £15 was posted to them after receipt of all of the completed questionnaires.  
 
The study process is displayed in Figure 15; a flow chart of the stages of the study from 
consent through to the end of the 8 week study period.  































Figure 15: Flow chart of events for study design 
Participant 
agrees to take 
part in study & 






Participant completes in 
hospital with researcher: 
1) Demographics 
Questionnaire 
2) EQ-5D-5L (continues this 
weekly) 
3) AQLQ 
4) TTO (if at the NNUH) 
5) Starts the peak flow and 
asthma symptom daily 
diary 
 
At week 3 after participant is discharged researcher calls participant: 
1) Asks how participant is getting on with study 
2) If participant has follow-up appointment booked at NNUH, then remind 
participant to bring the peak flow and asthma symptom diary, the EQ-
5D-5L questionnaires, the AQLQ and the productivity questionnaires.  
 
OR  
Arrange a convenient time for follow-up appointment over phone to discuss 
the above diary and questionnaires.  
 
 
Participant completes for follow-up 
appointment: 
1) AQLQ 
2) Productivity questionnaire 
3) TTO (this will be done in person or 
over phone if had A&E attendance 
or hospital admission at NNUH for 
their asthma-related crisis event) 











Week 8 – final follow up phone 
call from researcher: 
1) Participant completes 
AQLQ 
2) TTO (over phone for 
NNUH participants) 




phone call from 
researcher every 2 
weeks from follow up 
until end of study to 
see how participant is 
getting on  
End 





3.5  Outcome measures 
There were several questionnaires and forms included in this study that were completed 
by the research team and participants. Below Table 6 shows each questionnaire and the 
form in which it was completed at different time points of the study.  
 























         
Case Report Form 1 X         
Consent form X         
Patient and GP 
details form 
X         
Case Report Form 2     X     
Case Report Form  
3 
        X 
Time Trade Off X    X    X 
Participant 
completion 
         
Demographics 
questionnaire 




X X X X X X X X X 
Asthma Quality of 
Life Questionnaire 
X    X    X 























Peak flow and 
symptoms diary 




    X     
 
3.5.1 Case Report Forms 
These forms were completed at baseline (visit 1), week 4 (visit 2) and week 8 (visit 3), 
and gathered some basic information about the participant. At the initial visit (Case 
Report Form 1), the following information was captured: 
 Height and weight (the height is useful to predict the PEF) 
 Asthma history (last occurrence of having an asthma attack, A&E attendance, 
hospital admission and intensive care record) 
 Current asthma medications 
 Clinical observations (PEF recordings, respiratory rate, heart rate and oxygen 
levels; useful for the severity of the asthma attack) 
 Comorbidities  
 TTO 
 
The other two case report forms (visit 2 and visit 3), were follow-ups to capture any data 
that might have changed. Both forms recorded the following: 
 Adverse events 
 Any changes in asthma medications 
 Any new comorbidities 
 Any changes in smoking status 
 TTO 
3.5.2 Demographics questionnaire 
This questionnaire (Appendix VId) was completed by the participant at baseline to gather 
their general characteristics. The following data was captured: 
 Age 





 Smoking status 
 Ethnicity 
 Highest level of education 
 Employment status 
 Peak of asthma-related event 
 Route of entry into hospital 
 Number of asthma related A&E attendances and hospital admissions in the last 
year  
 List of medications before current asthma-related crisis event 
 
3.5.3 EuroQol-5 Dimensions 5 Levels (EQ-5D-5L) 
This questionnaire (Appendix VIe) was requested for completion by the participant at 
weekly intervals, with the first completed at baseline. The EQ-5D-5L is a generic 
questionnaire composed of five different categories (domains) of overall well-being: 
mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. There are 
five different levels to choose from within each category, which describes health on the 
day the questionnaire is completed. The five levels are no problems, slight problems, 
moderate problems, severe problems, extreme/unable problems. Each participant ticked 
one of these levels from each of the five domains that best described their health on the 
day they completed the questionnaire. In addition, there was also a Likert scale which is 
called an EQ Visual Analogue Scale (VAS), ranging from 0 (worst possible health) to 
100 (best possible health). Each participant recorded a value between these two points 
which best described their health on the day they completed the questionnaire.  
 
The EQ-5D-5L value set was developed, based on the responses of, individuals of the 
general population in England using TTO and discrete choice experiment methods 
(Devlin et al., 2016, van Hout et al., 2012, NICE, 2017). The EQ-5D is a widely used 
questionnaire and is recommended by NICE for use in economic evaluation studies 
(Drummond et al., 2015). When the participants completed the questionnaire and ticked 
a level on each of the five different domains, their responses were converted into a utility 
score for use in economic evaluations. The utility scores can range from -0.281 to 1.000, 
providing worse then dead values to full health values respectively (Mulhern et al., 2017). 




For this study, the EQ-5D-5L value set from Devlin et al. (2016) was used. However, this 
valuation set is currently not recommended by NICE, as highlighted from a recent 
position statement (NICE, 2017), and once further research has been conducted, (which 
has been laid out by NICE), then the position statement will be reviewed later in August 
2018.  
 
3.5.4 Asthma Quality of Life Questionnaire (AQLQ) 
Each participant was asked to complete the AQLQ questionnaire (Appendix VIf) three 
times (baseline, week 4 and week 8). The AQLQ is a disease specific questionnaire that 
consists of 32 asthma-related questions, with answers based on the last 2 weeks when 
completing the questionnaire. The participant had 7 different response choices for each 
question ranging from 1 (e.g. all of the time) to 7 (e.g. none of the time). The 32 questions 
are grouped into four categories, which are symptoms, emotions, activities and 
environment. AQLQ scores can be estimated as an overall score and also as a score 
corresponding to the four categories mentioned. 
 
This instrument was developed by a combination of unstructured interviews with 
clinicians and asthmatics discussing items important to asthma patients, of which 150 
items were identified. Following this, a wider asthma subject population was studied to 
help identify which items were the most important during an item reduction phase in order 
to create the 32 item AQLQ (Juniper et al., 1992).    
 
3.5.5 Justification for choosing the EQ-5D-5L and AQLQ 
The EQ-5D-5L and the AQLQ were chosen based on the lack of evidence in the literature 
for a disease-specific HRQL instrument for asthma patients that can be used to inform 
economic evaluations. However, previous literature shows an earlier development of a 
generic preference-based measure that can be used specifically for asthma patients in 
economic evaluations (Young et al., 2011). This developed instrument is called the AQL-
5D and uses an algorithm to translate the disease-specific HRQL (AQLQ) responses, into 
a utility score. This utility score can then be used in economic evaluations. Even though 
this measure was designed alongside supporting psychometric criteria, it is still a new 
measure and requires applied testing. This is highlighted by the recommendation that 
disease-specific HRQL instruments should be used in conjunction with generic HRQL 




instruments (Drummond et al., 2005). With awareness of this, and the fact that NICE 
recommends the use of EQ-5D in economic evaluations, a decision was made to use the 
AQLQ, (which can later be converted into AQL-5D for utility scores), and the EQ-5D-
5L.  
 
The expanded version of the EQ-5D (5L), was chosen as opposed to the EQ-5D-3L 
because it is thought that this would provide more sensitivity for the outcome responses 
(van Reenen and Janssen, 2015). The AQL-5D also has 5 dimensions, which corresponds 
with the EQ-5D-5L. Therefore, both the EQ-5D-5L and the AQL-5D seem useful for 
comparisons in economic evaluation studies. In light of the above, and based on the fact 
that the AQL-5D can be derived from the AQLQ, both the EQ-5D-5L and the AQLQ 
were used in this study to identify which questionnaire would be more appropriate to use 
when estimating HRQL in asthmatics.   
 
3.5.6 Peak flow and symptoms diary  
This diary (Appendix VIg) included recording the PEF and symptom severity of each 
participant during the study. The participants were asked to record their PEF morning and 
evening on a daily basis, and to also record their symptom severity in relation to the 
following three questions from the Royal College of Physicians (RCP) (Thomas et al., 
2009): 
1. Have you had difficulty sleeping because of your asthma?  
2. Have you had your usual asthma symptoms during the day (cough, wheeze, 
breathlessness, chest tightness)? 
3. Has your asthma interfered with your usual activities (e.g. housework, childcare, 
work, school etc.)?  
The above three questions were answered on a scale between 0 (no symptoms) and 3 
(severe symptoms).  
 
PEF readings and asthma symptoms are a regular way of monitoring how well controlled 
a patient’s asthma symptoms are (British Thoracic Society. Scottish Intercollegiate 
Guidelines Network, 2016, Pearson and Bucknall, 1999). By asking participants to record 
these daily, it helped to visualise the trajectory of asthma recovery in more detail 
throughout the 8 week study period. 





3.5.7 Productivity questionnaire  
A societal perspective is often regarded as a better approach in health economics 
compared to a healthcare perspective, as the estimations take account of all or broader 
costs and benefits. To ignore the wider costs that have been included in this study (e.g. 
implications with time off work), would be ignoring the opportunity cost, and therefore, 
would risk an inaccurate conclusion of the intervention being cost effective (Drummond 
et al., 2015). Additionally, this aspect is not currently being collected in the ARRISA 
study, so therefore, exploring these wider costs is also a good opportunity. Therefore, 
whilst in the process of collecting information that would inform the benefit part of the 
societal perspective (quality of life), it seemed appropriate to also collect information 
around productivity in this acute asthma group during the same asthma-related crisis 
event period. This would take account of some of the productivity costs associated with 
the event, and would enable other studies to use this information as well in order to better 
estimate the asthma-related crisis event. However, it is also important to note that there 
is a minor risk of double counting in relation to productivity, because participants were 
not asked to ignore income effects when valuing their health (Drummond et al., 2015). 
This means that QALYs might have captured the benefits or loss associated with changes 
in productivity.    
 
The productivity questionnaire (Appendix VIh) was adapted from the Work Productivity 
and Activity Impairment (WPAI) questionnaire (Margaret Reilly Associates. Inc., 2013), 
where permission was granted for adaptation, because some of the original questions were 
not completely appropriate for this study. For example, the questions were more relatable 
to the participant if the productivity questionnaire asked the participants questions 
relating to events that happened since or before, their asthma-related crisis event. Since 
the participants were asked to complete this questionnaire at week 4 of the study, the 
questions phrased were often based on the last four weeks as opposed to the past seven 
days as stated in the WPAI. I did not change questions from the WPAI questionnaire that 
were phrased around how the participants’ asthma crisis event had impacted them on their 
working, studying, or activity patterns. Additional questions also included were as 
follows: 




1. Compared to your asthma state when you were in hospital approximately 4 weeks 
ago, how would you rate your asthma now? (Responses included: Very good, 
Good, Moderate, Poor, Very poor) 
2. Do you think you have completely recovered from when you were in hospital 
approximately 4 weeks ago? (Responses included: Yes, No) 
3. If you are in employment (paid work), have you returned to work yet? (Responses 
included: Yes, No, Do not work) 
4. Since your last asthma-related A&E attendance or hospital admission have you 
bought any extra products (e.g. prescriptions, allergy-free bedding, cleaning 
products, food items) or used an additional service (e.g. a visit to a complementary 
therapist) to that which you would normally buy/use e.g. in the four weeks prior 
to your asthma-related A&E attendance or hospital admission?  
 
The additional questions above are useful for further understanding of the productivity 
losses associated with an asthma-related crisis event. Questions 1 and 2 are related to 
question 2 of the SF-36 questionnaire (Ware and Sherbourne, 1992), which has previously 
been used to assess responsiveness (Walters and Brazier, 2005), and asked:  
 
“Compared to one year ago, how would you rate your health in general” (Responses 
included: much better now than one year ago, somewhat better now than one year ago, 
about the same as one year ago, somewhat worse now than one year ago, much worse 
now than one year ago).  
 
Both questions 1 and 2, (added on in addition to the WPAI questionnaire), were important 
as they enabled the assessment of responsiveness to be conducted and provided the 
opportunity of detecting the sensitivity to change when compared against other 
questionnaires included in the study.  
 
The latter questions 3 and 4, allowed a more in depth assessment of the productivity loss. 
Although, if the participant is unfortunate to have more than one asthma-related crisis 
event within a short period of time, then dependent on the additional products purchased 
in the first instance, they may not be purchased again if a second event was to occur.  
 




3.5.8 Time trade off (TTO) 
The TTO was chosen as an alternative method to estimate utilities, which will later enable 
a comparison between the EQ-5D-5L and AQL-5D. Both the EQ-5D-5L and AQL-5D 
used the TTO in the valuation of health states, so this seemed to be an appropriate 
alternative for comparability purposes. Also, in addition to the other alternative direct 
elicitation techniques (e.g. standard gamble and discrete choice experiments), the TTO 
was favoured for several other reasons which involved thinking about the acute asthma 
patient group that were recruited into the study. Given that the participants recruited were 
acute patients and I had already planned to ask them to complete a number of 
questionnaires, I thought that the TTO would be an easier and faster choice for the 
participants to comprehend in a short time frame without burdening them. It might have 
also enabled the benefit to be differentiated from loss associated with co-morbidities. I 
also designed the TTO using a macro and presented this to the patients on my laptop, 
which provided a good visual and aided the explanations of the TTO. 
 
The TTO method used was slightly different to the normal statements used where the two 
options are typically the condition of interest and full health. In this case, the two options 
were current asthma health state (as the condition of interest) and well controlled asthma 
(as an alternative to full health). It is not unusual to use a different anchor comparator 
state compared to the more common “full health” state for the TTO. Alternative phrasing 
such as, “a comparator health state with no health problems”, or wording such as, 
“excellent health”, or “healthy” or in fact using the 11111 valuation from the EQ-5D as 
the comparator can also be used (Shah et al., 2016b).  However, the use of these utilities 
in valuation studies may cause difficulties when comparing across studies and countries. 
It is therefore argued that for full comparability, there should be consistency in the upper 
anchor by having QALYs anchored at full health (Brazier et al., 2007, Shah et al., 2016b). 
However, these two options (“current asthma health state” and “well controlled asthma”) 
were chosen for this study to reflect the quality of life of the asthma-related crisis event 
and to use terms that the participant was more familiar with. Most importantly, it is the 
loss in quality of life that was of specific interest and with this approach it was not 
necessary for the participant to imagine they had no asthma or no comorbidities. The 
hypothesis was that as the participants’ were recovering from the event, the TTO utility 
score would be higher and eventually reach a ceiling effect (where they would not be 
willing to reduce their life expectancy) of utility 1.0 if the participant had completely 




recovered from the asthma-related crisis event. Thus it would be possible to identify 
whether the patient had recovered by week 8. Conversely, if an EQ-5D score of 1 was not 
reached at this point it would be unclear whether this was because the patient had not 
recovered or there was another co-morbidity present. 
 
Even though this study was already addressing quality of life using the questionnaires 
mentioned above, (e.g. EQ-5D-5L and AQLQ), and by asking a question in the 
productivity questionnaire (see section 3.5.7 question 2), it was interesting to see if the 
participants’ responses differed at all when using the TTO method as well. The TTO had 
an advantage over using the quality of life questionnaires (such as the EQ-5D) because it 
was able to identify when the participant was returning or had returned back to their well-
controlled asthma state (i.e. no symptoms or attacks, and they would not be willing to 
reduce their life expectancy in order to improve their asthma). The EQ-5D-5L and the 
AQLQ gave overall utility and scores respectively, but was not able to identify if the 
participant was back to their well-controlled state. However, implications can arise if 
participants are not willing to trade fewer years of well controlled asthma compared to 
their current asthma health state (even when worse), by considering other life factors, 
such as family when valuing their health (Dolan and Roberts, 2002).  
 
The iterative process was informed by using the life expectancies of the general 
population (Office for National Statistics, 2017b), assuming that when asthma is well 
controlled then the individual should have the same life expectancy as someone who is a 
healthy individual (dependent of other comorbidities) (Papaioannou et al., 2015). With 
respect to the average life expectancy chosen based on each participant’s age, the 
incremental movements during the TTO process was by 10% of the average life 
expectancy. This was to ensure that each participant, (regardless of their age), would have 
the same number of increments before either reaching their maximum or minimum trade 
off. An example of the developed macro for the TTO is shown below in Figure 16 
representing a TTO example for a 35 year old female who has an average life expectancy 
of 85 years (i.e. 50 years remaining). For this study, the iterative questioning began at 
mid-point (in this case 25 years) with the upper and lower arrows being moved by the 
increment of 5 (10% of remaining life expectancy) dependent on the response of the 
participant.  
 




Figure 16: TTO for a participant aged 35 years old 
 
 
The TTO was only conducted at the primary site because it was imperative to provide a 
face to face consultation at baseline. This was deemed important because the initial 
interaction between the interviewer and respondent has been shown to improve data 
quality (Attema et al., 2013).  
 
Mixed approaches were used for the follow-up TTO conducted at week 4 and week 8 of 
the study due to the scheduled timing of the routine hospital follow-up appointments or 
if participants did not attend their appointments. Consistency in approaches was 
maintained as much as possible because the literature states that different TTO 
approaches could lead to different responses. (Attema et al., 2013, Norman et al., 2010). 
The alternative approach to conducting the TTO face to face was over the telephone 
instead. It was hoped that having the initial face to face consultation received at baseline 
would help participants remember the image displayed on the laptop (Figure 16) and the 
reasoning behind this. This was confirmed by participants during the telephone follow-
ups. It was difficult to know if the participants’ had completed their weekly EQ-5D-5L 
or monthly AQLQ before the time point at which the TTO was conducted as a specific 
time to complete these was not instructed. Therefore, an exact order of the completion of 
these questionnaires was unknown.  
 
An alternative approach to the conventional TTO approach mentioned above, was 
considered, as the comparative baseline health state was a chronic health state. This 
chronic health state can be considered as a temporary health state, due to the health state 
lasting less than 1 year (Wright et al., 2009). Therefore, a chained TTO can be another 
approach to value temporary health states (Stoniute et al., 2017). However, in this 




particular situation, the chained TTO approach was not deemed suitable, due to also 
requiring an anchor state as well, which should be considered as worse than the temporary 
health state, but not worse than death (Stoniute et al., 2017).  
 
3.5.9 Piloting Questionnaires 
The EQ-5D-5L, AQLQ, Peak flow and symptom diary, TTO and productivity 
questionnaire, were all piloted before the study commenced, and prior to ethical approval. 
Six patients from one asthma outpatient clinic were asked to provide feedback on these 
questionnaires. The feedback focused on the length of time it took to complete the 
questionnaires, the ease of understanding the questionnaires, and whether the patients 
thought that completing the questionnaires regularly over an 8 week time period was 
feasible given the acute health state that the recruited patients would be in. The feedback 
received from piloting the questionnaires was positive, and no concerning issues were 
raised. Therefore, there were no amendments made to the questionnaires.  
 
3.5.10 Where should utility values come from? 
There has been much literature discussing where utility values should come from. For 
example, should they come from the patient, the general population, proxy, (on behalf of 
patients through carers) or even health professionals (Dolan et al., 1996, Rowen et al., 
2015). Much of the literature discusses whether the patient or the general population 
values matter for valuing the health states. Some suggest that the patient should value the 
health states based on their experience of the condition and therefore will be able to 
provide a more accurate picture (Nord et al., 1999). Although this may be true, patients 
who have the condition may not be as willing to trade life years for healthier years if they 
have adapted to their condition and are able to overlook the extent of its effects. However, 
there has been much discussion on the impact of chronic conditions, previous illness 
experience and the valuation of TTO, where controversies lie in both directions (Sayah et 
al., 2016).  
 
Alternatively, those of the general population who have not been directly exposed to 
experiencing the health state may provide an inaccurate response due to not fully 
understanding the impact of the hypothetical health state. However, others suggest that 
the general population should be involved in valuing the health states because they have 




a role in allocating scarce resources through the taxes they pay due to the healthcare 
system being publicly funded (Drummond et al., 2005). Because an asthma event is such 
an acute event, the general population may have difficulties in providing a true valuation, 
as they may struggle with identifying with specific  health states. Buckingham (1993) 
stated a similar issue where they thought asking a 20 year old individual to imagine how 
they would value their health state at 70 years old would require a heavy amount of 
imagination. Whereas, asking a 70 year old about their health state and its importance at 
their age would provide more accuracy. With these accounts taken into consideration, and 
for the purpose of this study, patient completion and values were used for the TTO. 
 
3.5.11 Adverse events 
Adverse events for all participants were recorded during the study. This information was 
collected from the participant during the follow-ups at week 4 and week 8 of the study. 
Serious adverse events (such as hospitalizations), were recorded appropriately by 
completing a serious adverse event form and notifying the relevant Research & 
Development and sponsor team members. 
 
3.6  Prospective analysis plan 
Flow of participants:  
The number of participants across all three hospital sites will be combined to produce an 
overall consort diagram. The diagram will include the following information: 
• The number of participants assessed for eligibility 
• The number of participants (and proportions) excluded from assessment and their 
reasons for exclusion 
• The number of participants recruited from the hospitals from A&E attendance and 
hospital admission 
• The number of participants (and proportions) who were lost to follow up or had 
withdrawn from the study 
 
Data assessment:  
The data will be entered into Microsoft Excel (2016) by the chief investigator (myself). 
Ten percent of the data will be entered twice by another researcher to check for any errors 
or discrepancies. Once double data entry is completed, the number of errors/discrepancies 




will be identified. Assuming the error rate is <10% then these will then be considered in 
order to assess if any corrections are required to the original dataset. The dataset will then 
be locked by the chief investigator. 
 
Statistical software:  
The data will be entered into Microsoft Excel and statistical analysis will be conducted 
using either Microsoft excel or STATA v.12.  
 
Baseline demographic characteristics: 
A description of the baseline characteristics will be described from information obtained 
from the demographics questionnaire and other baseline quality of life questionnaires. 
The average age, height and weight will be reported, and the proportions of gender, 
ethnicity, smoking status, highest level of education, and employment status will also be 
reported. In addition, bar charts will be produced to depict the average number of 
participants who had the peak of their asthma-related crisis event either before, on route 
to hospital or in hospital. A bar chart will also be constructed to show the average number 
of participants who had different routes of entry into hospital (e.g. drove, by ambulance, 
by GP referral, or by nurse practitioner referral). 
 
Quality of life statistical characteristics:  
The baseline statistics for each of the quality of life baseline questionnaires (EQ-5D-5L, 
AQLQ, AQL-5D, and TTO) will also be reported. The statistics that will be tabulated will 
include means, standard deviations, ranges, response rates, floor and ceiling effects, 
(where floor effects mean that a  high proportion of participants have the lowest score on 
the observed variable, and ceiling effects mean that a high proportion of participants have 
the maximum score on the observed variable). This display of statistics at baseline, will 
also be repeated at week 4 and week 8 to compare any changes. If there is a suggestion 
of ceiling effects or floor effects at baseline for the utility values, then these participants 
will be explored by using the time of when the asthma-related event peaked and 
regression analysis. If any statistically significant differences are found between the 
utility data and the peak of their asthma-related event occurring before A&E attendance 
or hospital admission, then the data will be re-analysed after removing these participants 
from the dataset.  





Distribution of the data:  
The dataset will be explored to see if the assumptions of normality hold. Histograms, Q-
Q plots, and skewness / kurtosis tests will be conducted to see if there is a normal 
distribution. This is important to observe, as different statistical techniques will be used 
if the dataset satisfies either a normal or non-normal distribution.  
 
Missing data:  
There are different types of missing data definitions, and missing data are often described 
as missing completely at random (MCAR), missing at random (MAR) or missing not at 
random (MNAR). If data is MCAR, then the probability that the data is missing is not 
dependent on the observed or unobserved data. This therefore means that the observed 
data is representative of the sample distribution of the outcomes in the overall population.  
 
If the data is said to be MAR, then the probability of having missing data is independent 
on unobserved values, having taken account of observed data i.e. any systematic 
differences can be explained by observed variables. If the data is MNAR, then the 
probability of having missing data is dependent on unobserved data. Different methods 
can be used to analyse the data, depending on the assumptions taken in relation to missing 
data.  
 
To assess which assumption in relation to missing data was more appropriate the 
following analyses were undertaken. Firstly, missing data descriptions will include 
tabulating the proportions of missing data for each utility outcome measure. Secondly, 
the patterns of missing data will be observed to identify where the missing data is likely 
to be concentrated, and at which time points they occur. Thirdly, logistic regression 
analysis will be used to see if there are any predictors of missing data for each of the 
utility outcomes by using the baseline demographic variables as indicators. 
 
If the missing data is associated with observed predictors of missingness, then the data is 
assumed to be either MAR or MNAR. If the missing data is not associated with any 
predictors of missingness, then the data is also assumed to be MCAR or MNAR. If the 
data satisfies an assumption of MCAR, then the approaches that can be used to analyse 




the data include complete case analysis (CCA) and available case analysis (ACA). CCA 
is often regarded as a useful benchmark starting point in the analysis. However, it is also 
known to be inefficient in studies which have follow up data, as any participant that 
misses a data follow up point, will have to be excluded from the analysis. Alternatively, 
ACA can be used which provides a stronger dataset for analysis due to including all 
participants, regardless of any potential missing data. However, due to all the available 
data being used, the ACA can lead to a limitation of using different sample sizes and 
groups of participants for different analyses in the dataset.  
 
If missing data is assumed to be MAR then the missing data can be imputed via a 
technique called multiple imputation (MI), where the observed data is used to predict the 
missing values. MI can be used to impute values into the missing data points (with focus 
on ensuring that the missing utility values are correctly imputed).  STATA can be used 
to do this taking account of the predictors of missingness. Chained equations (MICE) 
can be used to implement this in STATA, using a code such as ‘mi impute chained’ or 
‘ice’ package (Faria et al., 2014). MICE is known to accommodate non-normality well 
and large datasets with many variables having missing data (Faria et al., 2014). 
Alternatively, a likelihood-based model (i.e. multi-level model given hierarchical 
structure), can also be used if the model assumes MAR, conditional on the variables 
included (Faria et al., 2014). If the dataset does indicate that the data is MAR, then the 
most likely method would be to choose the likelihood-based model based on the dataset 
having a hierarchal structure. 
 
Primary analysis: 
The mean utility values (for EQ-5D-5L, AQL-5D and TTO), mean scores, (EQ VAS, 
AQLQ overall, AQLQ symptoms, AQLQ activity, AQLQ emotional, AQLQ 
environmental), and standard deviations will be tabulated at each time point of the study. 
The mean differences, confidence intervals and p-values will be displayed for statistical 
tests between baseline and week 8, baseline and week 4, and week 4 and week 8.  
 
If normality assumptions hold, then paired t-tests (2-sided) will be conducted to test for 
statistical significant differences between the mean values. However, if the dataset shows 
evidence of non-normality, then Wilcoxon-signed rank tests will be used to test statistical 
significance. Scatter plots will be used to visually display the mean utility and score 




results at the different time points for the EQ-5D-5L, AQL-5D, TTO, EQ VAS, peak 
expiratory flow and symptoms score. QALYs will be estimated using the utility loss 
results associated with an asthma-related crisis event from the EQ-5D-5L, AQL-5D and 
TTO. QALYs will be estimated using the area under the curve approach and linear 
interpolation. The mean differences in utility between the time points mentioned above, 
will be used to estimate QALYs using different scenarios. 
 
Secondary analysis:   
Additional descriptive information (N, %, SD) relating to the number of adverse events, 
average length of stay, number of medications, changes in comorbidities and changes in 
smoking status throughout the study will also be included.  
 
If the data set is MAR then the relationship of the EQ-5D-5L, AQL-5D and TTO will be 
assessed against the demographic variables using a multi-level hierarchical model due to 
the dataset having a multi-level structure (responses at weekly intervals [level 1], 
participants [level 2] and hospitals [level 3]). Quadratic models will also be considered if 
there is evidence of non-linearity. Non-linearity can be assessed by observing the 
trajectories of the utility values for the first few participants at the different time points. 
If the lines observed between time points (e.g. EQ-5D-5L weekly time points from 
baseline to week 8) for each participant are not linear, then this confirms evidence of non-
linearity.  
 
Productivity loss associated with an asthma-related crisis event will also be estimated 
using the human capital approach and average weekly earnings taken from the office for 
national statistics. The productivity loss will take account of time lost from work and be 
based on a complete case analysis. Additional products purchased due to having an 
asthma-related crisis event will also be considered and will be asked in the questionnaire 
at week 4 of the study. As the reported cost of each product is requested these values will 
be summed to estimate the total out of pocket cost. 
 
 




3.7 Data management  
All research data was anonymised by assigning each consented participant with an 
identification (ID) number (e.g. 001) and site number (e.g. 01). Personal data was kept 
separate from the main research data to avoid any identification from the research data. 
The case report forms and questionnaires were stored in a folder in the secure respiratory 
research office in the Norfolk and Norwich University Hospital (NNUH). In addition, 
there was also a master site file holding the necessary documentation, some of which 
included protocols (superseded and current), regulatory approvals, screening logs, 
enrolment logs and delegation logs. This was also stored in the secure respiratory research 
office at the NNUH. The other sites kept a site file containing their documentation in a 
secure office located on their hospital premises. The files were kept abreast; both 
electronically and as a hard-copy.  
 
The data was collected through paper-based questionnaires and entered into Microsoft 
Excel software packages and stored on the University of East Anglia’s server. The 
Microsoft excel documents were encrypted with a secure entry password for security and 
data protection measures. This was done in accordance with Good Clinical Practice and 
the Data Protection Act, 1998. Once the study ended, the excel spreadsheet was cleaned 
and manipulated for analysis, and the anonymised hard copies were archived for a further 
10 years.  
 
3.8 Statistical analysis  
Random participant ID numbers were generated from using the Microsoft excel random 
number formula for the purpose of double data entry. Double data entry was conducted 
for 10% of the data collected across all sites to check for accuracy by another researcher. 
This process found a few discrepancies which were cross-checked against the original 
hardcopies and any errors were corrected for the final database used for analysis. Due to 
the very small number of errors found across the 10% checked (approximately 0.003), 
the spreadsheet did not warrant any further data entry checks.  
 
Every effort was made to reduce missing data, by double checking the questionnaires at 
baseline before leaving the participant’s bedside, and ensuring the participants were fully 
informed and knew what they had to do during baseline and again at the follow-up phone 




calls. Due to the large amount of participants who were lost to follow up and / or had 
missing data within questionnaires returned, the complete case analysis (listwise deletion; 
removing all data for a participant with one or more missing values) data set is reasonably 
smaller. Therefore, data was analysed using available cases (pairwise deletion; maximizes 
the use of all available data for each pair of variables considered in the analysis) in the 
first instance, meaning that there was a different sample size (N) for each statistical test 
conducted. Complete case analysis was also used afterwards to aid in comparability of 
the data points.  
 
After retrieving the results based on available case analysis, the data was then analysed 
by using a technique called multi-level modelling for the EQ-5D-5L, AQL-5D and TTO 
utilities. Missing data was accounted for by using the multi-level modelling technique 
coupled with the maximum likelihood estimation. This technique is discussed further in 
Chapter 4. 
 
There are several other approaches that could have been considered to handle the missing 
data. One option could be to use a mean substitution, where the mean is calculated from 
all observations in a variable for that particular time point and imputed to replace the 
missing value (Kang, 2013). A second option could be to take the last value within an 
observed variable before the missing data occurs, and impute the last observed data value 
in place of the missing data (Hamer and Simpson, 2009). A third option could be to 
substitute the missing values by using a method called multiple imputation. The missing 
data is predicted by using the variables and existing data set, and replacing the missing 
values with the prediction whilst formulating imputed data (Sinharay et al., 2001). 
 
The values retrieved from three quality of life questionnaires (EQ-5D-5L, AQLQ and 
TTO) were converted into utility values (values of a stated health state). The EQ-5D-5L 
utility values were estimated from a value set based on the England population (Devlin et 
al., 2016). The AQL-5D utility values were estimated using an algorithm based on the 
AQLQ (Yang et al., 2011). The TTO utility values were estimated based on the 
participants’ reaching a point of indifference. For example, going back to Figure 16, if 
the participant reached a point of indifference and chose health state B at 20 years of well 
controlled asthma, then the utility value would be 20 ÷ 50 (comparator health state ÷ 
remaining life expectancy) = 0.4; i.e. a loss in utility of 0.6. It should be noted that by the 




method adopted we inherently assumed the asthma state will not be considered worse 
than death, and therefore only positive TTO scores can be obtained.  
 
From the above utility conversions from the three questionnaires, the mean difference 
between the 8 week follow-up and baseline score was calculated to estimate the loss 
associated with a crisis event. The time points in between, from baseline to follow-up and 
the peak flow and symptoms scores, will also help to provide a more accurate estimation 
of the trajectory of this loss associated with a crisis event; i.e. assess whether linear 
interpolation is an appropriate assumption. The level of correlation (convergent validity) 
between the quality of life methods was tested as a way of assessing the appropriateness 
of the measures used. However, because generic and condition-specific measures were 
used in this study, the utility scores may not correlate strongly due to these differences in 
valuation and estimation techniques. In addition, the productivity questionnaire was used, 
to estimate the loss of productivity, by attaching the average hourly wage to estimate time 
off work. Further details of the statistical techniques used for the above analyses are 
detailed in Chapter 4 and Chapter 5. Microsoft excel and STATA packages were used 
for all analyses.  
 
3.9 Ethics approval 
This study was originally reviewed by the Proportionate Review Sub-Committee by the 
North West – Greater Manchester West Research Ethics Committee on 4th December 
2015 under the REC reference 15/NW/0961. They decided on ‘no opinion’ on the account 
of ethical issues surrounding recruitment of A&E patients. Following this, it was then 
reviewed by the Cambridge South Research Ethics Committee under the REC reference 
16/EE/0023. After attending the NHS Research Ethics Committee meeting on 28th 
January 2016, the committee decided upon ‘provisional opinion’ based on the information 
and documentation received. They provided advisory points and also required further 
clarifications and justifications on several points. The main issue was surrounding the 
recruitment of A&E patients as previously highlighted from the initial proportionate 
review, where they were concerned about the practicalities, chance of uptake, and ethics 
around approaching patients in the A&E department. A response was written to 
Cambridge South committee to address all points raised, with particular mention of 
liaisons with an A&E clinical director, a consultant in the acute medical unit and the 
Asthma UK Centre for Applied Research patient and public involvement (PPI) group. 




These members supported our approach to recruitment in A&E, but only after the critical 
1st hour had passed, the patient was free from hypoxaemia, and the patient was not in 
resuscitation. Shortly after responding to their request for further information and 
clarification, they awarded ‘favourable opinion’ on 29th March 2016. All ethics letters can 
be found in Appendix VIi.  
 
Due to this being a multi-site study the National Health Service (NHS) site approvals took 
place in stages and granted local approvals once all necessary checks were completed. 
The Norfolk and Norwich University Hospital NHS Foundation Trust awarded their 
permission on 26th April 2016, the Aberdeen Royal Infirmary NHS Grampian awarded 
their permission on 11th May 2016, and the University Hospital Birmingham NHS 
Foundation Trust awarded their permission on 31st October 2016. Further minor 
amendments were made once the study had started recruitment. These included slight 
changes to the PIS for the Aberdeen site (a slight change in wording at the request of the 
site principal investigator), and an increase in the number of participants permitted for 
recruitment. Both changes were appropriately actioned with approvals made from the 
health research authority. All documents relating to this study can be found in Appendix 
VI. This study is registered with ClinicalTrials.gov and can be identified through this 
number: NCT02771678.   
 
3.10 Summary  
In conclusion, this study will address the current gap in the literature where there is a 
general assumption of linear interpolation in between time points when measuring HRQL. 
As asthma attacks can occur sporadically from triggers and unknown factors, it can be 
difficult to measure HRQL at the particular time point of the attack. Current studies that 
measure quality of life at set points (such as baseline, 6 months and 12 months), may be 
missing the quality of life implications of an acute asthma attack that causes an A&E 
attendance or hospital admission to occur. Therefore, they may be underestimating the 
loss in quality of life for asthmatics if the patient has somewhat or wholly recovered by 
the next time point. As an alternative method, this study will  estimate the loss associated 
with an asthma-related crisis event. This will be useful for future studies, as they can 
count the number of crisis events that occur and attach the utility loss to them. This may 
in turn change the outcome and provide a different value when estimating what constitutes 




best value for money. This approach is particularly of use where routine data sources are 
used and utility scores are not available / could not be elicited e.g. ARRISA.  
 
This chapter comprehensively details the study design for acute asthmatics and their 
quality of life associated with either an A&E attendance or hospital admission. It provides 
in-depth details of the aims and recruitment process for this study, and outlines the 
outcome measures and statistical approach taken. This study forms the basis of the next 
two chapters, as further analysis is conducted to answer specific research questions, which 
were mentioned at the beginning of this chapter:  
 
What is the loss in quality of life associated with an asthma-related crisis event?  
 
To what extent does this loss vary depending upon which patient reported outcome 
measures is used? 
 
What is the comparative performance of different generic and/or disease-specific 
questionnaire(s) when they are used to assess quality of life in acute asthmatics?  
 
The next couple of chapters will provide further detail to the above and highlight the 
importance of this work. The next immediate chapter, chapter 4, will provide the 
descriptive results for this study, and will answer the first two research questions above. 
  





ESTIMATING THE LOSS IN QUALITY OF LIFE 
ASSOCIATED WITH AN ASTHMA-RELATED CRISIS 
EVENT (ESQUARE): RESULTS FROM A COHORT 
STUDY 
 
"I found myself in the resuscitation suite of my local hospital on 10 
occasions, and took myself to casualty at least 40 times in those first few 
years…..I was so sick of being sick, I wanted to die." 
(Celeste Abrahams; written by Trish Lesslie, 2005) 
 
Preface 
The previous chapter provided the methodology for the prospective cohort study design 
which was developed to address the research questions focused on estimating the change 
in quality of life associated with an asthma-related crisis event. This study was a multi-
site study and was aimed at an adult population group, (18 years and over), who were 
attending A&E or were admitted to hospital due to having an asthma attack. The main 
aim of the study was to estimate the loss in quality of life associated with an asthma-
related crisis event – A&E attendance or hospital admission – and so the time horizon of 
the study was 8 weeks. Routine hospital follow-up appointments are usually scheduled 
approximately 4 weeks after an asthma hospital admission. However, some patients are 
scheduled more follow-up appointments following their initial 4 week follow-up, because 
they require further clinical support from their hospital admission. Therefore, it seemed 
appropriate to have a time horizon of 8 weeks to capture the quality of life in this patient 
group. The 8 weeks allowed for additional observation time from the patient’s crisis 
event, and the time horizon was not too long to be burdensome for the patient’s to 
complete the questionnaires. Informed consent was obtained in hospital and a variety of 
outcome measures were used to capture quality of life. This chapter will describe and 
discuss the results of this study in order to address the research questions outlined in 
Chapter 3: 




1) When did the asthma-related crisis event peak (e.g. on route to hospital, after 2 
hours in hospital)?  
2) What are the mean quality of life scores, utility values, and peak flow and symptom 
scores for patients reporting these at weekly, monthly and daily time points during the 8-
week study?  
3) What is the loss in quality of life associated with an asthma-related crisis event?  
4) What is the relationship, (if any), between the demographic variables (e.g. age, 
gender, smoking status etc.) and utility estimates (EQ-5D-5L, AQL-5D and TTO)?   
5) What is the productivity loss & out of pocket cost associated with an asthma-
related crisis event?  
 
This chapter will give a brief background into health related quality of life for asthmatics 
and state the hypotheses. There will be more focused methods with statistical analysis 
pertinent for answering the above research questions. Then the results will proceed, with 
details about the recruitment process, mean estimations at different time points, multi-
level modelling and missing data. The discussion and conclusion sections will follow and 
conclude this chapter by discussing the results and draw on earlier studies for comparison.  
 
4.1 Background 
Health related quality of life (HRQL) can impact people differently. Some conditions can 
have prolonged disturbance in quality of life (e.g. cancer, stroke, or diabetes) (Megari, 
2013), other conditions can be more episodic, (e.g. epilepsy, bipolar disorder, or angina) 
(Kudo et al., 2001, Young and Melander, 2013), and furthermore, some conditions can 
have a combination of both prolonging and episodic disturbance in their quality of life.  
 
Quality of life in people with asthma can be episodic and a combination of both 
prolonging and episodic disturbance. Some people are labelled as difficult asthma or are 
severe and uncontrolled, (Barnes and Woolcock, 1998) even though there is much 
discussion in the literature about ways to encourage and maintain well-controlled asthma 
(British Thoracic Society. Scottish Intercollegiate Guidelines Network, 2016, Ring et al., 
2015, Juniper et al., 2006). Asthma attacks can occur amongst these groups of people, 
and can be a regular occurrence for some, and are for others far and few between. 




Nevertheless, asthma attacks negatively impact a person’s quality of life, and they can 
cause death (Royal College of Physicians, 2014).  
 
As mentioned in Chapter 3, there is a need to estimate quality of life more closely 
because of how quality of life data is currently captured in most studies, (i.e. at set time 
points, such as Willems et al. (2006)), as otherwise  biased estimations in QALYs could 
occur (Dritsaki et al., 2017). Initial estimations in HRQL should be captured as early as 
possible (Dritsaki et al., 2017), which is why the baseline point for this study was when 
the participant was in hospital, shortly after admission or attendance to A&E, subject to 
the participant meeting the inclusion criteria as mentioned earlier in Table 5.  
 
Quality of life can be measured using different questionnaires, (generic or disease-
specific) (Herdman et al., 2011, Brazier et al., 2002, Brazier et al., 2007, Horsman et al., 
2003), or even by direct elicitation methods in health (Gafni, 1994, Attema et al., 2013), 
and so a mixture of these techniques were used in this study. It was useful to use a mixture 
of questionnaires and techniques, as it enabled comparability across PROMs, which was 
particularly important for the research questions addressed in Chapter 5. The hypotheses 
for this study were as follows: 
 An improvement in quality of life will be seen after baseline (the asthma-related 
crisis event) in all quality of life questionnaires.  
 Participants will show the minimal important difference in quality of life 
between baseline and week 4 of the study for the EuroQol-5 Dimensions-5 Level 
questionnaire (EQ-5D-5L) and the Asthma Quality of Life Questionnaire 
(AQLQ). The minimal important difference (MID) for the EQ-5D-5L and 
AQLQ have been estimated to be 0.063 (McClure et al., 2017) and 0.5 (Juniper 
et al., 1993) respectively. The MID can be defined as: “the smallest difference in 
score in the domain of interest which patients perceive as beneficial and which 
would mandate, in the absence of troublesome side effects and excessive cost, a 
change in the patient’s management” (Jaeschke et al., 1989). The MID for the 
EQ-5D-5L is an estimate based on the same methodology that was first proposed 
to estimate the MID for the EQ-5D-3L (Luo et al., 2010) – instrument-defined 
MID estimation (average of the absolute difference in the index scores between 
the baseline health state (the first measured time point in a study), and all of the 
single level transitions from baseline). The MID for the AQLQ was calculated 




by using the global ratings of change in conjunction with changes from different 
quality of life scores (Juniper et al., 1993).  
 
The next section will expand on the methods described in Section 3, by providing more 
analytical detail for the statistical analysis specific to answering the research question 
for this chapter.  
 
4.2 Methods 
As detailed in Chapter 3, patients were recruited from three hospital sites in the United 
Kingdom. Participants were required to meet a specific inclusion criteria, which included 
being 18 years old and over, and either attending A&E or being admitted to hospital due 
to experiencing an asthma exacerbation (significant flare up of asthma symptoms). Once 
consented, participants completed several quality of life questionnaires over a period of 
8 weeks. These included completion of the following: 
 
 Peak flow and symptom diary (daily) 
 EQ-5D-5L (weekly) 
 AQLQ (monthly) 
 TTO (monthly) 
 
Other questionnaires, such as the demographics and productivity questionnaires were 
completed at baseline and week 4 respectively. Chapter 3, section 3.5 provides a more 
detailed overview of each outcome measure, and Chapter 3, section 3.7 gives reference 
as to how each questionnaire was converted into utilities for use in economic analysis. 
Ethical approval was granted for this study by the Cambridge South NHS Research Ethics 
Committee (REC reference 16/EE/0023). 
 
4.2.1 Statistical analysis  
As mentioned previously in Chapter 3, section 3.2, the sample size was informed from 
a combination of previous literature and the nature of the TTO design. The target sample 
size was 100 participants, but after several months of recruitment, the retention rate was 
50%. Therefore, the sample size was increased to account for this with allowance of up 




to 200 participants granted by the NHS ethics committee. A post-hoc power calculation 
was conducted to show that the sample size was sufficient for this study. 
 
Baseline and descriptive characteristics were performed using Microsoft Excel (2016) 
and STATA (version 12) packages. Available case analysis was used to perform 
statistical analysis and missing data descriptive statistics were detailed. Complete case 
analysis was also used in some instances for a more robust comparison. Demographic 
characteristics were explored through means and percentages to display the averages and 
proportions respectively. Tables and graphs were used as necessary to illustrate these 
statistics. Adverse events, changes in asthma medications, changes in comorbidities and 
changes in smoking status at week 4 and week 8 of the study were also presented. The 
mean values of the peak flow and symptom scores were also displayed graphically. 
 
The quality of life scores from the questionnaires were converted into utility values where 
appropriate. Mean values and standard deviations for each of the follow up time points 
were presented graphically and within tables. Some variables presented with normal 
distributions (mainly the demographics data) and others with non-normal distributions 
(mainly the outcome variables). Therefore, due to the outcome data not satisfying the 
assumptions of normality for the use of parametric tests, non-parametric tests were used 
in the analysis. However, it should be noted that prior research has also confirmed that 
non-parametric tests (e.g. Wilcoxon-Mann-Whitney test), have been shown to be less 
powerful than parametric tests (e.g. t-tests, ANCOVA), for non-normal distribution data 
where simulation methods were used to draw these conclusions (Vickers, 2005, 
Fagerland, 2012).  Despite this, this was not the case for this cohort study data set when 
checking and testing the data with parametric and non-parametric tests. 
 
The mean change between scores and utility values were tested by using Wilcoxon’s 
signed-rank teste at the 5% statistical level. Confidence intervals and p-values were also 
noted in these tables. The minimal important difference for the EQ-5D-5L has been 
reported as 0.063 (McClure et al., 2017) and for the AQLQ, it has been reported as 0.5 
(Juniper et al., 1993). Therefore, both the p-values and minimal importance differences 
for EQ-5D-5L and the AQLQ were taken into consideration in the analysis.  
 




Response rates, floor and ceiling effects (e.g. for the EQ-5D-5L, a floor effect would be 
defined as ‘extreme problems/unable to’ in all of the 5 domains; 55555, and a ceiling 
effect would be defined as ‘no problems’ in all of the 5 domains; 11111) were also 
tabulated at different time points of the study (baseline, week 4 and week 8), to identify 
those participants who had completed at that time point, and those with the lowest or 
highest levels of utility or scores chosen for their corresponding health states.   
 
Multi-level modelling was performed to demonstrate the relationships that occurred 
amongst the utility values. These models are useful for analysing grouped data which are 
clustered at different levels; in particular hierarchal data (Goldstein et al., 2002). An 
example of the hierarchal relationship for this study is displayed in Figure 40. Missing 
data is also accounted for by using this method and by taking into account, the maximum 
likelihood estimation that also provides an output with this method (Schminkey et al., 
2016). Variables taken from the baseline demographics questionnaire, were used to build 
up the model in a step-wise way for each utility measurement. Such variables included, 
smoking status, employment status and highest level of education. The base case for these 
variables (to enable comparison), were smoker, unemployed and school leaver 
respectively.  
 
To build the model using a step-wise approach, a null model with a random intercept was 
explored initially, followed by a random intercept fixed slope model, then a random slope 
model and finally a random polynomial model. Each of these base models were assessed 
to identify which model was the best model, by graphing the relationships (e.g. box plots, 
scatter plots and Q-Q plots), and producing log likelihood ratio tests. Once the best 
structural base model was identified, the factors predictive of missingness were added 
into the model. Following this, the other explanatory variables were added into the model 
separately using a step-wise approach to determine which variables fitted the model more 
strongly. The model with the strongest explanatory variable fitted was used to build on 
the model, fitting only those explanatory variables that had an impact on the model until 
a preferred, parsimonious model was achieved. This preferred model was used to estimate 
the disutility of an asthma attack.  
 
Additionally, bootstrapping was also conducted to estimate the disutility of an asthma 
attack to check the stability of the results, since it estimates confidence intervals of a 




population mean by resampling some data from a larger dataset randomly with 
replacement. Dummy variables were then added to this model to explore the impact of 
baseline quality of life on the disutility estimate. Finally, as the missing data patterns are 
explored and missing data proportions are tabulated, the final preferred parsimonious 
models were further improved by using an additional method called multiple imputation. 
This method increases the robustness of the results as it replaces the missing data from 
the available case dataset with values, and this in turn reduces the standard error and 
increases the precision of the estimations. The disutility of asthma attack was also 
estimated using the multiple imputed model.  
 
 
The human capital approach (Walter and Zehetmayr, 2006) was used to estimate the 
productivity loss associated with an asthma-related crisis event, as absences from work 
associated with the event are likely to be short-term. Other methods such as the friction 
cost method, involves the organization potentially training someone so that their initial 
production level is restored (Drummond et al., 2015). This could take days, weeks or even 
months depending on the job description. Therefore, the human capital approach was 
deemed more appropriate for this study. Data from the office for national statistics 
average weekly earnings (Office for National Statistics, 2017c) was used, and multiplied 
by the average hours missed from work (Office for National Statistics, 2017a, Francis, 
2017), to estimate the cost of the time lost at work from having the asthma-related crisis 
event. The latter data took into account the average hours worked in a week in the UK, 
including part-time work. This value was then added to the average cost of any additional 
products bought out-of-pocket by participants that were not normally purchased prior to 
the asthma-related crisis event. This provided an overall estimate of indirect and out of 
pockets costs associated with an asthma-related crisis event. 
 
4.3 Results 
The results in this section, will aim to address all that was outlined in Chapter 4, section 
4.2.1; the statistical analysis section of the methods section. The data collected was 
checked for accuracy, by entering 10% of the collected data again into Microsoft excel, 
and cross checking. The reported errors from the double data entry were very small 
(0.003). Nevertheless,  these were corrected for accuracy.  
  




4.3.1 Recruitment  
Across all three hospital sites, a total of 223 participants were screened for eligibility into 
the study (Figure 17). The eligibility criteria for this study was previously highlighted in 
Table 5. Of those participants assessed, 58 participants declined (26.0%), because they 
were either too busy (40 participants), or the study duration was too long (18 participants). 
In addition, 44 participants were not eligible (19.7%).  
 
The total number of participants who were recruited and consented into the study were 
121 (Figure 17). From the recruited total, 42 participants were lost to follow up (34.7%), 
where 25 participants did not post back the questionnaires that they were asked to 
complete over the 8 week time period, 14 participants could not be reached from their 
contact telephone numbers provided and 3 participants were too poorly. A further 8 
participants withdrew from the study (6.6%) because they were either too busy, (4 
participants), too poorly, (3 participants), or were newly diagnosed with a different 


























The characteristics of the 121 participants recruited and consented at baseline are depicted 
in Table 7. The mean age of the participants was 49.68 years old, with 26.45% male and 
73.55% female. The majority of the participants were of ‘white’ ethnicity (95.83%), with 
0.83% of ‘mixed white and black’ ethnicity and the remaining 3.33% of ‘white other’ 
ethnicity. Most of the participants either never smoked (42.50%), or were ex-smokers 
(40.83%). Only 15.00% were smokers, and a small proportion of participants were non-
smokers (1.67%). The latter proportion of participants who were non-smokers, were often 
those who rarely smoked, i.e. smoked in a social capacity. During the study, some 
participants changed their smoking status (N = 4, 3.31%), where 3 participants (75%) 
became ex-smokers and 1 participant (25%) reverted back to being a smoker. A high 
proportion of participants were those who had ‘school’ (leaving age of 16 years old) as 
223 participants assessed for 
eligibility 
121 participants recruited and consented from A&E and 
hospital wards: 
 42 lost to follow-up 
o 25 didn’t post back questionnaires 
o 14 couldn’t make contact 
o 3 too poorly 
 
 8 withdrawn 
o 4 too busy 
o 3 too poorly 
o 1 new diagnosis  
 
Excluded participants: 
 58 declined 
o 40 too busy 
o 18 study too 
long 
 44 not eligible  
 
Figure 17: Recruitment flow diagram 




their highest level of education (47.06%), and this was followed by ‘college’ (typically 
16 years old and older) (33.61%) and ‘degree’ (typically 18 years old and older) (19.33%). 
The participants’ employment status were varied with 27.50% full time, 15.83% part 
time, 28.33% retired, 7.50% stay at home parents, 3.33% student and 17.50% 
unemployed. The characteristics of adult asthmatics recruited in this study, were 
considered representative of the population as they were comparable to other studies, such 
as those in the UK (Pavord et al., 2017, Gibbison et al., 2013) and United States (Mirabelli 
et al., 2013).  
 
Table 7: Baseline characteristics 
Demographics  N = 121 
Age (mean, years) 49.68 
Height (mean, cm) 167.22 
Weight (mean, kg) 85.54 
    
Gender (%)   
Male 26.45 
Female 73.55 
    
Ethnicity (%)   
White 95.83 
Mixed White and Black 0.83 
White Other 3.33 
    





    




    




Stay at home parents 7.50 
Student 3.33 
Unemployed 17.50 





During this study, there were some non-responses from participants at times when the 
participants’ were asked to complete questionnaires. The remainder of this section 
(Chapter 4, section 4.3.2) and Chapter 4, section 4.3.3 represents statistics based on 
available data and complete data. Chapter 4, section 4.3.4 will go into more depth and 
will provide results which account for missing data statistics.  
 
At baseline, the participants’ completed a demographics questionnaire which included 
the following question:  
 
When did your asthma-related event peak (e.g. on route to hospital, after 2 hours in 
hospital)? 
 
There were 98 responses (81%), and the point at which their asthma symptoms were at 
their worst varied (Figure 18). For the majority, (59 participants), the peak of their asthma 
symptoms being their worst was before arriving in hospital. Being en-route to hospital 
(22 participants) and whilst in hospital (17 participants) were the two other categories that 
followed this as being the point at which the participants’ asthma symptoms peaked.  
 





























PEAK OF ASTHMA EVENT





The two most common modes of entry into hospital were by ambulance (51 participants 
and GP referral (50 participants) (Figure 19), with driving to hospital (18 participants) or 
being referred by a nurse practitioner (1 participant) being the two least common modes.  
 
Figure 19: The route of entry into hospital for the asthma-related crisis event 
 
 
For this study, the average length of stay for the participants’ was 4.64 days. The average 
number of A&E attendances in the last year was 0.66 (SD = 1.76) and the average number 
of hospital admissions in the last year was 0.74 (SD = 1.95). A small percentage of the 
participants recruited (N= 8; 6.61%), had an adverse event (in this case a hospitalization), 
during the study.   
 
All participants’ were taking medication for their asthma, with 55 participants’ (45%) 
taking more than 2 medications and 57 participants’ (47%) taking 2 medications. Over 
30 different asthma medications were noted across the participants’ recruited, and the 
average number of medications taken by participants’ were 2.82 (SD = 1.41) at baseline. 
Most participants also had several other comorbidities, which varied widely, and this 




























ROUTE OF ENTRY INTO HOSPITAL





During the study, at weeks 4 and weeks 8, participants were asked whether they had any 
changes to their asthma medications or comorbidities since the beginning of the study. 
Approximately a third of participants (N = 35; 28.92%), had changes made to their 
medications, and only 3 participants (2.48%), had changes to their comorbidities.  
 
4.3.3 Patient reported outcome measure results  
Participants were asked to complete a number of PROMs at different points over the 8 
week time period. The EQ-5D-5L, AQL-5D and TTO were all converted into utility 
values and the EQ VAS, AQLQ overall, AQLQ symptoms domain, AQLQ activity 
domain, AQLQ emotional domain, and AQLQ environmental domain remained as score 
values. The EQ VAS scores can range from 0 to 100, with 0 (the worst possible health 
state you can imagine) and 100 (the best possible health state you can imagine). The 
AQLQ overall and corresponding domain scores can range from 1 to 7, with 1 being the 
worst category and 7 the best. The response rates, floor and ceiling effects, (the lowest 
possible value and the highest possible value respectively) are shown in Table 8, Table 
9, and Table 10 for baseline, week 4 and week 8 time points respectively.




Table 8: Baseline statistics for each quality of life questionnaire 
*The response rate is based on the denominator being 112 due to only the participants based at the Norfolk and Norwich University Hospital (NNUH) 
being asked the TTO questions. All of the other response rates for the PROMS were based on the denominator being 121 as this was the total number 
recruited across all hospital sites where each participant was asked to complete PROM questionnaires.  
Ranges for PROMs: EQ-5D-5L (-0.281 to 1); EQ VAS (0 to 100); AQLQ (0 to 7); AQL-5D (0 to 1); TTO (0 to 1). 
 
Item N Mean SD Range Response rates Floor effects Ceiling effects 
EQ-5D-5L (utility) 120 0.635 0.274 -0.102 to 1.00 99.2% 0.00% 8.30% 
EQ VAS score 120 45.7 19.3 5.00 to 90.0 99.2% 0.00% 0.00% 
AQLQ overall score 120 3.28 0.963 1.18 to 5.30 99.2% 0.00% 0.00% 
AQLQ Symptoms score 121 2.81 1.06 0.00 to 5.50 100.0% 0.83% 0.00% 
AQLQ Activity score 121 3.51 1.05 0.00 to 5.82 100.0% 0.83% 0.00% 
AQLQ Emotional score 121 3.14 1.51 0.00 to 7.00 100.0% 0. 83% 4.10% 
AQLQ Environmental score 121 4.04 1.52 0.00 to 7.00 100.0% 0.83% 1.70% 
 
AQL-5D (utility) 118 0.608 0.128 0.450 to 0.935 97.5% 0.00% 0.00% 
TTO (utility) 112 0.626 0.277 0.100 to 1.00 100.0% * 0.00% 18.8% 




Table 9: Week 4 statistics for each quality of life questionnaire 
*The response rate is based on the denominator being 112 due to only the participants based at the Norwich hospital site (NNUH) being asked the TTO 
questions. All of the other response rates for the PROMS were based on the denominator being 121 as this was the total number recruited across all 
hospital sites where each participant was asked to complete PROM questionnaires.  
Ranges for PROMs: EQ-5D-5L (-0.281 to 1); EQ VAS (0 to 100); AQLQ (0 to 7); AQL-5D (0 to 1); TTO (0 to 1). 
 
 
Item N Mean SD Range Response rates Floor effects Ceiling effects 
EQ-5D-5L (utility) 71 0.740 0.264 -0.005 to 1.00 58.7% 0.00% 15.5% 
EQ VAS score 73 65.9 21.42 11.00 to 100.00 60.3% 0.00% 4.11% 
AQLQ overall score 70 4.09 1.48 1.47 to 6.94 57.9% 0.00% 0.00% 
AQLQ Symptoms 
score 
85 3.34 2.12 0.00 to 7.00 70.2% 17.65% 1.18% 
AQLQ Activity score 85 3.32 2.00 0.00 to 7.00 70.2% 14.12% 4.71% 
AQLQ Emotional 
score 
85 3.36 2.27 0.00 to 7.00 70.2% 16.67% 7.06% 
AQLQ Environmental 
score 
85 3.63 2.34 0.00 to 7.00 70.2% 16.67%  
4.71% 
 
AQL-5D (utility) 70 0.687 0.173 0.450 to 1.00 57.9% 0.00% 2.90% 
TTO (utility) 87 0.820 0.264 0.000 to 1.00 77.7%* 2.30% 51.7% 
















*The response rate is based on the denominator being 112 due to only the participants based at the Norwich hospital site (NNUH) being asked the TTO 
questions. All of the other response rates for the PROMS were based on the denominator being 121 as this was the total number recruited across all 
hospital sites where each participant was asked to complete PROM questionnaires.  
Ranges for PROMs: EQ-5D-5L (-0.281 to 1); EQ VAS (0 to 100); AQLQ (0 to 7); AQL-5D (0 to 1); TTO (0 to 1). 
 
 
Item N Mean SD Range Response rates Floor effects Ceiling effects 
EQ-5D-5L 
(utility) 
65 0.725 0.292 -0.215to 1.00 53.7% 0.00% 21.5% 
EQ VAS score 65 68.06 21.91 5.00 to 100.00 53.7% 0.00% 4.69% 
AQLQ overall 
score 
65 4.48 1.50 1.47 to 7.00 53.7% 0.00% 3.08% 
AQLQ Symptoms 
score 
66 3.64 2.22 0.00 to 7.00 54.5% 16.67% 3.03% 
AQLQ Activity 
score 
66 3.68 2.13 0.00 to 7.00 54.5% 16.67% 3.03% 
AQLQ Emotional 
score 




66 3.91 2.33 0.00 to 7.00 54.5% 16.67%  
7.58% 
 
AQL-5D (utility) 64 0.737 0.176 0.450 to 1.00 52.9% 0.00% 7.80% 
TTO (utility) 80 0.787 0.295 0.000 to 1.00 71.4%* 5.00% 51.3% 





There was some evidence of floor effects in Table 8 for the baseline statistics, but the 
EQ-5D-5L utility, AQLQ emotional and environmental scores and the TTO utility 
showed evidence of ceiling effects. The TTO utility had the highest percentage of 18.8% 
for ceiling effects. The baseline response rates ranged from 97.5% to 100.0%. For the 
statistics at week 4 shown in Table 9, the ceiling effects approximately doubled and 
trebled for the EQ-5D-5L utility and TTO utility respectively, which may suggest that the 
participants’ health was improving and they had recovered from their asthma crisis event. 
The response rates had reduced and ranged from 57.9% to 77.7%. For the week 8 statistics 
shown in Table 10, the ceiling effects continued to increase for the EQ-5D-5L, and had 
begun to stabilise for the TTO. There was, however, a spiked increase seen in the ceiling 
effects for the AQL-5D utility. The response rates had lowered very slightly to range 
between 53.7% and 71.4%.  Higher percentages of floor effects were observed for the 
AQLQ symptoms, activity, emotional and environmental scores at week 4 and 8. 
However, the AQLQ overall score and AQL-5D utility value were both absent from floor 
effects at these time points. This suggests that the participant’s triggers were beginning 
to affect them again.  
 
After considering the evidence of ceiling effects observed for utility in the baseline 
statistics (Table 8), I explored the EQ-5D-5L and TTO utility values further in relation 
to the peak of the asthma event data.  
 
The table below (Table 11) shows that 10 participants had a ceiling effect at baseline for 
the EQ-5D-5L, and 20 participants had a ceiling effect at baseline for the TTO. The 
majority of these participants (70% for the EQ-5D-5L, and 55% for the TTO) had the 










Table 11: Number of participants with ceiling effects at baseline for eq-5d-5l and 
TTO and their corresponding peak of asthma event 
 
Following this, I used regression analysis to explore the relationship between the EQ-5D-
5L and TTO baseline utility values and the peak of the asthma event data, since these two 
utility variables were reporting ceiling effects for a proportion of participants. Table 12 
below shows that there were no statistically significant differences found between the 
peak of the asthma event data (before or on route to A&E attendance or hospital 
admission) and the baseline TTO utility values. However, the sample size (N) was small, 
and the R-squared value was 0.0041, which indicates that the model doesn’t represent 
goodness of fit. Table 13 below also shows that there are no statistically significant 
differences found between the peak of the asthma event data and the baseline EQ-5D-5L 
utility values. Likewise, as above, the sample size (N) for Table 13, was small and the R-
squared value was 0.0031, which indicates that the model doesn’t represent goodness of 
fit.  
 
Table 12: Regression analysis to show the baseline TTO utility value compared to 
the peak of the asthma-related crisis event 




P-value 95% Confidence 
interval 
Intercept 0.6031 0.0701 0.000 (0.4641,0.7422) 
Before* 0.0162 0.0776 0.835 (-0.1377,-
0.1701) 
On route* 0.0556 0.0931 0.552 (-0.1290,0.2401) 
*Hospital was the comparator 
 
Peak of asthma event No. of participants with 
an EQ-5D-5L baseline 
utility of 1.000 
No. of participants with a 
TTO baseline utility of 
1.000 
Before A&E attendance / 
admission to hospital 
7 11 
On route to A&E 
attendance / admission to 
hospital 
2 4 
In hospital 1 5 
Total 10 20 




Table 13: Regression analysis to show the baseline EQ-5D-5L utility value compared 






P-value 95% Confidence 
interval 
Intercept 0.6742 0.0675 0.000 (0.5404, 0.8080) 
Before* -0.0431 0.0746 0.565 (-0.1909,0.1048) 
On route* -0.0431 0.0900 0.632 (-0.2213,0.1350) 
*Hospital was the comparator 
 
The relationship between the baseline EQ-5D-5L utility values and the peak of the asthma 
event data, and between the TTO utility values and the peak of the asthma event data were 
explored using regression analyses. Both regressions showed no statistically significant 
differences between the utility values and the peak of the asthma event data.  
 
Even though 10 participants had a ceiling effect in the EQ-5D-5L utility values at 
baseline, none of the participants had a ceiling effect for the EQ VAS scores at baseline. 
 
Therefore, given the non-statistically significant result, it was not necessary to exclude 
the participants at baseline who had demonstrated ceiling effects in the EQ-5D-5L and 
TTO utility values.  
 
The data set had missing data throughout the study as previously noted in Table 8 to 
Table 10. The majority of the missing data was found in the PROMs, where participants 
either did not post back their questionnaires (loss to follow up), or did post back their 
questionnaires with missing data (patient non-response). To highlight the percentage of 
missing data in the PROMs, the tables below provide this information for the EQ-5D-5L, 
EQ VAS, AQLQ overall scores, AQL-5D and the TTO.  
 
For the EQ-5D-5L questionnaires, a large amount of missing data was visible from the 
second time point (at week 1). Table 14 shows that 33.06% of the EQ-5D-5L data points 
were missing by week 1, compared to 0.83% missing at baseline. Between week 1 and 
week 8, the missing values for the EQ-5D-5L (missing overall utility values) ranged 
between 33.06% and 47.11%.  
 




Table 14: Missing data descriptive statistics for the EQ-5D-5L questionnaire at all 
time points 
Follow-up points Missing Values 
(%) 
SD Range 
Baseline 0.83 0.274 -0.102 – 1.00 
Week 1 33.06 0.264 -0.102 – 1.00 
Week 2 38.02 0.233 0.030 – 1.00 
Week 3 38.84 0.248 0.000 – 1.00 
Week 4 41.32 0.264 -0.005 – 1.00 
Week 5 46.28 0.235 0.092 – 1.00 
Week 6 46.28 0.249 0.108 – 1.00 
Week 7 47.11 0.232 0.108 – 1.00 
Week 8 47.11 0.294 -0.215 – 1.00 
 
The missing data values for the EQ VAS were very similar to the missing data values for 
the EQ-5D-5L, probably because the EQ VAS is part of the EQ-5D-5L questionnaire.  
Table 15 shows the missing values were very low at baseline for the EQ VAS, (0.83%), 
and rose to 33.06% at week 1. This peaked to 47.11% missing data for weeks 7 to week 
8.  
 
Table 15: Missing data descriptive statistics for the EQ VAS scores at all time points 
Follow-up points Missing Values (%) SD Range 
Baseline 0.83 19.26 5 - 90 
Week 1 33.06 19.88 10 - 100 
Week 2 38.02 20.70 10 - 100 
Week 3 38.02 18.95 10 - 100 
Week 4 39.67 21.42 11 – 100 
Week 5 45.45 18.94 10 – 100 
Week 6 46.28 19.33 30 – 100 
Week 7 47.11 18.76 30 - 100 
Week 8 47.11 22.03 5 - 100 
 
For the AQLQ overall scores and the AQL-5D values (missing overall utility values), the 
missing data percentages were also very similar with 0.83% and 2.48% missing at 
baseline for the AQLQ overall score (Table 16) and AQL-5D utility values (Table 17) 
respectively. Both the AQLQ overall score and the AQL-5D utility values had missing 
values of 42.15% at week 4. At week 8, the AQLQ overall score and the AQL-5D utility 
values had 46.28% and 47.11% missing data respectively.  
 




Table 16: Missing data descriptive statistics for the AQLQ overall scores at all time 
points 
Follow-up points Missing Values (%) SD Range 
Baseline 0.83 0.96 1.18 – 5.30 
Week 4 42.15 1.48 1.47 – 6.94 
Week 8 46.28 1.50 1.47 – 7.00 
 
 
Table 17: Missing data descriptive statistics for the AQL-5D utility values at all time 
points 
Follow-up points Missing Values (%) SD Range 
Baseline 2.48 0.128 0.45 – 0.935 
Week 4 42.15 0..173 0.45 – 1.00 
Week 8 47.11 0.176 0.45 – 1.00 
 
The TTO also showed the same pattern as the other PROMs for missing data. However, 
at week 4 and week 8 time points (Table 18), the missing data percentages were much 
lower, with 28.10% and 33.88% missing for week 4 and week 8 respectively. The reason 
for the lower missing value percentages in the TTO at week 4 and week 8 could be 
because the participant completed this with the researcher (for those who were not lost to 
follow up), either in person at a routine follow-up appointment or over the phone. The 
baseline TTO was missing for some participants, as those who were recruited at the 
hospital sites in Birmingham and Aberdeen were not asked the TTO. Therefore, the 
response rate could be higher if the participants in Birmingham and Aberdeen were asked. 
In comparison, the EQ-5D-5L and the AQLQ, showed much higher missing values after 
baseline, and this could be because the participants were completing this away from the 
researcher (e.g. at home), and therefore the researcher was not able to double check 
completion of the questionnaires in presence of the participant.  
 
Table 18: Missing data descriptive statistics for the TTO utility values at all time 
points 
Follow-up points Missing Values (%) SD Range 
Baseline 7.44 0.277 0.100 – 1.00 
Week 4 28.10 0.264 0.000 – 1.00 
Week 8 33.88 0.295 0.000 – 1.00 
 





As seen above, there is a substantial amount of missing data amongst the EQ-5D-5L, 
AQL-5D and TTO. Further tests were performed to explore this missing data further by 
observing the patterns of missing data and identifying whether there were any predictors 
of this missing data. This exploration was informed by LEMMA (Bristol) and Faria et al. 
(2014). Table 19 shows the highest frequencies of the missing data patterns. The first row 
indicates that all variables considered here were reported for 42 participants out of all 
who were recruited. However, the second row shows that the EQ-5D-5L, AQL-5D and 
TTO variables were reported at baseline for 18 participants, with the remaining variables 
showing missing data. Each row following on from this, shows a different pattern of 
missing data, but with lower frequencies.  
 
Table 19: Patterns of missing data 
 Pattern 
Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
42 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
18 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 
12 1 1 1 1 0 1 0 0 0 0 0 0 0 0 0 
7 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 
4 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 
Variables: (1) EQ-5D-5L baseline (2) AQL-5D baseline (3) TTO baseline (4) TTO week 4 (5) EQ-5D-5L 
week 1 (6) TTO week 8 (7) EQ-5D-5L week 2 (8) EQ-5D-5L week 3 (9) EQ-5D-5L week 4 (10) AQL-5D 
week 4 (11) EQ-5D-5L week 5 (12) EQ-5D-5L week 6 (13) EQ-5D-5L week 7 (14) EQ-5D-5L week 8 
(15) AQL-5D week 8 
Note: the 1 and 0 in the table are defined as observed (1) and missing (0).  
 
 
The visualization of the missing data points, was followed by logistic regression to 
explore whether the probability of missing data was associated with any baseline 
demographic variables at different time points (Table 20). The demographic variables 
were tested separately, one by one to see if there was any association with each of the 
utility variables at different time points. Most regressions produced statistically 
significant results (p< 0.05) between the age variable and missing data utility variables, 
except for the missing data on TTO at week 4 of the study. This implies that there was 
additional missing data points for every year of being older. In addition, some of the 




smoking status and employment status categorical variables, showed statistically 
significant results (p<0.05) for some of the utility variables. This implied that there was 
more additional missing data points if the participant was a smoker compared to being an 
ex-smoker. The variables, gender, ethnicity and highest education status did not show any 
association with levels of missing data amongst the utility values at different time points.  
 




Table 20: Logistic regression for missingness of utility values at different time points on baseline demographic variables 
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*statistically significant p< 0.05 
§ convergence not achieved 
ǂ confidence interval not reported 
ǂǂ omitted due to predicting failure perfectly 








The results above show that age is definitely a predictor of missingness for the majority 
of the utility values, where in some cases smoking status and employment status are also 
associated. This confirms that the data cannot be assumed to be MCAR due to 
observations of statistical significance i.e. data is associated with observed values. 
Therefore the data could be MAR or MNAR. Whilst missing data could be MNAR, for 
the purposes of this analysis it was assumed to be MAR.  
 
The utility data (EQ-5D-5L, AQL-5D and TTO), was further explored to assess whether 
the data was normally distributed. Histograms, Q-Q plots and skewness / kurtosis tests 
were conducted to explore the normality distributions. All utility data at the different time 
points showed evidence of non-normality. The EQ-5D-5L weekly time point data showed 
histograms that were left-skewed, with the corresponding Q-Q plots showing the data to 
be non-normally distributed as it deviates from the solid normal line (Figure 20 - Figure 
28). For the AQL-5D, the first baseline time point shows evidence of right-skewed data, 
with the following two data points at week 4 and 8 beginning to show a more bimodal 
relationship (Figure 29 - Figure 31). Again, the data points for the AQL-5D deviate from 
the normal distribution line on the Q-Q plots. Lastly, the TTO utility data shows a bimodal 
relationship for baseline and left skewed data for week 4 and week 8, indicating non-
































































0 .5 1 1.5
Inverse Normal
Figure 20: Histogram and Q-Q plot to show the distribution for participants completing the EQ-5D-5L at baseline 
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Inverse Normal
Figure 21: Histogram and Q-Q plot to show the distribution for participants completing the EQ-5D-5L at week 1 
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Figure 22: Histogram and Q-Q plot to show the distribution for participants completing the EQ-5D-5L at week 2 
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Figure 23: Histogram and Q-Q plot to show the distribution for participants completing the EQ-5D-5L at week 3 
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EQ-5D-5L week 4
Figure 24: Histogram and Q-Q plot to show the distribution for participants completing the EQ-5D-5L at week 4 
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EQ-5D-5L week 5
Figure 25: Histogram and Q-Q plot to show the distribution for participants completing the EQ-5D-5L at week 5 
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EQ-5D-5L week 6
Figure 26: Histogram and Q-Q plot to show the distribution for participants completing the EQ-5D-5L at week 6 
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Figure 27: Histogram and Q-Q plot to show the distribution for participants completing the EQ-5D-5L at week 7 
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Figure 28: Histogram and Q-Q plot to show the distribution for participants completing the EQ-5D-5L at week 8 
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Figure 29: Histogram and Q-Q plot to show the distribution for participants completing the AQL-5D at baseline 
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Figure 30: Histogram and Q-Q plot to show the distribution for participants completing the AQL-5D at week 4 
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Figure 31: Histogram and Q-Q plot to show the distribution for participants completing the AQL-5D at week 8 
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Figure 32: Histogram and Q-Q plot to show the distribution for participants completing the TTO at baseline 
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Inverse Normal
Figure 33: Histogram and Q-Q plot to show the distribution for participants completing the TTO at week 4 
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Figure 34: Histogram and Q-Q plot to show the distribution for participants completing the TTO week 8 




Additionally, the skewness / kurtosis test provided further confirmation that the utility 
data was not normally distributed as shown by the Chi2 test statistic being  p<0.05 for all 
variables (Table 21). This finding suggests one should reject the hypothesis that the 
variables are normally distributed.  
 
Table 21: Skewness / Kurtosis test to explore the normality assumptions of the 
utility variables at different time points 










120 0.0036 0.3898 8.25 0.0162 
EQ-5D-5L 
week 1 
81 0.0151 0.6418 5.83 0.0542 
EQ-5D-5L 
week 2 
75 0.0035 0.3175 8.36 0.0153 
EQ-5D-5L 
week 3 
74 0.0013 0.6132 9.11 0.0105 
EQ-5D-5L 
week 4 
71 0.0001 0.1504 13.39 0.0012 
EQ-5D-5L 
week 5 
65 0.0002 0.0812 13.36 0.0013 
EQ-5D-5L 
week 6 
65 0.0003 0.2727 11.59 0.0030 
EQ-5D-5L 
week 7 
64 0.0003 0.1452 12.16 0.0023 
EQ-5D-5L 
week 8 
64 0.0003 0.1512 12.39 0.0020 
AQL-5D 
baseline 
118 0.0013 0.2450 10.09 0.0064 
AQL-5D 
week 4 
70 0.2690 0.0000 17.33 0.0002 
AQL-5D 
week 8 
64 0.7739 0.0000 25.61 0.0000 
TTO 
baseline 
112 0.7991 0.0000 29.84 0.0000 
TTO  
week 4 
87 0.0000 0.0648 18.84 0.0001 
TTO  
week 8 
80 0.0000 0.2419 14.35 0.0008 
Skewness / Kurtosis test used to test for normality in data 
All variables show the Chi2 statistic as p < 0.05, which suggests to reject the hypothesis 
that the variables are normally distributed.   
 
 




The mean utility values, score values and their associated standard deviations for these 
questionnaires are displayed in Table 22 for the available cases. All of the questionnaires 
apart from the AQLQ activity domain, AQLQ emotional domain and the AQLQ 
environmental domain had statistically significantly different scores at the 1% level when 
the Wilcoxon-signed rank test were conducted between baseline and week 8. 
 
Graphical representations of these aforementioned utility values and scores are displayed 
in Figure 35 and Figure 36 for the available case analysis, where the N changes over the 
weekly time points as illustrated in Table 22. Both the mean utility values and EQ VAS 
scores progress by increasing in the same direction whilst tapering off at the end of the 8 
weeks.  
 
The mean PEF shown in Figure 37, also shows an increase in values over the course of 
the 8 weeks, but this progression is not as linear as the utility values and EQ VAS scores 
have illustrated. Figure 38 highlights the mean symptoms scores, (sleeping, symptoms 
and activities), which were recorded daily over the 8 weeks by the participants. The y-
axis of this graph represents the severity of the symptoms, (1 = mild, 2 = moderate and 3 
= severe). On average, by approximately half a week after the asthma-related crisis event, 
difficulties in sleeping had reduced from moderate severity to mild severity. The severity 
of symptoms and difficulties doing activities had reduced from moderate to mild severity 
by approximately 7 days from when the asthma-related crisis event had occurred. 
Approximately half of the recruited participants completed both the PEF and symptom 
diary over the 8 week period.   




Table 22: Mean utility values and scores at weekly time points shown between baseline and week 8 
Wilcoxon signed-rank test shown for the mean change between baseline and week 8. 
**p-value < 0.01 therefore statistically significant at the 1% level.  






( Mean  ± 
SD) 
Week 2 
( Mean  ± 
SD) 
Week 3 
( Mean  ± 
SD) 
Week 4 
( Mean  ± 
SD) 
Week 5 
(Mean  ± 
SD) 
Week 6 
(Mean  ± 
SD) 
Week 7 
(Mean  ± 
SD) 
Week 8 
( Mean  ± 
SD) 
p Value  
           
EQ-5D-5L N = 120 
0.64 ± 0.27 
N = 81 
0.65± 0.26 
N = 75 
0.70 ± 0.23 
N = 74 
0.72 ± 0.25 
N = 71 
0.74 ± 0.26 
N = 65 
0.76 ± 0.24 
N = 65 
0.77± 0.25 
N = 64 
0.78 ± 0.23 
N = 64 
0.72 ± 0.29 
N = 64 
P < 0.007** 
EQ VAS N = 120 
45.68 ± 
19.26 
N = 81 
57.70 ± 
19.88 
N = 75 
60.79 ± 
20.70 
N = 75 
63.21 ± 
18.95 
N = 73 
65.95 ± 
21.42 
N = 66 
68.09 ± 
18.94 
N = 65 
68.75 ± 
19.33 
N = 64 
71.56 ± 
18.76 
N = 64 
67.88 ± 
22.03 
N = 64 
P < 0.000** 
           
AQLQ overall N = 120 
3.28 ± 0.96 
   N = 70 
4.09 ± 1.48 
   N = 65 
4.48 ± 1.50 
N = 65 
P < 0.000** 
AQLQ 
Symptoms 
N = 121 
2.81 ± 1.06 
   N = 85 
3.33 ± 2.12 
   N = 66 
3.64 ± 2.22 
N = 66 
P < 0.003** 
AQLQ Activity N = 121 
3.51 ± 1.05 
   N = 85 
3.32 ± 2.00 
   N = 66 
3.68 ± 2.13 
N = 66 
P < 0.044* 
AQLQ 
Emotional 
N = 121 
3.14 ± 1.51 
   N = 85 
3.36 ± 2.27 
   N = 66 
3.72 ± 2.39 
N = 66 
P < 0.041* 
AQLQ 
Environmental 
N = 121 
4.04 ± 1.52 
   N = 85 
3.63 ± 2.34 
   N = 66 
3.91 ± 2.33 
N = 66 
P < 0.089 
           
AQL-5D N = 118 
0.61 ± 0.13 
   N = 70 
0.69 ± 0.17 
   N = 64 
0.74 ± 0.18 
N = 62 
P < 0.000** 
           
TTO N = 112 
0.63 ± 0.28 
   N = 87 
0.82 ± 0.26 
   N = 80 
0.79 ± 0.30 
N = 80 
P < 0.000** 




Note: Different N at each time point for each measure 
 
Figure 36: Mean EQ VAS scores at weekly time points 
Note: Different N at each time point for each measure 
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Figure 37: Mean Peak Expiratory Flow at daily time points 
 
 
From the above graph in Figure 37, the mean PEF indicates variability in the 
measurements from baseline (263) to week 8 (334) of the study. The mean change from 
these two time points (baseline and week 8) was 63.97, with a strong statistical significant 
difference at the 5% level. However, the participants’ mean best PEF and mean predicted 
PEF, was 377 and 490 respectively, and so it is clear that by week 8 of the study, the 
participants were not back to their best or predicted PEF values. This indicates that the 
study time period of 8 weeks, was not long enough for the participants to reach their best 
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Figure 38: Mean scores for difficulties sleeping, symptoms and activities at daily 
time points 
 
y-axis: 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms, 3 = severe symptoms 
 
Daily, weekly, and monthly data were collected over the 8 weeks from different PROM 
questionnaires. Three key time points, (baseline, week 4 and week 8), were compared 
using Wilcoxon signed-rank tests to test for differences in the mean rank and p-values.  
The mean changes in the PROM scores, (EQ-5D-5L, EQ VAS score, AQLQ overall 
score, AQL-5D, and the TTO), were all statistically significant at the 1% level between 
baseline and week 8 (Table 23), where there was an improvement in quality of life from 
baseline. Likewise, for the PROMs observed between baseline and week 4, they were 
also all statistically significant at the 1% level (Table 24), with an improvement in quality 
of life from baseline. However, for the PROM scores where the comparison was between 
week 4 and week 8, only two of them remained statistically significantly different at the 
5% level, and this was the AQLQ overall score and AQL-5D (Table 25). There was no 
statistical significant difference identified in the other PROMS in Table 25. This 
indicated that most of the loss associated with an asthma-related crisis event occurred 
during the first four weeks. The mean differences between the time points shown for the 
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23, Table 24 and Table 25), also highlighted that they exceeded the minimal important 
difference.  
 
Most of the loss in quality of life is seen by 4 weeks, as represented in Table 24. If 
estimating the QALY loss associated with an asthma-related crisis event for preference-
based measures from this table (over a 4 week period, assuming linear interpolation), then 
the loss associated would be as follows:  
𝐸𝑄 − 5𝐷 − 5𝐿 =
1
2
 × 0.127 ×
4
52
= 0.005 𝑄𝐴𝐿𝑌𝑠 
 
𝐴𝑄𝐿 − 5𝐷 =
1
2
 × 0.099 ×
4
52





 × 0.170 ×
4
52
= 0.007 𝑄𝐴𝐿𝑌𝑠 
 
 
If estimating the QALY loss associated with an asthma-related crisis event for preference-
based measures from Table 23 (over a 8 week period, assuming linear interpolation), then 
the loss associated would be as follows:  
𝐸𝑄 − 5𝐷 − 5𝐿 =
1
2
 × 0.086 ×
8
52
= 0.007 𝑄𝐴𝐿𝑌𝑠 
 
𝐴𝑄𝐿 − 5𝐷 =
1
2
 × 0.154 ×
8
52





 × 0.132 ×
8
52
= 0.010 𝑄𝐴𝐿𝑌𝑠 
 
 
As the aforementioned three tables were data based as available cases, the next three 
tables provided the same analytical information on mean changes but by using complete 
case analysis. Using data points from the same participants over the 8 week time period 
enables better comparability between the considered time points of interest.  
 




The data tables representing the complete case analysis, showed similar outputs to the 
available case analysis. However, the differences were that the EQ-5D-5L only showed a 
statistical significant difference at the 5% level in Table 26 and Table 27, for the mean 
changes between baseline and week 8, and baseline and week 4 respectively.  
 
In addition, the TTO had a slightly lower mean change for between baseline and week 4 
(Table 27), with a statistical significance at the 5% level as opposed to the 1% level as 
previously estimated in the available case analysis table (Table 24). None of the PROMs 
showed statistical significance for the last mean change between week 4 and week 8 in 
Table 28. Despite these differences, the majority of the loss associated with an asthma-
related crisis event for the complete case analysis data was during the first four weeks of 
the study, which was in line with the available case analysis data. Therefore, the QALY 
loss estimations associated with an asthma-related crisis event, over the four week period, 
assuming linear interpolation, are displayed below.  
 
𝐸𝑄 − 5𝐷 − 5𝐿 =
1
2
 × 0.067 ×
4
52
= 0.003 𝑄𝐴𝐿𝑌𝑠 
𝐴𝑄𝐿 − 5𝐷 =
1
2
 × 0.114 ×
4
52





 × 0.117 ×
4
52
= 0.005 𝑄𝐴𝐿𝑌𝑠 
 
𝐸𝑄 − 5𝐷 − 5𝐿 =
1
2
 × 0.073 ×
8
52
= 0.006 𝑄𝐴𝐿𝑌𝑠 
 
𝐴𝑄𝐿 − 5𝐷 =
1
2
 × 0.153 ×
8
52





 × 0.141 ×
8
52
= 0.011 𝑄𝐴𝐿𝑌𝑠 
 
 




As highlighted from above, the QALY losses associated with an asthma-related crisis 
event for the preference-based measures, were very similar in value for both the 
available case analysis and complete case analysis data sets.  





Table 23: Mean changes in utility and score values between baseline and week 8 (available case analysis) 
Outcome measure N Baseline 
Mean  (SD) 
8 weeks 
Mean  (SD) 
Mean difference (95% 
CI) 
P-value 
EQ-5D-5L (utility) 64 0.639 (0.267) 0.725 (0.294) 0.086 (0.153 to 0.019) 0.007** 
EQ VAS (score) 64 48.81 (18.58) 67.88 (22.03) 19.06 (25.69 to 12.44) <0.001** 
AQLQ overall (score) 65 3.20 (0.955) 4.48 (1.50) 1.28 (1.60 to 0.963) <0.001** 
AQL-5D (utility) 62 0.582 (0.120) 0.736 (0.178) 0.154 (0.196 to 0.112) <0.001** 
TTO (utility) 80 0.655 (0.273) 0.787 (0.295) 0.132 (0.201 to 0.063) <0.001** 
Wilcoxon signed-rank test 
**p-value <0.01 therefore statistically significant at the 1% level  
 
 
Table 24: Mean changes in utility and score values between baseline and week 4 (available case analysis) 
Outcome measure N Baseline 
Mean  (SD) 
4 weeks 
Mean  (SD) 
Mean difference (95% 
CI) 
P-value 
EQ-5D-5L (utility) 71 0.613 (0.275) 0.740 (0.264) 0.127 (0.193 to 0.061) <0.001** 
EQ VAS (score) 73 47.38 (20.08) 65.95 (21.42) 18.56 (23.40 to 13.72) <0.001** 
AQLQ (score) 70 3.16 (0.980) 4.09 (1.48) 0.929 (1.19 to 0.666) <0.001** 
AQL-5D (utility) 69 0.589 (0.126) 0.687 (0.174) 0.099 (0.134 to 0.063) <0.001** 
TTO (utility) 87 0.650 (0.278) 0.820 (0.264) 0.170 (0.243 to 0.097) <0.001** 
Wilcoxon signed-rank test 
**p-value <0.01 therefore statistically significant at the 1% level  
 
 




Table 25: Mean changes in utility and score values between week 4 and week 8 (available case analysis) 
Outcome measure N 4 weeks 
Mean  (SD) 
8 weeks 
Mean  (SD) 
Mean difference (95% 
CI) 
P-value 
EQ-5D-5L (utility) 59 0.745 (0.255) 0.720 (0.302) -0.025 (-0.033 to 0.082) 0.710 
EQ VAS (score) 61 67.41 (20.31) 68.51 (22.13) 1.10 (4.60 to 2.41) 0.575 
AQLQ (score) 57 4.23 (1.52) 4.52 (1.55) 0.291 (0.536 to 0.046) 0.017* 
AQL-5D (utility) 56 0.700 (0.179) 0.740 (0.181) 0.040 (0.078 to 0.002) 0.044* 
TTO (utility) 76 0.813 (0.268) 0.794 (0.290) -0.019 (-0.047 to 0.086) 0.488 
Wilcoxon signed-rank test 
*p-value <0.05 therefore statistically significant at the 5% level  
 
 
Table 26: Mean changes in utility and score values between baseline and week 8 (complete case analysis) 
Outcome measure N Baseline 
Mean  (SD) 
8 weeks 
Mean  (SD) 
Mean difference (95% 
CI) 
P-value 
EQ-5D-5L (utility) 44 0.658 (0.271) 0.732 (0.270) 0.073 (0.152 to 0.006) 0.036* 
EQ VAS (score) 44 49.55 (19.25) 68.52 (21.06) 18.98 (26.71 to 11.25) <0.001** 
AQLQ overall (score) 44 3.08 (0.863) 4.41 (1.45) 1.33 (1.74 to 0.923) <0.001** 
AQL-5D (utility) 44 0.580 (0.116) 0.733 (0.173) 0.153 (0.202 to 0.104) <0.001** 
TTO (utility) 44 0.701 (0.274) 0.842 (0.260) 0.141 (0.235 to 0.048) 0.002** 
Wilcoxon signed-rank test 
**p-value <0.01 therefore statistically significant at the 1% level  
*p-value < 0.05 therefore statistically significant at the 5% level 
 
 






Table 27: Mean changes in utility and score values between baseline and week 4 (complete case analysis) 
Outcome measure N Baseline 
Mean  (SD) 
4 weeks 
Mean (SD) 
Mean difference (95% 
CI) 
P-value 
EQ-5D-5L (utility) 44 0.658 (0.271) 0.725 (0.276) 0.067 (0.152 to 0.018) 0.051* 
EQ VAS (score) 44 49.55 (19.25) 66.70 (21.31) 17.16 (23.73 to 10.59) <0.001** 
AQLQ (score) 44 3.08 (0.863) 4.10 (1.44) 1.025 (1.38 to 0.667) <0.001** 
AQL-5D (utility) 44 0.580 (0.116) 0.694 (0.175) 0.114 (0.158 to 0.069) <0.001** 
TTO (utility) 44 0.701 (0.274) 0.818 (0.262) 0.117 (0.222 to 0.013) 0.014* 
Wilcoxon signed-rank test 
**p-value <0.01 therefore statistically significant at the 1% level  
*p-value <0.05 therefore statistically significant at the 5% level  
 
 
Table 28: Mean changes in utility and score values between week 4 and week 8 (complete case analysis) 
Outcome measure N 4 weeks 
Mean  (SD) 
8 weeks 
Mean (SD) 
Mean difference (95% 
CI) 
P-value  
EQ-5D-5L (utility) 44 0.725 (0.276) 0.732 (0.270) 0.006 (0.065 to 0.052) 0.842 
EQ VAS (score) 44 66.70 (21.31) 68.52 (21.06) 1.82 (6.12 to 2.48) 0.522 
AQLQ (score) 44 4.10 (1.44) 4.41 (1.45) 0.306 (0.617 to 0.006) 0.072 
AQL-5D (utility) 44 0.694 (0.175) 0.733 (0.173) 0.039 (0.085 to 0.007) 0.126 
TTO (utility) 44 0.818 (0.262) 0.842 (0.260) 0.024 (0.092 to 0.043) 0.279 
Wilcoxon signed-rank test




I also wished to observe the results of the dataset when all the participants who had 
showed evidence of ceiling effects at baseline for the utility data (Table 8) were removed 
from the dataset. This was because of ceiling effects potentially indicating that these 
participants were ‘healthy’ at baseline, and would therefore have a potential to bias the 
results in loss in quality of life associated with an asthma-related crisis event. In this 
instance, the evidence of ceiling effects could have arisen because the measures might 
not have fully captured the problems associated with an asthma crisis event or, for the 
TTO, less problems could have arisen that were not deemed to be of such value that the 
participant would be willing to reduce their life expectancy.  
 
For comparison purposes, the mean changes in utilities and scores will be compared for 
available cases. When observing the mean changes between baseline and week 8, the 
values when ceiling effects were removed (Table 29) compared to the full dataset (Table 
23), were generally lower at baseline, (with the exception of the VAS score), and lower 
and week 8. However, the statistical significance was still strong for all outcome 
measures, with only the EQ-5D-5L having a slightly weaker statistical significance when 
ceiling effects were removed (Table 29) compared to the full dataset (Table 23).  
 
Likewise, when comparing the mean changes between baseline and week 4, the values 
when ceiling effects were removed (Table 30) were lower at baseline and week 4 
compared to the full dataset (Table 24). All the statistical significance for the outcome 
measures were the same for both datasets, showing statistical significance at the 1% level. 
Similarly, when comparing the mean changes between week 4 and week 8, the values 
when ceiling effects were removed (Table 31), were lower at baseline and week 4, 
compared to the full dataset (Table 25). However, when ceiling effects were removed, 
there was no statistical significance for the mean changes between week 4 and week 8 for 
the AQL-5D (Table 31), compared to the full dataset when there was statistical 
significance (Table 25).  
 
Overall, the mean differences between weeks were only slightly different, with some of 
them being slightly higher or lower when the available cases had the ceiling effects 
removed. For example, the mean change between baseline and week 4 for the EQ-5D-5L 
when ceiling effects were removed was 0.163 (Table 30) compared to the mean change 




for the full dataset being 0.127 (Table 24). Therefore, there was only a 0.036 difference 
between datasets and statistical significance remained strong at the 1% level.  
 
Table 29: Mean changes in utility and score values between baseline and week 8 




Mean  (SD) 
8 weeks 







45 0.595 (0.262) 0.674 
(0.312) 
0.079 (0.168 to 
0.009) 
0.052* 
VAS (score) 46 48.89 (17.77) 65.39 
(22.91) 










45 0.562 (0.103) 0.714 
(0.175) 
0.152 (0.201 to 
0.102) 
0.000** 
TTO (utility) 58 0.551 (0.221) 0.744 
(0.299) 
0.194 (0.274 to 
0.113) 
0.000** 
Wilcoxon signed-rank test 
*p-value <0.05 therefore statistically significant at the 5% level  
**p-value <0.01 therefore statistically significant at the 1% level  
 
 
Table 30: Mean changes in utility and score values between baseline and week 4 




Mean  (SD) 
4 weeks 







51 0.557 (0.265) 0.720 
(0.253) 
0.163 (0.241 to 
0.084) 
0.000** 
VAS (score) 53 47.25 (19.76) 64.57 
(21.80) 
17.32 (23.23 to 
11.41) 
0.000** 





48 0.563 (0.111) 0.664 
(0.168) 
0.101 (0.145 to 
0.057) 
0.000** 
TTO (utility) 64 0.549 (0.230) 0.792 
(0.272) 
0.244 (0.325 to 
0.163) 
0.000** 
Wilcoxon signed-rank test 
**p-value <0.01 therefore statistically significant at the 1% level  
 
 





Table 31: Mean changes in utility and score values between week 4 and week 8 
without ceiling effects (available case analysis) 
Outcome 
measure 
N 4 weeks 









41 0.732 (0.235) 0.670 (0.324) -0.063 (0.233 to 
0.011) 
0.222 
VAS (score) 44 66.93 (20.36) 66.32 (22.98) -0.614 (4.90 to 
3.67) 
0.765 





38 0.689 (0.175) 0.715 (0.182) 0.026 (0.072 to 
0.021) 
0.309 
TTO (utility) 54 0.781 (0.277) 0.751 (0.294) -0.031 (-0.048 
to 0.109) 
0.466 
Wilcoxon signed-rank test 
*p-value <0.05 therefore statistically significant at the 5% level  
 
 
Figure 39 below, provides an example of a possible asthma-related crisis event 
happening once in a six month period (at two months), where it takes 2 months for the 
participant to recover back to the same health state as before the crisis event.  
Figure 39: Example of EQ-5D-5L utility values captured over 6 months with one 
asthma-related crisis event 
 
 
























1) By estimating the total QALYs based on scores at two time points, (baseline and 
6 months): 
 
0.8 ×  
6
12
= 0.40 QALYs  
 
2) By estimating the total QALYs based on scores at each time point at every 





) +  (
1
2
 × (0.6 + 0.8) ×
1
12
) +  (
1
2







 × (0.7 + 0.8) ×
1
12
) +  (0.8 ×
1
12
) +  (0.8 ×
1
12
) = 0.0667 + 0.0583 +
0.0542 + 0.0625 + 0.0667 + 0.0667 = 0.3751 QALYs    
 
3) By estimating the total QALYs at two time points, (baseline and 6 months), and 
taking account of the asthma-related crisis event in between using the mean EQ-
5D-5L utility loss estimated in this study (mean difference in utility value taken 




 ) − (
1
2
 × 0.086 ×
2
12
) = 0.4 −  0.0072 =  0.3928 𝑄𝐴𝐿𝑌𝑠 
 
From the above three estimation scenarios, option 1 is overestimated, as it doesn’t take 
account of the asthma-related crisis event. Option 2, has a more accurate estimation of 
the QALYs by estimating the QALYs at each month and adding the values together. 
Option 3 takes a different approach, by estimating the QALYs at two time points (baseline 
and 6 months), and subtracting the total QALY estimation from the utility loss associated 
for an asthma-related crisis event.  
Measuring quality of life at multiple time points is more accurate because the participant’s 
quality of life is captured more regularly (option 2). However, due to practicality issues, 
it may not always be possible to ask participant’s to complete quality of life 
questionnaires on such a regular basis. Therefore, an alternative can be used, (option 3), 
where the average utility loss associated with an asthma-related crisis event (taken from 
this study) is used alongside the number of asthma-related crisis events that have occurred 
in the time period for the estimation, assuming the recovery period is 2 months. 





As noted, throughout this study there were many repeated measures observed using 
different PROMs. For example, the EQ-5D-5L questionnaires were asked to be 
completed at weekly intervals over an 8 week time period, and the AQLQ and TTO were 
asked to be completed monthly over 8 weeks. The level of repetition within the PROMS 
and participants observed forms a hierarchal structure as demonstrated in Figure 40. 
However, only two levels were represented in this hierarchal structure, (participants and 




















To reflect on the hierarchal structure observed in this study, a multi-level modelling 
approach was conducted, (following the learning environment for multilevel 
methodology and applications [LEMMA] online course guidance from the University of 
Bristol), which aims to make the data more generalizable to a wider population. This 
approach was taken because it was assumed that the probability that the data is missing 
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Figure 40: Multivariate responses presented in a hierarchal structure for EQ-
5D-5L 




estimate the EQ-5D-5L, AQL-5D and TTO utility and disutility estimates using the model 
selection process outlined in Table 32.  
 
Table 32: Model selection process 
Choosing base model 
Run each of the below models separately: 
 Null model (Random intercept) 
 Random Intercept fixed slope model 
 Random slope model 
 Random polynomial model 
Conduct a log likelihood ratio test between two models to 
help identify the best model. For example:  
 Null model and random intercept fixed slope model 
Or 




missingness to the 
base model 
Once selected best base model, add the predictors of 
missingness to that model 
Adding remaining 
covariates to the 
model 
Add the best remaining covariate to the model (i.e. if it has 
stronger statistical significance and a higher log likelihood 
ratio compared to the other remaining covariates):  
 Model with predictors of missingness + best 
remaining covariate 
Add the next best remaining covariate to the model:  
 Model with predictors of missingness + best 
remaining covariate + next best remaining covariate 
Adding of the best remaining covariates continues until no 
further covariates need to be added and a parsimonious model 
has been achieved. 
 
 
Firstly, by reshaping the EQ-5D-5L data into a long format, the data can be visualized in 
a box plot, as shown in Figure 41. The box plot shows that there are varying differences 
amongst the EQ-5D-5L data, due to the lengths of the box and whisker plots and their 
minimum and maximum values at each time point. The median time point generally 
increases across the 8 weeks, and some outliers are observed from week 3 to week 8.  
 
 







Table 33: Null model (random intercept) for EQ-5D-5L 
EQ-5D-5L Coefficient Standard 
error 
z P > |z| 95% 
confidence 
interval 
Intercept 0.6935 0.0215 32.33 0.000 0.6514 to 
0.7355 
Log likelihood: 179.99 
 
The null model in Table 33 illustrates that the intercept coefficient is 0.6935 for the EQ-
5D-5L with strong statistical significance and a log likelihood of 179.99. The scatter plot 
in Appendix VIII Figure 44 shows the EQ-5D-5L at weekly time points with the null 
model fitted. The Q-Q plot shown in Appendix VIII Figure 45 shows there is non-
linearity around the predicted fitted values from the null model as the points deviate from 
the solid line. 
 
 
Figure 41: Box plot to show the spread of the EQ-5D-5L at weekly time points 




Table 34: Random intercept, fixed slope model for EQ-5D-5L 
EQ-5D-5L Coefficient Standard 
error 
Z P>|z| 95% CI 
Week 0.0153 0.0023 6.71 0.000 0.0108 to 
0.0197 
Intercept 0.6527 0.0221 29.50 0.000 0.6093 to 
0.6961 
Log likelihood = 201.68 
The random intercept model in Table 34 illustrates that the intercept coefficient is 0.6527 
and the week coefficient is 0.0153 both with strong statistical significance and a log 
likelihood of 201.68. The scatter plot in Appendix VIII Figure 46 shows the EQ-5D-5L 
at weekly time points with the random intercept model fitted. This model shows a more 
sloped fitted line in comparison to the null model. Appendix VIII Figure 47 shows there 
is non-linearity around the predicted fitted values from the random intercept model, as 
the points deviate from the solid line. A log likelihood ratio test was conducted between 
the null model and random intercept model which showed a value of 43.38 with strong 
statistical significance.  
 
Table 35: Random slope model for EQ-5D-5L 
EQ-5D-5L Coefficient Standard 
error 
Z P>|z| 95% CI 
Week 0.0161 0.0034 4.67 0.000 0.0093 to 
0.0228 
Intercept 0.6516 0.0222 29.31 0.000 0.6080 to 
0.6951 
Log likelihood = 221.52 
 
The random slope model in Table 35 illustrates that the intercept coefficient is 0.6516 
and the week coefficient is 0.0161 both with strong statistical significance and a log 
likelihood of 221.52. The scatter plot in Appendix VIII Figure 48 shows the EQ-5D-5L 
at weekly time points with the random slope model fitted. This model shows a more 
sloped fitted line in comparison to the null model, but a more relaxed slope is assumed in 
comparison to the random intercept model. Appendix VIII Figure 49 shows there is non-
linearity around the predicted fitted values from the random slope model, as the points 
deviate from the solid line. A log likelihood ratio test was conducted between the random 
intercept model and the random slope model which showed a value of 39.68 with strong 
statistical significance. This indicates that the random slope model is a slightly better fit 




compared to the random intercept model. Additionally, the log likelihood value has also 
increased from the null model to the random slope model.  
 
Table 36: Random polynomial model for EQ-5D-5L 
EQ-5D-5L Coefficient Standard 
error 
Z P>|z| 95% CI 
Week 0.0454 0.0076 5.99 0.000 0.0306 to 
0.0603 
Week2 -0.0039 0.0009 -4.33 0.000 -0.0056 to 
-0.0021 
Intercept 0.6288 0.0228 27.54 0.000 0.5841 to 
0.6736 
Log likelihood = 230.75 
 
The random polynomial model in Table 36 illustrates that the intercept coefficient is 
0.6288, the week coefficient is 0.0454 and the week2 coefficient is -0.0039 with strong 
statistical significance and a log likelihood of 230.75. The scatter plot in Appendix VIII 
Figure 51 shows the EQ-5D-5L at weekly time points with the random polynomial model 
fitted. Appendix VIII Figure 50 shows there is non-linearity around the predicted fitted 
values from the random polynomial model, as the points deviate from the solid line. A 
log likelihood ratio test was conducted between the random slope model and the random 
polynomial model which showed a value of 18.45 with strong statistical significance. 
This indicates that the random polynomial model is a much more improved model 
compared to the random intercept and random slope models. Additionally, the log 
likelihood value has also largely increased from the null model to the random polynomial 
model, indicating that the latter random polynomial model has the better model structure. 
Therefore, the explanatory variables were used to build upon the random polynomial 
model in a stepwise approach, and Table 37 summarises the results, which led to 









Table 37: A summary of identifying the best model for the EQ-5D-5L 











1 Null model (Random 
intercept) 
179.99 - 
2 Random Intercept fixed 
slope model 




3 Random slope model 221.52 39.68 (Random 
intercept fixed 
slope model vs 
random slope 
model) 
4 Random polynomial model 230.75 18.45 (Random 




5 Random polynomial model 
+ predictors of missingness 
239.22 - 
6 Random polynomial model 
+ predictors of missingness 
+ gender 
240.16* - 
7 Random polynomial model 
+ predictors of missingness 
+ ethnicity  
240.68* - 
8 Random polynomial model 
+ predictors of missingness 
+ education status 
240.83* - 
*There was no statistical significant difference when adding the covariates. Therefore, 
the model at step 5 is the preferred parsimonious model.  
 
The model below shows the preferred parsimonious model including the factors 









Table 38: Random polynomial model including explanatory variables providing the 
best model fit for the EQ-5D-5L 
EQ-5D-5L Coefficient Standard 
error 
Z P>|z| 95% CI 
Week 0.0471 0.0076 6.20 0.000 0.0322 to 
0.0620 
















 0.0571 0.1850 0.31 0.758 -0.3054 to 
0.4196 
Full time  ǂ 0.2088 0.0618 3.38 0.001 0.0877 to 
0.3299 
Part timeǂ 0.1768 0.0702 2.52 0.012 0.0392 to 
0.3143 
Retired ǂ 0.1614 0.0750 2.15 0.031 0.0144 to 
0.3084 
Home ǂ 0.1389 0.0911 1.52 0.127 -0.0397 to 
0.3175 
Student ǂ 0.2369 0.1246 1.90 0.057 0.0072 to 
0.4811 
Intercept 0.5762 0.0663 8.70 0.000 0.4463 to 
0.7061 
Log likelihood = 239.22 
Dummy variables comparators: ǂ Unemployed, ǂǂ Smoker 
 
The model above in Table 38 shows that on average the baseline EQ-5D-5L utility value 
is 0.5762, increasing by 0.0471 each week  for someone who is unemployed and a smoker. 
Additionally, bootstrapping could also be considered to estimate the disutility of an 
asthma attack. This is a method which is used to estimate confidence intervals of a 
population mean by resampling some data from a larger dataset randomly with 
replacement. It is appropriate to use a bootstrap method to check the stability of the 
results. Table 39 below shows the EQ-5D-5L QALY disutility for someone who has an 
asthma attack over 8 weeks. The QALY disutility was estimated by using the EQ-5D-5L 
time points at baseline, week 4 and week 8, using the algebra below.  
 




Ut = B0 +B1.t + B2.t
2 
Utility scores at weeks 0, 4 and 8 
U0 = B0 
U4 = B0 + B1.4 + B2.4
2 
U8 = B0 +B1.8 + B2.8
2 






























= B0 +4.B1 + 24.B2 
Average Disutility in weeks 0-8 (assuming week 8 is ‘normal’) 
U?̅? = U8 - U̅ = (B0 +8.B1 + 64.B2) – (B0 +4.B1 + 24.B2) 





(4.B1 + 40.B2) 
 
Table 39: EQ-5D-5L QALY disutility using bootstrapping 
EQ-5D-5L Coefficient Standard 
error 
T P>|t| 95% CI 
QALY 
disutility  




Table 40 shows the EQ-5D-5L disutility estimate when exploring the impact of baseline 
utility. This estimate does not hugely differ from Table 39.  
 
Table 40: EQ-5D-5L QALY disutility using bootstrapping: exploring the impact of 
baseline quality of life on the disutility estimate 
EQ-5D-5L Coefficient Standard 
error 
T P>|t| 95% CI 
QALY 
disutility  








Multiple imputation is an additional method that can be used to increase the robustness 
of the results as it replaces the missing data from the available case dataset with values, 
and this in turn reduces the standard error and increases the precision of the estimations. 
Therefore, the EQ-5D-5L QALY disutility was estimated using the same polynomial 
model as estimated in Table 38, but with the additional consideration of multiple 
imputation. Table 41 shows that the QALY disutility is 0.0075 compared to the bootstrap 
QALY disutility observed as 0.0045 in Table 39.  
 
Table 41: EQ-5D-5L QALY disutility using multiple imputation 
EQ-5D-5L Coefficient Standard 
error 
T  P>|t| 95% CI 
QALY 
disutility  
0.0075 0.0027 2.77 0.006 0.0021 to 
0.0128 
 
The AQL-5D utility values were explored in the same way as the EQ-5D-5L by 
estimating the most appropriate hierarchal model to estimate the values needed to 
estimate the disutility of an asthma attack over an 8 week time period.  Firstly, the AQL-
5D data was visually displayed using the box plots as observed in Figure 42. The box 
plot showed that the median time points had gradually increased over the 8 weeks. All 
time points had the same minimum values, but a smaller range of values were observed 
at baseline compared to week 4 and week 8 which had larger ranges with the maximum 
utility value reaching 1.0.  







Table 42: Null model for AQL-5D 
AQL-5D Coefficient Standard 
error 
Z P>|z| 95% CI 
Intercept 0.6602 0.0124 53.45 0.000 0.6360 to 
0.6844 
Log likelihood = 115.52 
 
 
The null model in Table 42 illustrates that the intercept coefficient is 0.6602 for the AQL-
5D with strong statistical significance and a log likelihood of 115.52. The scatter plot in 
Appendix VIII Figure 52 shows the AQL-5D at monthly time points with the null model 
fitted. The Q-Q plot shown in Appendix VIII Figure 53 shows there is some non-
linearity around the predicted fitted values from the null model as the points deviate 
slightly from the solid line. 
 
 
Figure 42: A box plot to show the distribution of AQL-5D across 8 weeks. 




Table 43: Random intercept, fixed slope model for AQL-5D 
AQL-5D Coefficient Standard 
error 
Z P>|z| 95% CI 
Week 0.0174 0.0022 8.01 0.000 0.0132 to 
0.0217 
Intercept 0.6122 0.0135 45.27 0.000 0.5857 to 
0.6388 
Log likelihood = 142.08 
 
The random intercept model in Table 43 illustrates that the intercept coefficient is 0.6122 
and the week coefficient is 0.0174 both with strong statistical significance and a log 
likelihood of 142.08. The scatter plot in Appendix VIII Table 54 shows the AQL-5D at 
monthly time points with the random intercept model fitted. This model shows a more 
sloped fitted line in comparison to the null model. Appendix VIII Figure 55 shows there 
is non-linearity around the predicted fitted values from the random intercept model, as 
the points deviate from the solid line. However, the fit is better compared to the null 
model. A log likelihood ratio test was conducted between the null model and random 
intercept model which showed a value of 53.12 with strong statistical significance.  
 
Table 44: Random slope model for AQL-5D 
AQL-5D Coefficient Standard 
error 
Z P>|z| 95% CI 
Week 0.0176 0.0024 7.27 0.000 0.0129 to 
0.0224 
Intercept 0.6123 0.0118 52.00 0.000 0.5892 to 
0.6353 
Log likelihood = 148.83 
 
The random slope model in Table 44 illustrates that the intercept coefficient is 0.6123 
and the week coefficient is 0.0176 both with strong statistical significance and a log 
likelihood of 148.83. The scatter plot in Appendix VIII Figure 56 shows the AQL-5D 
at monthly time points with the random slope model fitted. This model shows a more 
sloped fitted line in comparison to the null model, but a more relaxed slope is assumed in 
comparison to the random intercept model. Appendix VIII Figure 57 shows there is non-
linearity around the predicted fitted values from the random slope model, as the points 
deviate from the solid line. There is more non-linearity observed in this model compared 
to the other null and random models. A log likelihood ratio test was conducted between 




the random intercept model and the random slope model which showed a value of 13.49 
with strong statistical significance. This indicates that the random slope model is a much 
better fit compared to the random intercept model. Additionally, the log likelihood value 
has also increased from the null model to the random slope model.  
 
 
Table 45: Random polynomial model for AQL-5D 
AQL-5D Coefficient Standard 
error 
Z P>|z| 95% CI 
Week 0.0272 0.0073 3.71 0.000 0.0128 to 
0.0417 
Week2 -0.0013 0.0009 -1.39 0.163 -0.0030 to 
0.0005 
Intercept 0.6085 0.0121 50.15 0.000 0.5847 to 
0.6323 
Log likelihood = 149.75 
 
The random polynomial model in Table 45 illustrates that the intercept coefficient is 
0.6085, the week coefficient is 0.0272 and the week2 coefficient is -0.0013 with strong 
statistical significance for the intercept and week variable. The log likelihood was 149.75. 
The scatter plot in Appendix VIII Figure 58 shows the AQL-5D at monthly time points 
with the random polynomial model fitted. Appendix VIII Figure 59 shows there is non-
linearity around the predicted fitted values from the random polynomial model, as the 
points deviate from the solid line. A log likelihood ratio test was conducted between the 
random slope model and the random polynomial model which showed a value of 1.84. 
However, there was no statistical significant difference observed from the log likelihood 
ratio test and from the week2 variable. Therefore, the explanatory variables were used to 
build upon the random slope model in a stepwise approach, and Table 46 summarises the 









Table 46: A summary of identifying the best model for the AQL-5D 




Type of model Log Likelihood 
value 
Log likelihood 
ratio test (Previous 
model vs Current 
model) 
1 Null model 
(Random intercept) 
115.52 - 
2 Random Intercept 
fixed slope model 
142.08 53.12 (Null model 
vs random intercept 
fixed slope model) 
3 Random slope 
model 
148.83 13.49 (Random 
intercept fixed slope 
model vs random 
slope model) 
4 Random polynomial 
model 
149.75 1.84 (Random slope 
model vs random 
polynomial model)* 
5 Random slope 
model + predictors 
of missingness 
156.12 - 
6 Random slope 
model + predictors 
of missingness + 
gender 
156.96** - 
7 Random slope 
model + predictors 
of missingness + 
ethnicity  
156.68** - 
8 Random slope 
model + predictors 
of missingness + 
education status 
155.36** - 
*No statistical significance observed, so random slope model preferred.  
** There was no statistical significant difference when adding the covariates. Therefore, 
the model at step 5 is the preferred parsimonious model.  
 
The model below shows the preferred parsimonious model with the included explanatory 









Table 47: Random slope model including explanatory variables providing the best 
model fit for the AQL-5D 
AQL-5D Coefficient Standard 
error 
Z P>|z| 95% CI 




-0.0004 0.0010 -0.46 0.642 -0.0023  to 
0.0014 








-0.1646 0.0944 -1.74 0.081 -0.3496 to 
0.0204 
Full time ǂǂ -0.0229 0.0342 -0.67 0.504 -0.0900 to 
0.0442 
Part time ǂǂ -0.0299 0.0387 -0.77 0.440 -0.1058 to 
0.0460 
Retired ǂǂ 0.0108 0.0420 0.26 0.797 -0.0715 to 
0.0931 
Home ǂǂ -0.0500 0.0496 -1.01 0.313 -0.1471 to 
0.0471 
Student ǂǂ -0.0501 0.0676 -0.74 0.458 -0.1826 to 
0.0824 
Intercept 0.7106 0.0369 19.26 0.000 0.6382 to 
0.7829 
Log likelihood = 156.12 
Dummy variables comparators: ǂ Smoker, ǂǂ unemployed 
 
The model above in Table 47 shows that on average the baseline AQL-5D utility value 
is 0.7106, increasing by 0.0178 monthly for someone who is a smoker and unemployed. 
  
Additionally, bootstrapping could also be considered to estimate the disutility of an 
asthma attack. Table 48 below shows the AQL-5D QALY disutility for someone who 
has an asthma attack over 8 weeks. The QALY disutility was estimated by using the AQL-









Table 48: AQL-5D QALY disutility using bootstrapping 
AQL-5D Coefficient Standard 
error 
T P>|t| 95% CI 
QALY 
disutility  
0.0110 0.0016 7.07 0.000 0.0079 to 
0.0140 
 
Table 49 shows the AQL-5D disutility estimate when exploring the impact of baseline 
utility. This estimate does not differ from Table 48. 
 
 
Table 49: AQL-5D QALY disutility using bootstrapping: exploring the impact of 
baseline quality of life on the disutility estimate 
AQL-5D Coefficient Standard 
error 
T P>|t| 95% CI 
QALY 
disutility  




Multiple imputation is an additional method that can be used to increase the robustness 
of the results as it replaces the missing data from the available case dataset with values, 
and this in turn reduces the standard error and increases the precision of the estimations. 
Therefore, the AQL-5D QALY disutility was estimated using the same random slope 
model as estimated in Table 47, but with the additional consideration of multiple 
imputation. Table 50 shows that the QALY disutility is 0.0096 compared to the bootstrap 
QALY disutility which is observed as 0.0110 in Table 48.  
 
 
Table 50: AQL-5D QALY disutility using multiple imputation 
AQL-5D Coefficient Standard 
error 
T  P>|t| 95% CI 
QALY 
disutility  




The TTO utility values were explored in the same way as the EQ-5D-5L and AQL-5D by 
estimating the most appropriate hierarchal model to estimate the values needed to 




estimate the disutility of an asthma attack over an 8 week time period.  Firstly, the TTO 
data was visually displayed using the box plots as observed in Figure 43. The box plot 
showed that the median time points had increased from baseline to week 4 and week 8. 
The minimum values varied, with baseline holding the lowest minimum value, followed 
by week 8 and week 4. However, there were some anomalies in the data set observed at 





Table 51: Null model for TTO 
AQL-5D Coefficient Standard 
error 
Z P>|z| 95% CI 
Intercept 0.7247 0.0214 33.86 0.000 0.6827 to 
0.7666 
Log likelihood = -41.41 
 
The null model in Table 51 illustrates that the intercept coefficient is 0.7247 for the TTO 
with strong statistical significance and a log likelihood of -41.41. The scatter plot in 
Figure 43: A box plot to show the distribution of TTO across 8 weeks. 




Appendix VIII Figure 60 shows the TTO at monthly time points with the null model 
fitted. The Q-Q plot shown in Appendix VIII Figure 61 shows there is some non-
linearity around the predicted fitted values from the null model as the points deviate 
slightly from the solid line. 
 
 
Table 52: Random intercept, fixed slope model for TTO 
AQL-5D Coefficient Standard 
error 
Z P>|z| 95% CI 
Week 0.0203 0.0043 4.69 0.000 0.0118 to 
0.0288 
Intercept 0.6555 0.0256 25.61 0.000 0.6053 to 
0.7057 
Log likelihood = -30.88 
 
The random intercept model in Table 52 illustrates that the intercept coefficient is 0.6555 
and the week coefficient is 0.0203 both with strong statistical significance and a log 
likelihood of -30.88. The scatter plot in Appendix VIII Figure 62 shows the TTO at 
monthly time points with the random intercept model fitted. This model shows a more 
sloped fitted line in comparison to the null model. Appendix VIII Figure 63 shows there 
is non-linearity around the predicted fitted values from the random intercept model, as 
the points near the tail ends deviate from the solid line. However, the fit is better compared 
to the null model. A log likelihood ratio test was conducted between the null model and 
random intercept model which showed a value of 21.06 with strong statistical 
significance.  
 
Table 53: Random slope model for TTO 
AQL-5D Coefficient Standard 
error 
Z P>|z| 95% CI 
Week 0.0203 0.0044 4.61 0.000 0.0117 to 
0.0289 
Intercept 0.6555 0.0243 26.98 0.000 0.6079 to 
0.7031 
Log likelihood = -30.16 
 




The random slope model in Table 53 illustrates that the intercept coefficient is 0.6555 
and the week coefficient is 0.0203 both with strong statistical significance and a log 
likelihood of -30.16. The scatter plot in Appendix VIII Figure 64 shows the TTO at 
monthly time points with the random slope model fitted. This model shows a more sloped 
fitted line in comparison to the null model, but a more relaxed slope is assumed in 
comparison to the random intercept model. Appendix VIII Figure 65 shows there is non-
linearity around the predicted fitted values from the random slope model, as the points 
deviate from the solid line. A log likelihood ratio test was conducted between the random 
intercept model and the random slope model, which showed a value of 1.44 without a 
strong statistical significant difference. Additionally, the log likelihood value has also 
increased from the null model to the random slope model.  
 
Table 54: Random polynomial model for TTO 
AQL-5D Coefficient Standard 
error 
Z P>|z| 95% CI 
Week 0.0725 0.0149 4.85 0.000 0.0432 to 
0.1018 
Week2 -0.0067 0.0018 -3.65 0.000 -0.0103 to 
-0.0031 
Intercept 0.6275 0.0250 25.08 0.000 0.5785 to 
0.6766 
Log likelihood = -23.69 
 
The random polynomial model in Table 54 illustrates that the intercept coefficient is 
0.6275, the week coefficient is 0.0725 and the week2 coefficient is -0.0067 with strong 
statistical significance for the intercept and week variable. The log likelihood was -23.69. 
The scatter plot in Appendix VIII Figure 66 shows the TTO at monthly time points with 
the random polynomial model fitted. Appendix VIII Figure 67 shows there is non-
linearity around the predicted fitted values from the random polynomial model, as the 
points deviate from the solid line. A log likelihood ratio test was conducted between the 
random slope model and the random polynomial model which showed a value of 12.94 
with strong statistical significance. The log likelihood ratio is higher in this model but has 
a stronger statistical significance compared to the previous random slope model. 
Additionally, the log likelihood value has also increased from the null model to the 
random polynomial model, indicating that the latter random polynomial model has the 
better model structure. Therefore, the explanatory variables were used to build upon the 




random polynomial model in a stepwise approach, and Table 55, summarises the results, 
which led to choosing the random polynomial model as the best base model. 
 
 
Table 55: A summary of identifying the best model for the TTO 




Type of model Log Likelihood 
value 
Log likelihood 
ratio test (Previous 
model vs current 
model) 
1 Null model 
(Random intercept) 
-41.41 - 
2 Random Intercept 
fixed slope model 
-30.88 21.06 (Null model 
vs random intercept 
fixed slope model) 
3 Random slope 
model 
-30.16 1.44 (Random 
intercept fixed slope 
model vs random 
slope model) 
4 Random polynomial 
model 
-23.69 12.94 (Random 
slope model vs 
random polynomial 
model) 
5 Random polynomial 
model + predictors 
of missingness 
-18.98 - 
6 Random polynomial 
model + predictors 
of missingness + 
gender 
-18.52* - 
7 Random polynomial 
model + predictors 
of missingness + 
ethnicity  
-18.63* - 
8 Random polynomial 
model + predictors 
of missingness + 
education status  
-18.75* - 
* There was no statistical significant difference when adding the covariates. Therefore, 
the model at step 5 is the preferred parsimonious model.  
 
The model below shows the preferred parsimonious model with the included explanatory 
variables for the TTO.  
 





Table 56: Random polynomial model including explanatory variables providing the 
best model fit for the TTO 
TTO Coefficient Standard 
error 
Z P>|z| 95% CI 
Week 0.0716 0.0149 4.80 0.000 0.0424 to 
0.1009 
















0.0699 0.1746 0.40 0.689 -0.2724 to 
0.4122 
Full time ǂǂ 0.0303 0.0637 0.47 0.635 -0.0947 to 
0.1552 
Part time ǂǂ 0.0902 0.0751 1.20 0.229 -0.0569 to 
0.2374 
Retired ǂǂ -0.0899 0.0768 -1.217 0.242 -0.2404 to 
0.0606 
Home ǂǂ 0.1318 0.0899 1.47 0.143 -0.0445 to 
0.3080 
Student ǂǂ 0.0599 0.1216 0.49 0.622 -0.1785 to 
0.2983 
Intercept 0.5996 0.0663 9.05 0.000 0.4698 to 
0.7295 
Log likelihood = -18.98 
Dummy variables comparators: ǂ Smoker, ǂǂ Unemployed  
 
 
The model above in Table 56 shows that on average the baseline TTO utility value is 
0.5996, increasing by 0.0716 monthly for someone who is of average age, a smoker and 
unemployed.  
 
Additionally, bootstrapping could also be considered to estimate the disutility of an 
asthma attack. Table 57 below shows the TTO QALY disutility for someone who has an 
asthma attack over 8 weeks. The QALY disutility was estimated by using the TTO time 
points at baseline, week 4 and week 8.  





Table 57: TTO QALY disutility using bootstrapping 
TTO Coefficient Standard 
error 
T P>|t| 95% CI 
QALY 
disutility  
0.0031 0.0045 0.70 0.485 -0.0057 to 
0.0119 
 
Table 58 shows the TTO disutility estimate when exploring the impact of baseline utility. 
This estimate does not differ from Table 57. 
 
Table 58: TTO QALY disutility using bootstrapping: exploring the impact of 
baseline quality of life on the disutility estimate 
TTO Coefficient Standard 
error 
T P>|t| 95% CI 
QALY 
disutility  




Multiple imputation is an additional method that can be used to increase the robustness 
of the results as it replaces the missing data from the available case dataset with values, 
and this in turn reduces the standard error and increases the precision of the estimations. 
Therefore, the TTO QALY disutility was estimated using the same polynomial model as 
estimated in Table 56, but with the additional consideration of multiple imputation. Table 
59 shows that the QALY disutility is 0.0035 compared to the bootstrap QALY disutility 
observed as 0.0031 in Table 57.  
 
Table 59: TTO QALY disutility using multiple imputation 
TTO Coefficient Standard 
error 
T  P>|t| 95% CI 
QALY 
disutility  
0.0035 0.0033 1.05 0.297 -0.0031 to 
0.0101 
 





4.3.5 Productivity loss 
Participants were asked to complete the productivity questionnaire at week 4 of the study. 
Out of the total number of participants recruited (N = 121), 47 participants (38.84%) did 
not post back their productivity questionnaires. For those that completed the 
questionnaire, participants varied in their responses relating to how they thought their 
asthma was at four weeks compared to when they were in hospital four weeks ago. When 
asked to respond either ‘yes’ or ‘no’, 36.37% (N = 44) thought they hadn’t recovered 
from when they were in hospital four weeks ago, and 24.79% (N = 30) thought they had. 
Therefore, this meant that 59.5% of respondents (44 ÷ 74) thought they hadn’t 
recovered from when they were in hospital four weeks ago, and 40.5% of respondents 
(30 ÷ 74) thought they had. However, a further question showed more variation in the 
breakdown of the responses, when asked to rate their asthma at four weeks compared to 
how they were when in hospital by using options of poor, moderate, good and very good. 
Nine participants (7.44%), reported that their asthma was in a poor condition compared 
to when they were in hospital 4 weeks ago, 28 (23.14%) reported that their asthma was 
in a moderate condition, 20 (16.53%) reported that their asthma was in a good condition 
and 17 (14.05%) reported that their asthma was in a very good condition.  
 
 From completion of the demographics questionnaire, it was found that 33 participants 
were in full-time employment (27.50%) and 19 participants were in part-time 
employment (15.83%) out of the 121 participants recruited. However, out of the 52 
participants in employment, only 33 participants responded to the productivity 
questionnaire at week 4 of the study. Of those who responded to the productivity 
questionnaire, 21 participants (17.35%) had returned back to work by week 4 of the study 
and 12 participants (9.92%) had not returned back to work. On average, the number of 
hours worked per week (for those only in employment) before the asthma-related crisis 
event was 36.10 hours (N=24 respondents), and the average number of hours worked per 
week (for those only in employment) after the asthma-related crisis event was 25.11 hours 
(N=23 respondents). Assuming that these average number of hours worked per week 
applied to each of the four weeks, the productivity loss in working hours per week was: 
 
36.10 − 25.11 = 10.99 ℎ𝑜𝑢𝑟𝑠 





Taking into account the average weekly earnings (£503.00) (Office for National 
Statistics, 2017c) and the average number of hours worked in a week in the UK (31 hours 
reduced by part-time work) (Office for National Statistics, 2017a, Francis, 2017), this 
estimated to a total of £713.29 lost in productivity over the four weeks since their asthma-
related crisis event for those in employment (see equation below).  
 
(10.99 ℎ𝑜𝑢𝑟𝑠 × 4 𝑤𝑒𝑒𝑘𝑠)
31 ℎ𝑜𝑢𝑟𝑠
 × £503.00 = £713.29 
 
However, since the proportion of participants in employment was 43.33% (27.50% +
 15.83%), the average productivity loss per person is £713.29 × 0.4333 = £309.07.   
 
In addition to the above, 13 participants (10.74%) had purchased additional products after 
their asthma-related crisis event, that they would not have otherwise purchased prior to 
their event. From the 13 participants, this averaged out to be £95.74 per participant for 
the additional products, which included items such as; allergy free pillows, allergy free 
duvets, and humidifiers. In this case, the whole cost of the additional aforementioned 
items were considered in the out-of-pocket costs due to participants only purchasing new 
pillows and duvets because of their asthma-related crisis event. 
 
Since 13 participants reported purchasing additional products, out of the 74 respondents 
of the productivity questionnaire, the above cost is weighted accordingly. This means that 





 =  £16.82 
 
 
Therefore, in total, the average societal loss in the first four weeks per person was:  
£309.07 + £16.82 = £325.89 
 





This study explored the quality of life in people with acute asthma who attended A&E or 
were admitted to hospital with an asthma attack. The aim of this study was to identify the 
loss in quality of life associated with these events, by asking the participants to complete 
several PROMs over a period of 8 weeks at different time points. The PEF and symptom 
diary was asked to be completed daily, the EQ-5D-5L weekly, and the AQLQ and TTO 
monthly. The demographics questionnaire and productivity questionnaire were asked to 
be completed at baseline and week 4 of the study respectively. Values were converted 
into utility scores where appropriate and comparisons were made by statistical analysis.   
 
4.4.1 Summary of findings 
Within all three hospital sites, 121 participants were recruited into the study, with 
approximately 50% lost to follow up over the 8 week study time period. Most of the loss 
associated with an asthma-related crisis event occurred during the first four weeks of the 
study, as the statistical analysis demonstrated that there was a strong statistical 
significance for the mean changes between baseline and week 4 for all PROMs at the 1% 
level. The EQ-5D-5L and the AQLQ also exceeded their minimal important difference 
between baseline and week 4.  
 
The best structural multi-level model for the EQ-5D-5L and the TTO was the random 
polynomial model, and for the AQL-5D it was the random slope model. These models 
were used to find the preferred parsimonious models by using stepwise methodology. 
When using multiple imputation on these models, the QALY disutilities associated with 
an asthma-related crisis event over an 8 week time period for the EQ-5D-5L, AQL-5D 
and TTO were 0.0075, 0.0096 and 0.0035 respectively.   
 
Not all participants had completely recovered from their asthma-related crisis event by 
the week 4 time point. Just over a third thought they hadn’t completely recovered from 
their asthma-related crisis event, which corresponds with the responses from the TTO at 
week 8 of the study, as nearly a third had a utility value of less than 1. Nearly a quarter 
of the participants thought that their asthma was in a poor condition compared to when 
they were in hospital. Approximately a quarter of those who were in full-time or part-
time employment (43.33%) hadn’t returned back to work by the week 4 time point. The 




societal loss (loss of productivity plus out of pocket) averaged at £325.89 per person over 
the first four weeks.  
 
4.4.2 Comparison with other studies 
In comparison with an earlier study that analysed HRQL in asthmatics over a four week 
time period, their utility loss estimation for someone who was recruited at baseline from 
an outpatient clinic or in primary care, and was hospitalized with an acute asthma attack 
was 0.20 for the EQ-5D (Lloyd et al., 2007). However, for this current ESQUARE study 
the estimated utility loss over four weeks was 0.127 for the EQ-5D. It should be noted, 
that the earlier study EQ-5D estimation was based on the 3 level version (Lloyd et al., 
2007), compared to this study being based on the 5 level version, where the 5 level aims 
to improve sensitivity (Herdman et al., 2011). It is interesting that the earlier study 
estimated a utility loss which was reasonably higher than that of this current study, 
however that could be a result of overestimation, as the patients were not experiencing an 
asthma attack at the point at which they were recruited into the study (Lloyd et al., 2007), 
or it could be due to differences in the valuation methods of the EQ-5D-3L and EQ-5D-
5L. The patients were recruited from outpatient clinics and primary care, and even though 
every effort was made to recruit patients with an exacerbation history, all the patients 
recruited were not experiencing an exacerbation at the time of recruitment (Lloyd et al., 
2007). For this study, if participants were asked to complete the HRQL questionnaires at 
week 8 only, and not in between this time point (i.e. at week 4), then the utility loss would 
have been overestimated. This assumption of overestimation is because most of the 
quality of life improvement was observed in the first four weeks of the study, with very 
small changes seen past this time point that were not statistically significantly different.   
 
Additionally, the ceiling effects for the TTO were fairly high to begin with at baseline 
(18.8%), and then increased at week 4 and week 8 to 51.7% and 51.3% respectively. Even 
though the mean TTO utility value was close in value to the other PROMs at baseline, 
the high ceiling effect at baseline could be dependent on other factors as the TTO is more 
of a scenario-based question on number of life years compared to the other PROMs. For 
example, the participants’ trade off may be dependent on marital status and age (Sayah et 
al., 2016), or it may be dependent on whether a particular medication will still be 
administered to them (Hyland et al., 2015), or it may be that the enjoyment of life through 
children, friends, and other social affairs has a greater impact and is of more importance 




than their illness (Arnesen and Norheim, 2003). The steep rise in ceiling effect at week 4 
and week 8 was expected, as with improvements in asthma quality of life, it was expected 
that the participants would not want to trade any life years.  
 
For the multi-level models, the employment status was a predictor of the EQ-5D-5L 
estimation, and this is in line with other studies where being in employment and working 
full-time is associated with less symptoms and better quality of life compared to being 
unemployed (Taponen et al., 2017, Dimich-Ward et al., 2007). However, as stress can be 
a factor of asthma attacks, it has been found that over commitment at work can lead to 
poorer quality of life (Hartmann et al., 2017), and so striking a good work-life balance is 
essential.  
 
4.4.3 Strengths and limitations 
There are a number of strengths from this study. The participants were recruited over a 
whole year from three hospital sites, which enhanced the generalisability of the collected 
data. Data was entered by double entry for 10% of the collected data, with errors reported 
to be minimal (0.003), therefore enhancing the accuracy of the dataset. Another strength 
was that several PROMs were used in this study to gain a more comprehensive 
perspective on quality of life in people with acute asthma.  
 
A number of limitations arose from this study. Firstly, the peak of the asthma-related 
crisis event occurred before attendance to A&E or admission to hospital for most 
participants, indicating that the initial decrease in quality of life (whether that be gradual 
or sudden), occurred before the baseline point in this study. Therefore, the true time point 
for those participants’ who were at their worst before attending A&E or being admitted 
to hospital has not been recorded in this instance. Secondly, the retention rate for this 
study was problematic, with a large proportion of participants lost to follow up. The low 
retention rate could have been because the study time period was too long for participants 
to complete several questionnaires (Lloyd et al., 2007), or that a large number of 
asthmatics are often non-compliant (Gul and Ali, 2010, Mattei, 2012) with taking their 
medications, making compliance with a study less likely too. Thirdly, selection bias was 
reduced by visiting the hospital daily on weekdays, (both in A&E and on the hospital 
wards) during the recruitment period of one year, to capture as many potential participants 
as possible.   





4.4.4 Recommendations for future 
In light of the results given, the EQ-5D-5L and AQL-5D provide closely matched utility 
values based on a generic questionnaire and a disease specific questionnaire. However, 
there is some ambiguity over whether the EQ-5D-5L is appropriate to be used by NICE 
(NICE, 2017), and it is recommended that further research be conducted to explore 
whether the recent valuation set of the EQ-5D-5L (Devlin et al., 2016) should be adopted 
in the NICE reference case. NICE currently recommend that the utility values from the 
EQ-5D-5L should be mapped onto the EQ-5D-3L using a preferred mapping function 
(van Hout et al., 2012) for consistency until further review (NICE, 2017).  
 
Nevertheless, future studies can benefit from this research by counting the number of 
asthma-related crisis events and assigning a QALY loss to each occurrence. For example, 
if using the EQ-5D-5L or the AQL-5D, the utility loss was 0.127 or 0.099 respectively 
over four weeks for an asthma related crisis event (Table 24), and so these values could 
be used in modelling. This could also be useful for use in previous studies, by expanding 
upon work already conducted. For example, an asthma study which investigated at-risk 
asthma by using registers in GP practices for their intervention (Smith et al., 2012), could 
estimate that the mean QALY loss per participant associated with crisis events for their 
intervention and control groups was 0.215 and 0.322 respectively using the EQ-5D-5L, 
and 0.168 and 0.251 respectively using the AQL-5D. The calculations for the intervention 
and control group mean QALY loss estimations are as follows using the EQ-5D-5L utility 
estimation loss first, followed by the AQL-5D utility estimation loss second:  
𝑄𝐴𝐿𝑌 𝑙𝑜𝑠𝑠 𝑓𝑜𝑟 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝑔𝑟𝑜𝑢𝑝: (15 + 29) × (
1
2
 ×  0.127 ×
4
52
) = 0.215 
𝑄𝐴𝐿𝑌 𝑙𝑜𝑠𝑠 𝑓𝑜𝑟 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑟𝑜𝑢𝑝: (29 + 37) × (
1
2
 × 0.127 ×  
4
52
) = 0.322  
𝑄𝐴𝐿𝑌 𝑙𝑜𝑠𝑠 𝑓𝑜𝑟 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝑔𝑟𝑜𝑢𝑝: (15 + 29) × (
1
2
 ×  0.099 ×
4
52
) = 0.168 
𝑄𝐴𝐿𝑌 𝑙𝑜𝑠𝑠 𝑓𝑜𝑟 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑟𝑜𝑢𝑝: (29 + 37) × (
1
2
 × 0.099 ×  
4
52
) = 0.251  
Note, intervention group: hospitalisation for asthma exacerbation (N = 15) and A&E 
attendance for asthma exacerbation (N = 29). 




Control group: hospitalisation for asthma exacerbation (N = 29) and A&E attendance 
for asthma exacerbation (N = 37). 
 
Both equations show the addition of the number of hospitalizations and A&E attendances 
in 1 year multiplied by the area under the curve for asthma-related crisis events. By 
incorporating the utility loss value into estimations, this will enhance the area under the 
curve estimation when comparing a new intervention with another product or usual care, 
and may in fact alter the end result (i.e. the incremental cost effectiveness ratio).  
 
Alternatively, the QALY loss estimated from the multi-level modelling over 8 weeks 
can be applied to modelling studies. The best models were a random polynomial model 
for the EQ-5D-5L and TTO, and a random slope model for the AQL-5D, and this was 
improved by using multiple imputation to increase the precision of the estimation and 
minimize standard error. The EQ-5D-5L, AQL-5D and TTO QALY losses were 
0.00575, 0.0096 and 0.0035 respectively. These QALY losses can also be multiplied by 
the number of participants who have experienced an asthma-related crisis event. 
 
Patients should be aware of how asthma-related crisis events can impede on daily 
activities, (both recreational and work-related). By acknowledging the amount of time it 
took for the participants in this study to recover from their asthma-related crisis event and 
their financial implications, patients should aim to maintain well-controlled asthma (e.g. 
by taking medications and using PAAPs) and reduce the risk of asthma attacks (e.g. by 
avoiding known triggers such as exposure to pets) (British Thoracic Society. Scottish 
Intercollegiate Guidelines Network, 2016).     
 
Researchers and policy makers should take into account that this research is the first to 
explore quality of life in acute asthmatics associated with asthma-related crisis events in 
such depth. It provides useful estimations, which can be used in economic analyses to 
further the accuracy of results.  
 




4.5 Conclusion  
To conclude, this study aimed to estimate the QALY loss associated with asthma-related 
crisis events. These were defined as admission to hospital or attendance to A&E from 
having an asthma attack. Most of the loss associated with the asthma-related crisis events 
occurred within the first four weeks, causing loss in productivity, and showed strong 
statistical significant differences at the 1% level for all PROMs. The EQ-5D-5L and the 
AQL-5D showed closely matched utility values, which can be used to enhance research 
studies by using the loss in utility to estimate the QALY loss and assigning this to the 
number of asthma-related crisis events.  
 
To consolidate these findings further, it would be useful to examine the comparative 
performance of these PROMs using psychometric techniques in order to inform future 
research about which instrument(s) might be used. Therefore, the available cases from 
this study, will be used to explore techniques such as, construct validity and 
responsiveness, in the next chapter. 
 
  





WHAT IS THE APPROPRIATENESS OF DIFFERENT 
PREFERENCE-BASED MEASURES IN ACUTE 
ASTHMATICS? 
 




The previous chapter outlined various estimates for the loss in quality of life associated 
with an asthma-related crisis event. This event was defined as those who attended A&E 
or were admitted to hospital following an asthma attack. A total of 121 participants were 
recruited from three hospital sites in the UK. They were asked to complete several 
PROMs over a period of 8 weeks, to investigate their quality of life associated with the 
crisis event. Descriptive statistics, wilcoxon signed-rank test, and multi-level modelling 
were used to explain the data set.  
 
The participants recruited had mixed characteristics, with most of the estimated loss 
associated with the crisis events occurring during the first four weeks of the study. All 
PROMs showed strong statistical significant differences at the 1% level between the mean 
scores at baseline and week 4 of the study, with the EQ-5D-5L and AQLQ overall scores 
exceeding their minimal important difference threshold. Participants also lost 
productivity during those first four weeks and not all had returned back to work by the 
fourth week of the study. The EQ-5D-5L and the AQL-5D (converted into utility values 
from the AQLQ), showed closely matched utility values when observed. 
 
However, it is necessary to investigate all preference-based measures further. This is to 
identify the nature of their relationship to each other and other associated variables, and 
also the strength that this bears, in order to provide further confirmation as to which 
instrument is appropriate to be used. Therefore, this chapter will seek to explore the 




relationships between the preference-based measures by using psychometric techniques; 
in particular construct validity and responsiveness.   
 
5.1 Background  
PROMs are used widely in research as they are useful for capturing patient’s perceptions 
for different diseases (Black, 2013). The PROMs can be disease-specific or generic 
questionnaires, and they can be conducted in different modes and at different time points 
(Weldring and Smith, 2013).  
 
As seen earlier (Chapter 2, Figure 12) in my systematic review study (Crossman-Barnes 
et al., 2017), the use of PROMs in asthma is vast. It appears that there are many PROMs 
that can be used for asthma studies, such as the AQLQ, mini-AQLQ, SGRQ, and EQ-5D 
being the top common ones (Crossman-Barnes et al., 2017, Frew et al., 2013, Worth et 
al., 2014, Shah et al., 2016a). The AQLQ, mini-AQLQ and SGRQ are disease-specific 
questionnaires (questionnaires specifically tailored to a particular disease) and the EQ-
5D is a generic questionnaire (questionnaire that can be used for many different diseases). 
Both the AQLQ and EQ-5D have been outlined previously in sections 1.6 and 1.7. The 
mini-AQLQ is a shortened version of the AQLQ composed of 15 questions and still 
encompasses the same four domains as used in the AQLQ (symptoms, activities, 
emotions and environment) (Juniper et al., 1999). Additionally, the AQLQ has been used 
to develop a preference-based measure (AQL-5D), as previously discussed in Chapter 
3.5.5. The SGRQ is a 50 item questionnaire split into three domains (symptoms, activity 
and impacts), and can be used for people with asthma COPD, and bronchiectasis. As there 
are so many different PROMs available to use, it is important that there is transparency 
for their use and knowledge for which one is more appropriate. However, knowing what 
specific PROMs are appropriate for asthma are yet to be identified, and further research 
is warranted (Worth et al., 2014). 
 
The testing of preference-based measures through psychometric techniques has been 
conducted before in many different diseases. Earlier asthma studies have conducted 
psychometric tests on a range of different PROMs (Globe et al., 2016, Nguyen et al., 
2014, Bime et al., 2012, Nelsen et al., 2017, Apfelbacher et al., 2016, Kheir et al., 2008, 
van Bragt et al., 2014). To highlight a few examples, a previous study confirmed that the 
EQ-5D (3L) is valid and reliable for use on asthma patients after exploring its correlation 




strength  against other disease specific or generic questionnaires (e.g. to name a few, 
AQLQ, SF-36, SF-6D, SGRQ,  and 15D). This helped clinicians form better decisions 
about HRQL in people with asthma (Pickard et al., 2008), however, a more recent 
qualitative study explored the use of the EQ-5D-5L in asthma patients and identified that 
the acceptability (defined as the ease of using an instrument) and content validity (defined 
as the ability of an instrument to appropriately represent the most important and relevant 
aspects of a concept), was poorly aligned (Whalley et al., 2018) compared to the AQL-
5D and the asthma symptom diary (ASD). This demonstrates that further research is 
required to explore these discrepancies between studies. An earlier study also explored 
psychometric properties between several questionnaires in asthma patients, including the 
EQ-5D, SF-36 / SF-6D, SGRQ and TTO (Szende et al., 2004). Interestingly, after 
evaluating HRQL in asthmatics with different levels of disease control, Szende et al. 
(2004) indicated that the EQ-5D was better suited to the more severe asthma or poorly 
controlled asthma patient groups and the SF-6D was more suited to patients with milder 
or well controlled asthma. Furthermore, another study confirmed that when observing 
preference instruments, (rating scale (RS), SG, TTO, HUI3 and asthma symptom utility 
index (ASUI)), the SG showed no correlation with asthma severity markers (Moy et al., 
2004), but the RS was significantly associated with all symptoms.  
 
From assessing the literature discussed in these paragraphs above and throughout the 
thesis, it is evident that more research needs to be conducted to identify which instrument 
is more suitable for measuring quality of life in asthma patients. Therefore, based on the 
PROMs considered in my prospective cohort study, (see chapters 3 & 4), and the 
comparison of different instruments used by psychometric testing in the above literature, 
it appeared appropriate to use the three instruments, which could derive utilities as a 
comparison for the psychometric testing. The EQ-5D has been used in several studies 
already, however, the EQ-5D-5L warrants comparison since it has been recently 
developed. Furthermore, the AQL-5D has also been recently developed and comparisons 
amongst utility instruments have not currently been performed based on data from a 
critical asthma patient group. Finally, comparisons with the TTO are also limited, and in 
particular, since this TTO was modified, it also important for comparisons.   
 
Validity, reliability, repeatability, sensitivity and responsiveness, are the common types 
of psychometric properties that all measurements should aim to satisfy to be able to be 




clinically useful (Fayers and Machin, 2016). Since the prospective cohort study (see 
chapter 3), included patients where their quality of life status was expected to change 
over time and not remain a constant, then reliability and repeatability psychometric testing 
could not be performed (Fayers and Machin, 2016). Therefore, validity, sensitivity and 
responsiveness were considered, and these psychometric techniques are less well 
understood in this asthma patient group. 
 
 
This study will aim to answer prior hypotheses relating to the construct validity and 
responsiveness of the data set by comparing the three preference-based measures (EQ-
5D-5L, AQL-5D and TTO): 
 High levels of correlations (Spearman’s rank correlation coefficient > 0.5, 
(Cohen, 1988a))  are expected to be seen amongst all preference-based 
measures. (Convergent validity)  
 
 Participants with a PEF of <50% of best/predicted are expected to have a poorer 
quality of life than those patients with PEF >50% of best/predicted. 
(Discriminative validity). This is due to medical information stating that those 
with a PEF of <50% of best /predicted will have life threatening or acute severe 
asthma, those with between 50% and 75% will have moderate acute asthma and 
those >75% will have good/very good asthma (British Thoracic Society. Scottish 
Intercollegiate Guidelines Network, 2016).  
 
 All questionnaires would show improvements in asthma quality of life between 
baseline and week 4 of the study, with the responses to ‘very good’ and ‘poor’ 
showing greater changes at the extremities, as well as responses to ‘yes’ and ‘no’ 
also showing great changes at the extremities. (Responsiveness). These 
responses are taken from the productivity questionnaire where the participants 
are asked to complete this at week 4 of the study, and the questions relate to 
whether they feel their asthma has completely recovered since their A&E 
attendance or hospital admission. These questions are detailed further in the 
methods section of this chapter (section 5.2.1).  
 




The following section will discuss the methods used in this chapter, by providing more 
detailed information on the statistical analysis and definitions of the psychometric 
techniques used. The results will then follow with many tables highlighting the validity 
and responsiveness results at different time points. Then, the chapter will close, 
discussing the results, providing future recommendations and conclusions.  
 
5.2 Methods 
This study also draws on data from the prospective cohort study, the methods for which 
were described in Chapter 3. The data set used is the same as that used in Chapter 4 (the 
available cases), and the analysis for this chapter is described below. As the outcome 
variables were mostly non-normally distributed, non-parametric tests were used for the 
analysis.  
5.2.1 Statistical analysis  
The analysis for this study assessed the construct validity and responsiveness of the 
preference-based measures; EQ-5D-5L, AQL-5D and TTO. As mentioned previously in 
Chapter 3, section 3.7, the utility values for the EQ-5D-5L were estimated using the 
value sets based on England, and the AQLQ was converted into preference-based utility 
values based on an algorithm to form the AQL-5D.  
Construct validity  
Construct validity assesses whether the constructs of an instrument are measuring what it 
should be measuring (de Vet et al., 2015). Two forms of construct validity were 
considered; convergent and discriminative validity.  
Convergent validity addresses the level of correlation between constructs and 
instruments. It shows whether the constructs or instruments that are being compared are 
related to each other as expected. These relations may be strong or weak correlations 
depending on the relationship expected between the constructs or instruments compared 
(Fayers and Machin, 2016).  
The correlations for convergent validity have been assessed at baseline, week 4 and week 
8 of the study. The Spearman’s rank correlation coefficient was used to determine the 
correlations with statistical significance considered at the 5% level. Additionally, 
correlations were considered weak if < 0.3, moderate if 0.3 to 0.5 and strong if >0.5 
(Cohen, 1988a).  




Discriminative validity, (also known as known-groups validity), is another type of 
construct validity which has been considered in this analysis (Fayers and Machin, 2016). 
The groups tested are expected to differ between each other, and so a test is conducted to 
help discriminate against them. The analysis was conducted based on specific groups that 
were anticipated to provide different results between instruments at baseline. Three PEF 
groups were chosen to conduct this analysis (British Thoracic Society. Scottish 
Intercollegiate Guidelines Network, 2016): 
 < 50% of the best/predicted PEF (life threatening or acute severe asthma) 
 50-75% of the best/predicted PEF (moderate acute asthma) 
 > 75% of the best/predicted PEF (good/very good asthma) 
 
The Kruskal-Wallis test statistic was used to conduct the test for discriminative validity 
across the instruments using the above three PEF subgroups. P-values were used to 
display the statistical significance.  
In addition to the above, discriminative validity was also conducted to test between 
groups based on two questions asked in the productivity questionnaire which was 
completed at week 4 of the study. These questions were as follows:  
Question (a): Compared to your asthma state when you were in hospital approximately 
4 weeks ago, how would you rate your asthma now?  
Answers to choose (a): Very good, Good, Moderate, Poor or Very Poor.  
Question (b): Do you think you have completely recovered from when you were in 
hospital approximately 4 weeks ago?  
Answers to choose (b): Yes, No. 
The Kruskal-Wallis test was also used here to compare the answers to question (a) with 
the preference-based measures, where it was expected that there will be statistical 
significant differences between the change in the mean rank scores over a 4 week period 
in the good, moderate and poor categories. As none of the participants chose the last item, 
‘very poor’, this category was omitted from the groups. Likewise, the Kruskal-Wallis test 
was also used to compare the answers to question (b) against the preference-based 
measures, where it was expected that there will be strong statistical significant differences 
between both groups (change in mean rank scores over a 4 week period).  





This was an assessment of all of the quality of life questionnaires, including the PEF to 
detect any sensitivity to change (de Vet et al., 2015). Responsiveness should highlight 
whether the instruments are measuring the constructs as it should, e.g. by detecting 
whether an expected improvement or deterioration over a period of time is reflected in 
the scores for that instrument. Responsiveness was tested by using the responses of two 
anchor questions, which were incorporated into the productivity questionnaire (the same 
two questions as those used in the discriminative validity test above).  
Responses to the above question (a) were used as an anchor and grouped into 4 categories. 
As none of the participants chose the last item, ‘very poor’, this category was omitted 
from the groups. Responses to question (b) were grouped into 2 categories (Yes and No) 
for all questionnaires. Wilcoxon signed-rank tests were conducted to identify any 
significant changes in scores within each category, accompanied with effect size (ES) and 
standard response mean (SRM) calculations (Fayers and Machin, 2016).  
Effect size (ES): 
𝑀𝑒𝑎𝑛 𝑐ℎ𝑎𝑛𝑔𝑒
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑎𝑡 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
 
Standardised Response Mean (SRM): 
𝑀𝑒𝑎𝑛 𝑐ℎ𝑎𝑛𝑔𝑒
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑐ℎ𝑎𝑛𝑔𝑒
 
The SRM helped to indicate how responsive the questionnaires were to change. Values 
ranging between 0.20 and 0.50 were considered small, 0.50 to 0.80 were considered 
moderate and greater than 0.80 were considered large (Cohen, 1988b).  
The results for the construct validity and responsiveness will be presented in the following 
section below.  
 
5.3 Results 
The convergent validity for baseline, week 4 and week 8, are shown in Table 60, Table 
61 and Table 62 respectively using Spearman’s rank correlation coefficients for the 
preference-based measures. At baseline, the relationship between the EQ-5D-5L and the 
AQL-5D, showed statistical significant differences at the 1% level. The correlation 




coefficients for the EQ-5D-5L and the TTO, and the AQL-5D and the TTO were not 
associated.  
The convergent validity relationships highlighted at baseline had become stronger at 
week 4. The EQ-5D-5L and the AQL-5D remained having a strong statistical difference 
at the 1% level. The AQL-5D and the TTO had a better relationship at week 4, with a 
strong statistical difference at the 5% level.  
 
The same statistical significant relationships were also observed for the convergent 
validity at week 8 of the study, as compared to the convergent validity relationships 
observed at week 4 of the study. Both the EQ-5D-5L and the AQL-5D, and the AQL-5D 
and the TTO showed the same relationship. 
 
Table 60: Convergent validity at baseline using Spearman’s rank Correlation 
coefficient 
 EQ-5D-5L (utility) AQL-5D 
(utility) 
TTO (utility) 
EQ-5D-5L (utility) N = 120 
1.0000 
  
AQL-5D (utility) N = 118 
0.3888** 
N = 118 
1.0000 
 
TTO (utility) N = 111 
0.1287 




Pairwise correlation coefficients displayed.  
Correlation coefficients considered < 0.3 are weak, 0.3 to 0.5 are moderate and >0.5 are strong. 
**p-value is < 0.01 therefore statistically significant at the 1% level. 
 
 






TTO (utility) PEF 
EQ-5D-5L (utility) N = 71 
1.0000 
   
AQL-5D (utility) N =63 
0.5355** 
N = 70 
1.0000 
  
TTO (utility) N = 62 
0.1771 





Pairwise correlation coefficients displayed.  
Correlation coefficients considered < 0.3 are weak, 0.3 to 0.5 are moderate and >0.5 are strong. 
*p-value is < 0.05, **p-value is < 0.01 therefore statistically significant at the 5% level and 1% 
level respectively.  
 





Table 62: Convergent validity at week 8 using Spearman’s rank Correlation 
coefficient 
 EQ-5D-5L (utility) AQL-5D (utility) TTO (utility) 
EQ-5D-5L (utility) N = 64 
1.0000 
  
AQL-5D (utility) N =61 
0.6260** 
N = 64 
1.0000 
 
TTO (utility) N = 60 
0.1871 




Pairwise correlation coefficients displayed.  
Correlation coefficients considered < 0.3 are weak, 0.3 to 0.5 are moderate and >0.5 are strong. 
*p-value is < 0.05, **p-value is < 0.01 therefore statistically significant at the 5% level and 1% 
level respectively.  
 
Three different types of discriminative validity tests were also conducted for the 
preference-based measures. The first discriminative validity test, shown in Table 63, was 
based on three PEF groups. The PEF groups were split into categories of different asthma 
severities; <50% of best/predicted PEF, 50%-75% of best/predicted PEF and >75% of 
best/predicted PEF (British Thoracic Society. Scottish Intercollegiate Guidelines 
Network, 2016). The lower proportion (<50% of best/predicted PEF), indicates that the 
participants are the furthest away from their best or predicated PEF, indicating that they 
are more poorly (have life threatening asthma or acute severe asthma) than the 
participants who have a PEF of >75% of their best or predicted PEF (good or very good 
asthma).  
 
Most of the participants were within the 50-75% of best/predicted PEF category 
indicating that they had moderate acute asthma at baseline. Interestingly, at baseline some 
participants were in the third PEF category which indicated they had good/very good 
asthma based on their PEF being > 75% of their best/predicted value. Even though, most 
of the utility values were increasing as hypothesized from the lowest PEF group (< 50% 
of best/predicted PEF) to the highest PEF group (>75% of best/predicted PEF), the change 
was not very large and so the results showed no statistical significant differences between 
any of the preference-based measures displayed.   





Table 63: Discriminative (Known-groups) Validity at baseline using three PEF subgroups against preference-based measures 



























53.64 18 57.02 42 71.89 27 0.105 
AQL-5D utility 53.36 18 56.45 42 68.96 26 0.223 
TTO utility  49.91 16 58.11 40 56.70 28 0.713 
Kruskal-Wallis test conducted and PEF split into three subgroups: <50% of PEF best / predicted = life threatening / acute severe asthma; 50-75% of PEF best/predicted 
= moderate acute asthma and >75% of best/predicted asthma for good/very good asthma (British Thoracic Society. Scottish Intercollegiate Guidelines Network, 2016).  
*No statistical significant difference found for all PROMS between the three PEF subgroups. 





The second discriminative validity test, shown in Table 64, compares how participants 
were at baseline when in hospital with how they felt at four weeks from their asthma-
related crisis event. Most of the participants felt that their asthma had improved at four 
weeks compared to baseline, either moderately or very well, and very few rated their 
asthma as poor. All of the utility values either increased or decreased appropriately across 
the different recovery rates, and this was in line with earlier hypotheses. Both the EQ-5D-
5L and the AQL-5D were statistically significantly different at the 1% level.  
 
The third discriminative validity test, shown in Table 65, also related to the productivity 
questionnaire, and was a direct ‘yes’ or ‘no’ response to whether the participant thought 
that they had recovered from their asthma-related crisis event approximately four weeks 
ago. A higher proportion of responses were observed to be in the ‘no’ category. The 
discriminative validity in Table 65, was statistically significantly different at the 1% level 























Table 64: Discriminative (Known-groups) Validity at week 4 against preference-based measures  
























54.57 15 43.25 18 32.21 26 8.89 9 0.000 
AQL-5D 
utility 
48.53 15 48.15 17 29.72 27 14.89 9 0.000 
TTO utility  54.68 14 49.42 19 39.09 23 38.63 8 0.207 
Kruskal-Wallis test conducted and split into four recovery rates where the participants were asked to rate their asthma at four weeks compared to their asthma at 
baseline (in hospital upon consent).  





























45.18 25 32.21 43 0.013 
AQL-5D 
utility 
49.54 27 27.94 41 0.000 
TTO utility  49.22 27 42.80 37 0.253 
Kruskal-Wallis test conducted and split into two recovery response rates where the participants were asked to rate their asthma at four weeks compared to their asthma 
at baseline (in hospital upon consent).  
The P-values in bold are statistically significantly different at the 1% level.  
 
 




Two responsiveness tests were conducted, which also looked at the recovery rates and 
responses as to whether the participants had recovered from their asthma-related crisis 
event from approximately four weeks ago. The first responsiveness test is shown in Table 
66, and this shows the results of the changes in means between baseline and week 4 based 
on the anchor question taken from the productivity questionnaire. As hypothesized, most 
of the utilities demonstrated sensitivity to change (which is highlighted from the SRM 
values). The range for the mean change from poor to very good groups in the EQ-5D-5L 
utility was from -0.276 to 0.221, for the AQL-5D from -0.0065 to 0.169, and for the TTO 
from -0.173 to 0.254. The TTO was the only preference-based measure which didn’t have 
a large sensitivity to change in any of the four groups (poor, moderate, good and very 
good). Instead, moderate responsiveness was observed for the very good, good and 
moderate groups, with a small responsiveness observed for the poor group. The AQL-5D, 
showed large responsiveness to change for the very good and good groups, moderate 
responsiveness for the moderate group, and small responsiveness for the poor group. The 
EQ-5D-5L, showed large responsiveness for the good and poor groups, moderate 
responsiveness for the very good group and small responsiveness for the moderate group.  
 
For the second responsiveness test, shown in Table 67, the responses to the recovery 
question asked in the productivity questionnaire are observed against the preference-
based measures. It is clear that there is a large responsiveness to the ‘yes’ category for the 
AQL-5D utility value. However, both the EQ-5D-5L and the TTO had moderate 
responsiveness to the ‘yes’ category, and all of the preference-based measures had a small 














Table 66: Responsiveness of all preference-based measures between baseline and week 4  








ES SRM P value 
EQ-5D-5L          
Very good 14 0.747 0.922 0.175 0.280 0.235 0.625 0.745 ** 0.011 
Good 17 0.585 0.807 0.221 0.325 0.233 0.680 0.948*** 0.000 
Moderate 24 0.630 0.724 0.094 0.265 0.239 0.355 0.393* 0.031 
Poor 8 0.604 0.328 -0.276 0.148 0.268 -1.865 -1.030 *** 0.066 
AQL-5D          
Very good 15 0.629 0.798 0.169 0.135 0.187 1.252 0.904 *** 0.010 
Good 17 0.621 0.787 0.166 0.132 0.140 1.258 1.186 *** 0.001 
Moderate 26 0.560 0.621 0.061 0.113 0.110 0.540 0.555 ** 0.023 
Poor 9 0.529 0.524 -0.005 0.107 0.019 -0.047 -0.263* 0.356 
TTO          
Very good 14 0.679 0.932 0.254 0.250 0.329 1.016 0.772 ** 0.014 
Good 19 0.682 0.908 0.227 0.296 0.320 0.767 0.709 ** 0.013 
Moderate 23 0.598 0.787 0.189 0.297 0.348 0.636 0.543 ** 0.008 
Poor 8 0.881 0.708 -0.173 0.177 0.376 -0.977 -0.471* 0.468 
Wilcoxon signed-rank test conducted and p-values in bold are statistically significant at the 5% level. 
ES = Effect size (mean change / SD at baseline); SRM = Standardized response mean (Mean change / SD of change). 
If SRM = 0.2 to 0.50 equals small, 0.50 to 0.80 equals moderate and 0.80 and above equals large.  
*small change, small responsiveness 
**moderate change, moderately responsive 
***large change, largely responsive 




Table 67: Responsiveness of all preference-based measures between baseline and week 4  








ES SRM P value 
EQ-5D-5L          
Yes 25 0.641 0.810 0.169 0.317 0.221 0.533 0.765 ** 0.001 
No 43 0.613 0.701 0.088 0.253 0.308 0.348 0.286* 0.054 
AQL-5D          
Yes 27 0.618 0.802 0.183 0.124 0.162 1.476 1.130 *** 0.000 
No 17 0.566 0.614 0.049 0.123 0.103 0.398 0.476 * 0.023 
TTO          
Yes 37 0.677 0.883 0.206 0.277 0.388 0.744 0.531 ** 0.007 
No 37 0.675 0.817 0.142 0.290 0.334 0.490 0.425 * 0.007 
Wilcoxon signed-rank test conducted and p-values in bold are statistically significant at the 5% level. 
ES = Effect size (mean change / SD at baseline); SRM = Standardized response mean (Mean change / SD of change). 
If SRM = 0.2 to 0.50 equals small, 0.50 to 0.80 equals moderate and 0.80 and above equals large.  
*small change, small responsiveness 
**moderate change, moderately responsive 












This study used psychometric techniques to analyse the construct validity and 
responsiveness relationships between preference-based measures for people with acute 
asthma. The data used for this analysis was prospective cohort data collected from across 
three hospital sites in the UK from when people attended A&E or were admitted to 
hospital with acute asthma symptoms. This study analysed the observed findings by 
comparing the preference-based measures at three main time points during the study, 
which were baseline, week 4 and week 8.  
 
5.4.1 Summary of findings 
The correlations between the preference-based measures were mostly moderately to 
strongly correlated and had strengthened from time points at baseline, through to week 4 
and week 8. At baseline, the EQ-5D-5L and the AQL-5D were statistically significant at 
the 1% level. As the study progressed, the TTO also showed more of a statistical 
significance at the 5% level at week 4 and week 8 of the study.  
 
The discriminative validity comparing the three PEF with the EQ-5D-5L, AQL-5D and 
TTO showed no statistical significant differences across the groups, even though the 
utility values and scores were increasing as the proportion of PEF groups increased. 
However, statistical significant differences were observed at the 5% level in the two 
further discriminative validity tests. The latter tests observed responses at week 4 of the 
study to the participants’ recovery rates from their asthma-related crisis event (A&E 
attendance or hospital admission due to their asthma). The TTO utility value didn’t show 
statistical significance for both of the recovery rate tests.  
 
The preference-based measures also demonstrated good levels of responsiveness when 
comparing the participants’ responses to recovery rates at four weeks from when they had 
their asthma-related crisis event.  Moderate (SRM statistic > 0.50) and large 
responsiveness (SRM statistic > 0.80) was mostly observed on average across the 
preference-based measures for both responsiveness tests. The level of responsiveness was 
the largest for participants’ who felt their asthma had improved from when they were in 
hospital approximately four weeks ago, and in particular if they thought their asthma was 
good or very good in comparison to their asthma-related crisis event.   





5.4.2 Comparison with other studies 
It is not unusual for high levels of correlation to be observed between the AQLQ and the 
AQL-5D because, upon development of the AQL-5D, correlation tests were conducted 
between the AQLQ and the AQL-5D using rasch analysis coupled with psychometric 
techniques, equally displaying high levels of correlation (Young et al., 2011). The mini 
AQLQ has also been used in other asthma studies, such as, Thomas et al. (2009), where 
the royal college of physician three question scores were compared against the mini 
AQLQ, as opposed to the original AQLQ used in this study. Both of these questionnaires 
have been previously tested and have shown good measurement properties, (including 
reliability, responsiveness, construct validity and criterion validity), however, the original 
AQLQ performed the strongest overall (Juniper et al., 1999). 
 
In this study, the correlation coefficients between the TTO and the EQ-5D-5L were much 
weaker compared to the EQ-5D-5L and the AQL-5D.  Even as the study progressed, they 
stayed weak with no statistical significance. A previous cross-sectional study compared 
the TTO with the EQ-5D but had a higher correlation coefficient of 0.40, indicating a 
moderate correlation (Szende et al., 2004). However, there were several differences 
between that study (Szende et al., 2004), and this current study around the participant 
population group, the questioning of the TTO, and the number of levels on the EQ-5D. 
Nevertheless, the TTO correlations presented with lower correlations compared to the 
other preference-based measures for both studies, which potentially confirms the 
unsuitability for using the TTO (based on the format used in this study) in asthma 
measurement.  
 
The other two discriminative validity tests observing the recovery rates of the participants 
at week 4 of the study presented strongly in both categories. The participants responded 
with either a ‘yes’ or ‘no’ if they thought they had recovered from their asthma-related 
crisis event, and then categorised their response ranging from ‘very good’ to ‘very poor’. 
The questionnaire that performed the best overall from this test was the AQL-5D. This 
finding was in line with an earlier study, which also assessed the construct validity with 
disease specific and generic questionnaires for people with asthma (McTaggart-Cowan et 
al., 2008). They encouraged responsiveness tests for the AQL-5D to consolidate their 
findings.  





After reflecting on the analytical technique used to address responsiveness in this thesis, 
my interpretation of this is in line with other studies. For example, Shah et al. (2016a) 
also used an external reference anchor (in this case, question 1 from SF-12) to test 
sensitivity to change amongst the quality of life questionnaires. Additionally, Goranitis 
et al. (2016), also used an external anchor of how women felt their symptoms had 
changed. Similarly, with particular focus on non-normality data, other studies have also 
taken the same approach as I have done in this thesis by using the Wilcoxon signed-rank 
test for the p-values instead of the paired t-test (Goranitis et al., 2016, Goncalves et al., 
2010).  
 
When assessing the two responsiveness tests conducted in this study, (again using the 
recovery rates / questions from the participants at week 4 of the study), the AQL-5D 
performed the best as a measure of utility. The AQLQ has previously shown high levels 
of responsiveness in another asthma study at two different time points (Oga et al., 2003).  
As the AQL-5D is derived from the AQLQ, and it has been confirmed of their strong 
correlations in this study and others (Young et al., 2011), this shows promise for the AQL-
5D as high levels of responsiveness was observed in this study.  
 
5.4.3 Recommendation for the future 
In light of the findings from this study, both the construct validity and responsiveness 
tests have confirmed which preference-based measures perform the best for the acute 
asthma population group for the criteria assessed. Overall, the AQL-5D and the EQ-5D-
5L performed the best and should be considered for use in economic evaluations for 
asthma studies. Even though the AQL-5D is a recent development (Yang et al., 2011), 
previous literature and this current study have strongly confirmed its performance 
(McTaggart-Cowan et al., 2008, Young et al., 2011). Therefore, it is suggested that the 
disease-specific questionnaire, AQLQ, is used in asthma studies in order to estimate 
utilities using the AQL-5D.  
 
However, given that NICE have emphasised using the EQ-5D in economic evaluations 
(Drummond et al., 2005, Drummond et al., 2015), this should still be considered. In this 




study, it did not perform as strongly as the AQL-5D, but it was the second best option out 
of the utility measurements.  
 
5.5 Conclusion  
 
In conclusion, this study aimed to identify the relationships between the preference-based 
measures that were used in a prospective cohort study, which estimated the loss associated 
with an asthma-related crisis event. Psychometric techniques, in particular, convergent 
validity, discriminative validity and responsiveness were used in this analysis. 
 
The EQ-5D-5L and the AQL-5D, illustrated moderate to strong correlations throughout 
all three time points at baseline, week 4 and week 8. They were both also able to 
discriminate against groups for productivity rates, with the AQL-5D performing slightly 
more strongly. Moderate to large changes were observed in the preference-based 
measures for the level of sensitivity to change for the recovery rate responses. However, 
the discriminative test indicated that the preference-based measures were not very good 
at discriminating against the three PEF groups, and the TTO showed weak correlations 
between the EQ-5D-5L and the AQL-5D. 
 
Therefore, the results overall highlight that the AQL-5D and the EQ-5D-5L are well 
correlated and sensitive to change for participants who have had an asthma-related crisis 
event. From this study, the results suggest that the AQL-5D performed better overall, 
compared to the other preference-based measures. However, for the purposes of 
economic evaluation studies, and the fact that previous research recommends the use of 
the EQ-5D, both the EQ-5D-5L and the AQL-5D should be used in the future. 
Nevertheless, it is important to bear in mind that both of these questionnaires have been 
recently developed, and therefore further research is encouraged on a larger, more 











“Research is creating new knowledge” 
(Neil Armstrong, American astronaut) 
 
Preface 
This final chapter will discuss and conclude the findings from the whole thesis. It will 
begin with a summary of the main research findings, followed by contributions to the 
literature. Subsequently, there will be a discussion of the main strengths and limitations 
of the thesis, followed by a discussion of the implications and future directions.  
 
6.1 Summary of main research findings 
This thesis opened with an introduction chapter (Chapter 1), which provided some 
background on asthma and its impact on quality of life. The introduction described the 
scale of the problem (affects millions of people worldwide) and highlighted symptoms, 
(such as; breathlessness, wheezing, chest tightness and coughing), which can 
progressively worsen, reduce quality of life and impact healthcare resource use. Current 
literature shows that asthma can develop from a combination of genetic and 
environmental factors, and although it can be managed by medications and routine asthma 
reviews, when this does not happen asthma attacks are likely to occur. These attacks are 
the progressive worsening of symptoms and can be life threatening. Depending on the 
severity of the asthma attack, the reduction in quality of life can be substantial. There are 
many ways to measure quality of life through direct elicitation methods for use in 
economic evaluations, such as the TTO, standard gamble and EQ VAS. Alternatively, 
generic or disease specific questionnaires can also be used. 
 
This thesis aimed to address several research questions around acute asthmatics and 
quality of life. The rest of this chapter will discuss the main research objectives of this 
thesis. 
 




6.1.1 Cost effectiveness of enhanced asthma management interventions 
from 2012 to January 2016 
The primary objective of the systematic review was to investigate the cost effectiveness 
of asthma management interventions in studies published after 2012, since a previous 
review had already addressed this for studies published between 1990 and 2012 (Yong 
and Shafie, 2014). However, since the secondary objective expanded the search to include 
studies between 1990 and 2016, there were some studies that were included in this 
systematic review, which could have been included previously in the Yong and Shafie 
(2014) review. Therefore, these additional studies and studies found post 2012, were 
included to address the primary objective.  
 
The review found 15 new studies and showed that enhanced asthma management 
interventions were mostly cost effective, across the different types of economic 
evaluations included in the review. ICERs were either dominant or cost effective, and this 
was often reported for CEAs and the only reported CUA study. In comparison, Yong and 
Shafie (2014) also reported the studies to be cost effective for educational and 
environmental studies.  
 
In addition, the quality of these 15 new studies were ranked moderate to high quality, 
with an average QHES score of those post 2012 as 75.1. This was also an improvement 
from previous studies, where Campbell et al. (2008) averaged with a QHES score of 
(Campbell et al., 2008) 61.4 for an equivalent group of studies. The average  QHES score 
for Yong and Shafie (2014) was 75.6, which is very similar to the quality assessment of 
these studies found in this systematic review.  
 
The above highlights that these interventions have shown a level of consistency over the 
years since 1990, due to the positive cost effectiveness results and increase in average 
study quality. Therefore, these interventions should be considered for use in practice, if 
they have not already been implemented.  
 




6.1.2 Methods used in estimating and evaluating both costs and outcomes 
for economic analyses 
The secondary objective of the systematic review, was to explore the methods used to 
estimate and evaluate costs and outcomes in the included studies. This objective was 
useful in determining how costs and quality of life can be assessed and what tools and 
methods can be used to derive the costs and quality of life.  Out of the 64 studies assessed, 
the studies presented with heterogeneity across both costs and outcomes. The most 
commonly reported resource use were asthma-related hospitalizations, asthma-related 
accident and emergency visits, and physician visits, which were often recorded from 
medical records or patient self-reported data. Multiple methods were often used to 
estimate the resource use, due to different outcomes being reported. However, the detail 
in the reporting of the methods, was often limited, and lacking replicability, as unit costs 
and the approach taken to estimate costs (e.g. bottom-up or top-down), were not always 
clearly reported. Three different methods were also used to estimate productivity loss 
(human capital approach, friction cost method and caregiver multiplied by midpoint of 
family’s income), which makes it difficult to compare across studies.  
 
Likewise, comparability across the outcome measures is also challenging, because of 
differences in data collection methods, and quality of life questionnaires used across 
studies. Mixed methods were used, where patient self-report and face to face sessions 
were used in some instances or in conjunction with telephone sessions. The top four most 
commonly reported quality of life questionnaires from the studies were AQLQ, SGRQ, 
15 Dimensions and EQ-5D. Seventeen quality of life questionnaires were only reported 
once across the 64 included studies. 
 
Due to the heterogeneous nature of these studies, it is challenging to know what methods 
for costs and outcomes, and also what quality of life tool, is appropriate to use in the 
asthma population group. There is a lack of consistency in the reporting of these factors, 
where information is limited across some studies (e.g. microcosting of interventions), 
which leads to difficulties in the replicability of studies. Therefore, this review suggests 
using appropriate guidelines and checklists (e.g. TiDier statement, COMET initiative, 
CONSORT statement and international reference case), to ensure methods are reported 
sufficiently.   





Additionally, this review highlighted that quality of life is often captured at set time 
points, such as baseline, 6 months and 12 months. There is potential for asthma related 
studies to underestimate or overestimate quality of life if captured in this way, due to 
asthma attacks occurring sporadically. Therefore, quality of life, (taking into account the 
asthma attacks), may be missed in between such large time points. This gap in the 
literature led to the development of a prospective observational cohort study, which aimed 
to address this problem.  Several PROMs were used in this cohort study to estimate the 
loss associated with quality of life during an asthma-related crisis event, which was 
defined as an accident and emergency attendance or hospital admission.  
 
6.1.3 Peak of an asthma-related crisis event 
The objective was to identify when an asthma-related crisis event reached a peak and was 
at its worst. From the 121 participants recruited into this prospective cohort study, 98 
responded to this question. It was identified that 60% of participants thought their asthma-
related crisis event peaked before attending A&E or being admitted to hospital. On the 
other hand, 22% thought their asthma-related crisis event peaked on route and 17% 
thought their asthma-related crisis event peaked after attending A&E or being admitted 
to hospital. It could be inferred that those whose asthma-related crisis event peaked 
beforehand would have started to improve before they got to hospital, indicating that their 
perception of quality of life could possibly be higher than a participant whose peak was 
on route or in hospital. Likewise, when observing the mode of transport into hospital, 
participants who travelled via ambulance and had the peak of their asthma attack either 
before or on route to hospital, could have also improved in quality of life before reaching 
hospital.  From these inferences, and after comparing the association between participants 
whose asthma-related crisis event peaked before A&E attendance or hospital admission, 
and baseline EQ-5D-5L and TTO (due to some ceiling effects being present here), there 
was no statistical significant differences found. However, whilst there is a possibility for 
quality of life to be somewhat improved before attending A&E or being admitted to 
hospital, if the peak of their event occurred beforehand, the sample size was too small to 
detect a difference. The possibility of improvement in quality of life may be because it 
takes on average, a long period of time to recover from an asthma-related crisis event (as 
highlighted below in the next research question). Therefore, the time between when an 




asthma-related crisis event peaks before reaching hospital and attending A&E or being 
admitted to hospital maybe too small to make any significant impact.  
  
6.1.4 Loss in quality of life associated with an asthma-related crisis event 
Several outcome measures were used to estimate the loss in quality of life associated with 
an asthma-related crisis event from this prospective cohort study. Mean changes were 
reported for utility scores for the EQ-5D-5L, EQ VAS, AQLQ overall, AQL-5D and TTO 
between baseline and week 8, baseline and week 4, and week 4 and week 8 of the study. 
This study identified that when observing the available case dataset, the mean changes 
between the utilities and scores reported at baseline and week 8, and baseline and week 4 
showed strong statistical significant differences at the 1% level. However, only the AQLQ 
overall score and AQL-5D showed statistical significant differences between week 4 and 
week 8.  
 
Interestingly, some participants had ceiling effects at baseline in some of the outcome 
measures (EQ-5D-5L, AQLQ and TTO), suggesting that these participants had returned 
to a ‘healthy’ state by the time of recruitment into the study. However, when these 
participants were excluded from the dataset, and the mean changes were estimated again 
as above, the mean changes still showed statistical significance between the outcome 
measures, with very small differences in values between the full dataset and adjusted 
dataset.  
 
Since the cohort study collected data at several different time points, (e.g. EQ-5D-5L 
weekly, AQLQ monthly and TTO monthly), these initial results allow alternative 
scenarios to be considered when assessing the loss in quality of life associated with an 
asthma-related crisis event. For example, the loss in quality of life could have also been 
assessed at a more granular level, by considering the area under the curve for the EQ-5D-
5L at weekly time points, as opposed to baseline and week 8. This would in turn, produce 
a different, and potentially more accurate estimation of the loss associated with an 
asthma-related crisis event.  
 
This research study is particularly important, as it will enable researchers to estimate the 
loss associated with an asthma-related crisis event in an alternative way, which can also 




inform the estimation of QALY losses / gains. An example of a QALY loss estimation 
was conducted by using the mean change utility score estimated between baseline and 
week 8 for the EQ-5D-5L (0.086), applied to a hypothetical scenario. These techniques 
may improve cost effectiveness analyses findings by providing more granular estimations 
for asthma-related crisis events.  
 
 
6.1.5 The relationship between the demographic variables and the utility 
estimates (EQ-5D-5L, AQL-5D and TTO) 
The prospective cohort study dataset showed a non-normal distribution and a hierarchical 
structure. The missing data was assumed to be MAR, and therefore a multi-level model 
was conducted with inclusion of the covariates to estimate the utility loss. The EQ-5D-
5L and TTO both showed to have the same best structural model, which was the random 
polynomial model, and the best structural model for the AQL-5D was a random slope 
model. The model build was improved by adding the covariates in a stepwise approach, 
until a preferred model was achieved. The EQ-5D-5L, AQL-5D and TTO models 
accounted for the strong predictors of missingness. This suggests that these variables may 
influence the utility estimates of people with acute asthma differently, depending on 
which approach is taken. It also shows the importance of taking into consideration these 
variables in future analysis, and shows potential areas for future research if subgroup 
comparisons are using these variables. The model was further improved by using 
bootstrapping and multiple imputation to estimate the disutilities associated with an 
asthma-related crisis event. The EQ-5D-5L, AQL-5D and TTO QALY disutilities were 
0.0075, 0.0096 and 0.0035 respectively when using the preferred parsimonious model 
incorporated with multiple imputation.   
 
6.1.6 Productivity and out of pocket losses associated with an asthma-
related crisis event 
The prospective cohort study, also identified productivity and out of pocket losses 
associated with an asthma-related crisis event, particularly during the four weeks after 
attending A&E or being admitted to hospital. The study found that the average 
productivity loss per person was £309.07, and the average out of pocket costs (additional 
products purchased due to having the asthma-related crisis event), per person was £16.82. 




Not all participants reported that they were back to work after four weeks since their 
asthma-related crisis event.   
 
These new findings can be used in future research to better estimate the costs associated 
with an asthma-related crisis event. 
 
6.1.7 The correlation between the EQ-5D-5L, AQL-5D and TTO utility 
values 
The three utility instruments that were used in the prospective cohort study were 
compared against each other to identify if there were any correlations between them. It 
was found that the EQ-5D-5L and AQL-5D showed statistical significance in their 
correlations at baseline, week 4 and week 8. Initially the correlations were moderate at 
baseline, and then this increased to strong correlations at week 4 and week 8. The AQL-
5D and the TTO also were also weakly correlated at week 4 and week 8. 
 
Therefore, the results indicate that the EQ-5D-5L and AQL-5D are the two instruments 
which show strong potential for being considered for economic evaluation studies in acute 
asthma research, due to the increasing strength in correlations during the study.   
 
6.1.8 The discriminative validity between the EQ-5D-5L, AQL-5D and 
TTO utility values 
Several discriminative validity tests were conducted to identify if the utility instruments 
(EQ-5D-5L, AQL-5D and TTO), were measuring what they were supposed to be 
measuring. Firstly, three PEF anchor markers were used, which were, < 50% of best / 
predicted PEF, between 50 and 75% of best / predicted PEF and > 75% of best / predicted 
PEF. Approximately two-thirds of participants were categorised into the < 50% of best / 
predicted PEF and between 50 and 75% of best / predicted PEF at baseline. None of the 
utility instruments showed statistical significance with the PEF groups. For the next two 
discriminative validity tests, the EQ-5D-5L and the ALQ-5D showed statistical 
significance for the responses to whether participants thought their asthma had recovered 
or not at week 4 of the study compared to baseline when having their asthma-related crisis 
event. About two-thirds of respondents, thought that they hadn’t recovered from their 
asthma-related crisis event at week 4.  





The results show that it tends to take longer than 4 weeks to completely recover from an 
asthma-related crisis event, as not all of the respondents had returned to their optimum 
health by week 4 of the study.  These results also imply that the EQ-5D-5L and the AQL-
5D are better at measuring what they should be measuring in comparison to the TTO, as 
indicated from the statistical significance in the latter discriminative validity tests. 
Therefore, these two utility-based instruments (EQ-5D-5L and AQL-5D), initially appear 
to be best suited to asthma research.  
 
6.1.9 The responsiveness between the EQ-5D-5L, AQL-5D and TTO utility 
values 
Responsiveness tests were also conducted to test the sensitivity of the instruments. The 
test for the responsiveness was whether participants thought their asthma health had 
improved at week 4 of the study compared to when they attended A&E or were admitted 
to hospital. The EQ-5D-5L and the AQL-5D showed larger responsiveness compared to 
the TTO, with the AQL-5D slightly performing better than the EQ-5D-5L. The 
instruments were least sensitive at detecting participants’ response of poor health, 
compared to very good, good and moderate health for deciding on how they thought their 
asthma was at week 4 of the study. 
 
 
6.2 Contributions to the literature 
Asthma characteristics, symptoms, effect on quality of life, and interventional treatments 
or therapies, are well documented in asthma studies. However, there are fewer asthma 
studies focusing on the impact of quality of life in those who have had attacks that lead 
to hospital admissions or A&E attendance. A couple of studies have acknowledged this 
gap in the literature (Lloyd et al., 2007, Luskin et al., 2014). The former study conducted 
a 4 week study by assessing quality of life on a moderate to severe asthma population 
group recruited from outpatient clinics and primary care (Lloyd et al., 2007). The latter 
study included patients with severe or difficult to treat asthma recruited from community 
physicians, managed care organisations, academic centres and group practices (Luskin et 
al., 2014). Both studies concluded that there were significant decreases in quality of life 
associated with these events. This thesis confirms the findings from these two studies, 




and further improves on these conclusions because the quality of life measurement used 
is closer to the occurrence of the event, (asthma-related crisis event). The estimation of 
the asthma-related crisis event, is a similar approach as to an earlier study, which 
investigated recurrent cellulitis episodes and estimated QALY loss as a means to express 
QALY gains in the prevention of cellulitis recurrence (Mason et al., 2014).  Therefore, 
this idea of QALY loss for the estimation of an asthma-related crisis event is a new 
contribution to the literature influenced from earlier techniques and approaches.  
 
Another contribution of this thesis is from the findings from the PROMs for the asthma-
related crisis event, both in terms of the loss in quality of life associated with the event 
and the psychometric findings for the appropriateness of the PROMs. Both the EQ-5D-
5L and the AQL-5D are relatively new measures, so this contribution is of value.   
 
This thesis has also introduced a novel approach of the TTO. Other studies have also 
adapted the TTO to suit their needs by the method of elicitation, the timeframe (either 
fixed or life expectancy), and the description of the hypothetical health state (Arnesen 
and Trommald, 2005).. On reflection, is it practical to ask participants to imagine their 
life years in a hypothetical state where an asthma-related crisis event continues for the 
remainder of their life expectancy? Will this be a stretch of their imagination? The main 
purpose of using the TTO in the way that it was used in this thesis, was to see if the 
participants’ were back to their normal asthma state after their asthma-related crisis event, 
by not wanting to trade any life years. If the participants’ did not trade any life years then 
their TTO utility would by 1.00. This was useful because it was not known what their 
normal asthma state was before their asthma-related crisis event, and the other PROMs 
would not have been able to provide this information, (decrements in scores on other 
scales could potentially have been due to the presence of co-morbidities).    
 
6.3 Strengths and Limitations 
This thesis contributes new research and findings to the literature on utility estimation for 
those experiencing an asthma crisis event. An initial observation of the vast array of 
asthma PROMs, coupled with outcome measurement from a limited number of time 
points, was highlighted in the systematic review. Following this, utility values and scores 
were provided from estimating the loss associated with an asthma-related crisis event, 
which can be used in future research. Identifying appropriate PROMs for asthma studies 




was an additional strength. This thesis has added value and provided an awareness of how 
severe asthma can be, and widened the knowledge for more accurate estimations for 
quality of life in future studies.  
 
Additional limitations to those already discussed, include the lack of ethnic diversity in  
the prospective cohort study data set. A very high percentage of participants were of white 
ethnicity (95.83%), even though one of the three study sites included Birmingham, which 
is known to be ethnically diverse (Office for National Statistics, 2012). The number of 
participants recruited from Birmingham was considerably smaller than the number of 
participants recruited in Norwich, as were the number of participants recruited from 
Aberdeen in comparison to those recruited from Norwich. It was unfortunate that due to 
timing and resource, recruitment of participants was not at the same rate in Birmingham 
and Aberdeen as the NNUH in Norwich. This was because of reliance on the research 
support staff at the Birmingham and Aberdeen hospitals, and due to their other 
commitments, time was often limited for them to dedicate time for recruitment at these 
sites. This impacted on the richness of the study data set, as the data wasn’t equally 
reflective of participants from each city. Therefore, this also impacted the generalizability 
of the data in the UK.  
 
Another limitation, is the number of questionnaires that the participants had to complete 
over the course of the 8 weeks, which increased the likelihood of missing data or lost to 
follow up. To ensure that all of the data points were completed, and to reduce the number 
of missing data points, it was required to actively check that the participants had 
completed everything that they needed to. This process is often feasible when face to face 
with the participant, and this proved to be mostly successful at baseline in the study. 
However, due to the nature of the study (with participants asked to complete 
questionnaires, daily, weekly and monthly for 8 weeks), and the lack of face to face 
appointments, (as this would be impractical and burdensome to participants), this limited 
the amount of active checking whilst face to face with the participant. 
 
This leads to the next limitation of the study, which was related to the large loss to follow 
up. Participants either withdrew from the study or didn’t post back questionnaires. Due 
to this loss to follow up, it would have benefited the results if the sample size was much 
larger than the original aim of 100 participants for estimating the loss in quality of life 




associated with an asthma-related crisis event. Conversely, for comparing the PROMs 
using psychometric techniques, the sample size for the available case analysis was 
sufficient (Fayers and Machin, 2016).  
 
Another limitation is that the novel TTO that I designed to reflect slightly different anchor 
points (well controlled asthma and current asthma health states), were different from the 
original design of the TTO from Dolan et al. (1996), as their anchor points were (full 
health and diseased health state). As a result, I was assuming that the novel approach 
anchor, ‘well controlled asthma health state’ did not include any other potential 
comorbidities that the participants might have had, and just focused on their asthma 
comorbidity. Therefore, the interpretation of the TTO from my novel approach, cannot 
be the same as the Dolan et al. (1996) approach, due to the former not being weighted to 
reflect the Dolan et al. (1996) approach which includes all comorbidities when taking into 
account the anchor of ‘full health state’.  
 
 
6.4 Potential areas for future research  
There are a number of areas where future research could improve these findings further.  
Firstly, as mentioned previously in this thesis, the actual peak of the asthma crisis event 
occurred before attendance to A&E or admission to hospital for 60% of the recruited 
participants. Therefore, the true estimated loss in quality of life associated with an asthma-
related crisis event could be higher than that estimated here. It would be interesting to see 
if that peak in the asthma event could be captured. A possible way to do this would be to 
follow people with asthma more closely by asking them to complete PROMs regularly, 
including when they had an asthma-related crisis event and thereafter. Asthma apps could 
potentially be a great way to incorporate a PROM, to make it easier for potential 
participants to complete them.  
 
Secondly, estimating the cost of an asthma-related crisis event could also be an area of 
future research. The estimation could be categorised into three different groups of patients 
according to their PEF when the patient is having an asthma-related crisis event. For 
example, the cost could be estimated for those who had a PEF of < 50% of their 
best/predicted PEF (life threatening asthma), or a PEF of between 50% and 75% of their 




best/predicted PEF (moderate acute asthma), or a PEF of  > 75% of their best/predicted 
PEF (good/very good asthma).  
 
Thirdly, another area of future research could be to estimate the minimal important 
difference for the AQL-5D. As this is a relatively new development, and it has proven its 
usefulness in this thesis and a previous study, there is potential for this measure to be used 
more widely in research. With this in mind, having a metric of the minimal important 
difference is important for relatability and comparability in future studies.  
 
Fourthly, the findings reported in the thesis, and the above research ideas could be 
combined to enhance a previous study, which compared interventions to estimate cost-
effectiveness in terms of e.g. hospital admissions. This would enable the researcher to 
identify whether alternative estimations for asthma-related crisis events, in terms of 
cost/QALY, enable comparisons with a more recognised threshold (NICE, 2013) and 
other studies.  
 
Finally, a qualitative piece of research could be conducted amongst the participants who 
had experienced the asthma-related crisis events to find out from their perspective how 
they felt during the event, and their views about the aftercare post crisis event.  
 
Future researchers might benefit from learning about the challenges that I encountered 
during this research journey and strategies that I found helpful for overcoming these. 
Therefore, I will discuss this in more detail below. 
 
Conducting a systematic review is challenging in itself, and one of the main challenges 
lies in the creation of the search strings. These need to be carefully developed in order to 
ensure that the search is sufficiently capturing the amount of information needed in order 
to answer the research questions. One way of overcoming this challenge, is by seeking 
out other systematic reviews with similar research interests in order to get an idea of the 
search strings used in their reviews. These search strings can then be adapted to suit the 
systematic review that you are working on, with discussions with a specialist if 
uncertainty arises. 
 




Additionally, there were many challenges that were involved with the design and 
development of the prospective cohort study through to recruiting patients. Acute asthma 
patients are a difficult patient group to conduct research on, and due to this there were 
ethical concerns about this research project. Initially, the NHS research ethics committee 
granted a provisional opinion on this research project as they had some ethical concerns, 
particularly around approaching acute patients in hospital with questionnaires and the 
timing of when the questionnaires would be distributed. To overcome this concern, 
discussions with the A&E clinical lead, asthma specialist nurse and a patient and public 
involvement group took place in order to identify the best practical way to approach the 
acute patients as early as possible. These discussions offered plausible alternatives, such 
as, approaching this patient group within an early timeframe of them presenting to 
hospital. 
 
Recruiting the acute asthma patient group was challenging for two reasons. One of the 
reasons was due to needing to be made aware as soon as possible of patients attending 
A&E or being admitted to hospital. This was to ensure that as many patients as possible 
were approached as early as possible for the purpose of this study in order to maintain the 
accuracy of estimating the quality of life associated with an asthma-related crisis event as 
close to the event as possible. This recruitment procedure was challenging as it was not 
always easy to identify those groups of asthma patients who attended A&E or were 
admitted to hospital. Therefore, to overcome this challenge, I liaised with the A&E 
clinical lead and put up posters in the A&E department as a reminder for the staff to 
contact me if a suitable patient arrived fitting my inclusion criteria. For the hospital 
admissions, I liaised with the asthma specialist nurse and other respiratory nurses who 
were regularly involved in the daily triage of asthma patients. This enabled me to ensure 
that I was capturing the patients who had been admitted to hospital on a daily basis. The 
second reason was the challenge of loss to follow up for various reasons (e.g. too poorly 
or too busy). The retention rate was always going to be a challenge given the patient group 
recruited, however, I didn’t expect the loss to follow up to be so large. To overcome this 
challenge, I sent an amendment to ethics and ask to increase the recruitment target number 
to account for this loss.  
 
Overall, research brings challenges, but these challenges can be reduced with patience, 
willingness to learn and the right levels of expertise. 




6.5 Conclusion  
Overall, this thesis has investigated the quality of life in acute asthmatics, with a particular 
interest in their quality of life during an asthma-related crisis event (A&E attendance or 
hospital admission). Initially, a systematic review was conducted to explore the cost 
effectiveness of non-pharmacological asthma management interventions and identify the 
methodologies used to estimate costs and outcomes. Educational and environmental 
interventions were generally observed as being cost effective, which was in line with an 
earlier review, and the studies had also tended to improve in quality, compared to earlier 
studies. Due to also concluding that there were many PROMs used to measure quality of 
life, and that quality of life was mostly captured at set time points that were often months 
apart, a prospective cohort study was designed. The cohort study explored the loss in 
quality of life in people who had an asthma-related crisis event over 8 weeks. This study 
found most of the loss associated with an asthma-related crisis event to occur during the 
first four weeks of the study, with an estimated loss in EQ-5D-5L utility of 0.127 and 
AQL-5D utility of 0.099 (using available case analysis) for the  two most appropriate 
tools for measuring quality of life in economic evaluations.  When using multi-level 
modelling incorporated with multiple imputation, the QALY disutility was estimated to 
be 0.0075 and 0.0096 for the EQ-5D-5L and AQL-5D respectively over 8 weeks.   
 
Of the preference-based measures, the EQ-5D-5L and the AQL-5D performed well, as 
evidenced by strong correlations and large levels of responsiveness and the TTO 
produced poor results for construct validity and responsiveness. Therefore, given the poor 
results from the TTO, I do not consider this to be suitable for this asthma population. 
However, I do consider the EQ-5D-5L and AQL-5D to be suitable given the results, and 
I would consider using both in future studies. 
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Appendix I: Adapted version of the QHES checklist by Yong and Shafie 
(2014) 
 
No. Questions / Criteria Scoring system Highest 
total 
score 
1 Was the study objective presented 
in a clear, specific, and 
measureable manner? 
Clear, specific, measurable = 7 
Any two = 5 
Any one = 2 
None = 0 
7 
2 Were the perspective of the 
analysis (societal, third-party 
payer, etc.) and reasons for its 
selection stated? 
(1) Perspective = 2 
(2) Reasons = 2 
4 
3 Were variable estimates used in the 
analysis from the best available 
source (i.e., randomized control 
trial – best, expert opinion – 
worst)? 
Randomized control trial = 8 
Non-Randomized control trial 
= 7 
Cohort Studies = 6 
Case-control/case report/case 
series = 4 
Expert opinion = 2 
8 
4 If estimates came from a subgroup 
analysis, were the groups pre-
specified at the beginning of the 
study? 
Yes = 1 
No = 0 
1 
5 Was uncertainty handled by (1) 
statistical analysis to address 
random events, (2) sensitivity 
analysis to cover a range of 
assumptions? 
(1) Statistical analysis = 
4.5 
(2) Sensitivity analysis = 
4.5 
9 




No. Questions / Criteria Scoring system Highest 
total 
score 
6 Was incremental analysis 
performed between alternatives for 
resources and costs? 
If the case is CBA, then the question 
shall ask “Was net monetary 
benefit / cost benefit ratio 
performed between alternatives for 
resources and costs?” 
Yes = 6 
No = 0 
 
CCA type of economic 
evaluation = NA 
6 
7 Was the methodology for data 
extraction (including the value of 
health states and other benefits) 
stated?  
Yes = 5 
No = 0  
5 
8 Did the analytic time horizon allow 
time for all relevant and important 
outcomes? Were benefits and costs 
that went beyond 1 year discounted 
(3% and 5%) and justification 
given for the discount rate? 
If less than 1 year, only answer 
for the time horizon. Yes = 7, 
No = 0; If more than 1 year, 
done for  
(1) Time horizon = 3 
(2) Cost discounting = 1 
(3) Benefit discounting = 1 
(4) Justification = 2 
7 
9 Was the measurement of costs 
appropriate and the methodology 
for the estimation of quantities and 
unit costs clearly described? 
Done for 
(1) Appropriateness of 
cost measurement = 4 
(2) Clear description of 
methodology for the 
estimation of quantities 
= 2 
(3) Clear description of 
methodology for the 
8 




No. Questions / Criteria Scoring system Highest 
total 
score 
estimation of unit costs 
= 2 
10 Were the primary outcome 
measure(s) for the economic 
evaluation clearly stated and did 
they include the major short-term? 
Was justification given for the 
measures/scales used? 
Done for 
(1) Primary outcome 
clearly stated = 2 
(2) Include major short-
term outcome = 2 
(3) Justification = 2 
6 
11 Were the health outcomes 
measures/scales valid and reliable? 
If previously tested valid and 
reliable measures were not 
available, was justification given 
for the measures/scales used? 
Yes = 7 
No = 0 
7 
12 Were the economic model 
(including structure), study 
methods and analysis, and the 
components of the numerator and 
denominator displayed in a clear, 
transparent manner? 
If modelling study, done for  
(1) Economic model = 2 
(2) Study methods = 1.5 
(3) Analysis = 1.5 
(4) Components of 
numerator = 1.5 
(5) Components of 
denominator = 1.5 
If not a modelling study, done 
for 
(1) Study methods = 2 
(2) Analysis = 2 
(3) Components of 
numerator = 2 
(4) Components of 
denominator = 2 
8 




No. Questions / Criteria Scoring system Highest 
total 
score 
13 Were the choice of economic 
model, main assumptions, and 
limitations of the study stated and 
justified? 
If modelling study, done 
(stated and justified) for 
(1) Economic model = 2 
(2) Assumptions = 2.5 
(3) Limitations = 2.5 
If not a modelling study, done 
(stated and justified) for 
(1) Assumptions = 3.5 
(2) Limitations = 3.5 
7 
14 Did the author(s) explicitly discuss 
direction and magnitude of 
potential biases? 
(1) Direction = 3 
(2) Magnitude = 3 
6 
15 Were the 
conclusions/recommendations of 
the study justified and based on the 
study results? 
Yes = 8 
No = 0 
8 
16 Was there a statement disclosing 
the source of funding for the study? 
Yes = 3 


















Appendix II: Resource use, intervention components and method of 
estimation across all studies 
  
Anderson 
























        
Staff costs *  ** * * * * * 
Program materials 
and/or equipment  
supplies 
 ** * * * * * * 
Education and 
training sessions 
 ** * * * 
 
* * * 
 
Operating costs of 
activities (including 
meetings) 
    *    




  **      
Overhead costs    * *    
Wider resource use 
measured 





** ** * * * ** * * 
Healthcare 
professional costs 
(including visits and 
calls) 
**  *  * ** * * 
Transportation costs         
Medication costs   *    * * 
Lost productivity 
costs 







        
Method of 
estimation 
        
Bottom-up approach  * * *   * * 
Top-down approach *    * *   
*Reports item 
**Reports item and unit cost  































        
Staff costs  * * ** * *  * * 
Program materials 
and/or equipment  
supplies 
* * ** * *  ** * 
Education and 
training sessions 
* * ** * *  ** * 
Operating costs of 
activities (including 
meetings) 
     *   




      **  
Overhead costs      * **  
Wider resource use 
measured 





* ** * * * ** * * 
Healthcare 
professional costs 
(including visits and 
calls) 
* ** * * * ** * * 
Transportation costs        * 
Medication costs *  * * * ** * * 
Lost productivity 
costs 







        
Method of estimation         
Bottom-up approach * * *  * * *  
Top-down approach    *    * 
*Reports item 
**Reports item and unit cost 
  































        
Staff costs  * ** ** * * * * * 
Program materials 
and/or equipment  
supplies 
* ** ** * * * * * 
Education and 
training sessions 
* ** * * * * * * 




    *   * 




        
Overhead costs         
Wider resource 
use measured 












* * ** ** ** * ** ** 
Transportation 
costs 
        
Medication costs *  **  **  ** ** 
Lost productivity 
costs 







        
Method of 
estimation 
        
Bottom-up 
approach * * * * 
  *  
Top-down 
approach 
    * *  * 
*Reports item 
**Reports item and unit cost 
  









et al, 1998 
Kauppinen 
et al, 1999 
Kauppinen 
















        





** * * * * * * * 
Education and 
training sessions 





** * * * * * * * 




        
Overhead costs         
Wider resource 
use measured 











visits and calls) 
** ** ** * *    
Transportation 
costs 
 **       
Medication costs ** * ** *   *  
Lost productivity 
costs 








*        
Method of 
estimation 
        
Bottom-up 




       * 
*Reports item 
**Reports item and unit cost 
  





























        
Staff costs  * * ** * ** * ** ** 
Program materials 
and/or equipment  
supplies 
* * ** * ** * ** ** 
Education and training 
sessions 
* * ** * ** * ** ** 
Operating costs of 
activities (including 
meetings) 
 * ** * **    




       ** 
Overhead costs         
Wider resource use 
measured 





** ** * ** ** ** ** * 
Healthcare 
professional costs 
(including visits and 
calls) 
** ** * ** **  ** * 
Transportation costs    **     
Medication costs ** ** *    **  
Lost productivity costs  ** * ** **  **  
Miscellaneous 
expenses (e.g. mattress 
covers, pillow covers, 
air-conditioning, 
cleaning devices) 
        
Method of estimation         
Bottom-up approach * * * * * * * * 
Top-down approach         
*Reports item 
**Reports item and unit cost 
  































        
Staff costs  * ** * ** * * * * 
Program materials 
and/or equipment  
supplies 
* ** * ** * * * * 
Education and 
training sessions 
* ** * ** * * * * 
Operating costs of 
activities (including 
meetings) 
* ** * ** * * *  




        
Overhead costs        * 
Wider resource use 
measured 





* ** * * ** * * * 
Healthcare 
professional costs 
(including visits and 
calls) 
* ** * * * * * * 
Transportation costs  **       
Medication costs * **  **  * * * 
Lost productivity 
costs 







        
Method of estimation         
Bottom-up approach  * * *   * * 
Top-down approach *    * *   
*Reports item 
**Reports item and unit cost 
  






























        
Staff costs  * * ** * * * * * 
Program materials 
and/or equipment  
supplies 
* * ** * * * * * 
Education and 
training sessions 
* * ** * * * * * 
Operating costs of 
activities (including 
meetings) 
* * ** * *  * * 




        
Overhead costs         
Wider resource use 
measured 





* ** ** * * * * * 
Healthcare 
professional costs 
(including visits and 
calls) 
* ** ** *  * * * 
Transportation costs      *   
Medication costs *   *  * * * 







  **   *   
Method of estimation         
Bottom-up approach * * * *  * * * 
Top-down approach     *    
*Reports item 
**Reports item and unit cost 
  






et al, 2005 
Turcotte 
















Intervention resource use 
measured 
       
Staff costs  * * * ** * * ** 
Program materials and/or 
equipment  supplies * * * ** * * ** 
Education and training 
sessions 
* * * ** * *  
Operating costs of activities 
(including meetings) * * 
    ** 




 **   **   
Overhead costs    **    
Wider resource use 
measured 
       
Hospital costs (including 
inpatient, outpatient and 
emergency visits) 
** ** ** ** * * ** 
Healthcare professional 
costs (including visits and 
calls) 
** ** ** ** * * ** 
Transportation costs        
Medication costs    **   ** 
Lost productivity costs **   **    
Miscellaneous expenses (e.g. 
mattress covers, pillow 
covers, air-conditioning, 
cleaning devices) 
       
Method of estimation        
Bottom-up approach * * * * * * * 
Top-down approach        
*Reports item 




















y et al 
2009 
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Outpatient visits 
        
 
Physician (clinic) visits 
    
* 




        
 
Symptoms 








* * * 
 
Psychiatric difficulties 
























Forced Vital Capacity 
(FVC) 
        
 




     
 
Medications 
        
 
Prescriptions 
        
 
Airway responsiveness 
        
 
Disability weights 
        
Data collection methods 
        
 
Telephone interviews * 




Face to Face visits 



















   
* 
    
 
Patient diary 
        
 
Medical records * 
       
 
Claims records 





        
 
Previous reviews & 
studies 
        
Methods used to estimate 
outcomes 
        
 
Spirometry 




Peak Flow meter 
 
* * 
     
 
Histamine dosage 
        
 
QALYs 
        
 
DALYs 
        















et al 2008 
Drummo
nd et al 
1994 
D'Souz
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Physician (clinic) visits 
  

















Quality of Life * 
 
* 
     
 
Psychiatric difficulties 







   
* * 
 
Asthma Knowledge / 
education 
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Disability weights 
        
Data collection methods 









Face to Face visits 























        
 
Patient diary * 
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* 
   
 
Letters 
        
 
Previous reviews & 
studies 
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studies 
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Peak Flow meter 
 
* 
      
 
Histamine dosage 





     
 
DALYs 
        
 






n et al 
2005 
Kauppine
n et al 
1998 
Kauppine
n et al 
1999 
Kauppine








n et al 
1997 
Lindber
g et al 
2002 
Luca
s et al 
2001 
Outcomes measured 
        
 
Emergency departments (ED) 
visits 
* 





Hospitalization visits * 





Intensive care admissions 





       
* 
 
Physician (clinic) visits * 
     
* * 
 
Frequency of exacerbations 
        
 
Symptoms * 






Quality of Life 
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Asthma Knowledge / 
education 
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Forced Expiratory Volume 
(FEV) 
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Peak Expiratory Flow (PEF) 
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Disability weights 
        
Data collection methods 
        
 
Telephone interviews * 
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Face to Face visits 
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Case managers self-reported 
questionnaires 
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outcomes 
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et al,  
1997 
Mogasale 

















1 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 
2  2 4 0 4 0 0 4 0 0 2 2 2 2 0 2 
3 8 6 8 4 8 6 8 6 8 8 8 8 6 6 8 
4 0 0 0 1 0 0 1 0 0 0 0 0 0 0 1 
5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 0 9 9 4.5 0 4.5 9 
6 6 6 0 0 6 0 0 0 0 6 0 6 0 0 6 
7 5 5 5 0 5 5 5 5 0 5 5 5 5 5 5 
8 7 7 0 5 7 7 7 7 0 0 7 7 0 7 7 
9 6 6 2 6 8 8 8 6 8 8 6 6 8 8 8 
10 6 6 4 0 6 4 4 6 4 0 4 6 0 4 4 
11 0 7 7 0 7 7 7 7 7 7 0 7 0 7 7 
12 4 8 8 4.5 4 8 8 5 2 8 8 8 2 4 8 
13 3.5 7 3.5 7 3.5 3.5 3.5 3.5 3.5 7 7 7 7 7 3.5 
14 0 6 6 0 0 6 6 3 0 0 3 0 6 0 6 
15 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 
16 0 3 3 3 3 0 3 3 3 3 3 3 0 3 0 
Total 67 90.5 66 54 77 74 84 71 50.5 78 77 84.5 51 70.5 89.5 
 























(Int. & Con.) 






Outcome results Response 
rates 
Anderson 

















Not stated Int. Before = 








Comparing annual rates 
of hospitalizations, 
emergency department 





were used to 
contact the 




















Pre-period (Int. = 
0.95; Con. =0.94) 
Post-period: (Int. = 
0.55; Con. = 0.89) p 
= 0.05. ED visits 
(per year/child): 
Pre-period (Int. = 
1.1; Con. = 1.3) 
Post-period: (Int. = 
0.5; Con. = 1.3) p = 
0.04. Follow up 
visits (per 
year/child): Pre-
period (Int. = 3.3; 
Con. = 2.0) Post 
period: (Int. = 0.8; 




























(Int. & Con.) 






Outcome results Response 
rates 
pre-period = 3.5. 
Post-period = 0.1 p 
< 0.01. Intensive 
care unit (ICU) (per 
days/year/child): 
pre-period = 1.0 
post-period = 0. p < 
0.004. ED visits 
(per 
days/year/child): 
pre-period = 2.1 
post-period = 0.6. p 
= 0.02. Follow up 
visits (per 
days/year/child): 
pre-period = 6.8 
post-period = 2.1. p 
= 0.02]. 
 




















plans – based 
on literature;  
ER visits & 
hospitalizatio
ns – based on 
Not stated Program cost of 
peak flow plan 
= $63 per 
patient. 
Program cost of 
symptom based 
plan = $35 per 
patient 
 
Reduction in the number 
of ER visits and 
hospitalizations caused 
from asthma 
exacerbations during the 






Reduction in ER 





Reduction in ER 
visits = 0%; 
Reductions in 
Not stated 




















(Int. & Con.) 

























Direct costs - 
medical service 






costs - lost 
productivity, 
school absences, 


















($25 for teachers, 




spent by students 
(2.25 hrs per 
student), parents 
(0.42 hrs per 
parent), teachers 
(0.67 hrs per 
teacher), school 
nurses (1.01 per 
nurse), program 
Intervention 
cost = $6500 per 




measuring impact of 
program's knowledge, 
understanding of asthma 
disease process, self-
management techniques, 
attitudes toward asthma, 
self-management 
behaviours, asthma 
related quality of life, 
health status 
 
Surveys Baseline: In 
previous 4 weeks - 
any hospitalizations 
(Int = 2.54%, Con = 
3.08%, p-value = 
0.725). Any ED 
visits (Int = 5.08%, 
Con = 9.25% p = 
0.082). Post 
intervention: In 
previous 4 weeks - 
any hospitalizations 
(Int = 1.27%, Con = 
1.76% p = 0.667). 
Any ED visit (Int 
=3.39%, Con = 
3.52% p = 0.937). 































(Int. & Con.) 






Outcome results Response 
rates 
facilitators (1.17 
hrs per program 
facilitator). No. of 
hours spent by 
respondent/partici




baseline (Int = -
0.18, Con = 0.09 p = 
0.125). Change in 
no. of days with 
asthma symptoms 
among those with 
symptoms at 
baseline (Int = -1.97 

























costs, it did 
not include 
physician 
costs). No. of 





clinical budget of 
the program (staff 




cost of instruction 
for each student 
per day was 
computed using 
the annual budget 
for the Boston 
school districts for 
money spent on 
instruction 




savings: Year 1 
per patient (Int 
= $1780, Con = 
$436).  Year 2 
per patient (Int 
= $2305, Con = 
$746). Year 3 
per patient (Int 
= $1873, Con = 
$1003) 
 
Quality of life 
improvements - missed 
days from work/school 





by CAI Case 
managers at 
baseline, 6 
months and 1 






hospitalized. Year 1 
(Int = 0.37 
(p<0.001), Con = 
0.09 p = 0.11) Year 
2 (Int = 0.43 (p < 
0.001), Con = 0.12 p 
= 0.03) Year 3 (Int = 
0.43 (p<0.001), Con 
= 0.16 p = 0.003) 
 
Not stated 




















(Int. & Con.) 





















and divided by 
180 (assuming 
180 classes are 
































& materials) plus 
operating costs of 
day to day 
activities  
 
Per person per 
year. ED visits; 
Int = $408 Con 
= $1,036. 
Physician; Int = 
$281 Con = 
$351. 
Hospitalization; 
Int = $2,250 
Con = $3,461. 
Total; Int = $2, 
936 Con = $4, 
849 p = 0.10 
 









every 4 months 




Mean per 100 
persons. First 4 
months: ED visits; 
Int = 68 Con = 220 
p= 0.003. Physician 
visits; Int = 197 Con 
= 287 p = 0.35. 
Hospitalization; Int 
= 26 Con = 39 p = 
0.4. Limited activity 
days; Int = 622 Con 
= 888 p = 0.03. 
Monthly average 
for 12 months: ED 
visits; Int = 16 Con 
= 39 p = 0.0005 
Physician; Int = 46 



























(Int. & Con.) 










g the actual 
cost. Wage 






= 7 Con = 10 p = 
0.23. Limited 
activity days; Int = 

















visit ($600), "sick" 
visits ($135), 




























$16,250. 1 year 
= $1,902. 2 
years = $690. (P 
< 0.0001 
between 
admission and 1 
year) 
 
Functional severity of 
asthma scale (FSAS), 
Paediatric asthma 
caregiver's quality of life 
questionnaire, Paediatric 










competent > 7 
year olds, and 
families) at 
baseline, 12 







frame is not 
provided) then 






Baseline = 16.5, 1 
year = 9.5, 2 years = 
8.3 (P < 0.0001). 
CQLQ: Baseline = 
4.2, 1 year = 5.6, 2 
years = 6.1 (P < 
0.0001). PQLQ: 
Baseline = 4.4, 1 
year = 5.8, 2 years = 
6.1 (P < 0.0001). 
Medication: 
Corticosteroids: 
Baseline = 66% use; 
1 year = 26% use; 2 
years = 13% use. 
(P=0.0001). 
Corticosteroid 
dosage decreased to 
0mg/day at 1 and 2 
years follow up (P < 
0.0001).  
Between 







Year 1 = 
83/98; 
84.7%; 





Year 1 = 
87/98; 
88.8%; 
Year 2 = 
71/90; 
78.9% 




















(Int. & Con.) 



















data was used 
to derive a 
medical 
encounter 


































and 24 months. 
  




















(Int. & Con.) 











QLQ for those 
> 7 years old. 
Perceived 









costs (the amount 












using the US 
Consumer Price 
Index for medical 
care; medical 
records. Indirect 
costs (cost to the 













data. For loss 
of 
productivity 






Not stated Combined 
absenteeism and 
presenteeism: 





ear savings in 
indirect costs. 
Cost saving: 
Direct = $725 
per patient per 
year. Indirect = 
$1230 per 
patient per year. 
 
Changes in Forced 
expiratory volume 
(FEV) over time, 
changes in severity and 
frequency of asthma 
symptoms at night and 
asthma attacks. How 
asthma had affected the 
patient's lives (Quality 
of life). Also 
investigated the number 
of ED visits, 
hospitalizations, and 
asthma related health 













FEV: Baseline = 
50% had normal 
FEV, 1 year or more 
= 75% had normal 
FEV. At baseline 
17% were severe, at 
1 year or more this 
reduced to 4%. 
Asthma 
questionnaire: 
Baseline = 28% 
patients were 
awakened 2 or more 
times per week in 
the night, at 1 year 
or more this reduced 
to 12%. Baseline = 
35% indicated high 
frequency of asthma 
episodes of 2 or 


























(Int. & Con.) 






Outcome results Response 
rates 








week, at 1 year or 
more this reduced to 
16%. Baseline = 
50% indicated low 
frequency of asthma 
episodes, increased 
to 75% at 1 year or 
more. 272 observed 
before and 320 
patients observed 
after. ED visits/100 
patients/year: 




Before = 5.1, After 
= 1.9 Combined 
inpatient events/100 
patients/year: 





















Not stated Intervention 
costs = $186. 
Total healthcare 
costs (Int = 
$5,726, Con = 
$12, 188 p = 
0.03) 
 
Readmission due to 
asthma, total 
readmissions, ED visits, 
Quality of Life, direct 
and indirect healthcare 
costs, lost school or 
work days and 
Asthma 
Quality of Life 
Questionnaire 
at baseline, 6 
months.  
 




readmissions (Int = 
21, Con = 42 p = 
0.04). No. of 
readmissions not for 
Not stated 




















(Int. & Con.) 






Outcome results Response 
rates 
 cumulative number of 
days of hosp.  
 
asthma (Int = 10, 
Con = 29 p = 0.19). 
No. of hospital days 
for asthma (Int = 53, 
Con = 129 p = 0.04). 
No. of ED visits (Int 
= 93, Con = 64 p = 
0.52) No. of 
healthcare provider 
visits (Int = 166, 
Con = 157 p = 0.82) 
AQLQ change (Int 
= 1.4, Con = 1.2 p = 
0.55) 
 




Direct costs - 





service, lab test, 
registration fee 
and drug costs. 
Costs based on 
reimbursement 
cost for healthcare 










Not stated Currency = NT 





483 $NT. Lab 
test per patient: 







Baseline = 277 
Cost of healthcare 
services. Asthma 
knowledge, quality of 
life, self-management, 
PEF variation, 





quality of life 
questionnaire 
(AQLQ) at 













Baseline = 5.1(1.0), 
Intervention = 
9.2(1.5) (P < 0.05). 
AQLQ all 
categories had (P < 
0.001). PEF 
variation (%): 
Baseline = 25.25, 1 
month = 19.39 
(P<0.001), 2 months 
= 13.52 (P<0.001), 
3 months = 11.49 
(P<0.001). Beta-2-
agonist: Baseline = 



































(Int. & Con.) 










46 $NT. ER 
visits: Baseline 









Baseline = 102 
$NT, 
Intervention = 
68 $NT.  Total 










385 $NT.  
 
corticosteroids 
use and peak 





diary chart.  
 
0.67 (P=0.276), 2 
months = 0.33 
(P=0.034), 3 months 
= 0.22 (P=0.039). 
Inhaled 
corticosteroids: 
Baseline = 1.77, 1 
month = 1.70 
(P=0.317), 2 months 
= 1.60 (P=0.157), 3 
months = 1.50 
(P=0.083) 
 
Doan et al, 
1996, 
Medical intensive 
care unit with 
Inpatient 
hospitalizatio
Not stated 1 Year before 
intervention: 





clear. After = 22% 
From 21 
patients: 7 




















(Int. & Con.) 























visit for asthma 
($1409), Office 






Spirometry ($25)  
 
n - multiplied 
number of 












no. of visits 
by cost of 
standard care 













costs of each 
Hospitalization 




services = $939; 
Medicine = 














severity and duration of 
hospitalizations, ER 
visits, number of office 
and outpatient lab visits, 
number, frequency use 






















Before = 77% 
medication use; 
After = 66% 









After this, 3 
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Outcome results Response 
rates 
medication. 
Total cost of 













Cost of face to face 
session:  $40.15 
(mean time 66 
minutes) + $36.50 
(administration 
time 60 minutes) + 
$1.00 (Printing, 
postage and call 
costs) + $12.00 
(Peak Expiratory 
Flow Meter) = 





(average  educator 
spent on all calls is 



















Mean time spent 
by educators' on 
calls (92 minutes) 
multiplied by the 
cost of 6 calls 
($1.32).  
 
Total costs of 
hospital 
readmissions: 
Int = $2,063.60 




Asthma quality of life. 
Patients telephoned on a 
weekly basis to gather 
information about 
waking at night due to 
asthma, lost days from 
work/study due to 
asthma, use of oral 
corticosteroids, 
unplanned visits to the 











at baseline, 6 
months, 12 











baseline = 4.96; 12 
months = 5.63; 
difference is 
clinically important 
= 0.67. Control 




SES: no significant 
difference between 
intervention & 
control = p > 0.9 or 
within groups 
across the three 
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Outcome results Response 
rates 
92 minutes; cost of 




and cost of 
call (standard 
local call rate 




- average cost 

















d et al, 
1994, 
Scotland 













stated as relevant 
staffing, material 
costs, savings to 
the changes in no. 










patient per year 
for hospitals; 
£2.41 per 
patient per year 
for GPs; £39.52 
The use of 
bronchodilators and oral 
steroids, the number of 
GP consultations and 
hospital admissions, 
sleep disturbance, 
restrictions on normal 
activity and 








After 12 months: 
No. of 
bronchodilators 
prescribed: Int. = 
10.1 Con = 10.6. 
No. of inhaled 
steroids prescribed: 
Int. = 6.4 Con = 6.5. 
No. of courses of 
oral steroids used: 
Int. = 1.6 Con = 1.6 
Not stated 




















(Int. & Con.) 



















 per patient per 
year for patients 
 
scale (SES); living with 
asthma scale;  
 
No. of general 
practice asthma 
consultations: Int. = 
2.7 Con. = 2.5. No. 
of hospital 
admissions for 
asthma: Int. = 0.15. 
Con = 0.11. No. of 
nights disturbed: 
Int. = 2.4 Con. = 2.4. 
No. of days 
restricted 
activity/month: Int. 
= 5.7 Con. = 4.8. 
Psychological 
outcome: Anxiety:  
Int. = 6.5 Con. = 
6.5; SES: Int. = 2.0 
Con. = 2.0; Living 
with asthma scale: 
Int. = 2.9 Con = 2.9; 
Depression: Int. = 


























Int. = $192 Con 




ns/ER visits. No. of 
short acting canisters 








for the study 
No. of inhaled 
corticosteroid 
prescription: Int. = 
73.5% Con = 64.2% 
P = 0.007. No. of 
asthma-related 
outpatient visits in 
Not stated 
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Int. = $313 Con 
= $262 P = 




costs: Int. = $43 












(Int = $224; Con 
= $155; p = 
0.002) 
Pharmacy costs 
(Int = $145; Con 







Int. = 1.68 Con = 
1.25 P = 0.031. At 
baseline No. of 
physician visits: Int. 
= 1.38 Con. = 1.08 P 
=0.123. At follow 
up no. of physician 
visits: Int. = 1.20 
Con. = 0.96 
P=0.108. Baseline 
no. of SABA 
canisters: Int. = 1.72 
Con. = 1.57 
P=0.324. At follow 
up no. of SABA 
canisters: Int. = 1.76 
Con. = 1.49 
P=0.114.  
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Outcome results Response 
rates 
up Medical 
costs (Int = 
$170; Con = 
$229; p = 0.004) 
Pharmacy costs 
(Int. = $181; 
Con = $124 p < 
0.01) Total 
overall costs 
(Int = $362; Con 








visits ($156), ER 
visits ($638), 
Hospitalizations 
($10,167). Cost of 
medications used 
daily per day: 
SABA low dose 
ICS ($4.05), 
SABA medium 





















Not stated Installation of 
kitchen fan: 
Cost savings for 
healthcare 
utilization = 




Cost savings for 
$302 per year 





visits and clinic visits 
with prescribed oral 
steroid bursts, FEV1% 
 
Not stated Baseline model: 
Hospitalizations per 
year = 0.023, ER 
visits per year = 0.1, 
Serious events per 
year = 0.78. Many 






intervention had a 
significant increase 
in prevalence of 
damp homes. As a 
result of fix fans, 
replaced gas stoves, 
Not stated 
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Outcome results Response 
rates 
no oven for heat, no 
smoking HEFA 
filters, IPM, asthma 














income costs from 



























($88), PM training 











cost = $120.84 
per child for 
first and final 
month of study.  
 
Frequency of child's 
symptoms and asthma 
exacerbations. Missed 
school and work days. 
Scores on the Paediatric 
Quality of Life 
Inventory (PedsQL). 
Scores on Paediatric 
Asthma Caregiver's 
Quality of Life 
Questionnaire 
(PACQLQ). ED visits. 
Asthma hospitalizations. 
Scores on Patient 
Asthma Management 
Self-efficacy scale 








collect data for 





























missed school days, 
missed parental 
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quality of life.  
 




reductions only in 
coughing. Controls 
also had a reduction 
in missed school 
and parental work 
days, improvements 
in PedsQL and 
PACQLQ scores, 
with a significant 
improvement in the 
activity sub-score of 



















of day of 
asthma 
hospitalizatio










Cost of public 
health system and 








annual costs of 
treatment per 
patient (median 
values): Cost of 
outpatient 
treatment: 
Before = $184; 
After = $359. 
Cost of hospital 
treatment: 
Before = $590; 
After = $0. 
Total annual 




lung function tests of 
forced vital capacity 
(FVC), and forced 
expiratory volume in 1 
second (FEV1) and peak 
expiratory flow rate 
(PEF). Other outcomes 



















value): Before = 0; 
After = 9. 
Spirometries 
performed: Before = 
1; After = 2. 
Emergency/unsched
uled visits: Before = 
36; After =1. 
Hospitalizations: 
Before = 1; After = 
0. Total AQLQ 
score: Before = 2; 
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Outcome results Response 
rates 
hospitalized 




The costs of 
ambulatory 
health care in 
The 
Programme 







patient / year) 








ons and staff, 




costs: Before = 
$750; After = 
$363. Family 





= $2768; After 
= $3280. Family 
expenses with 
asthma: Before 
= $615; After 
=$74. Losses 
for patient and 
companion: 
Before = $0; 
After = $0. 
Total family 
costs: Before = 
$807; After = 
$74.  
 




admissions due to 
asthma.  Effectiveness 














After = 4. ACQ 
scores: Before = 4; 
After =2. 
Percentage of FEV: 
Before = 69%; After 
= 76%. Percentage 
of PEF: Before = 
45%; After = 66%. 
For ProAR no. of 
hospitalizations = 1; 
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et al, 2001, 
Norway 
Asthma education; 
peak flow; GP 























costs according to 





Int = NOK 
10,500 Con = 
NOK 16,000 
 
Health related quality of 














quality of life 
SGRQ at 12 months 
(mean): Int.=20.2; 
Con.=36.5; 
p=0.0002 for CI. 
FEV change: Int. = 
3.4%; Con. = -2.7%; 
p=0.043 for CI. 
Percentage of those 
answering: A better 
year: Int = 81%; 
Con. = 43%. 
Not stated 
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visits - based 
on NHI fee. 
Pharmaceutic


























and at 12 
months follow 
up.   
 
Symptom free days: 
Int. = 81%; Con. = 
36%. Symptom free 
nights: Int. = 94%; 
Con. = 60%. No 
impact on daily life: 
Int. = 88%; Con. = 
62% 
 




















(Int. & Con.) 





































wage rate in 
NOK. 




















(Int. & Con.) 











care - bus 
fares from 
patients' 





Cost of ER therapy 
= Rs. 75 per 
private hospital 
visit and Rs.50 per 
public hospital 
visit. Cost of 
hospitalizations 
per day = Rs.115. 
Intervention 
costs - used 

















visit. Per day 




was calculated by 
estimating the unit 
cost of personnel 
and resource cost 
of materials - The 
four training 
sessions = Rs. 28 
per patient, cost of 
the public 
transport system 
for 4 sessions = 
Rs.12 per patient, 
and indirect cost 
(e.g. lost time at 







costs: Int = 
Rs.4224; Con = 
Rs.5052. 
Indirect costs: 
Int = Rs.879; 
Con = Rs.1704. 
Total = Rs. 
5263; Con = Rs. 
6756 
Health status; peak 
expiratory flow rate 
(PEFR); no. of 
hospitalizations, ER 
visits. 





8th and 12th 
month. Mini 
peak flow 
meter used to 
measure daily 
PEFR. 
Mean PEFR: Int. = 
332; Con. = 290. 
Hospital days: Int. = 
5.8; Con. = 12.5. 
Percent 
hospitalized: Int. = 
27.1% Con. = 
36.8%. ER visits: 
Int. = 11.6; Con. = 
21.8. Percent ER 
visits: Int. = 42.9%; 
Con. = 50% 
Not stated 




















(Int. & Con.) 






















days lost by 
wages earned 
(minimum 
wage paid for 
a daily 











time. Costs used in 
model. Albuterol 
(salbutamol) mean 












minutes per visit). 
Hourly fee = 
$A70. Cost of 
Annual review 
5 years: Total 
costs (Int = 
$A2136 and 
Con = $A1514) 
Assessment of Quality 







Annual review 5 
years (Int = 3.443, 
Con = 3.312) 
Not stated 
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et al, 1999, 
United 
States 
Albuterol - Mild 
asthma ($A 9.66), 
Moderate asthma 
($A 9.66), Severe 
asthma ($A22.60) 
GP visits - Mild 
Costs outside 





Not stated Total outside 
plan use: Before 
(Int. = $A 
78,070; Con = 
$A 63,450) 
After (Int = $A 








EW use: Con.: 
Before = 44 visits 
and After = 27 
visits; Int. Before = 
45 visits and After = 
12 visits. 
Not stated 




















(Int. & Con.) 












asthma ($A 67.26) 
Hospital 
admission - Mild 
asthma ($A24.70), 
Moderate asthma 
($A 89.33), Severe 
asthma ($A 89.33) 











13,672; Con = 
$A 45,862) 
a printout of 




Con. Before = 28 
admissions and 
After = 16 
admissions. Int. 
Before = 25 
admissions and 















($2552.16 for 2.1 
days - average 





al costs - 
military 
pharmacy 














= $214.40). ER 









Hospital admissions, ED 
visits, Outpatient clinic 
visits (Paediatric, 
Family Practice, 
Primary Care), visits 
with the same provider 
(continuity measure), 
number of chest 
radiographs ordered, 
number of prescriptions 
for inhaled anti-
inflammatory agents and 













= 0.149, After = 
0.007, p = 0.164). 
ED visits (Before = 
0.113, After = 
0.028, p = 0.147). 
Clinic visits (Before 
= 0.463, After = 
0.312, p = 0.083). 
Visits with same 
provider (Before = 
0.181, After = 
0.201, p = 0.610). 
None 




















(Int. & Con.) 



















drugs (Before = 
$7.86, After = 
$16.47). Beta 2 
agonists (Before 
= $8.94, After = 
$5.86). Total 




Total cost per 
patient year 
after class = 
$4845.29 
Chest radiographs 
(Before = 0.163, 





(Before = 0.094, 
After = 0.197, p = 
0.007). 
Prescriptions of beta 
2 agonists (Before = 
0.256, After = 






















for the 12 
Not stated Savings from: 
Inpatient 


























from baseline to 
program: Inpatient: 
Participants in 
program = -50%; 
non-participants 




medical claims = 
25.2%. Emergency 
Not stated 




















(Int. & Con.) 






Outcome results Response 
rates 

























number of IP 
admissions, 
ED/MD visits 
by the average 
membership 
for the 12 




program = -28.2%; 
non-participants 




medical claims = 
10.1%. Outpatient: 
Participants in 
program = -6.2%; 
non-participants 




medical claims = -
2.5% 




















(Int. & Con.) 












All costs relating 
to outpatient 
management; both 





outpatient visits to 
nurse (€28.90) or 
paediatrician 








travel costs (€0.12 
per km), 
productivity loss 
(€8 per hour 
independent of 




























based on a 5 
day course of 
2 
mg.kg¯¹.day
¯¹, cost of 





(Int = €307.40; 
Con = €330.80). 
Outside 
healthcare 
sector (Int = 
€35.50; Con = 
€25.50). Overall 
costs (Int = 
€342.60; Con = 
€357.20) 
Healthcare utilization 1, 3, 6 and 12 
months for 
follow up 










more follow up 
visits were 
planned. Each 
patient kept a 
diary two 
weeks prior to 









visits due to 
respiratory 
problems. Data 
1 excluded from the 
study due to being 
diagnosed with 
tracheomalacia, 
therefore new total 
of patients in study 
is 73. Fluticasone 
propionate (median 
daily dose): Int. 
=200; Con. = 200. 
Salbutamol (median 
daily use): Int. =0.2; 
Con. = 0.1. 
Prednisolone 
(median): Int. = 0; 
Con. =0. Antibiotics 
(median): Int. = 0; 
Con. = 0. Additional 
outpatient visits 
(median): Int. = 2; 
Con. =0. Extra visits 
to GP (median): Int 
= 0; Con = 0. 
Hospitalisations 
(median): Int. = 0; 
Con. = 0. 
Emergency 
department visits 
(median): Int. = 0; 
Con. = 0 
98.6% 
completed 




















(Int. & Con.) 






Outcome results Response 
rates 
antibiotics 




































days, ED visits 
($132), 
medications and 
clinic visits ($19).  
Telephone or 






Sum of: Salary of 
health educator 
and case manager, 
start-up and 
operating costs. 





child / year. 











values of the 
health resource 
utilization. If a 
Percentage change 
from baseline and 
FU: 
Hospitalizations 
(Group 1 = - 76%, 
Group 2 = - 81%, 

























(Int. & Con.) 













those lost to 
follow-up were 
also integrated 
into each group's 
program costs.  
Group 3: 
$5,166.26 








bias this recall 
was limited to 
less than 3 
months). In 
place of a 
missing data 
point, used the 
participant's 
average value.  
Hospital days 
(Group 1 = - 55%, 
Group 2 = - 66%, 
Group 3 = - 86%). 
ED visits (Group 1 
= - 52%, Group 2 = 
- 65%, Group 3 = - 
74%). Clinic Visits 
(Group 1 = - 45%, 
Group 2 = - 49%, 



































Skin test = $50, 
Equipment = 
$422, Salary = 
$784, Average 
travel costs = 
$100, Pest 
management 
services = $113.  
Direct medical 
costs per child 2 
years. Int = 
$4704; Con = 
$3662 
Ambulatory visits, 
scheduled clinic visits, 
hospitalizations, 
pharmaceutical use, 
length of stay 
Symptom free 









use and asthma 
symptoms 
Average annual use: 
Scheduled medical 
visits: Int. =1.44; 
Con. = 1.51 p=0.62. 
Unscheduled clinic 
visits: Int. = 1.06; 
Con. = 1.20 p=0.03. 
Emergency 
department visits: 
Int. = 0.77; Con. = 
0.87; p=0.30. 
Inpatient hospital 
days: Int. = 0.62; 





in both arms 

























(Int. & Con.) 
















0.39. No. of inhaled 
steroid inhalers: Int. 
= 4.84; Con. = 5.35 
p =0.30. No. of 
cromolyn inhalers: 
Int. = 2.64; Con = 
2.60 p=0.86. No. of 
beta-agonist 
inhalers: Int. = 5.95; 
Con. = 6.81 p 
<0.001 
Kauppinen 
et al, 1998, 
Finland 
Lung clinic visits 
(FIM 773), 
Inpatient day (FIM 
1200), Emergency 
clinic visit (FIM 
1200), Public 
health centre visits 
(FIM 178); 
Nurses/physiother






Average return of 
transportation 
costs to hospital 
visit (FIM 48) and 




Not stated Mean direct 
costs (Int = FIM 
1269; Con = 
FIM 595). Mean 
indirect costs 
(Int = FIM 
1489; Con = 
FIM 1727) 
Mean Total 
costs (Int = FIM 
2757; Con = 
FIM 2351) 
HRQL measured: St. 
Georges Respiratory 
Questionnaire and 
Generic 15D. Forced 
vital capacity (FVC) and 
forced expiratory 
volume (FEV). Peak 
expiratory flow (PEF). 













FVC and FEV 
were measured 








Baseline = 26.4, 
1year = 16.5. 
Control: Baseline = 
27.9, 1 year =20.5 p 
= 0.16. 15 D: 
Intervention: 
Baseline = 0.89, 1 
year = 0.93. 
Control: Baseline = 
0.89, 1 year = 0.91. 




they did not 
show up for 
their follow 
up visits. In 
control; 1 
patient died 
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Outcome results Response 
rates 
(FIM 24). Average 
daily gross wage 
(FIM 711 /day)  
Wright's peak-
flow meter 
during the visit 












the dosage of 
histamine 
required to 
cause a 15% 
fall in FEV.  
Kauppinen 




(£13 per hour). 
Drugs - valued at 
retail price. 
Working time lost; 
average daily 
gross wage (£89 















drugs = £247 
Mean total 
costs. Int = £464 
and Con. = £476 
Clinical and Quality of 
Life measurements. 









after 12 hours 





HRQL scores: 15D: 
Baseline - Int. = 
0.89, Con. = 0.89. 3 
years - Int. = 0.92; 
Con. = 0.92, 
Difference: p < 0.01 
SGRQ: Baseline - 
Int. = 27.0, Con = 
27.7. 3 years - Int. = 









the 1st year, 
3 moved 
away, 2 
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Outcome results Response 
rates 
measured by 




































out in the 
1st year, 1 






to attend at 
3 years) 
Kauppinen 










Average total 5 
year costs without 
drug costs = £220 
Mean total costs 
over 5 year. Int 
= £1906, Con = 
£2287 
Lung functions, airway 
hyperreponsiveness and 
quality of life 
Baseline, 12, 
36, and 60 
months 
measurements 
15 D: Baseline - Int. 
= 0.89, Con. = 0.89. 
5 years - Int. = 0.93, 
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the first year. 

















taken at least 















Baseline - Int. = 
27.0, Con. = 27.7. 5 
years - Int. = 15.0 
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Outcome results Response 
rates 










ED visit charges, 
stratified by age 
group and gender 






























values of ED 
Not stated Mean costs: ED 
visits - Pre = 
$1996, Post = 
$818. 
Hospitalizations 
- Pre =$11,187, 
Post = $6452. 
Total 
expenditures - 
Pre = $13,183, 
Post = $7270 
Improved symptom 
control. Hospitalizations 
and ED visits 
Survey data 
collected face 






clinic) and 12 
month follow 
up (at home). 
Parent -
reported. 
Mean total 8-item 
symptom score in 
the past month: 
Baseline = 21.12, 12 
month follow up = 
13.03, p = 0.000. 
Hospitalizations in 
past 12 months: 
Baseline = 35.9%, 
12 month follow up 
= 13.7% p <0.001. 
ED visit: Baseline = 
82.1%, 12 month 
follow up = 45.3%, 
p < 0.001. Any 
controller 
medication in past 
month: Baseline = 
17.2%, 12 month 
follow up = 35.2%, 
p < 0.001. 
Appropriate daily 
controller 
medication use in 
past month: 
Baseline = 13.8%, 
12 month follow up 
= 30.3%, p < 0.001. 
Any rescue 
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Baseline = 70.3%, 
12 month follow up 
= 16.6%, p < 0.001. 
Rescue medication 
in past 2 week: 
Baseline = 62.2%, 
12 month follow up 
= 24.7%, p< 0.001. 
Have a regular 
provider for asthma 
past 12 month: 
Baseline = 65.2%, 
12 month follow up 
= 93.4%, p<0.001. 
Talked to a health 
care provider about 
asthma in past 12 
month: Baseline = 
74.3%, 12 month 
follow up = 99.1%, 
p < 0.001. Had a 
nebulizer: Baseline 
= 64.1%, 12 month 
follow up = 87.2%, 
p< 0.001. Had a 
spacer: Baseline = 
12.6%, 12 month 
follow up = 74.4%, 
p < 0.001. Had a 
peak flowmeter: 
Baseline = 0.7%, 12 
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Outcome results Response 
rates 
month follow up = 
43%, p < 0.001. 
Taught to respond 
to early symptoms 
of an attack: 
Baseline = 37.2%, 
12 month follow up 
= 88.8%, p < 0.001. 
Taught what to do in 
case of attack: 
Baseline = 49.0%, 
12 month follow up 
= 88.8%, p < 0.001. 
Taught how to use 
inhaler: Baseline = 
26.9%, 12 month 
follow up = 87.1%, 
p< 0.001. Taught 
how to use a spacer: 
Baseline = 17.9%, 
12 month follow up 
= 79.1%, p < 0.001. 
Taught how to use a 
peak flowmeter: 
Baseline = 5.5%, 12 
month follow up = 
47.8%, p< 0.001. 
Given an asthma 
action plan in past 
12 month: Baseline 
= 3.5%, 12 month 
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Outcome results Response 
rates 
follow up = 53.4%, 
p < 0.001 
Levenson 




($362.20), 4 day 
hospital admission 
($6, 663.30), 1 day 


























to July 1995 
Not stated Mean before 
intervention per 








Emergency Room visits, 
Intensive Care Unit 
Not stated Mean cases per 
patient: 
Hospitalizations 
(Before = 6.25, 
After = 2.38), ICU 
(Before = 0.5, After 
= 0), ER (Before = 
6.38,After = 1.25) 
100% 
Lindberg 
et al, 2002, 
Sweden 

















Use a PEF 
instrument: ANP = 
84%, Non-ANP = 






es = 82%. 
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Outcome results Response 
rates 
by patients at 





used to find 




















Int = SEK 2879, 







issued at 3 
months for 
those older 
than 6 years 















status - they 
dropped these 
in boxes at 
their GP visits 
or at their ANP 
visits in the 
medication: ANP = 
95%, Non-ANP = 
90%. Instruction on 
how to use asthma 
inhaler medication: 
ANP = 98%, Non-
ANP = 96%. 
Written plan of 
action: ANP = 66%, 
Non-ANP = 45% p 
< 0.001. Received 
information about 
asthma prevention: 
ANP = 89%, Non-
ANP = 75% p < 
0.001. Adequate 
knowledge about 
the disease: ANP = 
91%, Non-ANP = 
81% p < 0.01. 
Knowing which 
Doctor is 
responsible for your 
treatment: ANP = 
92%, Non-ANP = 
94%. Automatic 
appointments for an 
asthma check-up: 
ANP = 94%, Non-







es = 53% 
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Cost per visit/day. 
Hospital days 
($1640); ED visits 
($383); Urgent 






baseline, 3, 6, 
12 and 24 















Follow up at 
baseline, 3, 6, 








least 5 out of 







(at 12 and 24 
months), 
telephone 
surveys (at 3 





Baseline = 16, 1 
year = 5, 2 years = 6. 
No. of days in 
hospital: Baseline = 
64, 1 year = 15, 2 
years = 24. No. of 
ED visits: Baseline 
= 38, 1 year = 21, 2 
years = 6. No. of 
urgent care visits: 
Baseline = 151, 1 
year = 108, 2 years 
= 71. No. of 
scheduled visits: 
Baseline = 254, 1 
year = 279, 2 years 
= 208. 
Not stated 
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Outcome results Response 
rates 
McCowan 






(£9.61) GP or 














per child per year: 
Step 1 - 
bronchodilator 
only (£7.60), Step 
2 - bronchodilator 
and cromoglycate-
like drugs 
(£102.24), Step 3 - 
inhaled 
corticosteroids 
low dose, < 400 µg 
daily (£84.69), 
Step 4 - inhaled 











Not stated Overall costs. 
Pre visit (Year 
1): Int = 
£68,500, Con = 
£57,780. Post 
visit (Year 2): 
Int = £62, 300. 
Con = £53, 910. 
Follow up (Year 
3): Int = £45, 
700. Con = £45, 
280. Follow up 
(Year 4): Int = 






of asthma, anti-asthma 
prescriptions (classified 











of children):  
Patient-initiated for 
asthma (YEAR 1: 
Int = 182, Con = 203 
YEAR 2: Int = 198, 
Con = 163. YEAR 
3: Int = 236, Con = 
252. YEAR 4: Int = 
213, Con = 250). 
Patient-initiated for 
other respiratory 
problems (YEAR 1: 
Int = 706, Con = 
711; YEAR 2: Int = 
564, Con = 537; 
YEAR 3: Int = 325, 
Con = 291; YEAR 
4: Int = 269, Con = 
225). Practice 
reviews of asthma 
(YEAR 1: Int = 184, 
Con = 187; YEAR 
2: Int = 355, Con = 
158; YEAR 3: Int = 
170, Con = 174; 
YEAR 4: Int = 166, 
Con = 171).  
Maintenance 
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Outcome results Response 
rates 
corticosteroids 
high dose > 400 µg 
daily (£161.78).  
children): 
Bronchodilators 
only (YEAR 1: Int = 
391, Con = 395; 
YEAR 2: Int = 398, 
Con = 317; YEAR 
3: Int = 314, Con = 
313; YEAR 4: Int = 
282, Con = 307). 
Cromoglycate-like 
drugs (YEAR 1: Int 
= 80, Con = 82; 
YEAR 2: Int = 95, 
Con = 64; YEAR 3: 
Int = 52, Con = 42; 
YEAR 4: Int = 32, 
Con = 27). Inhaled 
corticosteroids 
(YEAR 1: Int = 79, 
Con = 78; YEAR 2: 
Int = 125, Con = 
133; YEAR 3: Int = 
169, Con = 164; 
YEAR 4: Int = 172, 
Con = 199). Acute 
prescribing (no. of 
children): 
Exacerbations of 
asthma (YEAR 1: 
Int = 336, Con = 
352; YEAR 2: Int = 
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Outcome results Response 
rates 
286, Con = 227; 
YEAR 3: Int = 102, 
Con = 132; YEAR 
4: Int = 107, Con = 
114). Courses of 
oral corticosteroids 
(YEAR 1: Int = 7, 
Con = 4; YEAR 2: 
Int = 22, Con = 16; 
YEAR 3: Int = 35, 
Con = 28; YEAR 4: 




(YEAR 1: Int = 38, 
Con = 31; YEAR 2: 
Int = 42, Con = 40; 
YEAR 3: Int = 29, 
Con = 32; YEAR 4: 
Int = 18, Con = 32). 
Hospital contacts 
for asthma (no. of 
children): 
Admissions (YEAR 
1: Int = 33, Con = 
18; YEAR 2: Int = 
24, Con = 25; 
YEAR 3: Int = 11, 
Con = 12; YEAR 4: 
Int = 9, Con = 14). 
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1: Int = 9, Con = 8; 
YEAR 2: Int = 4, 
Con = 4; YEAR 3: 
Int = 6, Con = 8; 
YEAR 4: Int = 5; 
Con = 6). 
Outpatients (YEAR 
1: Int = 67, Con = 
64; YEAR 2: Int = 
62, Con = 56; 
YEAR 3: Int = 37; 
Con = 33; YEAR 4: 












(per year cost). 
Pharmacist fees 
















them to the 
pharmacist. 
Valued using 
prices / costs 
Not stated Total major 
costs (direct & 
indirect) per 
month. Usual 
care = $351, 
Enhanced care 
= $150 
Recorded PEFR, quality 
of life on 5 point scale, 
medical and emergency 
room visits, hospital 
visits, days off from 
school or work. 






daily in diary, 
quality of life 
survey 
including 15 
questions on a 
5 point scale. 
Clinical outcomes: 
Asthma symptoms 
= 50% reduction. 
Peak flow rate = 
11% increase. Beta-
agonist use = 50% 
reduction. Inhaled 
steroid use = not 
significant. Quality 
of Life Outcomes: 
Quality of life 
scores = 19% 
improvement. 
Knowledge levels = 









total of 119 






out, 14 had 
insufficient 
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Physician visits = 
75% reduction. 
Emergency room 




Days off of work or 
school = 61% 
reduction. Overall 




total of 105 

























Meer et al, 
2011, the 








($7917 per year), 
Total health 
care costs: (Int = 
$2555, Con = 
QALY and VAS Patients 
completed EQ-
5D and VAS at 
EQ-5D difference: 
Baseline = 0.026, p 
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resources in a 
quarterly cost 
questionnaire 

































($26 per hr), 
education sessions 
($26 per hr), data 
review and patient 
communication 
($26 per hour) 
travel costs for 
session ($6 per 
session), travel 
costs for sessions 
incl. travel time 
($20 per session), 
time costs for 
monitoring ($0.50 
per log in - 3 
minutes per log 
in), internet log in 
costs ($0.0016 per 






$2518 p = 0.94). 
Total societal 
costs: (Int = 
$6289, Con = 
$5647, p = 0.63) 


















measures at all 
time points.  
0.037, p = 0.099; 12 
months = 0.006, p = 
0.80; QALY = 
0.024, p =0.25. 
VAS difference: 
baseline = - 0.013, p 
=0.43; 3 months = 
0.012, p = 0.54; 12 
months = 0.013, p = 
0.37; QALYs = 
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et al, 2013, 
Australia 
GP consultation 
($30.20), ED visit 
for age < 50 yrs 
($301), ED visit 
for age > 49 yrs 
($346), 
Hospitalization for 
age < 50 yrs ($1, 
655), 
Hospitalization for 
age > 49 yrs ($2, 
509), Hourly cost 
of nurse ($24.46), 
One way travel 
cost per GP visit 
($3.70), hourly 


















from a 2005 
salary 











Not stated Median costs 
without time & 
travel: Scenario 
1 = $263 
million, 
scenario 2 = 
$263 million, 
scenario 3 = 
$189 million 
Acute exacerbation and 
GP visits; Acute 


































Health benefit- all 
DALY: Scenario 2 
= 11,000 and 
Scenario 3 - 11,000 
Not stated 
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($1.90) per patient. 
Room and video 
recorder rental 
($1.00) per patient 
per lesson. 
Hospital 
Drug costs = 
the unit cost 














- 30 minutes), 
Spirometry 
($39.30 - 15 
minutes), PEF 
monitoring 
($77.50 - 30 
minutes), Lessons 
1-4,6 ($37.10 - 
4x5x60 minutes), 
Lesson 5 ($6.30 - 





($264 - 6 x 30 
minutes), 
Cost by episode 
prevented (by 
unit of effect). 
Asthma attacks: 
Complete 
Program (CP) = 
$193.80, 
Reduced 




CP = $758.70, 
RP = $669.84. 
Admission 
days: CP = 
$110.20, RP = 
$94.01. 
Working days 
Spirometry, PEF Outcomes 
recorded daily 
by patient in a 
custom-
designed diary 







Year before (mean) 
- no. of asthma 
attacks = 8.40; no. 
of urgent medical 
examinations = 
1.66; no. of 
admission days = 
6.59, no. of working 
days lost = 9.4. Year 
after (mean) - no. of 
asthma attacks = 
4.72, no. of urgent 
medical 
examinations = 
0.72, no. of 
admission days = 
0.12, no. of working 
days lost = 2.1. 
CP = 7 
dropouts 
(17.5%); RP 
= 8 dropouts 
(20%) 
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Outcome results Response 
rates 
admissions 
(general per diem 
cost of Italian 
hospital) 
($244.50). Salary 
per day of work 
lost ($75.00), 




($235.80 - 6 x 15 
minutes) 
lost: CP = 




after.  Before 
(CP = $2641.80, 
RP = $2837.30). 
After (CP = 
$747.10, RP = 
$1139.50) 
Reduced Program: 
Year before (mean) 
- no. of asthma 
attacks = 7.84, no. 
of urgent medical 
examinations = 
1.87, no. of 
admission days = 
7.24, no. of working 
days lost = 10.4. 
Year after: no. of 
asthma attacks = 
7.91, no. of urgent 
medical 
examinations = 
2.18, no. of 
admission days = 
0.12, no. of working 
days lost = 5.1 




Average cost of 
public ward 
services 
(HK$1702 / day). 
Hospitalization 
















Not stated HK $969 net 
savings per 
patient 
No. of ER visits, no. of 
GP visits due to acute 
asthma attack, no. of 
nocturnal symptoms, no. 
of episodes of asthma 










No. of ER visits:  0 
visits: Int. = 39, 
Con. = 19; 1 visit: 
Int. = 8, Con. = 10, 
2 visits: Int. = 8, 
Con. = 7, 3 visits: 
Con. = 3, 4 visits: 
Con. = 6. p = 0.004. 
No. of patient 
hospitalizations: 0 
episodes: Int. = 52, 
Con. = 32; 1 
Not stated 
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Outcome results Response 
rates 
$5003 / patient). 





episode: Int. = 3, 
Con. = 13 p = 
0.0037. No. of 
unscheduled GP 
visits: 0 visit: Int. = 
39, Con. = 30; 1 
visit: Int. = 1, Con. = 
10; 2 visits: Int. = 
15, Con. = 2, 3 
visits: Con. = 1, 4 
visits: Con. = 2. No. 
of nocturnal 
symptoms (mean): 
Int. = 2.13, Con. = 
1.84 p = 0.332. 
Episodes of asthma 
attack (mean): Int. = 
2.04, Con. = 2.36 p 
= 0.281. Days off 
school (mean): Int. 
= 1.58, Con. = 1.67 








($80.75; 3 hours 






unit price for 




for all items 
from, 
Unit cost of 






spent with nurse x 
nurses' hourly 
Inpatient care: 
Int. = $937, 
Con. = $832. 
Emergency 
visits: Int. = 
$320, Con. = 
$286. Family 
physician 
services: Int. = 
Demographics, 
medication use, health 
service use, receipt of 











visits: Int. = 91, 
Con. = 334. p<0.01, 
Paediatrician 
visits: Int. = 57, 
Con. = 192. 
Respiratory 
specialist visits: Int. 
= 173, Con. = 329 p 
Not stated 
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($53.15; 1 hour). 
Family practice 









in-patient case cost 
($836.90; 1 to < 5 
yrs); $860.60 (> 4 
to <12 yrs old); 
$803.40 (>11 to < 
19 yrs old). 
Dispensing fee - 
public plan 
($6.54). 



































length of stay 
(LOS). 
Physician 






services: Int. = 
$239, Con. = 
$133. 
Paediatrician 
services: Int. = 
$97, Con. = 
$92. Asthma 
medication 
costs: Int. = 
$505, Con. = 
$374. 
Dispensing 
fees: Int. = 
£272, Con. = 
$238. 
Nebulizers: Int. 
= $35, Con. = 
$38. Spacers: 
Int. = $13, Con. 
= $13. Peak 
flow meter: Int. 
= $12, Con. = 
$5. Asthma 
education: Int. = 
$27, Con. = $6. 
Parent's 
productivity 
loss: Int. = 
<0.01. Hospital 
admissions: Int. = 
51, Con. = 169. 
Emergency 
department visits: 
Int. = 111, Con. = 
351.  
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flow meter ($43). 
Homemaker time 




care: 1 full 
consultation 









child: Cost of 
each 
prescription 
x 8. Daily 
wage: 
(Annual 
income / 239 
total working 
days per 









$4,350. Con. = 
$3,940 
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hourly wage.  










visits, and school 
clinic visits 















led program = 
$173. Adult-led 
program = 
$162. Net cost 
saving per 
participant in 
study: 3 months 
= $5.8, 9 
months = $5.0. 
Hospitalizations, ED 
visits, asthma specialist 
visits, primary care 
provider (PCP) visits for 
worsening asthma, 
scheduled visits, school 















(mean): 3 months: 
Int. = 0, Con. = 0.09. 
p =0.29 6 months: 
Int. = 0.02, Con. = 
0.11. p = 0.49. 9 
months: Int. = 0.02, 
Con. = 0. p=0.33. 
No. of ED visits 
(mean): 3 months: 
Int. = 0.05, Con. = 
Not stated 
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months = $51.8, 












0.02. p=0.62 6 
months: Int. = 0.05, 
Con. = 0.09 p = 
0.58. 9 months: Int. 
= 0.07, Con. = 0 p = 
0.16. No. of 
specialist visits 
(mean): 3 months: 
Int. = 0.14, Con. = 
0.11 p = 0.87. 6 
months: Int. = 0.15, 
Con. = 0.13. p = 
0.65. 9 months: Int. 
= 0.12, Con. = 0.20 
p = 0.63. No. of 
acute PCP visits 
(mean): 3 months: 
Int. = 0.07, Con. = 
0.28 p = 0.01. 6 
months: Int. = 0.17, 
Con. = 0.15 p = 
0.61. 9 months: Int. 
= 0.07, Con. = 0.27 
p = 0.04. No. of 
routine PCP visits 
(mean): 3 months; 
Int. = 0.10, Con. = 
0.25. p = 0.11. 6 
months: Int. = 0.24, 
Con. = 0.15. p = 
0.24. 9 months: Int. 
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Outcome results Response 
rates 
= 0.26, Con. = 0.32 
p = 0.43. No. of 
school clinic visits 
(mean): 3 months: 
Int. = 0.76, Con. = 
0.19 p = 0.23. 6 
months: Int. = 0.67, 
Con. = 0.15, p = 
0.29. 9 months: Int. 
= 0.74, Con. = 0.10, 




































savings = $659. 
Incremental 




skills was $235 
per physician.  








visit by quarters: 
Pre-intervention = 
Q1-96 (Int = 180.6, 
Con = 128.4, p < 
0.001). Q2-96 (Int = 
222.9, Con = 171.9, 
p < 0.001). Post 
Intervention: Q3-96 
(Int = 140.7, Con = 
135.4, p < 0.001). 
Q4-96 (Int = 83.6, 
Con = 65.2, p < 
0.001). Q1-97 (Int = 
132.8, Con = 100.5, 
p < 0.001). Q2-97 
(Int = 225.2, Con = 
147.6, p < 0.001). 
Q3-97 (Int = 147.7, 
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Inhaler: Q1-96 (Int 
= 23.6, Con = 21.5, 
p < 0.001). Q2-96 
(Int = 22.5, Con = 
20.7, p < 0.001). 
Q3-96 (Int = 25.6, 
Con = 21.7, p < 
0.001). Q4 - 96 (Int 
= 26.6, Con = 22.6, 
p < 0.001). Q1-97 
(Int = 32.5, Con = 
23.8, p < 0.001). 
Q2-97 (Int = 34.3, 
Con = 23.8, p < 
0.001). Q3-97 (Int = 
31.8, Con = 23.7, p 
< 0.001). Inhaled 
Albuterol 
Nebulizer: Q1-96 
(Int = 72.1, Con = 
117.7, p < 0.001). 
Q2-96 (Int = 69.6, 
Con = 116.1, p = 
0.126). Q3-96 (Int = 
68.7, Con = 112.8, p 
= 0.015). Q4-96 (Int 
= 79.9, Con = 122.7, 
p = 0.188). Q1-97 
(Int = 92.5, Con = 
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Outcome results Response 
rates 
126.3, p = 0.827). 
Q2-97 (Int = 98.0, 
Con = 122.4, p < 
0.001). Q3-97 (Int = 
104.24, Con = 
124.3, p = 0.602). 
Inhaled Steroid 
Metered Dose 
Inhaler: Q1-96 (Int 
= 16.2, Con = 10.4, 
p < 0.001) Q2-96 
(Int = 12.5, Con = 
10, p = 0.101). Q3-
96 (Int = 13.0, Con 
= 11.5, p = 0.1). Q4-
96 (Int = 13.2, Con 
= 10.6, p < 0.001). 
Q1-97 (Int = 11.9, 
Con = 10.9, p = 
0.107). Q2-97 (Int = 
11.3, Con = 12, p = 
0.866). Q3-97 (Int = 
11.4, Con = 11, p = 
0.014). Inhaled 
Cromolyn Metered 
Dose Inhaler: Q1-96 
(Int = 22.7, Con = 
14.6, p < 0.001). 
Q2-96 (Int = 17.8, 
Con = 16.2, p = 
0.584). Q3-96 (Int = 
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Outcome results Response 
rates 
17.1, Con = 15.0, p 
= 0.156). Q4-96 (Int 
= 15.9, Con = 15.3, 
p = 0.546). Q1-97 
(Int = 15.3, Con = 
14.2, p = -0.081). 
Q2-97 (Int = 14.0, 
Con = 17.1, p = 
0.057). Q3-97 (Int = 
16.8, Con = 14.5, p 
= 0.313). Inhaled 
Cromolyn 
Nebulization 
Inhaler: Q1-96 (Int 
= 166.8, Con = 
139.7, p = 0.418). 
Q2-96 (Int = 
161.60, Con = 
145.8, p = 0.055). 
Q3-96 (Int = 170.0, 
Con = 147.3, p = 
0.704). Q4-96 (Int = 
160.7, Con = 142.2, 
p = 0.429). Q1-97 
(Int = 181.5, Con = 
147.8, p = 0.086). 
Q2-97 (Int = 171.1, 
Con = 148.4, p = 
0.053). Q3-97 (Int = 
169.4, Con = 148.4, 
p = 0.851) 
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Direct costs: GP 
consultation 
(€34.20 for first 
visit; €23.60 for 
subsequent visits 
in a quarter). 
Specialist 
consultation fee 
(€43.40 for first 
visits; €34.00 for 
subsequent visits 








































































(Con = €57.50, 
SPMP = 
€333.20, SPMP 
& IEP = 
€467.05 
Quality of life, lung 
function, use of rescue 
medication, number of 
days absent from school 
















consultations (con = 
3.5; SPMP = 3.4; 
SPMP&IEP = 5.2, p 
=0.11). Hospital 
days (Con = 0.3, 
SPMP = 0.1, 
SPMP&IEP = 0.1, p 
= 0.16). 
Emergencies (Con = 
0.4, SPMP = 0.6, 
SPMP & IEP = 0.4, 
p =0.99). Working 
days lost for 
caregivers (Con = 
0.51, SPMP = 0.65, 
SPMP & IEP = 
0.25, p = 0.23). 
Daily use of rescue 
medication (Con = 
0.20, SPMP = 0.23, 
SPMP & IEP = 
0.26, p = 0.16). 
Days absent from 
school (Con = 2.0, 
SPMP = 3.4, SPMP 
& IEP = 4.0, p = 
0.78). Visit 1 
(mean): Physician 




data: Con = 
48 (56%), 
SPMP = 86 
(68%), 
SPMP & 
IEP = 44 
(30%). 
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- public transport 
per scheduled or 
unscheduled visits 
(€3.10). Internet 
fees within 6 
months (€14.40). 
Indirect costs - 
productivity loss 





























3.3; SPMP = 2.3; 
SPMP&IEP = 2.7, p 
=0.49). Hospital 
days (Con = 0, 
SPMP = 0.3, 
SPMP&IEP = 0.2, p 
= 0.43). 
Emergencies (Con = 
0.2, SPMP = 0.3, 
SPMP & IEP = 0, p 
=0.04). Working 
days lost for 
caregivers (Con = 
1.07, SPMP = 0.56, 
SPMP & IEP = 
0.14, p = 0.77). 
Daily use of rescue 
medication (Con = 
0.12, SPMP = 0.21, 
SPMP & IEP = 
0.10, p = 0.10). 
Days absent from 
school (Con = 1.3, 
SPMP = 1.7, SPMP 
& IEP = 1.3, p = 
0.01). Visit 2 
(mean): Physician 
consultations 
(SPMP = 1.9; 
SPMP&IEP = 2.3, p 
=0.63). Hospital 




















(Int. & Con.) 






Outcome results Response 
rates 
days (SPMP = 0, 
SPMP&IEP = 0, p = 
0.22). Emergencies 
(SPMP = 0.2, SPMP 
& IEP = 0.1, p 
=0.68). Working 
days lost for 
caregivers (SPMP = 
0.17, SPMP & IEP 
= 0.25, p = 0.93). 
Daily use of rescue 
medication (SPMP 
= 0.21, SPMP & 
IEP = 0.06, p = 
0.25). Days absent 
from school (SPMP 
= 1.0, SPMP & IEP 
= 1.0, p = 0.14).  






















) and use of 
healthcare 
resources 
over 6 month 
Not stated Mean total 
healthcare costs 
(Int = £315, Con 





(ACQ) - change in 
asthma control between 
baseline and 6 months. 
Knowledge, attitude, 
and self-efficacy asthma 
questionnaire (KASE-
AQ) - change in self-
efficacy between 
intervention and control 






at final trial 
visit. Postal 
questionnaires 







ACQ - (Int = 0.75, 
Con = 0.73). KASE-
AQ self-efficacy 
scale (Int = -4.4, 
Con = -2.4). KASE-
AQ attitude scale 
(Int = -1.7, Con = -
1.8). Secondary 
outcomes: mini-
AQLQ (Int = -0.75, 




at 3 months 





at 6 months 
(Int = 81%, 
Con = 77%) 




















(Int. & Con.) 














quality of life 
questionnaire. Adverse 
occurrences obtained 
from practice records 
(admissions for asthma 
exacerbations, 
prescribed courses of 
oral steroids and 
unscheduled 
consultations). 
Prescriptions of asthma 
















(Int = -0.96, Con = 
0.22) 
Schermer 
































Cost per unit 
multiplied by no. 
of units, and then 









aids, peak flow 
meters, education 
Mean per 2 
years: Int = 
€1,084, Con = 
€1,097 
No. of successfully 















QALYs (Int = 
0.039, Con = 
0.024). No. of 
successfully treated 
weeks (Int = 81, 
Con = 75). 
Proportion of 
patients with MCID 
for AQLQ total 










2 lost to 
follow up; 7 
other 
reason) 




















(Int. & Con.) 







































































health state on 
a rating scale. 
No. of 
successfully 


























(Int. & Con.) 












































Not stated Mean values at 
6 months: 
Hospitalizations 






Mean values for 
HRQL: SGRQ 
(AMP-RN = -6.0, 
Not stated 
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RT = $73, Con 
= $313). Total 
hospitalization 
costs: (AMP-
RN = $0, AMP-
RT = $9,292, 
Con = $62,835) 
for Health Related 
Quality of Life (HRQL). 
Borg dyspnoea score 
and severity of asthma 
symptoms. Patient 


















repeated at 6 
months. 
AMP-RT = -11.0, 
Con = -2.5). SF-36 
physical component 
(AMP-RN = 9.4, 
AMP-RT = 16.9, 
Con = -3.1). SF-36 
mental component 
(AMP-RN = 8.5, 
AMP-RT = 15.0, 
Con = 1.9). 
Environmental 
assessment (AMP-
RN = 69, AMP-RT 
= 75, Con = 68). 
AESM (AMP-RN = 
24, AMP-RT = 37, 
Con = 22). Patient 
satisfaction (AMP-
RN = 83, AMP-RT 







days, ICU days, 
ED visits, doctor's 









Not stated Mean values 
compared 





ICU days, non-ICU 
days, ED visits, office 









Mean values for 
outcomes: 
Hospitalizations 
(Before = 1.78, 
After = 0.33). ICU 
days (Before = 3.67, 
After = 0.28). Non-
100% 




















(Int. & Con.) 






























































ICU hospital days 
(Before = 6.22, 
After = 0.61). No. of 
ED visits (Before = 
4.22, After = 0.61). 
Doctor's office 
visits (Before = 
6.39, After = 2.17). 
School days missed 
(Before = 19.0, 
After = 6.69). 































Total cost (Int = 
£60.23, Con = 
£149.14) 
Primary outcome: no. of 





medical contact, or 















exacerbation (Int = 
53.6%, Con = 
46.5% p = 0.105). 
Hospitalizations 
(Int = 3.3%, Con = 
6.4% p =0.051). 
A&E attendance 
(Int = 6.4%, Con = 

























(Int. & Con.) 











care and out 








primary care contacts, 














8.2% p = 0.284). 
Out of hours (Int = 
5.7%, Con = 7.1% p 
= 0.350). Oral 
prednisolone course 
(Int = 54.1%, Con = 
46.9% p = 0.112). 
Ambulance call for 
asthma 
exacerbation (Int = 
2.8%, Con = 2.6% p 
= 0.954). Nebulised 
short-acting beta 
agonist (Int = 7.9%, 
Con = 13.9% p = 
0.061). Secondary 
care outpatient 
consultations (Int = 
17.7%, Con = 
15.6% p = 0.283). 
DNA of primary 
care (Int = 17.9%, 










No. of non-routine 
consultations due 
to an exacerbation. 







trial - data 
was collected 
Not stated Base case (Int = 




had higher costs 
= + €757, 
Pulmonologist 






Base case: (Int = 
3.4, Con = 2.7). 
Subgroup analyses: 
RNS = Int had 
higher QALYs of 
+1.2, Pulmonologist 
= +0.2, GP = +0.1 
Quality of 



























(Int. & Con.) 











No. & duration of 
hospital 
admissions. No. of 




on of DMP, 
and then ever 
3-6 months 

























= - €3,687, GP = 
+€23. 




















(Int. & Con.) 






Outcome results Response 
rates 




























the RNS, the 
costs of an 
administrativ




















(Int. & Con.) 
















the RNS use, 
telephone 
and travel 
costs of the 
RNS, and 
salary costs 
of the unit 
leader). 
Productivity 


















in $ (Int): 
Hospitalization 
(Before = 4183, 
After = 3734, p 
= 0.4851). 
Emergency 
room (Before = 
Hospitalization length of 
stay, emergency room 
visits, physician office 
visits, no. of 
prescriptions 
Claims data Frequency of 
medical service use 
per patient (Int): 
No. of 
hospitalizations 
(Before = 0.047, 
After = 0.043, p = 
0.5989). No. of 
emergency room 
Not stated 




















(Int. & Con.) 






Outcome results Response 
rates 
215, After = 
217, p = 
0.0075). 
Physician visits 
(Before = 153, 




(Before = 220, 




in $ (Con): 
Hospitalization 
(Before = 3373, 
After = 3491, p 
= 0.7861). 
Emergency 
room (Before = 
169, After = 
167, p = 
0.4837). 
Physician visits 
(Before = 98, 




(Before = 96, 
visits (Before = 
0.115, After = 
0.083, p = 0.0017). 
No. of physician 
office visits (Before 
= 3.059, After = 
2.227, p = 0.0001). 
No. of prescriptions 
(Before = 5.794, 
After = 5.456, p = 
0.0001). Frequency 
of medical service 
use per patient 
(Con): No. of 
hospitalizations 
(Before = 0.026, 
After = 0.025, p = 
0.8605). No. of 
emergency room 
visits (Before = 
0.064, After = 
0.060, p = 0.5636). 
No. of physician 
office visits (Before 
= 2.091, After = 
1.859, p = 0.0001). 
No. of prescriptions 
(Before = 1.601, 
After = 1.893, p = 
0.0002). 




















(Int. & Con.) 






Outcome results Response 
rates 






















the cost of the 



















Fixed and variable 







Wage rages for 
personnel: 
national average 






patient: PLE = 
$591, PACI = 
$1591, Usual 
care = $385 
Primary outcome: 
Symptom free days 
(coughing, wheezing, 





days in the 2 
weeks before 
the follow up 
interviews. 
Symptom free days: 
PLE = gained 6.5 
days per year 
compared to usual 
care. PACI = gained 
13.3 days per year 
compared to usual 
care. Usual care = 
gained 14.8 per 
year. 
Not stated 




















(Int. & Con.) 






Outcome results Response 
rates 
d daily dose 
of drug for 
children. 



























































Wage rates: used 






Int = $2589.30, 
Con = $2344.65 


















Int = 565.10, Con = 
538.51 
Not stated 
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Outcome results Response 
rates 

















Not stated Not stated Direct costs: 
Before (Int 
~975 Yen, Con 
= ~875 Yen) 
During trial (Int 
= ~650 Yen, 
Con = ~1000 
Yen) 
PEF; frequency of 
asthma exacerbations 
defined as episodes 
which required 
admission to hospital, 
ER visit, intravenous 
administration of 
bronchodilators 




at week 4, 8, 
12, 18, 24. 
PEF (Int = 9.3% 
increase at 3 
months, then 
remaining at high 
levels until 6 
months). No. of 
visits to GP: Before 
(Int ~0.8, Con = 
0.98) After (Int ~0.7 
p < 0.01, Con ~1.0). 
Patients with 
exacerbations: 
Before (Int ~24%, 
Con ~28%) After 
(Int ~ 18 p < 0.05, 
Con ~28%). 
100% 




ER visits ($195 











8 public data 
sources used to 










Reduction in ER use, 




Reduction in ER 
use: 6.3% in SBHC. 
Reduction in 
hospital use: 76.4%. 
not stated 




















(Int. & Con.) 










































2006: Trends in 
Asthma Morbidity 
& Mortality. 2. 











2005 (NHIS). 4. 






2004. 5. Medical 
Expenditure Panel 
Survey (MEPS), 
















asthma deaths = 
$192.60 million 




















(Int. & Con.) 


























2004: Schools and 
Staffing Survey 
(SASS: 2003-










= 205,777 full 
time equivalent 




























visits = $5,199, 
medication = 
$25,555, 







Average benefit per 
cost category: 




department visits = 
30.96, medication = 
-104.89, antigen 
injections = 46.31, 
laboratory fees = -




data = 62% 




















(Int. & Con.) 






Outcome results Response 
rates 
travel to health 
care facilities, lost 










= $1,820, travel 
= $4,354, 



















= $2,315, travel 
= $3,101, 




























(Int. & Con.) 






Outcome results Response 
rates 
Tinkelman 

















Not stated Per member per 
month: 
Baseline (Int = 
$351.97, Con = 
$361.79). 
Intervention 
year (Int = 
$179.17, Con = 
$250.76) 
Reduction in night-time 
symptoms, reduction in 
emergency department 
visits, reduction in anti-
inflammatory 
medications 
Not stated Intervention group: 
Inflammatory 
medications: 
(Baseline = 72.6%, 
6 months = 85.2%). 
Night-time 
symptoms = 
reduction of 75% at 

























cost of day's 
hospital stay 
or lost work 






at 3, 6, 9, and 
12 months 
Not stated Indirect costs = 
CHF 202,510. 
Direct costs = 
CHF 131,200. 
Cost savings = 
CHF 5,056. 




quality of life. 
Overall QoL: 
Before = 4.5, After 
= 5.2, p < 0.001. 
Hospitalizations 
(Before = 35%, 
After = 8%). 
Emergency 
consultations 
(Before = 88%, 
After = 53%). Lost 
workdays (Before = 
























(Int. & Con.) 


























ns and work 
absenteeism: 
data obtained 






























(Before = 232€, 
After = 68€). 
Emergency 
visits (Before = 
314€, After = 
128€). 
Outpatient visits 
(Before = 339€, 




42799€, After = 
51143€). 
Quality of life - Asthma 









quality of life 
and severity of 
asthma. 
Hospitalizations = 
Before = 35%, After 
= 8%, p < 0.001. 
Emergency visits: 
Before = 88%, After 
= 53%, p < 0.001. 
Work absenteeism = 
Before = 39%, after 
























(Int. & Con.) 

























































Decreased no. of 


























Hospitalization = 8, 
Emergency 
department = 29, 
Doctor visit = 76 
Not stated 




















(Int. & Con.) 















Sick office visit 
($68.25) 
Costs based 








care at Kaiser 
Health Plan 
clinics 
Not stated Total savings: 
Sick office 
visits = $9,487. 





emergency room visits, 
sick office visits 
Not stated Sick office visits 
(Before = 308, After 
= 169, p = 0.0001), 
ER visits (Before = 
266, After = 118, p 
= 0.0001), 
Hospitalizations 








GP visit (€20.20), 
































cost diary at 







(€476), price of 
modem (€1428); 5 
year depreciation 
with 4.5% interest 
= €434 annual 
cost per patient. 
Annual cost of 
insurance for 








Total costs for 
adults (Int = 
€2,973, Con = 
€1948). Total 
costs for 
children (Int = 
€1,206, Con = 
€597) 
EQ-5D and SF-6D to 
obtain utility values. 
Also captured Asthma 
Quality of Life 
Questionnaire (AQLQ) 
or Paediatric Asthma 




at baseline, 4, 
8, and 12 
months 
Mean EQ-5D utility 
for adults (18 yrs 
and over): Baseline 
(Int = 0.89, Con = 
0.78). Month 4 (Int 
= 0.91, Con = 0.80). 
Month 8 (Int = 0.86, 
Con - 0.78). Month 
12 (Int =0.90, Con = 
0.79). Mean EQ-5D 
utility for children 
(7-18 years): 
Baseline (Int = 0.92, 
Con = 0.96), Month 
4 (Int = 0.98, Con = 
0.99). Month 8 (Int 
= 0.98, Con = 0.98). 
Month 12 (Int = 





























(Int. & Con.) 























care (€26.70 per 
hour), over the 
counter 
medication (out of 
pocket costs) 
informal care 




ld work (€8.30 per 
hour), loss of 
productivity at 
paid work (friction 
costs) 
each time 
point of cost 
diary was 
multiplied by 
3 to capture 













given a price 












printer) = €1,150; 
5 year 
depreciation with 
4.5% interest = €5 
per patient per 





material = €4 and 
€7 per patient per 
year. 
Administrative 
tasks of nurse 
practitioner = €7 




per year) and 1540 
workable hours 
per year = €29 per 
hour. Overhead 
costs calculated 
over all direct 
material and 
personnel costs 
Mean SF-6D utility 
for adults (18 yrs 
and over): Baseline 
(Int = 0.75, Con = 
0.69). Month 4 (Int 
= 0.71, Con = 075). 
Month 8 (Int = 0.74, 
Con = 0.71). Month 
12 (Int = 0.75, Con 
= 0.74) 




















(Int. & Con.) 
























by unit price 













ns, and ED 
visits and 
documented 




Not stated Significant 
reductions in 
costs. 













number and length 
of stay for 
physician, hospital, 
and ED visits. 
Not stated 




















(Int. & Con.) 











charges to the 



















Summed: 1.0 full 
time equivalent 





0.25 FTE program 
coordinator, 0.1 
program director, 







Costs of ED 
visits and 
hospitalizations 
for CAI per 
patient: 
Baseline = 
$2956, 1 year = 







$2093, 1 year = 





















n missed work 
days because 
of asthma 
ED visits (Baseline 
= 1.0, 6 month = 
0.3, 12 months = 
0.3, p < 0.0001). 
Hospitalizations: 
Baseline = 0.5, 6 
months = 0.1, 12 
months = 0.1, p < 
0.0001 .Days of 
limitation of 
physical activity: 
Baseline = 2.7, 6 
months = 1.2, 12 
months = 1.2, p < 
0.0001. Missed 
school days: 
Baseline = 5.1, 6 
Not stated 




















(Int. & Con.) 












months = 3.1, 12 
months = 2.4, p < 
0.0001. Missed 
work days: Baseline 
= 2.1, 6 months = 
1.1, 12 months = 
1.1, p < 0.0001 


























of Health and 
Ageing. 
Nurse salary for 
fortnightly calls 
($35.31 per hour), 








In 6 month trial 
period: lower 
healthcare costs 








utilizations (GP visits, 














Quality of Life 
Questionnaire 
(PAQLQ), and 





the 3 groups for ED 
visits, oral steroid 
use, hospital 
admission, school 
days lost, work days 
lost, quality of life 
data 
Control = 1 
lost to 
follow up. 





end of study 
questionnair
es. Nurse 
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Appendix VI: Estimating the loss associated with an asthma-related crisis 
event (ESQUARE) - Study documents  
 






Version Number: 4.1 
 
Date (dd/mm/yyyy): 23/02/2016 
 
Chief investigator: Christina-Jane Crossman-Barnes 
 
All participants should be given a copy of the participant information 
sheet to keep. If you agree to take part in this study, then please sign the 
consent form at the end of the booklet. A copy of the signed consent form 
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Part 1 
 
Study Title  




We would like to invite you to take part in our research study. Our study 
focuses on people with asthma (asthma alone, asthma with COPD, or asthma 
with a respiratory condition) who have had an asthma-related flare up and 
been admitted to hospital or had an accident and emergency (A&E) 
attendance. Before you decide we would like you to understand why the 
research is being done and what it will involve for you. One of our team will 
go through the information sheet with you and answer any questions that you 
may have.  
Part 1 of the information sheet will tell you the purpose of this study and 
what will happen to you if you take part.  
Part 2 of the information sheet will give you more detailed information about 
the conduct of the study.  
Do not hesitate to ask us anything if you feel that it is unclear. 
 
What is the purpose of the study? 
There are many people across the world who have asthma. It is important to 
find ways to improve their quality of life. The main aim of this study is to 
estimate the quality of life of people with asthma. This will inform other 
studies which seek to work out the benefits of different asthma health care 
services.  
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Why have I been invited?  
You have been invited to participate in this study because the asthma nurse 
or a member of the respiratory team has noticed that you fit the criteria for 
this study. This is because you have had an asthma-related flare up, been 
admitted to hospital or had an A&E attendance and are aged 18 years old or 
above. We aim to recruit 100 patients into this study.   
Do I have to take part? 
No, the treatment you receive will not be affected by your decision. It is up 
to you whether you take part. We will describe the study and go through this 
information sheet. If you agree to take part, we will then ask you to sign a 
consent form. You are free to withdraw at any time, without giving a reason.  
 
What will happen to me if I take part?  
If you agree to take part in this study, you will be involved in the research 
for approximately 8 weeks. We will ask you to complete some questions 
about your asthma and your quality of life from when you are in hospital and 
every day following that until approximately 8 weeks after you have been 
discharged. We will ask you to complete some of these questions on paper-
based questionnaires, and some with the researcher. At your follow-up 
appointment (approximately 4 weeks after discharge) extra questions about 
your time off work/education and quality of life will be asked, and this 
should last approximately 30 minutes. Your self-completed peak flow diary, 
which is to be completed as part of your usual care from your A&E 
attendance or hospital admission until your follow-up appointment, will also 
be important for this study. We will take a copy of your self-completed peak 
flow diary at your follow-up appointment.  
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Expenses and payments 
You will not have to do any additional travel, however you may need extra 
parking time when going to your follow-up appointment. As a thank you for 
taking part in this study and for allowing extra time, we would like to give 
you some reward vouchers. A £15 Love2shop voucher will be given to you 
at your follow-up appointment and if you continue to take part in the study, 
you will receive another £15 Love2shop voucher at the end of the study.  
 
What will I have to do? 
You will be involved in the research for approximately 8 weeks. This will be 
from when you have consented at the hospital until 8 weeks later. Your first 
interaction with the researcher will be face to face before you are discharged 
from hospital. We will talk you through the research study, making sure that 
you are aware of what will be involved, and answer any questions that you 
may have. Should you choose to take part, we will ask you to provide some 
information about yourself, (age, gender, ethnicity, etc.) and to confirm your 
address and contact telephone number. We will ask you to complete some 
questions about your asthma and quality of life daily for approximately 8 
weeks. At approximately 4 weeks, before your follow-up appointment, we 
will also ask you to complete another questionnaire about your time off 
work/education. We will contact you 3 weeks after your discharge to either 
remind you to bring these completed questionnaires to your follow up 
appointment with your peak flow and symptom diary and allow extra time 
at the appointment, or to review these over the phone at a convenient time 
for you. We will also be able to help you complete these questionnaires if 
you so wish. We will contact you after your follow-up appointment at two 
weekly intervals until the end of the study in week 8. Up to three attempts 
will be made to contact you; we will only leave a message once if there is no 
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response. You will also have the option to post these questionnaires back to 
us in a pre-paid freepost envelope that will be provided in the first pack of 
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to take part in 






Participant completes in 
hospital with researcher: 
6) Demographics 
Questionnaire 
7) EQ-5D-5L (continues 
this weekly) 
8) AQLQ 
9) TTO (if at the NNUH) 
10) Starts the peak flow 
and asthma symptom 
daily diary 
 
At week 3 after participant is discharged researcher calls participant: 
3) Asks how participant is getting on with study 
4) If participant has follow-up appointment booked at NNUH, then remind 
participant to bring the peak flow and asthma symptom diary, the EQ-5D-5L 
questionnaires, the AQLQ and the productivity questionnaires.  
 
OR  
Arrange a convenient time for follow-up appointment over phone to discuss the 
above diary and questionnaires.  
 
Participant completes for follow-up 
appointment: 
5) AQLQ 
6) Productivity questionnaire 
7) TTO (this will be done in person or over 
phone if had A&E attendance or hospital 
admission at NNUH for their asthma-
related crisis event) 
8) Participant receives £15 reward voucher 
 
Participant continues to 
complete: 






Week 8 – final follow up phone call from researcher: 
4) Participant completes AQLQ 
5) TTO (over phone for NNUH participants) 
6) Participant receives a £15 reward voucher 
 
Participant receives 
phone call from 
researcher every 2 weeks 
from follow up until end 
of study to see how 
participant is getting on  
END 
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What are the possible disadvantages and risks of taking part? 
The only disadvantage of taking part in this study is the time it will take you 
to participate. This will involve approximately 20 minutes before discharge, 
approximately 10 minutes daily for 8 weeks and approximately 30 minutes 
extra will be needed at your follow up appointment (approximately week 4 
and week 8). This study will not affect the care given now or in the future. 
 
What are the possible benefits of taking part? 
This research study aims to inform future research about the costs and health 
benefits for health care services for asthma patients.   
 
What happens when the research study stops? 
When the research study stops you will be informed of the study’s results 
through a one page summary that will be posted or emailed to you. This will 
be predicted to arrive in 2017.  
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or 
any possible harm you might suffer will be investigated. The detailed 
information on this is given in Part 2. 
 
Will my taking part in the study be kept confidential?  
Yes. We will follow ethical and legal practice and all information about you 
will be handled in confidence. All study results will be reported in an 
anonymous format. The details are included in Part 2.  
 
This completes part 1. 
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If the information in Part 1 has interested you and you are considering 




What will happen if I don’t want to carry on with the study? 
If you wish to withdraw from the study that will be fine. However, we will 
use the data collected up to your withdrawal. If you do not wish for us to use 
this data, please let the researcher know.  
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak 
to the researchers who will do their best to answer your questions. 
 




Dr Garry Barton, Academic Supervisor 
Email: G.Barton@uea.ac.uk 
Phone: 01603 591 936 
 
If you remain unhappy and wish to complain formally, you can do this by 
following the NHS Complaints Procedure. Details can be found on the 
following website: www.england.nhs.uk/contact-us/complaint/. Otherwise, 
you can contact the Patient Advice and Liaison Service (PALS) for a more 
informal and confidential chat about your concerns. Details for PALS are 
01603 289036 or pals@nnuh.nhs.uk.  
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In the event that something does go wrong and you are harmed during the 
research and this is due to someone’s negligence, then you may have grounds 
for a legal action for compensation against the University of East Anglia, but 
you may have to pay your legal costs. The normal National Health Service 
complaints mechanisms will still be available to you. 
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the 
research will be kept strictly confidential in accordance with the data 
protection act. The data will be collected through paper based questionnaires 
which will be locked in a filing cabinet in a secure room on site at the 
University of East Anglia.  The information will be stored securely in a 
password protected Microsoft Excel document and coded to ensure your 
details will remain anonymous. Only members of the research team will have 
access to your data. With your consent we will use your data that has been 
collected for this study in other ethically approved asthma studies. The 
researchers from both studies will know your identity but otherwise it will 
remain anonymous. At the end of the study the anonymised research data 
will be kept for 10 years. Once the time period has passed, your data will be 
disposed of securely.  
 
Involvement of the General Practitioner/Family Doctor (GP) 
Your GP will be written a letter in order to be notified of your participation 
in the study. They will be given a copy of the participant information sheet 
with the letter. If you do wish to withdraw from the study, your GP will also 
be notified. 
 
What will happen to the results of the research study? 
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This study will form part of a PhD thesis for the chief investigator, Christina-
Jane Crossman-Barnes. The results will be used to estimate the difference 
between your quality of life at 8 weeks, your follow-up appointment and 
your A&E attendance or hospital admission. The different quality of life 
measures will also be compared. The loss of productivity questionnaire will 
help us to better estimate the costs involved with asthma, after an A&E 
attendance or hospital admission. The results may be published in scientific 
journals, but all the data will be anonymised so that none of the participants 
are identified. The results of the research study will be summarised and 
posted or emailed to each participant involved in the study. This is predicted 




Who is organising and funding the research? 
The University of East Anglia will be sponsoring the research. The research 
will be funded by the Collaborations for Leadership in Applied Health 
Research and Care East of England (CLAHRC EoE). 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, 
called a Research Ethics Committee, to protect your interests.  
 
Further information and contact details. 
If you have any further questions and would like to know more information 
about this study, please do not hesitate to contact the researchers: 
Christina-Jane Crossman-Barnes, PhD student 
Email: C.Crossman-Barnes@uea.ac.uk 
Christina-Jane Crossman-Barnes 100066687 
 
388 
Version 5.2 17th October 2016 
Phone: 07763775509 (study research phone number) 
 
Dr Garry Barton, Academic Supervisor 
Email: G.Barton@uea.ac.uk 
Phone: 01603 591 936 
 
If you wish to agree to take part in this study please complete the consent 
form. 
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Centre Number:  
 
Study Number:  
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CONSENT FORM 
 
Title of Project: Estimating the loss in quality of life associated with an 
asthma-related crisis event. 
  





1. I confirm that I have read and understand the information sheet  
dated 23rd February 2016 (version 4.1) for the above study. I have had 
the opportunity to consider the information, ask questions 
and have these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical 
care or legal rights being affected as your data will be kept 
securely and anonymously.  
 
3. I understand that relevant sections of my medical notes and data 
collected during the study, may be looked at by individuals from 
University of East Anglia, from regulatory authorities or from the 
NHS trust, where it is relevant to my taking part in this research. I 
understand that my data may be examined as part of monitoring this 
study and assessing the PhD qualification. I give permission 
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4. I agree that my data will be used in other ethically approved  
asthma studies. 
 
5. I give permission for my contact details to be used by the 
researchers to contact me by phone or mail as part of the 
research process. 
 
6. I agree to my GP being informed of my participation in the 
study. 
 
7. I agree to take part in the above study. 
 
PLEASE SIGN BELOW 











When completed a copy of the consent form should be given to: 
 The participant 
 The researcher for site file 
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Appendix VI c GP letter 
Version Number: 1.1 
Date (dd/mm/yyyy):  23/02/2016 
Norwich Medical School 
Faculty of Medicine and Health Sciences 





Miss C Crossman-Barnes 
Email: C.Crossman-Barnes@uea.ac.uk 









Study Title: Estimating the loss in quality of life associated with an asthma-related 
crisis event.  
 
Patient’s name: 
Patient’s D.O.B:   
 
I am writing to inform you that your patient, (PATIENT’S NAME), has agreed to take 
part in the study entitled above at (HOSPITAL NAME). This study is part of a PhD 
project and is sponsored by the University of East Anglia and funded by Collaborations 
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393 
Version 5.2 17th October 2016 
for Leadership in Applied Health Research and Care East of England (CLAHRC EoE). It 
is a cohort study which will estimate the loss of utility associated with an asthma-related 
crisis event (in this case an asthma-related accident and emergency attendance or hospital 
admission) through economic evaluation methods.  
 
Your patient’s consent was obtained when they had an asthma-related accident and 
emergency (A&E) attendance or hospital admission, and they will be involved in the 
study for approximately eight weeks. They will be asked to self-complete quality of life 
questionnaires (EQ-5D-5L and AQLQ), peak flow and symptom questions during their 
hospital stay and for approximately eight weeks after discharge. They will also be asked 
to complete a loss of productivity questionnaire at approximately four weeks time. We 
will follow-up their responses by either reviewing this at their routine follow-up 
appointment, or over the phone. Your patient will also have the option of posting their 
responses back to us. If your patient was admitted to the Norfolk and Norwich University 
Hospital, they will also be asked time trade-off questions (a way of valuing their state of 
health) during their A&E attendance or hospital admission and at their follow-up 
appointment. After we have reviewed your patient’s responses at approximately eight 
weeks after discharge, their involvement in the study will end.  
  
I have enclosed a copy of the participant information sheet (Version 4.1, Dated 23rd 
February 2016) for your reference, however if you have any questions please don’t 








PhD student researcher 
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Centre number:  
Version 4.1 
 
Please can you answer these questions about yourself. This will help us with 
our research.  
Before you start please can you fill in your: 
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Please can you complete these questions. 
1) What is your age?       
2) What gender are you? 
Male    Female   
 
3) What is your smoking status? 
Never smoked  Non-smoker  Ex-Smoker  Smoker 
If you have ticked ‘non-smoker’ or ‘ex-smoker’, how long ago did you 
stop smoking?  
4) What is your ethnic group?  
White   
English/Welsh/Scottish/Northern Irish/British 
Irish 
Gypsy or Irish Traveller 
Any other white background, please describe: 
 
Mixed/Multiple Ethnic groups 
White and Black Caribbean   
White and Black African 
White and Asian 
 







Any other Asian Background, please describe: 
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Any other Black/African/Caribbean background, please describe: 
 
Other Ethnic group 
Arab 




5) What is the highest level of education that you have completed? 
School    College/Sixth Form   University degree 
 
6) What is your employment status?  
Full-time   Part-time   Unemployed 
 
Student   Retired        Stay at home parents 
 
7) When did your asthma-related event peak (e.g. on route to hospital, after 
2 hours in hospital)?  
 
8) What was your route of entry to the hospital (e.g. did you call for the 
ambulance, did your GP refer you)? 
 
 
9) In the last year, relating to your asthma and excluding your current A&E 
attendance or  hospital admission: 
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How many hospital accident and emergency attendances did you have 
that did not result in a hospital admission? 
How many hospital admissions did you have?  
10) Before your current asthma A&E attendance or hospital admission, 
what medications (including your dosage e.g. in micrograms) have you 
been prescribed for your asthma (e.g. budesonide, salbutamol, 
terbutaline, formoterol, salmeterol, montelukast etc)? 
NAME OF 
MEDICATION 
DOSAGE  QUANTITY 
FREQUENCY 
OF USE 
    
    
    
    
    
    
 
END OF QUESTIONS 
 
Thank you for completing the questionnaire.  
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English version for the UK 
 
Patient ID number: 
 
Date (dd/mm/yyyy): 
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Under each heading, please tick the ONE box that best describes your health TODAY. 
MOBILITY  
I have no problems in walking about  
I have slight problems in walking about  
I have moderate problems in walking about  
I have severe problems in walking about  
I am unable to walk about  
SELF-CARE  
I have no problems washing or dressing myself  
I have slight problems washing or dressing myself  
I have moderate problems washing or dressing myself  
I have severe problems washing or dressing myself  
I am unable to wash or dress myself  
USUAL ACTIVITIES (e.g. work, study, housework, family or leisure activities) 
 
I have no problems doing my usual activities  
I have slight problems doing my usual activities  
I have moderate problems doing my usual activities  
I have severe problems doing my usual activities  
I am unable to do my usual activities  
PAIN / DISCOMFORT  
I have no pain or discomfort  
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I have slight pain or discomfort  
I have moderate pain or discomfort  
I have severe pain or discomfort  
I have extreme pain or discomfort  
ANXIETY / DEPRESSION  
I am not anxious or depressed  
I am slightly anxious or depressed  
I am moderately anxious or depressed  
I am severely anxious or depressed  
I am extremely anxious or depressed  
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The worst health 
























We would like to know how good or bad your health is TODAY. 
This scale is numbered from 0 to 100. 
100 means the best health you can imagine. 
0 means the worst health you can imagine. 
Mark an X on the scale to indicate how your health is TODAY. 
Now, please write the number you marked on the scale in the box below. 
The best health you 
can imagine 
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 Appendix VI f Asthma Quality of Life Questionnaire  
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Peak flow and symptom score 
 
Centre number:  
Version 1.0 
 
Please can you answer these questions about your peak flow, symptoms and 
activities. It is important that you answer these questions every day as this 
will help us with our research.  
Before you start please can you fill in your: 
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Please complete the following table, and bring this with you to 
your hospital follow-up appointment. 
 
For the peak expiratory flow readings, please enter the morning 
and evening scores that you see on your peak flow after blowing. 
 
For the sleeping, usual asthma symptoms and usual activities 
questions, please enter a number between 0 and 3: 
0 – absent symptoms (no sign/symptoms evident) 
1 – mild symptoms (sign/symptoms clearly present, but minimal 
awareness and easily tolerated) 
2 – moderate symptoms (definite awareness of sign/symptoms 
that is bothersome but tolerable) 
3 – severe symptoms (sign/symptoms that is hard to tolerate; 
causes interference with activities of daily living) 
 
For the EQ-5D check question, this is a reminder to complete 
your EQ-5D questionnaire and tick the box when complete.  
 
Reminder: 
The week of your follow-up appointment, please complete and 




0 – absent symptoms (no sign/symptoms evident); 1 – mild symptoms (sign/symptoms clearly present, but minimal awareness and easily tolerated); 2 
– moderate symptoms (definite awareness of sign/symptoms that is bothersome but tolerable); 3 – severe symptoms (sign/symptoms that is hard to 




















Day 10 Day 11 Day 12 
Peak Expiratory Flow reading (AM): Please record AM 
reading here 
            
Peak Expiratory Flow reading (PM): Please record PM 
reading here 
            
Sleeping: Have you had difficulty sleeping because of your 
asthma?  
            
Usual asthma symptoms: Have you had your usual asthma 
symptoms during the day (cough, wheeze, breathlessness, 
chest tightness)? 
            
Usual activities: Has your asthma interfered with your usual 
activities (e.g. housework, child care, work, school etc.)? 
            
EQ-5D check: Have you completed your EQ-5D today? 
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0 – absent symptoms (no sign/symptoms evident); 1 – mild symptoms (sign/symptoms clearly present, but minimal awareness and easily tolerated); 2 
– moderate symptoms (definite awareness of sign/symptoms that is bothersome but tolerable); 3 – severe symptoms (sign/symptoms that is hard to 


























Peak Expiratory Flow reading 
(AM): Please record AM reading here 
            
Peak Expiratory Flow reading (PM): 
Please record PM reading here 
            
Sleeping: Have you had difficulty 
sleeping because of your asthma?  
            
Usual asthma symptoms: Have you 
had your usual asthma symptoms 
during the day (cough, wheeze, 
breathlessness, chest tightness)? 
            
Usual activities: Has your asthma 
interfered with your usual activities 
(e.g. housework, child care, work, 
school etc.)? 
            
EQ-5D check: Have you completed 
your EQ-5D today? 
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0 – absent symptoms (no sign/symptoms evident); 1 – mild symptoms (sign/symptoms clearly present, but minimal awareness and easily tolerated); 2 
– moderate symptoms (definite awareness of sign/symptoms that is bothersome but tolerable); 3 – severe symptoms (sign/symptoms that is hard to 


























Peak Expiratory Flow reading 
(AM): Please record AM reading here 
            
Peak Expiratory Flow reading (PM): 
Please record PM reading here 
            
Sleeping: Have you had difficulty 
sleeping because of your asthma?  
            
Usual asthma symptoms: Have you 
had your usual asthma symptoms 
during the day (cough, wheeze, 
breathlessness, chest tightness)? 
            
Usual activities: Has your asthma 
interfered with your usual activities 
(e.g. housework, child care, work, 
school etc.)? 
            
EQ-5D check: Have you completed 
your EQ-5D today? 
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0 – absent symptoms (no sign/symptoms evident); 1 – mild symptoms (sign/symptoms clearly present, but minimal awareness and easily tolerated); 2 
– moderate symptoms (definite awareness of sign/symptoms that is bothersome but tolerable); 3 – severe symptoms (sign/symptoms that is hard to 
tolerate; causes interference with activities of daily living) 


























Peak Expiratory Flow reading 
(AM): Please record AM reading here 
            
Peak Expiratory Flow reading (PM): 
Please record PM reading here 
            
Sleeping: Have you had difficulty 
sleeping because of your asthma?  
            
Usual asthma symptoms: Have you 
had your usual asthma symptoms 
during the day (cough, wheeze, 
breathlessness, chest tightness)? 
            
Usual activities: Has your asthma 
interfered with your usual activities 
(e.g. housework, child care, work, 
school etc.)? 
            
EQ-5D check: Have you completed 
your EQ-5D today? 
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Please can you answer these questions about yourself, your ability to work, 
and/or attend classes and do activities. When you answer these questions we 
would like you to think about how you are affected by having your asthma-
related A&E attendance or hospital admission compared to when you did not 
have your asthma event. This will help us with our research.  
Before you start please can you fill in your: 
 
Patient ID number:  
 
Today’s date (dd/mm/yyyy):  
 
 














2) How long were you in hospital for? 
 
3) Compared to your asthma state when you were in hospital approximately 
4 weeks ago, how would you rate your asthma now?  
 










4) Do you think you have completely recovered from when you were in 
hospital approximately 4 weeks ago? 
 
Yes    No  
 




Yes   No    
 
Do not work (unemployed/student/retired/stay at home parents)  
Tick and circle  
IF YES, GO TO PART 2 
IF YOU ARE A STUDENT, GO TO PART 3. OTHERWISE 
CONTINUE TO PART 4. 
PART 2 
 
1) What was the date that you returned to work after having your asthma-
related A&E attendance or hospital admission? 
(Day/Month/Year) 
 
2) On average, how many hours per week did you work in the four weeks 
before your asthma-related A&E attendance or hospital admission?  
 
       Hours per week 
 
3) Since your asthma-related A&E attendance or hospital admission, on 
average, how many hours or minutes per week have you missed from 
work because of your asthma? Include hours you missed on sick days, 
times you went in late, left early, because of your asthma. Do not include 
time you missed to participate in this study. 
 





4) Since your asthma-related A&E attendance or hospital admission, on 
average per week, how much did your asthma affect your productivity 
while you were working?   
 
Think about days you were limited in the amount or kind of work you 
could do, days you accomplished less than you would like, or days you 
could not do your work as carefully as usual.  If your asthma affected 
your work only a little, choose a low number.  Choose a high number if 
your asthma affected your work a great deal. 
 
Consider only how much your asthma affected  
productivity while you were working. Circle a number. 
 
Your asthma 
had no effect 
on my work 
           Your asthma 
completely 
prevented me             
 0 1 2 3 4 5 6 7 8 9 10 from working 
 
 
GO TO PART 4 
PART 3 
 
1) Do you currently attend classes in an academic setting (school, sixth-form 
college, university, etc.)? 




2) During term time, before your asthma-related A&E attendance or hospital 
admission, on average how many hours per week did you usually attend 
classes? 
 Hours per week 
 
3) Since your asthma-related A&E attendance or hospital admission, on 
average, how many hours or minutes per week have you missed class 
because of your asthma? Do not include time you missed to participate in 
this study. 
 
 Hours per week  OR    Minutes per week 
 
 
4) Since your asthma-related A&E attendance or hospital admission, on 
average per week, how much did your asthma affect your productivity 
while in school or attending classes in an academic setting?  
 
Think about days your attention span was limited, you had trouble with 
comprehension or days in which you could not take tests as effectively as 
usual. If your asthma affected your productivity at school or in class only 
a little, choose a low number. Choose a high number if your asthma 
affected your productivity at school or in class a great deal. 
 
Consider only how much your asthma affected 
productivity while in school or attending classes. Circle a number.  
 
Your asthma 
had no effect on 
my class work 





from doing my  
 0 1 2 3 4 5 6 7 8 9 10  class work 
 
 
GO TO PART 4 
PART 4 
 
1) Since your asthma-related A&E attendance or hospital admission, on 
average per week, how much did your asthma affect your ability to 
do your regular daily activities, other than work at a job or attending 
classes?   
 
By regular activities, we mean the usual activities you do, such as 
work around the house, shopping, child care, exercising, studying, etc. 
Think about times you were limited in the amount or kind of activities 
you could do and times you accomplished less than you would like.  If 
your asthma affected your activities only a little, choose a low number.  




Consider only how much your asthma affected your ability  
to do your regular daily activities, other than work at a job or attending 






had no effect on  
my daily 
           Your asthma 
completely 
prevented me 
activities 0 1 2 3 4 5 6 7 8 9 10 from doing my 
daily activities 
 
GO TO PART 5 
PART 5 
 
1) Since your last asthma-related A&E attendance or hospital admission 
have you bought any extra products (e.g. prescriptions, allergy-free 
bedding, cleaning products, food items) or used a service (e.g. a visit to a 
complementary therapist) to that which you would normally buy/use e.g. 
in the four weeks prior to your asthma-related A&E Attendance or 
hospital admission? 
 
YES      NO IF NO, GO TO 
PART 6  
 
2) If YES, list the name of the product and the cost in the table below 
including any new medicines and dosage in micrograms prescribed (e.g. 


















    
    
    
    
    
    
    














END OF QUESTIONNAIRE 
 
Thank you for completing the questionnaire. 


































































Appendix VII: STATA code for post-viva revisions  
STATA version 12 
*Chapter 2 
 
*Comparison of Qhes scores between Yong & Shafie 8 studies (post 2008) and Campbell 
policy 14 studies (< 2008) 
ttest  Y_8== campbell_policy 
*Comparison of Qhes scores between all Yong & Shafie 49 studies and Campbell policy 
14 studies (note, Y&S all years included) 
ttest  y_49== campbell_policy 
*Comparion of the additional 15 studies in my Sys Rev and Campbell policy 14 studies 
ttest  c_15== campbell_policy 
*Comparison of all Yong and Shafie and all additional 15 studies found in my Sys Rev 




*Post-hoc power calculation 





*exploring ceiling effect of eq5d5l at baseline* 
tab asthma_peak if eq5d5l0==1 
 
tab asthma_peak, gen(asthma_peak) 
rename asthma_peak1 before 
rename asthma_peak2 hospital 




regress eq5d5l0 before route 
 
tab asthma_peak if tto0==1 
regress tto0 before route 
 
 
*missing data table for all variables (nb demographic variables all observed, not missing) 
misstable summ eq5d5l0 eq5d5l1 eq5d5l2 eq5d5l3 eq5d5l4 eq5d5l5 eq5d5l6 eq5d5l7 
eq5d5l8 tto0 tto4 tto8 aql5d0 aql5d4 aql5d8 age gender ethnicity employment_status 
smoking_status  highest_education 
*missing data patterns 
misstable patterns eq5d5l0 eq5d5l1 eq5d5l2 eq5d5l3 eq5d5l4 eq5d5l5 eq5d5l6 eq5d5l7 
eq5d5l8 tto0 tto4 tto8 aql5d0 aql5d4 aql5d8 age gender ethnicity employment_status 
smoking_status  highest_education, freq 
 
*predictors of missingness using logistic regression (Odds ratios and CI) 
gen r_eq5d5l1=(eq5d5l1!=.) 
xi: logistic r_eq5d5l1  age 
xi: logistic r_eq5d5l1 i.gender 
xi: logistic r_eq5d5l1 i.smoking_status 
xi: logistic r_eq5d5l1 i.ethnicity 
xi: logistic r_eq5d5l1 i.employment_status 
xi: logistic r_eq5d5l1 i.highest_education 




xi: logistic r_eq5d5l2  age 
xi: logistic r_eq5d5l2 i.gender 
xi: logistic r_eq5d5l2 i.smoking_status 
xi: logistic r_eq5d5l2 i.ethnicity 
xi: logistic r_eq5d5l2 i.employment_status 
 435 
 
xi: logistic r_eq5d5l2 i.highest_education 




xi: logistic r_eq5d5l3  age 
xi: logistic r_eq5d5l3 i.gender 
xi: logistic r_eq5d5l3 i.smoking_status 
xi: logistic r_eq5d5l3 i.ethnicity 
xi: logistic r_eq5d5l3 i.employment_status 
xi: logistic r_eq5d5l3 i.highest_education 




xi: logistic r_eq5d5l4  age 
xi: logistic r_eq5d5l4 i.gender 
xi: logistic r_eq5d5l4 i.smoking_status 
xi: logistic r_eq5d5l4 i.ethnicity 
xi: logistic r_eq5d5l4 i.employment_status 
xi: logistic r_eq5d5l4 i.highest_education 




xi: logistic r_eq5d5l5  age 
xi: logistic r_eq5d5l5 i.gender 
xi: logistic r_eq5d5l5 i.smoking_status 
xi: logistic r_eq5d5l5 i.ethnicity 
xi: logistic r_eq5d5l5 i.employment_status 
xi: logistic r_eq5d5l5 i.highest_education 
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xi: logistic r_eq5d5l6  age 
xi: logistic r_eq5d5l6 i.gender 
xi: logistic r_eq5d5l6 i.smoking_status 
xi: logistic r_eq5d5l6 i.ethnicity 
xi: logistic r_eq5d5l6 i.employment_status 
xi: logistic r_eq5d5l6 i.highest_education 




xi: logistic r_eq5d5l7  age 
xi: logistic r_eq5d5l7 i.gender 
xi: logistic r_eq5d5l7 i.smoking_status 
xi: logistic r_eq5d5l7 i.ethnicity 
xi: logistic r_eq5d5l7 i.employment_status 
xi: logistic r_eq5d5l7 i.highest_education 




xi: logistic r_eq5d5l8  age 
xi: logistic r_eq5d5l8 i.gender 
xi: logistic r_eq5d5l8 i.smoking_status 
xi: logistic r_eq5d5l8 i.ethnicity 
xi: logistic r_eq5d5l8 i.employment_status 
xi: logistic r_eq5d5l8 i.highest_education 






xi: logistic r_tto4 age 
xi: logistic r_tto4 i.gender 
xi: logistic r_tto4 i.smoking_status 
xi: logistic r_tto4 i.ethnicity 
xi: logistic r_tto4 i.employment_status 
xi: logistic r_tto4 i.highest_education 




xi: logistic r_tto8  age 
xi: logistic r_tto8 i.gender 
xi: logistic r_tto8 i.smoking_status 
xi: logistic r_tto8 i.ethnicity 
xi: logistic r_tto8 i.employment_status 
xi: logistic r_tto8 i.highest_education 




xi: logistic r_aql5d4  age 
xi: logistic r_aql5d4 i.gender 
xi: logistic r_aql5d4 i.smoking_status 
xi: logistic r_aql5d4 i.ethnicity 
xi: logistic r_aql5d4 i.employment_status 
xi: logistic r_aql5d4 i.highest_education 






xi: logistic r_aql5d8  age 
xi: logistic r_aql5d8 i.gender 
xi: logistic r_aql5d8 i.smoking_status 
xi: logistic r_aql5d8 i.ethnicity 
xi: logistic r_aql5d8 i.employment_status 
xi: logistic r_aql5d8 i.highest_education 




/*exploring removing 'healthy' baseline participants*/ 






















/* change orientation of data into long data set where each time point for eq5d5l is on a 
new line for the same id*/ 
reshape long eq5d5l, i(id) j(time) 
 
xtmixed eq5d5l time || id: time, covariance(unstructured) variance 
xtmixed eq5d5l time age || id: time, covariance(unstructured) variance 
 
 
/* renaming variables*/ 
tab gender, gen(gender) 
rename gender1 female 
rename gender2 male 
 
xtmixed eq5d5l time female, || id: time, covariance(unstructured) variance 
xtmixed eq5d5l time age female, || id: time, covariance(unstructured) variance 
 
tab smoking_status, gen(smoking) 
rename smoking1 exsmoker 
rename smoking2 never 
rename smoking3 nonsmoker 
rename smoking4 smoker 
 
xtmixed eq5d5l time exsmoker never nonsmoker, || id: time, covariance(unstructured) 
variance 
xtmixed eq5d5l time age exsmoker never nonsmoker, || id: time, covariance(unstructured) 
variance 
xtmixed eq5d5l time age female exsmoker never nonsmoker, || id: time, 
covariance(unstructured) variance 
 
tab ethnicity, gen(ethnicity) 
rename ethnicity1 mixed 
rename ethnicity2 white 
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rename ethnicity3 wother 
 
xtmixed eq5d5l time mixed white, || id: time, covariance(unstructured) variance 
xtmixed eq5d5l time age mixed white, || id: time, covariance(unstructured) variance 
xtmixed eq5d5l time age female mixed white, || id: time, covariance(unstructured) 
variance 
xtmixed eq5d5l time age female exsmoker never nonsmoker mixed white, || id: time, 
covariance(unstructured) variance 
 
tab highest_education, gen(education) 
rename education1 college 
rename education2 degree 
rename education3 school 
 
xtmixed eq5d5l time college degree, || id: time, covariance(unstructured) variance 
xtmixed eq5d5l time age college degree, || id: time, covariance(unstructured) variance 
xtmixed eq5d5l time age female college degree, || id: time, covariance(unstructured) 
variance 
xtmixed eq5d5l time age female exsmoker never nonsmoker college degree, || id: time, 
covariance(unstructured) variance 
xtmixed eq5d5l time age female exsmoker never nonsmoker mixed white college degree, 
|| id: time, covariance(unstructured) variance 
 
tab employment_status, gen(employment) 
rename employment1 fulltime 
rename employment2 parttime 
rename employment3 retired 
rename employment4 home 
rename employment5 student 




xtmixed eq5d5l time fulltime parttime retired home student, || id: time, 
covariance(unstructured) variance 
xtmixed eq5d5l time age fulltime parttime retired home student, || id: time, 
covariance(unstructured) variance 
xtmixed eq5d5l time age female fulltime parttime retired home student, || id: time, 
covariance(unstructured) variance 
xtmixed eq5d5l time age female exsmoker never nonsmoker fulltime parttime retired 
home student, || id: time, covariance(unstructured) variance 
xtmixed eq5d5l time age female exsmoker never nonsmoker mixed white fulltime 
parttime retired home student, || id: time, covariance(unstructured) variance 
xtmixed eq5d5l time age female exsmoker never nonsmoker mixed white college degree 
fulltime parttime retired home student, || id: time, covariance(unstructured) variance 
 
*graph to show the first 10 IDs and connection between eq5d5l and the 8 time points* 
twoway connected eq5d5l time if id<10, connect(ascending) 
 
*generating a quadratic time variable* 
gen time2 = time*time 
 
*model including time2* 
xtmixed eq5d5l time time2 || id: time, covariance(unstructured) variance 
xtmixed eq5d5l time time2 age female exsmoker never nonsmoker mixed white college 





*insert data set* 
*for aql5d*  
*rename categorical variables as above* 
reshape long aql5d, i(id) j(time) 
xtmixed aql5d time || id: time, covariance(unstructured) variance 
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xtmixed aql5d time age || id: time, covariance(unstructured) variance 
 
tab gender, gen(gender) 
rename gender1 female 
rename gender2 male 
 
xtmixed aql5d time age female, || id: time, covariance(unstructured) variance 
 
tab smoking_status, gen(smoking) 
rename smoking1 exsmoker 
rename smoking2 never 
rename smoking3 nonsmoker 
rename smoking4 smoker 
 
xtmixed aql5d time age female exsmoker never nonsmoker, || id: time, 
covariance(unstructured) variance 
 
tab ethnicity, gen(ethnicity) 
rename ethnicity1 mixed 
rename ethnicity2 white 
rename ethnicity3 wother 
 
xtmixed aql5d time age female exsmoker never nonsmoker mixed white, || id: time, 
covariance(unstructured) variance 
 
tab highest_education, gen(education) 
rename education1 college 
rename education2 degree 
rename education3 school 
 
xtmixed aql5d time age female exsmoker never nonsmoker mixed white college degree, 




tab employment_status, gen(employment) 
rename employment1 fulltime 
rename employment2 parttime 
rename employment3 retired 
rename employment4 home 
rename employment5 student 
rename employment6 unemployed  
 
xtmixed aql5d time age female exsmoker never nonsmoker mixed white college degree 
fulltime parttime retired home student, || id: time, covariance(unstructured) variance 
 
*graph to show the first 10 IDs and connection between aql5d and the 8 time points* 
twoway connected aql5d time if id<10, connect(ascending) 
 
*generating a quadratic time variable* 
gen time2 = time*time 
 
*model including time2* 
xtmixed aql5d time time2 || id: time, covariance(unstructured) variance 
xtmixed aql5d time time2 age female exsmoker never nonsmoker mixed white college 
degree fulltime parttime retired home student, || id: time, covariance(unstructured) 
variance 






*insert data set* 
*for tto*  
*rename categorical variables as above* 
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reshape long tto, i(id) j(time) 
xtmixed tto time || id: time, covariance(unstructured) variance 
xtmixed tto time age || id: time, covariance(unstructured) variance 
 
tab gender, gen(gender) 
rename gender1 female 
rename gender2 male 
 
xtmixed tto time age female, || id: time, covariance(unstructured) variance 
 
tab smoking_status, gen(smoking) 
rename smoking1 exsmoker 
rename smoking2 never 
rename smoking3 nonsmoker 
rename smoking4 smoker 
 
xtmixed tto time age female exsmoker never nonsmoker, || id: time, 
covariance(unstructured) variance 
 
tab ethnicity, gen(ethnicity) 
rename ethnicity1 mixed 
rename ethnicity2 white 
rename ethnicity3 wother 
 
xtmixed tto time age female exsmoker never nonsmoker mixed white, || id: time, 
covariance(unstructured) variance 
 
tab highest_education, gen(education) 
rename education1 college 
rename education2 degree 




xtmixed tto time age female exsmoker never nonsmoker mixed white college degree, || 
id: time, covariance(unstructured) variance 
 
tab employment_status, gen(employment) 
rename employment1 fulltime 
rename employment2 parttime 
rename employment3 retired 
rename employment4 home 
rename employment5 student 
rename employment6 unemployed  
 
xtmixed tto time age female exsmoker never nonsmoker mixed white college degree 
fulltime parttime retired home student, || id: time, covariance(unstructured) variance 
 
*graph to show the first 10 IDs and connection between aql5d and the 8 time points* 
twoway connected tto time if id<10, connect(ascending) 
 
*generating a quadratic time variable* 
gen time2 = time*time 
 
*model including time2* 
xtmixed tto time time2 || id: time, covariance(unstructured) variance 
xtmixed tto time time2 age female exsmoker never nonsmoker mixed white college 




*General: graphing data and relationships 
 
*Histograms for utility data 
hist eq5d5l0, normal 
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hist eq5d5l1, normal 
hist eq5d5l2, normal 
hist eq5d5l3, normal 
hist eq5d5l4, normal 
hist eq5d5l5, normal 
hist eq5d5l6, normal 
hist eq5d5l7, normal 
hist eq5d5l8, normal 
hist aql5d0, normal 
hist aql5d4, normal 
hist aql5d8, normal 
hist tto0, normal 
hist tto4, normal 
hist tto8, normal 
 




































STATA version 15 
Power calculation  
*estimate correlation between AQLQ baseline and AQLQ week 8 
correlate aqlq_baseline_overall aqlq_week8_overall 
*estimate power required for a sample size of 65 as observed in table 32 of thesis using 
correlation estimated above  
power pairedmeans 0 0.5, n(65) sd (1.5) 
 
Multi-level modelling - eq5d5l 
*Growth curve modelling 
reshape long eq5d5l, i(id) j(week) 




order week2, after(week) 
 
*generate dummy variables 
tab gender, gen(gender) 
rename gender1 female 
rename gender2 male 
tab smoking_status, gen(smoking) 
rename smoking1 exsmoker 
rename smoking2 never 
rename smoking3 nonsmoker 
rename smoking4 smoker 
tab ethnicity, gen(ethnicity) 
rename ethnicity1 mixed 
rename ethnicity2 white 
rename ethnicity3 wother 
tab highest_education, gen(education) 
rename education1 college 
rename education2 degree 
rename education3 school 
tab employment_status, gen(employment) 
rename employment1 fulltime 
rename employment2 parttime 
rename employment3 retired 
rename employment4 home 
rename employment5 student 
rename employment6 unemployed 
sum age, meanonly  
gen agecentered = age -r(mean) 
 




regress eq5d5l agecentered exsmoker never nonsmoker fulltime parttime retired home 
student 
 
*generating new variable to identify missing eq5d5l data points 
gen include_eq5d5l=0 
replace include_eq5d5l=1 if e(sample)==1 
 
*Null model (random intercept) 
xtset id week 
mixed eq5d5l ||id: if include_eq5d5l==1 
est store null 
predict predri1, fitted 




*Random intercept, fixed slope 
mixed eq5d5l week ||id: if include_eq5d5l==1 
est store r_intercept 
predict predri2, fitted 
twoway (scatter eq5d5l week, mcolor(black) msymbol(smx))(lfitci predri2 week, 
clpattern(solid)ytitle("eq5d5l") xtitle("week")) 
qnorm predri2 
lrtest null r_intercept 
 
*Random slope model - relaxing assumption slope is constant over all individuals 
mixed eq5d5l week ||id: week if include_eq5d5l==1, cov(unstruc) 
est store r_slope 
predict predri3, fitted 





lrtest r_intercept r_slope 
 
*random polynomial model - non-linear over time 
*can explore quadratic model with week^2 as fixed and random effect 
mixed eq5d5l week week2 ||id: week if include_eq5d5l==1, cov(unstruc) 
est store r_nlin 
predict predri4,fitted 
twoway (scatter eq5d5l week, mcolor(black) msymbol(smx))(lfitci predri4 week, 
clpattern(solid)ytitle("eq5d5l") xtitle("week")) 
qnorm predri4 
lrtest r_slope r_nlin 
 
 
*adding to the polynomial model (which includes the factors predictive of missingness) 
one covariate at a time.  
mixed eq5d5l week week2 agecentered exsmoker never nonsmoker fulltime parttime 
retired home student||id: week, cov(unstruc) 
mixed eq5d5l week week2 agecentered exsmoker never nonsmoker fulltime parttime 
retired home student female||id: week, cov(unstruc) 
mixed eq5d5l week week2 agecentered exsmoker never nonsmoker fulltime parttime 
retired home student mixed white||id: week, cov(unstruc) 
mixed eq5d5l week week2 agecentered exsmoker never nonsmoker fulltime parttime 
retired home student college degree||id: week, cov(unstruc) 
 
 
*best eq5d5l polynomial model with added covariates 
mixed eq5d5l week week2 agecentered exsmoker never nonsmoker fulltime parttime 
retired home student||id: week, cov(unstruc) 
 
*bootstrap preferred eq5d5l model 
bootstrap _b[_cons] _b[week] _b[week2] _b[agecentered] _b[exsmoker] _b[never] 
_b[nonsmoker] _b[fulltime] _b[parttime] _b[retired] _b[home] _b[student], reps(500) 
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seed(1): mixed eq5d5l week week2 agecentered exsmoker never nonsmoker fulltime 
parttime retired home student||id: week, cov(unstruc) 
 
*estimate of AUC disutility 
bootstrap((4*_b[week]+40*_b[week2])*8/52), reps(500) seed(1): mixed eq5d5l week 
week2 agecentered exsmoker never nonsmoker fulltime parttime retired home student||id: 
week, cov(unstruc) 
 
*generate dummy variable for baseline utility which is either 1 or <1 
gen baseeq5d5lutility = 0 
replace baseeq5d5lutility = 1 if eq5d5l0<1 
 
*exploring the impact of baseline utility on disutility estimate 
mixed eq5d5l week week2 agecentered exsmoker never nonsmoker fulltime parttime 
retired home student  baseeq5d5lutility ||id: week, cov(unstruc) 
bootstrap((4*_b[week]+40*_b[week2])*8/52), reps(500) seed(1): mixed eq5d5l week 
week2 agecentered exsmoker never nonsmoker fulltime parttime retired home student  
baseeq5d5lutility||id: week, cov(unstruc) 
 
*Multiple Imputation - eq5d5l 
mi set wide 
mi register imputed eq5d5l1 eq5d5l2 eq5d5l3 eq5d5l4 eq5d5l5 eq5d5l6 eq5d5l7 eq5d5l8 
agecentered exsmoker never nonsmoker fulltime parttime retired home student 
mi misstable patterns, frequency 
 
*impute missing values 
mi impute chained (pmm, knn(30)) eq5d5l1 eq5d5l2 eq5d5l3 eq5d5l4 eq5d5l5 eq5d5l6 
eq5d5l7 eq5d5l8 agecentered exsmoker never nonsmoker fulltime parttime retired home 
student, add(30) rseed(285019) 
mi reshape long eq5d5l, i(id) j(week) 
gen week2 = week^2 




sort week id 
by week: summ 
_1_eq5d5l_2_eq5d5l_3_eq5d5l_4_eq5d5l_5_eq5d5l_6_eq5d5l_7_eq5d5l_8_eq5d5l 
sort id week 
 
*generate dummy variables 
tab gender, gen(gender) 
rename gender1 female 
rename gender2 male 
tab smoking_status, gen(smoking) 
rename smoking1 exsmoker 
rename smoking2 never 
rename smoking3 nonsmoker 
rename smoking4 smoker 
tab ethnicity, gen(ethnicity) 
rename ethnicity1 mixed 
rename ethnicity2 white 
rename ethnicity3 wother 
tab highest_education, gen(education) 
rename education1 college 
rename education2 degree 
rename education3 school 
tab employment_status, gen(employment) 
rename employment1 fulltime 
rename employment2 parttime 
rename employment3 retired 
rename employment4 home 
rename employment5 student 
rename employment6 unemployed  
sum age, meanonly  
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gen agecentered = age -r(mean) 
 
mi estimate: mixed eq5d5l week week2 agecentered exsmoker never nonsmoker fulltime 
parttime retired home student mixed white college degree female||id: week, cov(unstruc) 
mi estimate (dis_u: (4*_b[week]+40*_b[week2])*8/52): mixed eq5d5l week week2 
agecentered exsmoker never nonsmoker fulltime parttime retired home student mixed 
white college degree female||id: week, cov(unstruc) 
 
 
Multi-level modelling - aql5d 
*Growth curve modelling 
reshape long aql5d, i(id) j(week) 
graph box aql5d, over(week) 
gen week2=week^2 
order week2, after(week) 
 
*generate dummy variables 
tab gender, gen(gender) 
rename gender1 female 
rename gender2 male 
tab smoking_status, gen(smoking) 
rename smoking1 exsmoker 
rename smoking2 never 
rename smoking3 nonsmoker 
rename smoking4 smoker 
tab ethnicity, gen(ethnicity) 
rename ethnicity1 mixed 
rename ethnicity2 white 
rename ethnicity3 wother 
tab highest_education, gen(education) 
rename education1 college 
rename education2 degree 
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rename education3 school 
tab employment_status, gen(employment) 
rename employment1 fulltime 
rename employment2 parttime 
rename employment3 retired 
rename employment4 home 
rename employment5 student 
rename employment6 unemployed 
sum age, meanonly  
gen agecentered = age -r(mean) 
 
*regression model with factors predictive of missingness added to aid in identifying 
missing values 
regress aql5d agecentered exsmoker never nonsmoker fulltime parttime retired home 
student 
 
*generating new variable to identify missing eq5d5l data points 
gen include_aql5d=0 
replace include_aql5d=1 if e(sample)==1 
 
*Null model (random intercept) 
xtset id week 
mixed aql5d ||id: if include_aql5d==1 
est store null 
predict predri1, fitted 




*Random intercept, fixed slope 
mixed aql5d week ||id: if include_aql5d==1 
est store r_intercept 
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predict predri2, fitted 
twoway (scatter aql5d week, mcolor(black) msymbol(smx))(lfitci predri2 week, 
clpattern(solid)ytitle("aql5d") xtitle("week")) 
qnorm predri2 
lrtest null r_intercept 
 
*Random slope model - relaxing assumption slope is constant over all individuals 
mixed aql5d week ||id: week if include_aql5d==1, cov(unstruc) 
est store r_slope 
predict predri3, fitted 
twoway (scatter aql5d week, mcolor(black) msymbol(smx))(lfitci predri3 week, 
clpattern(solid)ytitle("aql5d") xtitle("week")) 
qnorm predri3 
lrtest r_intercept r_slope 
 
*random polynomial model - non-linear over time 
*can explore quadratic model with week^2 as fixed and random effect 
mixed aql5d week week2 ||id: week if include_aql5d==1, cov(unstruc) 
est store r_nlin 
predict predri4,fitted 
twoway (scatter aql5d week, mcolor(black) msymbol(smx))(lfitci predri4 week, 
clpattern(solid)ytitle("aql5d") xtitle("week")) 
qnorm predri4 
lrtest r_slope r_nlin 
 
*adding to the random slope model (which includes the factors predictive of missingness) 
one covariate at a time.  
mixed aql5d week agecentered exsmoker never nonsmoker fulltime parttime retired home 
student||id: week, cov(unstruc) 
mixed aql5d week agecentered exsmoker never nonsmoker fulltime parttime retired home 
student female||id: week, cov(unstruc) 
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mixed aql5d week agecentered exsmoker never nonsmoker fulltime parttime retired home 
student mixed white||id: week, cov(unstruc) 
mixed aql5d week agecentered exsmoker never nonsmoker fulltime parttime retired home 
student college degree||id: week, cov(unstruc) 
 
*best aql5d random slope model with added covariates 
mixed aql5d week agecentered exsmoker never nonsmoker fulltime parttime retired home 
student||id: week, cov(unstruc) 
 
*bootstrap preferred aql5d model 
bootstrap _b[_cons] _b[week] _b[agecentered] _b[exsmoker] _b[never] _b[nonsmoker] 
_b[fulltime] _b[parttime] _b[retired] _b[home] _b[student], reps(500) seed(20619): 
mixed aql5d week agecentered exsmoker never nonsmoker fulltime parttime retired home 
student||id: week, cov(unstruc) 
 
*estimate of AUC disutility 
bootstrap((4*_b[week])*8/52), reps(500) seed(20076): mixed aql5d week agecentered 
exsmoker never nonsmoker fulltime parttime retired home student||id: week, cov(unstruc) 
 
*generate dummy variable for baseline utility which is either 1 or <1 
gen baseaql5dutility = 0 
replace baseaql5dutility = 1 if aql5d0<1 
 
*exploring the impact of baseline utility on disutility estimate 
mixed aql5d week agecentered exsmoker never nonsmoker fulltime parttime retired home 
student baseaql5dutility ||id: week, cov(unstruc) 
bootstrap((4*_b[week])*8/52), reps(500) seed(20096): mixed aql5d week agecentered 




*Multiple Imputation - aql5d 
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mi set wide 
mi register imputed aql5d0 aql5d4 aql5d8 agecentered exsmoker never nonsmoker 
fulltime parttime retired home student 
mi misstable patterns, frequency 
 
*impute missing values 
mi impute chained (pmm, knn(5)) aql5d0 aql5d4 aql5d8 agecentered exsmoker never 
nonsmoker fulltime parttime retired home student, add(30) rseed(20830) 
mi reshape long aql5d, i(id) j(week) 
 
 
sort week id 
by week: summ _0_aql5d_4_aql5d_8_aql5d 
sort id week 
 
*generate dummy variables 
tab gender, gen(gender) 
rename gender1 female 
rename gender2 male 
tab smoking_status, gen(smoking) 
rename smoking1 exsmoker 
rename smoking2 never 
rename smoking3 nonsmoker 
rename smoking4 smoker 
tab ethnicity, gen(ethnicity) 
rename ethnicity1 mixed 
rename ethnicity2 white 
rename ethnicity3 wother 
tab highest_education, gen(education) 
rename education1 college 
rename education2 degree 
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rename education3 school 
tab employment_status, gen(employment) 
rename employment1 fulltime 
rename employment2 parttime 
rename employment3 retired 
rename employment4 home 
rename employment5 student 
rename employment6 unemployed 
sum age, meanonly  
gen agecentered = age -r(mean)  
 
mi estimate: mixed aql5d week exsmoker never nonsmoker female mixed white fulltime 
parttime retired home student agecentered college degree||id: week, cov(unstruc) 
mi estimate (dis_u:(4*_b[week])*8/52): mixed aql5d week exsmoker never nonsmoker 




Multi-level modelling - tto 
*Growth curve modelling 
reshape long tto, i(id) j(week) 
graph box tto, over(week) 
gen week2=week^2 
order week2, after(week) 
 
*generate dummy variables 
tab gender, gen(gender) 
rename gender1 female 
rename gender2 male 
tab smoking_status, gen(smoking) 
rename smoking1 exsmoker 
rename smoking2 never 
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rename smoking3 nonsmoker 
rename smoking4 smoker 
tab ethnicity, gen(ethnicity) 
rename ethnicity1 mixed 
rename ethnicity2 white 
rename ethnicity3 wother 
tab highest_education, gen(education) 
rename education1 college 
rename education2 degree 
rename education3 school 
tab employment_status, gen(employment) 
rename employment1 fulltime 
rename employment2 parttime 
rename employment3 retired 
rename employment4 home 
rename employment5 student 
rename employment6 unemployed 
sum age, meanonly  
gen agecentered = age -r(mean) 
 
*regression model with factors predictive of missingness added to aid in identifying 
missing values 
regress tto agecentered exsmoker never nonsmoker fulltime parttime retired home student 
 
*generating new variable to identify missing eq5d5l data points 
gen include_tto=0 
replace include_tto=1 if e(sample)==1 
 
 
*Null model (random intercept) 
xtset id week 
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mixed tto ||id: if include_tto==1 
est store null 
predict predri1, fitted 




*Random intercept, fixed slope 
mixed tto week ||id: if include_tto==1 
est store r_intercept 
predict predri2, fitted 
twoway (scatter tto week, mcolor(black) msymbol(smx))(lfitci predri2 week, 
clpattern(solid)ytitle("tto") xtitle("week")) 
qnorm predri2 
lrtest null r_intercept 
 
*Random slope model - relaxing assumption slope is constant over all individuals 
mixed tto week ||id: week if include_tto==1, cov(unstruc) 
est store r_slope 
predict predri3, fitted 
twoway (scatter tto week, mcolor(black) msymbol(smx))(lfitci predri3 week, 
clpattern(solid)ytitle("tto") xtitle("week")) 
qnorm predri3 
lrtest r_intercept r_slope 
 
*random polynomial model - non-linear over time 
*can explore quadratic model with week^2 as fixed and random effect 
mixed tto week week2 ||id: week if include_tto==1, cov(unstruc) 
est store r_nlin 
predict predri4,fitted 





lrtest r_slope r_nlin 
 
*adding to the polynomial slope model (which includes the factors predictive of 
missingness) one covariate at a time.  
mixed tto week week2 agecentered exsmoker never nonsmoker fulltime parttime retired 
home student||id: week, cov(unstruc) 
mixed tto week week2 agecentered exsmoker never nonsmoker fulltime parttime retired 
home student female||id: week, cov(unstruc) 
mixed tto week week2 agecentered exsmoker never nonsmoker fulltime parttime retired 
home student mixed white||id: week, cov(unstruc) 
mixed tto week week2 agecentered exsmoker never nonsmoker fulltime parttime retired 
home student college degree||id: week, cov(unstruc) 
 
*best tto polynomial slope model with added covariates 
mixed tto week week2 agecentered exsmoker never nonsmoker fulltime parttime retired 
home student||id: week, cov(unstruc) 
 
*bootstrap preferred tto model 
bootstrap _b[_cons] _b[week] _b[week2] _b[agecentered] _b[exsmoker] _b[never] 
_b[nonsmoker] _b[fulltime] _b[parttime] _b[retired] _b[home] _b[student], reps(500) 
seed(210698): mixed tto week week2 agecentered exsmoker never nonsmoker fulltime 
parttime retired home student ||id: week, cov(unstruc) 
 
*estimate of AUC disutility 
bootstrap((4*_b[week]+40*_b[week2])*8/52), reps(500) seed(210699): mixed tto week 
week2 agecentered exsmoker never nonsmoker fulltime parttime retired home student 
||id: week, cov(unstruc) 
 
*generate dummy variable for baseline utility which is either 1 or <1 
gen basettoutility = 0 




*exploring the impact of baseline utility on disutility estimate 
mixed tto week week2 agecentered exsmoker never nonsmoker fulltime parttime retired 
home student basettoutility ||id: week, cov(unstruc) 
bootstrap((4*_b[week]+40*_b[week2])*8/52), reps(500) seed(20096): mixed tto week 
week2 agecentered exsmoker never nonsmoker fulltime parttime retired home student 
basettoutility||id: week, cov(unstruc) 
 
*Multiple Imputation - tto 
mi set wide 
mi register imputed tto0 tto4 tto8 agecentered exsmoker never nonsmoker fulltime 
parttime retired home student 
mi misstable patterns, frequency 
 
*impute missing values 
mi impute chained (pmm, knn(5)) tto0 tto4 tto8 agecentered exsmoker never nonsmoker 
fulltime parttime retired home student, add(30) rseed(1) 
mi reshape long tto, i(id) j(week) 
gen week2 = week^2 
order week2, after(week) 
 
sort week id 
by week: summ _0_tto_4_tto_8_tto 
sort id week 
 
*generate dummy variables 
tab gender, gen(gender) 
rename gender1 female 
rename gender2 male 
tab smoking_status, gen(smoking) 
rename smoking1 exsmoker 
rename smoking2 never 
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rename smoking3 nonsmoker 
rename smoking4 smoker 
tab ethnicity, gen(ethnicity) 
rename ethnicity1 mixed 
rename ethnicity2 white 
rename ethnicity3 wother 
tab highest_education, gen(education) 
rename education1 college 
rename education2 degree 
rename education3 school 
tab employment_status, gen(employment) 
rename employment1 fulltime 
rename employment2 parttime 
rename employment3 retired 
rename employment4 home 
rename employment5 student 
rename employment6 unemployed 
sum age, meanonly  
gen agecentered = age -r(mean)  
 
mi estimate: mixed tto week week2 fulltime parttime retired home student mixed white 
agecentered female exsmoker never nonsmoker college degree||id: week, cov(unstruc) 
mi estimate (dis_u: (4*_b[week]+40*_b[week2])*8/52): mixed tto week week2 fulltime 
parttime retired home student mixed white agecentered female exsmoker never 








Appendix VIII: Scatter plots and Q-Q plots which support the step-wise 
multi level model build  
 
Figure 44: A scatter plot to show the EQ-5D-5L against weekly time points with the 









Figure 46: A scatter plot to show the EQ-5D-5L against weekly time points with the 





Figure 47: A Q-Q plot based on the predicted random intercept, fixed slope 
model for the EQ-5D-5L 
Figure 48: A scatter plot to show the EQ-5D-5L against weekly time points with 
the predicted random slope model 
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Figure 51: A scatter plot to show the EQ-5D-5L against weekly time points with the 
predicted random polynomial model 
 




Figure 52: A scatter plot to show the AQL-5D against monthly time points with the 
predicted null model 
 





Figure 54: A scatter plot to show the AQL-5D against monthly time points with the 
predicted random intercepts model 
 
 
Figure 55: A Q-Q plot based on the predicted random intercept, fixed slope model 
for the AQL-5D 
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Figure 56: A scatter plot to show the AQL-5D against monthly time points with the 
predicted random slope model 
 
 












Figure 58: A scatter plot to show the AQL-5D against monthly time points with the 




Figure 61: A Q-Q plot based on the predicted null model for the TTO 
 
Figure 60: A scatter plot to show the TTO against monthly time points with the 
predicted null model 
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Figure 62: A scatter plot to show the TTO against monthly time points with the 
predicted random intercepts model 
 
 
Figure 63: A Q-Q plot based on the predicted random intercept, fixed slope model 




Figure 64: A scatter plot to show the TTO against monthly time points with the 








Figure 66: A scatter plot to show the TTO against monthly time points with the 
predicted random polynomial model 
  
 
Figure 67: A Q-Q plot based on the predicted random polynomial model for the 
TTO 
 
